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Abstract
Equine grass sickness (EGS) is a fatal dysautonomia of unknown aetiology. It is
characterised by severe neuronal degeneration and widespread neuronal loss in
both the enteric and autonomic nervous systems. Similar dysautonomias have also
been described in other animal species such as the cat and hare. This thesis
investigates the hypothesis that EGS is caused by a toxicoinfection with C.
botulinum type C, where the organism grows and produces toxin in the
gastrointestinal tract (Gl). The study has taken three main directions: (1) detection
of the botulinum type C neurotoxin (BoNT/C) in the Gl tract of horses with and
without EGS, (2) isolation and characterisation of organisms phenotypically
resembling C. botulinum type C, and (3) detection of antibodies to the type C
neurotoxin and surface antigens in the serum, Gl tract, colostrum and milk.
BoNT/C was detected by ELISA both directly in Gl contents and after enrichment of
the sample in order to determine the presence of both preformed toxin, and toxin-
producing organisms. BoNT/C was detected by direct detection and/or enrichment
in 74% of horses with acute grass sickness, 67% of horses with subacute grass
sickness and 67% of horses with chronic grass sickness, compared to 10% of
controls. BoNT/C was also detected directly and/or after enrichment in the Gl tract
of 81% cats with feline dysautonomia. These results support the hypothesis that
toxicoinfection with C. botulinum type C is involved in the aetiology of EGS and
possibly other similar dysautonomias, such as feline dysautonomia.
C. botulinum type C is phenotypically indistinguishable from C. botulinum type D and
Clostridium novyi type A. These three organisms are grouped together as "Group
III" botulinum strains and are differentiated on the basis of the major toxins they
produce. However, the type C and D neurotoxins and the C. novyi alpha toxin are
encoded on separate pseudolysogenic bacteriophages that can be readily lost.
Loss of these phages results in loss of toxigenicity and non-toxigenic isolates are
essentially indistinguishable from each other. Sixteen isolates phenotypically
resembling Group III botulinum were isolated from the Gl tract of nine horses, one
cat and one hare. The animals from which these organisms were isolated all had
some association with dysautonomia: five horses, one cat and one hare had
dysautonomia at the time of sampling; two horses had recovered from EGS; two
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horses had been in recent contact with EGS. None of the 16 isolates produced
BoNT/C; the novyi alpha toxin gene was detected by PCR in three of the isolates. A
novel method of distinguishing between C. botulinum type C/D and C. novyi type A
was developed using antiserum raised against the surface antigens of C. novyi type
A. This antiserum bound to a major immunogenic band that was present at 46kDa
in C. novyi but absent in C. botulinum type C/D; a band at 43kDa was recognised in
C. botulinum type C/D. By this method all 16 of the isolates were identified as C.
novyi type A. There were striking similarities between the EDTA-extracted surface
protein profiles of the isolates irrespective of species differences and the
geographical distances between the animals from which the organisms were
isolated. These isolates may have produced BoNT/C in vivo.
The immune response to the surface antigens of either C. novyi type A (serologically
cross-reactive with C. botulinum type C/D) or C. botulinum type C and to BoNT/C
was investigated at both the systemic and mucosal level. Horses with EGS had
significantly lower levels of IgG both to surface antigens and BoNT/C; horses in
contact with EGS had significantly higher levels of IgG to these antigens compared
to horses with the disease. IgG to the surface antigens and BoNT/C was detected
in the colostrum of all 36 mares investigated. These findings are in agreement with
epidemiological findings that there is a reduced incidence of EGS in horses that
have previously been in contact with the disease, and that suckling foals rarely get
the disease. However, horses with EGS had significantly higher levels of IgA to
BoNT/C in Gl contents compared to controls, suggesting that horses with EGS had
recently been exposed to the toxin in the Gl tract.
Detection of BoNT/C, BoNT/C-producing organisms and IgA to BoNT/C in the Gl
tract of horses with EGS, support the hypothesis that toxicoinfection with C.
botulinum type C is involved in the aetiology of EGS. There is also evidence that an
antibody response to BoNT/C and surface antigens may protect horses in contact
with EGS from developing the disease.
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1.1 Equine Grass Sickness (EGS)
Equine grass sickness is a dysautonomia of unknown aetiology. It is usually fatal
and at present is not preventable. The disease was first recognised in 1909 in army
horses at Barry Camp, Forfarshire, Scotland. The majority of cases occur in Great
Britain, with a higher incidence of the disease in Scotland (Milne et al, 1994); the
disease is said to affect an estimated 2-4% of horses per annum (Cottrell et al,
1999). Grass sickness also occurs in Scandinavia and sporadically in other parts of
northern Europe (Obel, 1955; Gilmour, 1987); cases have also been documented in
Australia (Stewart, 1977) and the Falkland Islands (Woods and Gilmour, 1991). Mai
Seco (dry sickness), an equine dysautonomia that occurs in Argentina and Chile, is
thought to be identical to equine grass sickness (Uzal and Robles, 1993). In 1999,
the first case of equine dysautonomia to occur in USA was confirmed (C. Hahn,
personal communication).
The clinical, pathological and epidemiological features of the disease are now well
recognised. The disease is characterised by severe neuronal degeneration and
widespread neuronal loss in the enteric and autonomic nervous systems. However,
despite almost a century's research into the aetiology of equine grass sickness, the
cause of this disease is still not known.
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1.1.1 Clinical signs
Equine grass sickness can occur in three forms - acute, subacute and chronic -
classified on the basis of severity of clinical signs and duration of the disease
(Doxey et al, 1991a). The mortality rate from grass sickness approaches
approximately 90% (Pogson et al, 1992) - horses with acute and subacute grass
sickness invariably die or are euthanased, whereas some horses with milder forms
of chronic grass sickness can recover. Acute grass sickness is the most severe
form of the disease with a sudden onset of clinical signs and death or euthanasia
within 48 hours; horses with subacute grass sickness can survive up to seven days.
Chronic grass sickness has a more insidious onset and can last from seven days up
to several weeks or months, ending in either euthanasia or recovery.
The clinical symptoms of grass sickness have been extensively described (Greig,
1928; Edwards, 1987; Gilmour, 1988; Pinsent, 1989; Doxey et al, 1991a; Milne,
1997). The characteristic symptoms of the three categories of equine grass
sickness are summarised in Table 1.1. The disease is characterised by dysfunction
of the gastrointestinal (Gl) tract. The severity and significance of this Gl
dysfunction is thought to account for the high mortality rate associated with the
disease (Scholes et al, 1993a). There is a spectrum of symptoms within the three
forms of grass sickness, with the clinical signs reflecting the extent of the neuronal
damage. Horses therefore present with varying degrees of Gl stasis/dysfunction,
dysphagia (inability to swallow) and colic. In the acute form of the disease there can
be complete Gl stasis with impaction of the large colon and accumulation of fluid in
the stomach and small intestine. Gastric reflux, either spontaneously or induced, of
several litres of foul smelling fluid, is a characteristic of acute grass sickness.
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Table 1.1: Clinical signs of equine grass sickness in the acute, subacute and









































Horses with the acute form of the disease are depressed, tachycardic and exhibit
hypersalivation. On rectal examination small, firm faecal pellets with varying
amounts of mucus are present.
The clinical signs in the subacute form of the disease are similar but less severe
than those seen in the acute form. There is reduced gut motility with colonic
impactions. As the disease progresses horses exhibit a rapid loss of weight and
condition with the development of a tucked-up abdomen. This is particularly marked
in the chronic form of the disease, where the exaggerated tucked up abdomen has
been likened to that of an emaciated greyhound (Edwards, 1987; Gilmour, 1988;
Pinsent, 1989) (Fig. 1.1). The tucked-up abdomen is not entirely due to loss in body
weight. Other characteristics of chronic grass sickness are a base narrow stance,
rhinitis sicca and the presence of little or no gut contents on rectal examination.
Ptosis (drooping of the eyelid), muscle fasiculations and patchy sweating can also
be seen in all three forms of the disease.
Subclinical cases are thought to occur but have not been proven (Pinsent, 1989;
Doxey et al, 1995a; Milne, 1997).
There is no single pathognomonic sign for grass sickness, either clinical or
biochemical (Doxey et al, 1991a). Biochemical investigation of the blood reflects
anhydraemia (Greig, 1942; Doxey et al, 1991a). Serum vitamin E levels and vitamin
B12 levels are within normal ranges in grass sickness suggesting the disease affects
thriving animals (Doxey et al, 1991a). Diagnosis is based on clinical signs and
confirmed at postmortem by the histological examination of peripheral autonomic
ganglia for the neuronal degenerative changes characteristic of grass sickness.
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Figure 1.1: A horse with chronic grass sickness, showing the characteristic tucked
up abdomen and base narrow stance.
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Treatment of the disease
There is currently no treatment for horses with acute or subacute grass sickness
and animals are euthanased on humane grounds. Previously it was thought that
horses with chronic grass sickness very rarely recovered and that if they did they
were not capable of work (Greig, 1942; Pinsent, 1989). However, it has been
demonstrated that with appropriate treatment, the mainstay of which is thorough
nursing care, selected cases of chronic grass sickness can recover and be capable
of work (Milne et al, 1994; Doxey et al, 1995b; Milne, 1997; Doxey et al, 1998).
Horses with milder symptoms, in particular with respect to dysphagia, appetite, colic,
gut sounds and rhinitis, have a greater chance of survival (Milne et al, 1994) and
can be selected for treatment on these grounds. The recovery rate from chronic
grass sickness at the Large Animal Hospital at the Easter Bush Veterinary Centre
was shown to be 48% of all chronic cases entering the hospital, with a recovery rate
of 70% in cases selected for treatment (Milne, 1997). The time taken for recovery
is variable (Doxey et al, 1998; Doxey et al, 1999), but it has been found that the
majority of recovered horses regain weight and return to work within a year (Doxey
et al, 1998); 81% of competitive horses returned to their original work.
The horses are encouraged to eat appetising, easily swallowed high-energy food,
are groomed, kept dry and warm and their interest stimulated by human contact
(Milne, 1997). The prokinetic drug Cisapride, was shown to be of some therapeutic
benefit in the treatment of selected cases of chronic grass sickness (Milne et al,
1996). It is an indirect cholinergic agent that facilitates the release of acetylcholine
from the postganglionic nerves of the myenteric plexus in the gut. However, it has
not been routinely used in the treatment of horses with chronic grass sickness and
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has recently been withdrawn from the market. Probiotics have also been used but
their benefits have not been scientifically evaluated.
There has been some controversy as to whether horses that have recovered from
chronic grass sickness had been correctly diagnosed. Ante-mortem diagnosis is
based on clinical signs, and confirmed at postmortem by histopathological
investigation of the peripheral autonomic ganglia. Histopathological investigation of
ileal biopsies collected at laparotomy can be used to confirm an antemortem
diagnosis (Scholes et al, 1993b). However, this procedure requires anaesthesia
and surgery, and is considered to reduce the chances of recovery in a horse with
chronic grass sickness that is being considered for treatment (Doxey et al, 1995b).
In 63 consecutive cases of chronic grass sickness diagnosed clinically antemortem
and subsequently euthanased, all were confirmed histologically at postmortem
(Doxey et al, 1995b), suggesting that diagnosis by experienced clinicians based on
clinical signs is indeed accurate. Recently, recovery from chronic grass sickness
has been confirmed in four horses by histological examination of ganglia after their
death from other causes several years after recovery (Doxey et al, 2000). There
was severe depletion of enteric neurons in all four horses to the extent that it was
surprising that two of the horses had not suffered from repeated colic. The other
two horses had suffered from intermittent colic after recovery from chronic grass
sickness and their ileum showed hypertrophied walls suggesting that the intestinal
musculature had adapted to make up for the neuronal deficit. The findings




Equine grass sickness is a primary dysautonomia with severe neuronal
degeneration and loss primarily seen in the autonomic and enteric nervous systems.
The characteristic neuronal lesions of grass sickness were first observed by Obel
(1955) in the vertebral and prevertebral ganglia and the alimentary mural plexi of the
autonomic nervous system. Subsequent investigations of the neuropathology of
grass sickness have demonstrated the presence of the neuronal lesions in the
central nervous system (CNS): in specific brainstem nuclei, and within the spinal
cord, in the dorsal root ganglia, the intermediolateral nucleus and ventral horn
(Barlow, 1969, Gilmour, 1973a). Neuronal degeneration in the CNS is not as
widespread as that seen in the autonomic nervous system, lesions appear to be
restricted to specific nuclei. Equine grass sickness can thus be described as a
polyneuropathy as neuronal degeneration occurs in the peripheral, central and
enteric nervous systems (Cottrell et al, 1999).
A wide variety of neurotransmitter systems are affected in equine grass sickness.
Neuronal degeneration is observed in both the parasympathetic and sympathetic
ganglia. Increased amounts of noradrenaline have been observed in intraganglionic
swellings (Gilmour, 1976). There are increased levels of circulating adrenaline and
noradrenaline in horses with grass sickness, although this might be due to
overactivity of the adrenal medulla initiated by stress as much as to overactivity of
the central and peripheral sympathetic nervous systems (Hodson et al, 1984a). The
enteric cholinergic neurons from the ileum of horses with grass sickness exhibited
altered cholinergic mechanisms with a reduction in the release of acetylcholine
(Murray et al, 1994). Noncholinergic nonadrenergic neurotransmitters also appear
to be affected. There are abnormalities of the regulatory peptide system of the gut
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with a marked reduction in the numbers of nerve fibres staining for vasoactive
intestinal polypeptide (VIP), substance P, bombesin and enkaphalin in each layer of
the gut (Hodson et al, 1982). No peptidergic neurons could be found in some areas
of the gut. Extensive degeneration was observed with degranulation and formation
of multiple vacuoles in the P-type nerve fibres (Hodson et al, 1982). Electron
microscopy has demonstrated the almost lack of neuronal vesicles in the enteric
neurones, except those thought to be adrenergic (Hodson and Wright, 1987).
However, a mixture of abnormal and normal neurons is seen in immediate proximity
suggesting that there may be some selectivity in the neuronal damage process.
Neuronal degenerative changes
The affected neurons have a characteristic "chromatolytic" appearance (Obel,
1955). Chromatolysis is the term used to describe the loss of Nissl substance
(stacks of rough endoplasmic reticulum). Light microscopy shows that in the early
stages of degeneration the perikarya of the affected neurons are rounded and
moderately swollen, and later become shrunken and irregular; the nuclei are
commonly eccentric and pyknotic (Pollin and Griffiths, 1992). The observation of
these degenerative changes in peripheral autonomic ganglia is diagnostic for equine
grass sickness. As the disease progresses the autonomic ganglia contain fewer
neurons (Pollin and Griffiths, 1992).
Ultrastructural investigation has identified that the earliest recognisable changes
affect the rough endoplasmic reticulum (RER) and Golgi (Pollin and Griffiths, 1992).
A variety of changes have been observed in the RER: it can have an unusual
distribution, with dispersion of individual cisternae throughout the cytoplasm, the
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cisternae can be distended, or in some cases the RER is unrecognisable and cells
may have a marked increase in smooth endoplasmic reticulum (Pollin and Griffiths,
1992). Most cells no longer have a recognisable Golgi complex; ultrastructural and
histological investigations have demonstrated that loss of the Golgi is an early event
(Griffiths et al, 1993). Affected neurons can also have increased numbers of
mitochondria, lysosomes, dense bodies and autophagic vacuoles (Pollin and
Griffiths, 1992). Marked abnormalities have been observed in neuronal cytoskeletal,
cytoplasmic and secretory proteins thus various proteins with different functions,
localisations and synthetic pathways are affected in the neuronal cell (Griffiths et al,
1993).
Neuronal degeneration and clinical outcome - a toxic aetiology?
The pattern of neuronal degeneration observed in equine grass sickness was
thought to reflect a toxic insult. However, the nature and distribution of the neuronal
damage in equine grass sickness is unlike that previously observed for any known
neurotoxin (Gaskell, 1987). The damage to the enteric nervous system is thought to
be the primary event in grass sickness (Hodson and Wright, 1987; Pogson et al,
1992; Doxey et al, 1995a). There is evidence that neuronal destruction and loss
had occurred in the jejunum of horses with acute grass sickness prior to cell loss in
the peripheral ganglia (Pogson et al, 1992).
The clinical severity of the disease correlates with the extent of the enteric neuronal
damage (Scholes et al, 1993a). Neuronal degeneration was observed in the acute
cases at most sites investigated along the length of the Gl tract whereas in chronic
cases it was restricted to the terminal small intestine, particularly the ileum (Scholes
et al, 1993a; Doxey et al, 1995a). It has been hypothesised that equine grass
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sickness could be caused by an ingested or enterically produced neurotoxin
(Pogson et al, 1992; Doxey et al, 1995a). The damage in the ileum is usually
severe and extensive irrespective of the clinical differences in the disease and it has
been proposed that the ileum could be the main site of entry for a putative ingested
neurotoxin (Scholes et al, 1993a; Doxey et al, 1995a). Histological examination of
transmural ileal biopsies can be used as an ante-mortem diagnostic tool for
confirmation of equine grass sickness (Scholes et al, 1993b).
Dosage and duration of exposure to the putative toxin are thought to be important in
the differences in enteric damage seen between chronic and acute cases (Pogson
et al, 1992; Doxey et al, 1995a). It is proposed that acute cases are exposed to
large amounts of toxin present in both the jejunum and ileum over a short period of
time resulting in massive damage. Horses with the chronic form of the disease have
less neuronal damage due to exposure to smaller amounts of toxin present only in
the distal ileum over a longer period of time. Horses that recover from chronic grass
sickness may be exposed to very small amounts of toxin with recovery occurring
only when the remaining neurons are able to operate effectively (Doxey et al,
1995a). Exposure to very small doses of toxin could result in subclinical cases;
these have been thought to occur during an outbreak of grass sickness (Pinsent,
1989; Doxey et al, 1995a; Milne, 1997).
Damage to the peripheral autonomic ganglia could occur via toxin that has entered
the circulation (Doxey et al, 1995a) or by retrograde axonal transport (Griffiths et al,
1994). Investigation of the peripheral ganglia also suggested that more severe
neuronal degeneration was found in the acute cases than chronic cases (Gilmour,
1973a; Pogson et al, 1992). Approximately 50% of the peripheral ganglion neuron
population was either lost or damaged in horses with acute and chronic grass
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sickness (Pogson et al, 1992). Horses with acute grass sickness had extensive
neuronal damage but little cell loss, whereas chronic cases had fewer damaged
neurons present but lower total counts of neurons. The rate of neuronal loss from
the peripheral autonomic ganglia, as opposed to the total number of neurons
damaged/lost, was therefore considered a possible factor in determining the severity
of the disease (Pogson et al, 1992). Significant differences in the extent of neuronal
damage in the peripheral autonomic ganglia between acute and subacute cases
were not observed despite clinical differences in the severity of disease (Doxey et al,
1992); chronic cases did have significantly less damage in the peripheral ganglia.
1.1.3 Similar dysautonomias in other species
Primary dysautonomias with clinical, pathological and epidemiological similarities to
equine grass sickness have been described in other species: cases of
dysautonomia in cats, dogs, hares and rabbits have been described since 1982
(Key and Gaskell, 1982; Rochlitz and Bennett, 1983; Whitwell, 1991; Whitwell and
Needham, 1996). The striking similarities between these dysautonomias would
suggest a potential common aetiological agent (Pollin and Griffiths, 1992).
However, no causative agent has yet been described for any of these
dysautonomias.
Feline dysautonomia
Feline dysautonomia was first reported in 1982 by Key and Gaskell. Prior to this the
disease appears to have been unrecognised. The disease was seen throughout the
UK between 1982 and 1986, when there were very few instances of more than one
cat in a household being affected (Rochlitz, 1984 cited in Symonds et al, 1995).
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However, since 1986 the numbers of cases of feline dysautonomia have declined
with the disease appearing to be mainly restricted to outbreaks associated with
closed cat colonies (Symonds et al, 1995).
The neuronal degeneration seen in feline dysautonomia is strikingly similar to that
seen in grass sickness. However, large complex stacks of smooth parallel
membranes are frequently seen in the affected perikarya of autonomic neurons of
cats, but these are not seen in equine neurons (Sharp et al, 1984). These stacks
may originate from the cell's Golgi complex.
There are some differences in the clinical symptoms of dysautonomia between
species: some horses with dysautonomia are tachycardic and show patchy
sweating, whereas almost 50% of cats with feline dysautonomia are bradycardic;
horses with acute grass sickness drool saliva, whereas cats and dogs with
dysautonomia have very dry mucous membranes; fixed dilatation of the pupils is a
striking feature in feline dysautonomia but seldom occurs in grass sickness. The
majority of clinical signs in feline and canine dysautonomia suggest that
parasympathetic dysfunction is occurring (Pollin and Griffiths, 1992). Grass
sickness was said to be a "sympathicotonia" (Greig, 1928). It was recognised that
this was not necessarily due to a primary sympathetic stimulation but could also be
caused by a depression of the parasympathetic system. However, the picture is
considered more complex than this as the classical concept of antagonism between
the parasympathetic and sympathetic branches of the autonomic nervous system is
now known not to be appropriate for all body systems (Cottrell et al, 1999). In
addition, nonadrenergic noncholinergic neurotransmitters have been recognised in
the regulation of gut motility (Malone et al, 1999). The difference in clinical signs
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seen between the dysautonomias is thought to be due to interspecies differences
(Gaskell, 1987).
Leporine dysautonomia
Leporine dysautonomia was first recognised in two hares found dead on an estate
on which cases of equine grass sickness had occurred (Whitwell, 1991). Gross,
histological and ultrastructural findings were reminiscent of grass sickness
(Whitwell, 1991; Griffiths and Whitwell, 1993). Chromatolytic neurons were found in
the autonomic ganglia and in brain stem nuclei. The cisternae of the rough
endoplasmic reticulum were distended and the Golgi apparatus was not
recognisable in affected neurons (Griffiths and Whitwell, 1993). However, stacks of
parallel smooth membranes and large lectin-staining cytoplasmic inclusions were
seen in some diseased neurons; these are not seen in grass sickness (Griffiths and
Whitwell, 1993), but similar stacks are often seen in feline dysautonomia (Sharp et
al, 1984). Besides these small differences, the similarities between leporine and
equine dysautonomias were thought to be sufficient as to indicate exposure to a
common causal agent (Griffiths and Whitwell, 1993).
Rabbit mucoid enteropathy (RME)
Rabbit mucoid enteropathy (RME) has been recognised for many years but the
cause is unknown. Recently it has been demonstrated that RME is a dysautonomia
after identification of chromatolytic neurons in autonomic ganglia, brain nuclei and
the spinal cord in an outbreak in "fancy" rabbits in Norfolk (Whitwell and Needham,
1996). Caecal dysbiosis is a feature of RME, and was hypothesised to result from
sudden caecal hyperacidity, with the consequence of overgrowth of bacteria such as
Escherichia coli and Clostridium species (Lelkes and Chang, 1987). RME has the
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potential for being a good model for the study of dysautonomia (Whitwell and
Needham, 1996).
1.1.4 Epidemiology
The epidemiology of equine grass sickness has been extensively investigated in an
attempt to identify an aetiological agent, risk factors and ways of preventing the
disease. Many of the observations from the early investigations have been
confirmed by more recent epidemiological studies that have used a case-control
methodology.
Grass sickness has been associated with grazing ever since the disease was first
recognised, hence the name it was given (Tocher et al, 1923, Pool, 1928; Greig,
1942). This association has been confirmed more recently by epidemiological
studies of the disease (Gilmour and Jolly, 1974; Doxey et al, 1991b; Wood et al,
1998). It has been shown that there is a reduced incidence of the disease in horses
that are even part-stabled (Gilmour and Jolly, 1974). Traditionally, horses used in
farming were turned out part time at the beginning of May, with full time grazing
commencing at the end of May (Greig, 1942). The majority of cases of grass
sickness were seen from May to July with a particularly high incidence of the
disease in June (Greig, 1942); cases were occasionally but rarely seen in stabled
horses or during the winter months. Although grass sickness can occur in any
month there is a definite seasonal occurrence with the majority of cases occurring
between April and July (Doxey et al, 1991b; Gilmour and Jolly, 1974; Wood et al,
1998). The older literature reports a predominance of the acute form of the disease
in the early summer months, with a subsequent increase in the number of subacute
and chronic cases as the season progresses (Pool, 1928; Greig, 1942).
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Grass sickness is associated with particular premises, with the disease more likely
to occur on premises where grass sickness has previously occurred (Wood et al,
1998), particularly if the disease has occurred within the previous two years
(Gilmour and Jolly, 1974). There is an increased risk of the disease in horses that
have been on a particular premises for less than two months (Gilmour and Jolly,
1974), and in horses that have recently changed pasture (Greig, 1942; Wood et al,
1998). One study found that 50% of cases had a pasture change in the prior four
weeks and 20% of the cases in the prior two weeks (Wood et al, 1998).
Warm dry weather with ground frosts were thought to be climatic conditions
predisposing to outbreaks of the disease, whilst wet weather was associated with a
decrease in incidence of the disease (Tocher, 1924; Pool, 1928; Greig, 1942).
However, investigation of meteorological records could not correlate any particular
weather condition with the occurrence of the disease (Greig, 1942). In eastern
Scotland, it was found that the disease was associated with cooler drier weather
with ground frosts occurring at irregular intervals (Doxey et al, 1991c). The study
emphasised the local nature of Scottish weather, making the association of
meteorological data with outbreaks of the disease difficult. In a study involving the
whole of the UK, 66% of the cases were found to occur after predominantly dry
weather (Wood et al, 1998).
Scotland is thought to have a higher incidence of grass sickness than England, with
more cases occurring in the east of the country than the west; there is no statistical
data to support these observations (Doxey et al, 1991c). The differences in regional
occurrence may be due to climatic differences, with the eastern weather pattern
predisposing to outbreaks of the disease (Doxey et al, 1991c). Climatic differences
may influence vegetation. The incidence of the disease is particularly low in August,
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a factor which could be related to August having the highest rainfall in eastern
Scotland (Doxey et al, 1991b; Doxey et al, 1991c).
There is a significantly higher incidence of the disease in young animals (Doxey et
al, 1991 b; Wood et al, 1998; Greig, 1942), with two to seven year olds being most at
risk (Gilmour and Jolly, 1974). The disease is rarely documented in suckling foals.
Thriving animals have also been reported to be more at risk from the disease
(Doxey et al, 1991b), but this has not been confirmed by others. There is a lower
incidence of the disease in mares (Wood et al, 1998), but no definite differences in
susceptibility between breed types (Gilmour and Jolly, 1974).
Prior contact with a previous case of grass sickness has been associated with a ten¬
fold decrease in likelihood of disease (Wood et al, 1998). This suggests that non¬
fatal exposure to grass sickness results in resistance to the disease. This
resistance may be in the form of an immune response to the aetiological agent, but
it could also demonstrate the presence of inherent resistance to the disease in some
horses. Grass sickness seems to occur sporadically with often only one horse being
affected. Outbreaks do occasionally occur with multiple cases being reported.
Epidemiological studies have implicated an incubation period for grass sickness,
which has been estimated at approximately two weeks. Cases of grass sickness
were seen in agricultural horses turned out full time to grass at the end of May - a
high incidence of the disease occurred 10 to 14 days later (Pool, 1928). Observation
of the development of the disease in horses imported from Ireland where the
disease is extremely rare has also suggested a two-week incubation period (Doxey
et al, 1991c).
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Epidemiological investigations have therefore identified that young horses with no
previous exposure to grass sickness, having recently changed pasture or being new
to the premises and grazing pasture between April to July where grass sickness has
previously occurred, will be at increased risk from the disease. However, the
sporadic nature of this disease makes it difficult to implement preventative measures
such as restriction to grazing, based on these findings.
With respect to the aetiology of the disease, the epidemiological evidence would
suggest that the causal agent was related to grazing. Resistance can develop to
the disease in older horses, those remaining on a pasture for longer and those in
prior contact with the disease. This resistance to grass sickness may be in the form
of an immune response to the aetiological agent, thus providing evidence for an
infectious aetiology. Climatic conditions may also influence disease occurrence,
possibly through effects on vegetation.
1.1.5 Aetiology of EGS
Identification of the aetiology of equine grass sickness is essential to enable both
the specific treatment of the disease and its prevention. Many putative aetiological
agents have been considered since the disease was first recognised, including
poisonous plants, fungi, deficiency disease, chemical toxins, toxins elaborated in the
gut and toxin-producing bacteria. The inability to elucidate the aetiological agent of
grass sickness has led to re-examination of some of the older hypotheses as well as
the investigation of novel agents.
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Poisonous plants
Poisonous plants were among the very first putative aetiological agents to be
investigated due to the clear association of the disease with grazing. However, no
plants that had a toxic effect on horses were identified from pastures where the
disease occurred (Tocher et al, 1923). Alsike clover (Trifolium hybridum), in
particular, had been suspected, but animals that grazed on pasture where this
clover was abundant did not succumb to the disease, and extracts of the clover
were not toxic when fed to horses (Tocher, 1924; Greig, 1942). A botanical survey
in 1927 could not identify any plant common to all pastures where grass sickness
had occurred (Greig, 1942). More recently a survey in UK and Patagonia also failed
to identify a plant common to all pastures where grass sickness or mal seco had
occurred (Robb et al, 1997a).
Festuca argentina, a plant known to be toxic to animals, was consistently found in
the diet of nine horses suffering from mal seco (Uzal et al, 1996). However,
attempts to reproduce the disease by feeding the plant to three horses over a 28-
day period, failed to produce either the clinical symptoms or pathology of grass
sickness.
Fungi
Fungi, growing on the plants on pasture-land, were also considered as potential
causes of grass sickness. It was noted that the weather conditions that predisposed
for grass sickness also suited the spread of parasitic fungi (Wilson cited in Pool,
1928). Cultures of fungi from fields with grass sickness were tested on horses but
failed to reproduce the disease (Greig, 1942). Subsequent work has isolated fungi
from horses with grass sickness, but not any one particular species was found to be
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associated with the disease (Doxey et al, 1990). It was considered that an
endophytic fungus of the plant Festuca argentina might have been responsible for
mal seco and that the conditions during the feeding experiment were not suitable for
elaboration of toxin by this fungus (Uzal et al, 1996). However, endophytic fungi
have been identified in fewer than 20% of plants examined from fields where grass
sickness and mal seco have occurred (Robb et al, 1997a). Endophytic fungi were
not found on all pastures with a history of the disease.
Fusarium species were found on all the pastures investigated in the UK and
Patagonia where grass sickness/mal seco had occurred (Robb et al, 1997a).
Fusaria have also been shown to out-compete other fungi under dry weather
conditions, bringing together the association of weather patterns and outbreaks of
grass sickness (Robb et al, 1997a). Fusarium species can produce mycotoxins that
have been demonstrated to be cytotoxic in vitro to equine sympathetic chain
ganglion cells, lung and liver cells (Robb et al, 1997b). However, dosing of horses
in Patagonia with Fusarium cultures, originally isolated from fields where the disease
had occurred, did not reproduce the clinical signs of the dysautonomia nor the
histopathological changes (Uzal and Robles, 1997). It has been hypothesised that
fusarial toxins might act as a predisposing factor to grass sickness, as mycotoxins
are known to have detrimental effects on the immune system, vitamin utilisation and
can alter intestinal flora (Robb et al, 1997a).
Altered plant biochemistry and oxidative stress
The role of oxidative stress in horses with grass sickness is currently being
investigated. Neurons are particularly vulnerable to oxidative stress, which can
result from an excess of free radicals or from depletion in antioxidants (McGorum et
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al, 1998). It has been hypothesised that grass sickness is associated with the
ingestion of plants that are under metabolic stress due to adverse weather or fungal
colonisation (McGorum et al, 2000). Plants collected from fields immediately after a
case of grass sickness had altered biochemical composition, decreased antioxidant
activity and increased prooxidant activity compared to plants collected form the
same fields outside the grass sickness season (McGorum et al, 2000). It was
considered unlikely that the prooxidant activity of these plants was sufficient to
cause the neuronal degeneration seen in the disease. However, it was considered
that the metabolically stressed plants could play a role in the development of the
disease, either directly through the production of an undetected neurotoxic
metabolite, or indirectly through association with a fungus capable of producing a
neurotoxin or through the alteration of the intestinal milieu enabling the overgrowth
of neurotoxin-producing bacteria.
Toxin-producing bacteria/ invasive bacterium
Clostridium botulinum
In 1919, a large anaerobic bacillus, morphologically and toxigenically resembling
Clostridium botulinum (Bacillus botulinus as it was then called), was detected in
anaerobic cultures of stomach and intestines from horses with grass sickness
(Tocher et al, 1923). It was also noted at this time that there were similarities
between the clinical symptoms of grass sickness and those of classical botulism.
In 1924, Tocher reported that he and his colleagues felt that the results of their
investigations were sufficient to conclude that Clostridium botulinum was the cause
of grass sickness.
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Tocher (1923; 1924) put forward various pieces of evidence in support of his theory
that C. botulinum was the cause of grass sickness. The organism had also been
isolated form the spleens of horses with subacute grass sickness. The toxin of this
organism could be neutralised by antitoxin against known strains of Bacillus
botulinus. Both the isolated organism and toxin were toxigenic in experimental
animals, and said to reproduce the symptoms of "grass sickness" (Tocher et al,
1923). Antitoxin to botulinum type A was found in chronic and recovered horses but
not in normal horses or those with the acute form of the disease (Tocher et al,
1923). Tocher considered that grass sickness was an infection with C. botulinum
with toxin produced in vivo, rather than an intoxication. In support of this view,
complement-binding antibodies specific for both botulinum type A and B were
detected in horses with the subacute form of grass sickness, but not in normal
horses or those immunised with the toxin only (Tocher et al, 1923).
A protection study was carried out using a toxin-antitoxin mixture prepared from
known strains. In total, 1433 horses were vaccinated, 961 in 1922 and 472 in 1923,
and uninoculated horses were left on each farm as controls, 355 in 1922 and 453 in
1923. In 1922, mortality in vaccinated horses was 2.8% compared to 9.3% in
uninoculated controls, and in 1923 the mortality rate in vaccinated horses was 1.5%,
compared to 8.2% of the controls (Tocher et al, 1923; Tocher, 1924). The reduction
of mortality from grass sickness in the vaccinated horses has been shown to be
highly statistically significant (p<0.0001) (Wood et al, 1999). However, it appears
that Tocher's contemporaries were not convinced by this protection study.
The work of Tocher et al (1923) was the focus for considerable discussion and
criticism when it was presented. There was criticism for the use of an antitoxin toxin
mixture prepared from human strains of botulinum, rather than the strains isolated
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from the grass sickness horses in the protection study. There was also criticism that
the organism isolated from the grass sickness horses had not been conclusively
identified as Clostridium botulinum (Gaiger in Tocher et al, 1923). The organism had
not been isolated in pure culture. A major hindrance to Tocher's hypothesis was
that at the time botulism was only known as a primary intoxication and not an
infection. The production of toxin within a living animal was not considered possible
(Anon, 1927; Greig, 1942). There was therefore significant scepticism as to how the
organism could cause the disease. It was not until 1976 that a toxicoinfectious form
of botulism, infant botulism, was described in humans (Midura and Arnon, 1976).
Tocher was aware that spores of Bacillus botulinus could be swallowed and pass
through the gut of animals leaving them unharmed, and he therefore thought that
there must be a predisposing cause such as a nutritional or metabolic disturbance
for example, leading to gastric irritation (Tocher, 1924). However he assumed that
the predisposing cause would enable the spores to cross the gut wall and gain
access to the tissue (Tocher, 1924), rather than producing the toxin in the gut as is
the case in intestinal toxicoinfection.
Tocher's work consequently failed to find support among the veterinarians.
Experimental studies demonstrated that the administration of type B toxin to horses
by stomach tube induced acute botulism, not grass sickness (Greig, 1942). It was
felt that veterinary opinion was justified in concluding grass sickness was not
botulism (Anon, 1927).
The role of C. botulinum in the aetiology of grass sickness re-emerged in 1994,
when it was hypothesised that toxicoinfection with C. botulinum type C could
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account for both the clinical and pathological features of this disease (J.K. Miller,
unpublished).
Other bacteria
A diplostreptococcus was isolated from the central nervous system of an acute case
of grass sickness in (Gaiger, 1922, cited in Greig, 1942). This organism was similar
to that which had been aetiologically implicated in Borna disease, a neurological
disease of horses that shared some clinical similarities with grass sickness (as well
as clear differences). However, attempts to reproduce the disease by injection with
the organism failed to reproduce grass sickness (Greig, 1942).
Clostridium perfringens type D (Clostridium welchii type D as it was then known)
was implicated as an aetiological agent in grass sickness in 1934, when toxin was
detected in a small number of acute cases (Gordon, 1934). However, attempts to
reproduce the disease by administration of the toxin were negative as was a
protection study in 1937 that failed to protect against grass sickness (Greig, 1942).
C. perfringens type A has been implicated as the causative agent in a grass
sickness-like illness in Colombia, where the disease has been recognised since
1966. The disease was experimentally reproduced, both clinically and
pathologically, by inoculation of horses with supernatants of C. perfringens type A
cultures, isolated from cases of grass sickness (Ochoa and de Valendia, 1978).
Horses that had recovered from the disease were also shown to have higher titres
of neutralising antibody to the C. perfringens enterotoxin, than controls, thus
implicating the enterotoxin as the aetiological or complicating agent of the disease
(Ochoa and de Valendia, 1978). However, neutralising antibody to the enterotoxin
could not be demonstrated in cases of grass sickness in Scotland (Gilmour et al,
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1981). There are some clinical and pathological differences between the disease
known as grass sickness in Europe and that described in Colombia, and it has been
suggested that they may be different diseases.
Other causes
In 1942, a review of the progress in the investigation into the aetiology of grass
sickness ruled out the involvement of plant poisoning, a deficiency disease,
anaphylaxis, the production of toxic chemicals at pasture, or poisonous products of
intestinal origin as causes of this disease (Greig, 1942). Invasive and/or toxin
producing bacteria and protozoan parasites were also disregarded as possible
causes.
"Filterable viruses" were therefore left as the most likely candidate as the causative
agent in 1942. However the nature of this virus or its mode of transmission was
unclear. Due to the way in which the disease had initially spread, together with both
the epizootic and sporadic nature of the disease, an unwinged motile insect was
considered as the most likely vector for transmission. However, an investigation to
implicate an insect vector was negative (Greig, 1942) and a virus has never been
isolated.
Selenium deficiency was implicated in the aetiology of grass sickness when it was
noted that the majority of cases of grass sickness occurred on farms where cattle
suffered from muscular dystrophy (MacPherson, 1978). Although selenium levels
from horses were reported to be low, so were the selenium levels in healthy animals
on the same farm (MacPherson, 1978).
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Toxic aetiology
Although the aetiological agent of grass sickness has yet to be identified, it is now
generally thought that an ingested or enterically produced neurotoxin is the cause of
the disease (Griffiths et al, 1994; Doxey et al, 1995a). Further evidence for a toxic
aetiology was acquired when it was discovered that intraperitoneal injection of
serum from acute cases of grass sickness could induce the characteristic autonomic
lesions of the disease in experimental ponies (Gilmour et al, 1973b), thus
demonstrating the presence of a toxic factor in the blood of horses with acute grass
sickness.
Inoculation of the ponies with different fractions of the blood identified a plasma
protein fraction of molecular weight 30,000Da or greater that was neurotoxic
(Gilmour and Mould, 1977). This toxic factor was proteinaceous or was bound to a
high molecular weight plasma protein. Later, investigations using thin layer
chromatography identified a low molecular weight compound present in extracts of
sera from acute cases but not in sera from healthy controls (Johnson, 1985, cited in
Pemberton et al, 1990). However, subsequent investigations suggest that this
compound was Cortisol, a substance found in high concentrations in equine grass
sickness (Pemberton et al, 1990). No recognised neurotoxin was detected using
chromatography.
However, despite extensive damage to the peripheral autonomic nervous system, in
particular the coeliacomesenteric ganglia, there were no clinical signs in the
experimental ponies injected intraperitoneal^ with the acute sera (Gilmour, 1973b).
No neuronal lesions were induced by oral administration (Gilmour and Mould, 1977).
The absence of clinical signs in these ponies may be due to the fact that the enteric
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nervous system was not sufficiently damaged. It is thought that both the peripheral
autonomic and enteric nervous systems have to be severely damaged for clinical
disease to develop (Pogson et al, 1992; Doxey et al, 1995a).
1.2 Clostridium botulinum
The species Clostridium botulinum encompasses a phenotypically and genotypically
heterogeneous group of organisms, classified as one species on the basis of
production of a neurotoxin with the same pharmacological action. The botulinum
neurotoxin is one of the most potent toxins known in nature, causing botulism
through the inhibition of neurotransmitter release from cholinergic synapses.
1.2.1 Toxin types
C. botulinum has been divided into seven types, A to G, based on the antigenicity of
the neurotoxin that they produce. C. botulinum, or Bacillus botulinus as it was
originally named, was first isolated from an outbreak of botulism, in Belgium in 1895,
caused by salt-cured, uncooked ham (van Ermengem, 1897 cited in Hatheway,
1989). The toxin types were designated in chronological order of discovery.
Botulinum types A, B, E and F are implicated in human cases of botulism whereas
types C and D appear to cause only animal botulism. Type G botulinum, first
isolated in a soil survey (Gimenez and Ciccarelli, 1970 cited in Hatheway, 1989),
has not conclusively been shown to be the cause of botulism in either humans or
animals.
The nomenclature of toxin types has been complicated by the isolation of strains
that can produce combinations of two distinct toxin types. An isolate from soil
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produced 93% type A and 7% type F (Gimenez and Ciccarelli, 1970, cited in
Hatheway, 1989) and two strains from children with infant botulism produced 90%
type B and 10% type F toxins (Hatheway and McCroskey, 1987), these strains have
been designated AF and BF respectively. An organism producing a mixture of type A
and B toxins has also been identified (Poumeyrol et al, 1983, cited in Collins and
East, 1998). Minor variations in toxins produced by different strains of toxin type A
(Ciccarelli and Gimenez, 1971, cited in Hatheway, 1989) and toxin type B
(Hatheway et al, 1981) have also been discovered. In addition, other species of
Clostridia have been isolated that are capable of producing botulinum neurotoxin:
isolates of Clostridium baratii and Clostridium butyricum have been identified
producing type F and E toxins respectively (Hall et al, 1985; McCroskey et al, 1986).
1.2.2 Phenotypic and genotypic groups of C. botulinum
C. botulinum has been grouped into four groups based on phenotypic characteristics
(Holdemann and Brooks, 1970; Smith and Hobbs, 1974). Group I contains type A,
and proteolytic strains of type B and F; group II contains type E and non-
proteolytic/saccharolytic strains of type B and F; group III contains types C and D
(usually non-proteolytic); group IV contains type G. The phenotypic characteristics
of these organisms are compared in Table 1.2. These groups also contain
phenotypically related non-toxigenic organisms.
Genotypic studies, based on nucleic acid hybridisation and 16S ribosomal RNA
sequencing studies, have demonstrated the presence of four phylogenetically
distinct lineages that agree with the four groups that were based on phenotypic
differences (Hutson et al, 1993; Collins and East, 1998). However, comparison of
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nucleotide sequences of the botulinum neurotoxin (BoNT) genes does not agree
with the four phylogenetic groups of organisms, suggesting that there has been
lateral gene transfer of the BoNT genes. BoNT genes are thought to have spread
on mobile genetic elements such as transposons, plasmids and bacteriophages:
botulinum neurotoxin types E (BoNT/E) and G (BoNT/G) have been found on
plasmids (Hauseret al, 1992; Eklund et al, 1988), and BoNT/C and BoNT/D toxins
are phage encoded (Eklund et al, 1971; Eklund et al, 1972).




Group Type Milk Glucose Lipase Volatile Non¬ Phenotypically
of digestion fermentation volatile related
toxin Clostridium
I A,B,F + + + A, iB,
B, iV
PP C. sporogenes
II B,E,F - + + A, B
III C,D +/- + + A, P, B C. novyi




Metabolic acid end products in peptone-yeast extract-glucose medium. A, acetic; P,
proprionic; iB, isobutyric;B, butyric; iV, isovaleric; PP, phenylproprionic; PA, phenylacetic.
It has been suggested that C. botulinum should be reclassified into four separate
species based on these phenoiypic and genotypic differences (Hutson et al, 1993;
Collins and East, 1998). Species classification based on neurotoxin production
alone is both taxonomically incorrect and increasingly complicated. Neurotoxin
production is not a stable phenotype in many organisms; other species have been
identified as neurotoxin producers, e.g. C. baratii and C. butyricum; some strains
29
produce mixtures of two toxin types, and silent BoNT genes have been detected in
others. A precedent has been set by the reclassification of C. botulinum type G as
Clostridium argentinense; this organism did not produce lipase, a characteristic of
the other C. botulinum organisms. Reclassification of the species would enable
accurate identification of toxin-producing organisms, important for both the study of
the ecology of these organisms and the aetiology of the diseases they cause. The
significance of the neurotoxin in disease requires that any reclassification should
also account for neurotoxin production by these organisms.
1.2.3 Group III botulinum
C. botulinum type C and D are grouped together by their phenotypic properties into
Group III. C. novyi type A is phenotypically similar to these organisms and is a non-
neurotoxigenic variant of Group III. These organisms cannot be distinguished from
each other by traditional methods such as culture, biochemical properties or gas
liquid chromatography (GLC) profiles. The surface antigens of C. botulinum types C
and D and C. novyi type A are immunologically cross-reactive (Poxton, 1984;
Poxton and Byrne, 1984).
Group III organisms can only be identified to the species/toxin type level by
detection of the major toxin produced: type C and D neurotoxins for C. botulinum
types C and D respectively and the novyi alpha toxin for C. novyi type A. These
major toxins are each encoded on separate pseudolysogenic bacteriophages. The
phage-host relationship is consequently unstable and the phage is readily lost. A
cycle of phage loss and reinfection is thought to occur in vivo (Eklund and Poysky,
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1974). Repeated subculturing in the laboratory can predispose to loss of the phage.
Non-toxigenic Group III organisms are essentially indistinguishable from each other.
On the basis of 16S ribosomal RNA gene sequence analysis the group III strains,
including C. novyi, are grouped as a separate phylogenetic lineage (Hutson et al,
1993). However, there is some genetic diversity within the Group III strains. There
is approximately 99% 16SrRNA sequence similarity between types C and D
corresponding to 12 base mismatches and seven unmatched bases over 1500
nucleotides (Hutson et al, 1993). This 1% sequence divergence indicates genetic
heterogeneity and suggests that C. botulinum type C and D are different species
(Collins and East, 1998). There is approximately 38% chromosomal DNA
relatedness between these two organisms (Lee and Riemann, 1970). Analysis of
16S rRNA shows that C. novyi is also closely related to these organisms with
approximately 98% sequence similarity (Hutson et al, 1993); this difference is again
sufficient for C. novyi to be considered a different species. Analysis of DNA-DNA
homology in Group III strains, placed C. botulinum type C into two separate
genetically related groups and placed C. novyi type A into a third group (Nakamura
et al, 1983). Consequently if C. botulinum was reclassified and Group III became
one species, there would still be some genetic diversity within this species.
However, the organisms would be phenotypically very similar.
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1.2.4 Toxin production in Group III
Toxins produced by C. botulinum type C and D
C. botuiinum type C and D can produce up to three toxins: C1 (BoNT/C) or D
(BoNT/D) neurotoxin, C2, a binary ADP-ribosylating toxin, and C3, an exoenzyme
also with ADP-ribosylating activity. The C3 exoenzyme is encoded on the
bacteriophage together with BoNT/C or BoNT/D.
The C2 toxin is located on the bacterial chromosome and is produced by the
majority of type C strains and some type D strains, but not by other botulinum toxin-
producing organisms. The C2 toxin is produced only during sporulation and not
during vegetative growth; the highest titre of C2 toxin is detected in cultures
producing the most spores (Nakamura et al, 1978). The toxin has been extracted
from the spore coat suggesting it may be part of the spore structural proteins
(Yamakawa et al, 1983). C2 toxin production is not governed by the presence of
bacteriophages (Eklund and Poysky, 1974). However, it has been proposed that a
plasmid may be involved in mediating C2 toxin production as a derivative of a C2
producing type C strain was isolated that no longer produced the C2 toxin (Eklund et
al, 1987).
C. botulinum type C was first isolated in 1922 from the fly larvae of Lucilia caesar
(green bottle fly) obtained from a carcass of a chicken that had died from botulism in
the US (Bengston, 1922). It was also isolated from cattle in Australia in the same
year (Seddon, 1922). The organisms isolated from the two separate sources were
similar enough to be given the same toxin type. However, differences in the ability
of antitoxins to cross-neutralise the toxins from the two organisms led to the
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designations of subtypes Ca and Cp (Gunnison and Meyer, 1929). Anti-sera raised
against the Bengston strain cross-neutralised the Seddon strain, whereas antisera
raised against the Seddon strain only neutralised the homologous toxin. The
Bengston strain was designated as Ca and the Seddon strain as Cp. C. botulinum
type D was isolated from an outbreak of botulism in cattle in South Africa (Meyer
and Gunnison, 1928). Ca strains were said to produce a combination of BoNT/C,
C2 and BoNT/D, with type C1 as the dominant toxin, whereas Cp produced C2; type
D cultures were said to produce BoNT/D, BoNT/C and C2 toxins, with BoNT/D being
the dominant toxin (Jansen, 1971).
However, it has subsequently been shown that there are common epitopes in types
BoNT/C and BoNT/D toxins resulting in cross-neutralisation between the toxins
(Oguma et al, 1980; Oguma et al, 1981; Oguma et al, 1982; Oguma et al, 1984) and
therefore type C cultures do not produce BoNT/D, and type D cultures do not
produce BoNT/C. Different phages govern the production of BoNT/C and BoNT/D
(Oguma et al, 1981). The identification of these phages carrying the neurotoxin
genes has rendered the subtypes of type C obsolete; a Cp strain is one in which the
converting bacteriophage has been lost. C2-toxin producing strains of both C.
botulinum types C and D can potentially produce Cp strains if the converting phage
is lost.
BoNT/C and BoNT/D are closely related with 52.2% sequence identity (Sunagawa
et al, 1992). The toxins have antigenic sites that are common to both toxins as well
as antigenic sites specific for the toxin type (Moriishi et al, 1989; Oguma et al, 1984).
BoNT/C and BoNT/D have also been shown to have strain specific epitopes
(Moriishi et al, 1989; Oguma et al, 1984). The heterogeneity that exists in the type
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C and D neurotoxins has probably arisen from the mutation or recombination of
phage genomes that is thought to occur during the cycles of curing and reinfection
of type C and D strains in the environment (Sunagawa and Inoue, 1991).
C3 exoenzyme produced by C. botulinum types C and D can be divided into two
groups based on antigenicity (Moriishi et al, 1993). There is evidence to suggest
that the 21.5kbp DNA fragment encoding the C3 exoenzyme is a mobile genetic
element (Hauser et al, 1995) with similarities with the site-specific transposon family
of Tn554. It is thought that transposable elements may also be responsible for the
transfer of other botulinum toxin genes.
Toxins produced by Clostridium novyi
C. novyi is a heterogeneous group of organisms, classified into four types, A to D
based on the production of eight different soluble antigens (Table 1.3). Types A, B
and D are pathogenic, causing gas gangrene in man and animals, infectious
necrotic hepatitis in sheep and bacillary haemaglobinuria in cattle, respectively
(Smith, 1975a). Type C, however, does not produce any of the eight soluble
antigens and is not known to be pathogenic to laboratory animals. C. novyi type A
and B both produce the lethal alpha toxin; types B and D produce the lethal beta
toxin. The alpha and beta toxins are encoded by separate bacteriophages (Eklund
et al, 1976).
34
Table 1.3: Toxins produced by C. novyi types A, B and C and C. haemolyticum
(Hatheway, 1990)
Clostridium novyi
Toxin Activity Type A Type B Type C Clostridium
haemolyticum







Delta Oxygen-labile haemolysin + - -
Epsilon Lipase + - -
Zeta Haemolysin - + -
Eta Tropomyosinase - + +
Theta Opalescence in egg yolk - trace +
C. novyi type D is also considered as a different species - Clostridium haemolyticum
- due to the fact that it does not produce the alpha toxin and the disease it causes is
different from those caused by types A and B (Smith, 1975a). However, despite
these differences, the cultural characteristics of types B and D are very similar and
they both produce the beta, eta and theta toxins. The soluble cellular antigens of
types B and D are identical (Cato et al, 1982). DNA-DNA homology showed that C.
novyi type D and C. novyi type B form a genetically homologous group (Nakamura
et al, 1983). On this basis it appears that C. haemolyticum should be considered as
C. novyi type D.
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1.2.5 Bacteriophages and Group III
Pseudolysogenic phage and C. botulinum types C and D
Although phages have been identified in Groups I, II and III, they have only been
associated with toxigenicity in Group III (Eklund et al, 1989). Production of
neurotoxins by C. botulinum type C and D is governed by the presence of specific
converting bacteriophages (Inoue and lida, 1970; Inoue and lida, 1971; Eklund et al,
1971; Eklund et al, 1972). Loss of the bacteriophage is associated with a loss of
toxigenicity and sensitivity to reinfection by the converting phage. Non-toxigenic
isolates of toxigenic parent strains could be reinfected with the converting phage
resulting in a return to toxigenicity. (Eklund et al, 1971; Eklund et al, 1972). Loss of
toxigenicity, in the absence of converting phage, was a stable and permanent state
(Eklund et al, 1971). The gene for BoNT/C is encoded on a separate phage to the
gene for BoNT/D.
These converting phages are thought to be pseudolysogenic because the host-
phage relationship is unstable and the phage readily lost from the host cell.
Nontoxigenic Clostridia resembling C. botulinum have frequently been isolated from
the environment and toxigenic cultures can become nontoxigenic in the lab (Eklund
et al, 1987). This suggests that the phage is not stably integrated into the host
chromosome. Bacterial cells can be cured of the converting phage by either
ultraviolet irradiation or acridine orange (Eklund et al, 1971); ultraviolet irradiation is
a standard method for curing bacteria of lysogenised prophages and acridine
orange has been used to remove extrachromosomal elements from bacteria. As
both methods cure C. botulinum type C and D of the converting bacteriophage, this
has been taken as further evidence of pseudolysogeny (Eklund et al, 1971).
Subculture of bacteria in the presence of phage specific antiserum also results in
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curing, supporting a pseudolysogenic relationship between phage and host (Eklund
et al, 1971). Although loss of phage also occurs spontaneously during subculturing,
a higher number of nontoxigenic strains are isolated in the presence of anti-phage
serum (Oguma, 1976). This suggests that in the absence of anti-phage serum,
nontoxigenic strains can be reinfected by free converting phages present in the
culture media. Heat treatment of spores of toxigenic strains also resulted in non¬
toxigenic isolates (Eklund et al, 1972).
Interconversion of C. botulinum type C and D by bacteriophage
C. botulinum types C and D have been shown to be interconvertible (Eklund and
Poysky, 1974). Loss of the converting phage from these bacteria renders them
indistinguishable from each other. The non-toxigenic derivative strains of C.
botulinum type C could be infected with a converting phage from a C. botulinum type
D strain, resulting in production of BoNT/D and essentially changing the non¬
toxigenic C. botulinum type C into a toxigenic type D. The non-toxigenic derivative
of a C. botulinum type D could also be infected with a type C converting phage
resulting in production of BoNT/C. Infection with different specific converting phages
effectively changed the toxin type of C. botulinum.
Interconversion of toxin types was demonstrated both between strains that were C2
toxin producers and between strains that were not (Eklund and Poysky, 1974).
However, in the non-C2 producing strains, the type C strains when cured could be
infected by either the type C phage or the type D phage, but the type D strains could
only be reinfected by the homologous phage. Cultures infected with type C phages
were immune to infection with type D phages and vice versa indicating the
antigenically relatedness of the phage (Eklund et al, 1987). It has been proposed
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that interconversion between type C and D strains could occur in nature due to the
pseudolysogenic state: nontoxigenic strains could be converted to type C or D by
different converting phages.
These results suggest that types C and D can arise from a common nontoxigenic
strain. However, genetic differences based on the 16S rRNA gene sequence
suggests that C. botulinum type C and D are different species (Hutson et al, 1993).
This observation was based on the comparison of only one strain of C. botulinum
type C and one strain of C. botulinum type D. Therefore it is possible that these
genetic differences may also be observed within strains designated type C or type D
if more strains were investigated. Genetic heterogeneity has been demonstrated
within C. botulinum type C strains (Nakamura et al. 1983).
Phages and C. novyi toxins - interconversion of toxin types
The lethal alpha and beta toxins produced by C. novyi types A, B and D are
encoded by pseudolysogenic bacteriophages (Eklund et al, 1976). A C. novyi type
B strain that has lost the phage encoding the alpha toxin resembles a C. novyi type
D strain. A phage has been isolated from a C. novyi type A strain that can infect a
C. novyi type D strain, converting it to alpha toxin production and essentially
converting the organism to C. novyi type B strain (Schallehn and Eklund, 1980).
However, a phage carrying the alpha toxin gene that can infect both type A and B
strains has not yet been isolated.
C. novyi type A when cured of the alpha toxin phage continues to produce the
gamma and epsilon toxins; C. novyi type B when cured of the alpha toxin phage
continues to produce the beta toxins (Eklund et al, 1976). Whilst the gamma toxins
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and beta toxins are both lecithinases, they are immunologically distinct, moreover,
the epsilon toxin is a lipase enabling differentiation between type A and B by the
opalescence produced by colonies of the former and not by the latter on egg yolk
agar plates. The production of the gamma toxin (lecithinase) and epsilon toxin
(lipase) by C. novyi type A results in the close resemblance of the cultural
characteristics of this novyi type with C. botulinum types C and D. In fact the epsilon
toxin is shared in common with botulinum types C and D (Hatheway, 1990).
Therefore, when C. novyi type A loses the phage for the alpha toxin it phenotypically
resembles C. botulinum type C and D, whereas when C. novyi type B lose the
phage for the alpha toxin it phenotypically resembles C. novyi type D. It has been
suggested that C. novyi type D is a subtype of type B (Oakley et al, 1947).
Analysis of DNA-DNA homology demonstrated that: C. novyi type B and D are
genetically more closely related to C. botulinum type C than to C. novyi type A
(Nakamura et al, 1983). C. haemolyticum has been shown to have 99.3% 16S
rDNA sequence similarity with C. botulinum type C and D (Stackebrandt et al, 1999).
This suggests that while C. novyi type A is phenotypically similar to C. botulinum
type C, it appears that that C. novyi type B and D are genotypically more similar to
C. botulinum type C.
Species interconversion between C. botulinum and C. novyi by phage
The main phenotypic difference between C. botulinum types C and D and C. novyi
type A is toxin production. Loss of the specific phage carrying the relevant toxin
gene by any of these three organisms results in non-toxigenic strains that are
essentially indistinguishable from each other. It has been shown that interspecies
conversion can also occur between C. novyi and C. botulinum by infection with the
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relevant specific converting bacteriophage (Eklund et al, 1974). A non-toxigenic
derivative of a toxigenic C. botulinum type C could be infected with a phage from a
toxigenic C. novyi type A resulting in production of novyi alpha toxin by a strain that
was originally producing type C neurotoxin; the nontoxigenic derivative could also be
converted to C. botulinum type D by infection with a type D converting phage. The
phage could be carried through the spore state. When the strain was infected with
either the type C or type D phage it was immune to infection by both the type C and
D phages but continued to be sensitive to infection with the novyi alpha phage.
Consequently the strain could simultaneously produce botulinum and novyi toxins.
When the organism was infected both by the novyi phage and the type C or D
phage, both phages were often carried through the spore state but one of the
phages was frequently lost on subculture (Eklund et al, 1987). On the basis of these
findings it has been suggested that a common bacterial strain could exist in nature,
with the infecting phage governing toxigenicity and therefore the resulting disease
(Eklund et al, 1974).
The parent strain of the nontoxigenic derivative that was used in this interconversion
study was isolated from a broiler chicken from an outbreak of botulism and identified
as C. botulinum type C on the basis of the production of the type C neurotoxin
(Roberts et al, 1973). However, the nontoxigenic derivative strain was found to
produce the gamma toxin of C. novyi type A. On this basis it was thought that the
strain involved in the botulism outbreak could have been a C. novyi type A strain in
nature before being infected with the type C phage; the organism may have
produced both the novyi alpha toxin and the type C toxin in nature with loss of the
alpha toxin phage occurring before or during isolation and subculture in the
laboratory (Eklund et al, 1987).
40
Antigenicity and stability ofphage
The type C and D converting phages, share similar biological and biophysical
properties, have similar physiochemical characteristics and close DNA homology
and are thought to form a phage family (Sunagawa and Inoue, 1992). However,
these converting phages are heterogeneous and have been divided into four groups
according to the spectrum of host cells infected and antigenicity of the phage
(Oguma et al, 1976; Sunagawa and Inoue, 1991). This classification is similar to
that derived from the antigenic structures of the toxin themselves (Oguma et al,
1986). Conversion to toxigenicity therefore occurs only with specific phages and
bacterial hosts. Other phages have been isolated from C. botulinum type C, D and
C. novyi type A strains that do not convert nontoxigenic strains to toxin production
(Eklund et al, 1987; Sunagawa and Inoue, 1991). Strains of C. botulinum type C
have been found to carry the converting phage and/or the non-converting phage.
The non-converting phages are identical in their antigenicity and host specificity, are
smaller than the converting phages and do not determine toxigenicity of the host
organism (Sunagawa and Inoue, 1991).
Some strains differ in their stability of toxin production, due to varying instabilities of
the pseudolysogenic phage. Loss of toxigenicity is observed at different rates with
different combinations of phage and host (Oguma, 1976). It has been shown that
the toxigenicity can vary depending on the passage history of the particular phage,
with the converting ability of phage decreasing after many propagations through a
strain (Oguma and lida, 1979). Incubation of cultures at 37°C selected virulent
mutants of converting phage that lacked the ability to pseudolysogenise bacteria,
inducing lysis of their host cells (Eklund et al, 1987).
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Strains of type C isolated from areas where avian botulism is enzootic can differ
greatly in their toxigenicity (Jensen and Allen, 1960, cited in Wobeser, 1987).
Certain environmental conditions may predispose to instability of the phage-
bacterium relationship thereby influencing the epidemiology of disease caused by
type C botulinum such as avian botulism (Hariharan and Mitchell, 1976). Avian
botulism outbreaks rarely occur in areas of high alkalinity but often occur in areas of
moderate to low alkalinity such as in the marshes near the mouths of rivers
(Kalmbach et al, 1934, cited in Eklund et al, 1987). High salt concentrations inhibit
the multiplication of C. botulinum type C (Eklund et al, 1987), but low concentrations
of salt increase both the rate of infection of C. botulinum type C by phage and the
stability of this phage-host relationship (Eklund and Poysky, 1974). This may result
in the increase in the number of toxigenic C. botulinum type C found in peripheral
areas of salt flats where a diluted salt concentration is found. These areas are often
associated with outbreaks of avian botulism (Eklund et al, 1987).
Flies, maggots and invertebrate carcasses have been implicated in avian botulism
and may act as reservoirs of toxigenic bacteria and/or free converting phages
capable of converting nontoxigenic strains to toxigenic forms (Hariharan and
Mitchell, 1976). Reservoirs of spores carrying converting phages are found in areas
where avian botulism is endemic; toxigenic bacteria and phages can also be
transferred by migrating birds, winds and floods (Eklund et al, 1987). It has been
shown that many different C. botulinum type C strains carry phages that are capable
of converting strains from geographically distant sources (Eklund et al, 1987),
suggesting that this can and does occur in nature. The presence of specific
converting bacteriophages, governs the pathogenicity of disease caused by the
Group III botulinum organisms. C. botulinum types C and D cause botulism through
the action of the types C and D neurotoxins respectively, whereas C. novyi type A
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causes gas gangrene through the action of the alpha toxin. These bacteriophages
also define the identity of the organism.
1.3 Toxin action and role in pathogenesis
The catalytic modes of action of BoNT/C, C2, C3 and novyi alpha toxins are well
defined at the intracellular level due to their use as biological tools to study
neuroexocytosis, the actin cytoskeleton and the involvement of Rho GTPases in
eukaryotic signal transduction cascades. However, less is known about these
toxins with respect to receptor binding and cell entry. Consequently the role in
pathogenesis of disease is less well established than their catalytic action, for some
of these toxins.
1.3.1 Botulinum neurotoxin
Botulinum neurotoxins inhibit the release of the neurotransmitter acetylcholine from
cholinergic synapses. The neurotoxin is synthesised as a single inactive 150kDa
polypeptide chain that is cleaved by bacterial or host proteases to produce the
dichain, covalently linked by a single disulphide bond. The dichain is composed of a
heavy chain (100kDa) and a light chain (50kDa). Determination of the
crystallographic structure of the neurotoxin (type A) has confirmed the presence of
three functionally distinct domains (Lacy et al, 1998) that had previously been
proposed from biochemical data (Montecucco and Schiavo, 1993) (Fig. 1.2).
Botulinum neurotoxins have been proposed to act by way of a four-step model
(Montecucco and Schiavo, 1994; Montecucco, Papini and Schiavo, 1994), involving
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(1) cell binding, (2) internalisation, (3) membrane translocation and (4) target
modification in the cytosol. Whilst the intracellular action of the toxins has been well






Figure 1.2: Schematic structure of botulinum neurotoxin, showing the three
functionally distinct domains (adapted from Oguma et al, 1995).
L=light chain,
Hn = N-terminal end of heavy chain
Hc = C-terminal end of heavy chain.
Progenitor toxin
The neurotoxin is produced in a stable complex termed progenitor toxin. There are
three forms of the complexes, ranging in size from 300-900kDa (with sedimentation
constants of 12S, 16S and 19S) (Schiavo et al, 2000). BoNT/C and BoNT/D form
both 12S and 16S complexes (Ohishi and Sakaguchi, 1980). The 12S complex
consists of the neurotoxin and a non-toxic non-haemagluttinin component (NTNH);
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the 16S toxin consists of the neurotoxin, a NTNH component and a haemagglutinin
component in the ratio 1:1:2 (Fujinaga et al, 1997). The genes encoding the
haemagglutinin and NTNH component are encoded immediately upstream of the
neurotoxin gene (Hauser et al, 1995).
There is evidence of gene recombination due to the observation of chimera-like or
mosaic non-toxic-non-haemagglutinins (NTNH); the phylogeny of the NTNHs is not
the same as that of the botulinal toxins despite their genes being contiguous (Collins
and East, 1998). The non-toxic components associated with the BoNT/C and
BoNT/D are reported to be identical in their antigenicity (Oguma et al, 1980) and
nucleotide sequence (Inoue et al, 1999), whilst the neurotoxins are antigenically
distinct.
The non-toxic components are thought to be important in the pathogenesis of
botulism as they protect the neurotoxin from proteases and acidity in the Gl tract
(Ohishi and Sakaguchi, 1980). The larger the progenitor complex, the higher the
oral toxicity.
Neurotoxin Binding
The most common route of entry for botulinum toxin is via the Gl tract, either
through ingestion of preformed toxin or production of toxin in the Gl tract. There are
two stages of binding before botulinum toxin in the Gl tract can cause neurotoxicity.
First, the toxin must leave the Gl tract and enter the circulation, secondly, the
neurotoxin must bind to the presynaptic nerve terminal.
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Binding to intestinal epithelium
The HA component of the 16S type C progenitor toxin has been shown to bind to
glycolipids or glycoproteins in guinea pig small intestine (Fujinaga et al, 1997). It
has been shown that 16S type C and D toxins bind to sialylglycolipids and
sialoglycoproteins but not neutral glycolipids or asialoglycoproteins (Inoue et al,
1999). Neither the type C neurotoxin, nor the NTNH component bound to the small
intestine (Fujinaga et al, 1997). The neurotoxin did not dissociate from the 16S
complex in the intestine. It is now thought that the 16S complex has greater oral
toxicity than the 12S complex or 7S (neurotoxin alone) due to a higher binding
affinity for the intestinal epithelial cells (Fujinaga et al, 1997). The 16S type C
complex has been shown to bind to peptidoglycan of certain C. botulinum type C
strains at pH2 and this cell-bound form was shown to have higher oral toxicity in
chickens than the cell-free form (Hyun and Sakaguchi, 1988; Hyun and Sakaguchi,
1989).
Botulinum toxins are thought to cross the intestine by transcytosis (Maksymowych
and Simpson, 1998). Human intestinal cells bound and transcytosed BoNT/A and
BoNT/B in a functionally active form, but BoNT/C toxin was not efficiently
transcytosed. The lack of an efficient mechanism for transcytosis for BoNT/C in
human intestinal epithelial cells may explain why type BoNT/C is not associated with
human cases of botulism (Maksymowych and Simpson, 1998). However,
uncomplexed toxin was used - the 16S form may bind to human cells. Uptake by
M cells has not been excluded as a mechanism of entry into the circulation (Schiavo
et al, 2000).
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Binding to the presynaptic nerve terminal
BoNT/C has been shown to bind to both cholinergic and adrenergic cells in vitro
(Yokosawa et al, 1989; Kurokawa et al, 1987). BoNT/C bound with higher affinity to
neuroblastoma cell lines of mouse origin compared to those of human origin
(Yokosawa et al, 1989). The heavy chain is associated with binding (Yokosawa et
al, 1989; Agui et al, 1983).
The C terminal domain of the heavy chain (Hc) has been implicated in neurospecific
binding (Schiavo et al, 2000). This C terminal domain is composed of two distinct
subdomains HCN and HcC. The HCN is highly conserved between the botulinum
toxins and there are structural similarities between this subdomain and carbohydrate
binding proteins (Schiavo et al, 2000). The HcC domain is poorly conserved
between the neurotoxins and is required for binding. A double receptor model for
binding of neurotoxins to the presynaptic nerve terminal has been proposed,
involving a polysialoganglioside receptor that is similar for the different neurotoxins,
and a glycoprotein receptor that is specific for the different neurotoxins (Schiavo et
al, 2000). Preincubation of botulinum toxins with gangliosides can inhibit binding;
the degree of inhibition varies with different gangliosides. GT1b binds to botulinum
neurotoxins causing loss of toxicity irrespective of toxin type (Kozaki et al, 1984).
However, binding of BoNT/C is also completely inhibited by pre-treatment of cells
with neuraminidase, trypsin or pronase implicating a glycoprotein containing sialic
acid as a receptor for BoNT/C (Yokosawa et al, 1989).
Internalisation
Internalisation of botulinum neurotoxin into vesicles is temperature and energy
dependent (Black and Dolly, 1986). Receptor mediated endocytosis via clathrin
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coated pits is proposed to be the mechanism of internalisation (Niemann, 1991).
The Hc domain has been shown to be sufficient for internalisation (Schiavo et al,
2000).
Membrane translocation
The light chain has to enter the cytosol to reach its intracellular substrate, and
therefore must be able to leave the compartment in which it has been internalised.
It is thought that this stage is brought about by acidification of the vesicle, with the
low pH inducing a conformation change in the structure of the toxin, enabling
penetration of both the H and L chains into the hydrocarbon core of the vesicle
membrane. The neurotoxins have been shown to form pH-dependent and voltage-
dependent channels in planar lipid bilayer membranes (Donovan and Middlebrook,
1986); the N terminal of the heavy chain is involved in the formation of channels
(Blaustein et al, 1987). Translocation of the L chain across the membrane is
followed by refolding in the cytosol (Schiavo et al, 2000).
Intracellular action
The botulinum neurotoxins are zinc dependent metalloproteases with the ability to
cleave, at specific sites, the protein components involved in neuroexocytosis
(Schiavo et al, 1992; Schiavo et al, 1993a; Schiavo et al, 1993b; Blasi et al 1993a;
Blasi et al, 1993b). BoNT/C cleaves syntaxin (Blasi et al, 1993b, Schiavo et al,
1995) and SNAP-25 (Williamson et al, 1996; Foran et al, 1996; Osen-Sand et al,
1996). BoNT/D cleaves synaptobrevin/VAMP (vesicle associated membrane
protein) (Schiavo et al, 1993b). The light chain contains the zinc-binding motif
HEXXH; zinc plays a central role in peptide bond hydrolysis (Schiavo et al, 1993c).
48
The toxins cleave a single site in their target proteins resulting in sustained blockage
of neurotransmitter release.
Syntaxin and SNAP-25 are bound to the presynaptic membrane, and
synaptobrevin/VAMP is a synaptic vesicle membrane protein. Together these three
proteins form the synaptic SNARE complex, the core of the neuroexocytosis
apparatus. These three proteins act as v-SNARES and t-SNARES and interact with
the soluble factors NSF (N-ethylmaleimide-sensitive protein), and a/p and y SNAPS
(soluble NSF fusion protein) to bring about membrane fusion and exocytosis
(Sollner et al, 1993) (Fig. 1.3). This complex has high structural stability and when
assembled, the proteins are resistant to the action of the neurotoxins (Hayashi et al,
1994).
It is thought that the neurotoxins recognise their substrate through a double
recognition process; they recognise the substrate by interaction with a region A, a
structural motif which is common to all three toxin targets, and region B which
contains the peptide bond to be cleaved (Rossetto et al, 1994). This explains the
observation that short peptides containing only the cleavage site are not cleaved
(Montecucco and Schiavo, 1994), and why only one of several identical peptide
bonds in the protein are cleaved by the toxin. The structural motif common to all
three toxin targets is the SNARE motif, consisting of nine amino acid residues











Figure 1.3: Schematic diagram showing the proteins of the proposed
neuroexocytosis apparatus involved in vesicle docking and fusion, and the targets of
the botulinum neurotoxins (adapted from Oguma et al, 1995).
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Cytotoxicity of type C toxin
BoNT/C is severely cytotoxic in vitro to murine spinal cord neurones (Kurokawa et
al, 1987; Williamson et al, 1995; Williamson and Neale, 1998), and rat hippocampal
and cortical neurons (Osen-Sand et al, 1996). This cytotoxicity is unique to the
BoNT/C toxin; the other clostridial neurotoxins block neurotransmission, but only the
BoNT/C can cause overt neuronal degeneration (Williamson et al, 1995). BoNT/C is
cytotoxic to both mature and developing neurons in vitro (Williamson and Neale,
1998). Primary neuronal cultures incubated with BoNT/C showed a loss of normal
structures after 48 hours with accumulation of degenerated mitochondria,
membranous dense bodies and vesicles; the neuronal somas were spherical with
distorted nuclei and loss of Nissl bodies (Kurokawa et al, 1987). The ultrastructural
changes are similar to the axon reaction i.e. retrograde degeneration, in vivo,
therefore BoNT/C might disturb axonal flow resulting in degeneration. In mature
cultures the synaptic terminals first became enlarged, shortly after exposure to
BoNT/C and this was followed by the degeneration of axons, dendrites and cell
bodies (Williamson and Neale, 1998). It is thought that the neuronal death is
mediated by the effect of BoNT/C on syntaxin in the synapse.
Syntaxin is the intracellular target for BoNT/C but not for the other botulinum
neurotoxins. Consequently, BoNT/C has been used to show that syntaxin is
essential for neuronal survival and development (Williamson et al, 1995; Kurokawa
et al, 1987; Igarashi et al, 1996). The intracellular targets of the botulinum
neurotoxin, are conserved within neuronal synapses, and therefore as would be
expected, botulinum neurotoxins can inhibit other neurotransmitters besides
acetylcholine in vitro (Williamson and Neale, 1998; Mackenzie et al, 1982; Foran et
al, 1996; Bigalike and Habermann, 1981; Sugiyama, 1980). It is therefore possible
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that BoNT/C can cause damage to a wide range of neurons in vivo. However, the
BoNT/C has not been shown to cause loss of motor neurons in humans when used
to treat dystonias (Eleopra et al, 1997).
Botulinum neurotoxins in disease
Botulism can occur in three forms: classical botulism and two forms of
toxicoinfectious botulism. Classical botulism is caused by the ingestion of
preformed toxin, whereas toxicoinfectious botulism results from absorption of toxin
that has been produced in vivo following colonisation of the intestinal tract or a
wound with C. botulinum. This latter form, wound botulism, is relatively rare; the
main route of exposure to botulinum toxin is via the Gl tract.
Botulinum types A, B, E and F are mainly but not exclusively associated with
botulism in humans, while types C and D affect only animals (Rocke, 1993). There
have been very few reports of botulism in humans caused by type C: two human
cases in USSR in the 1960s (Matveev et al, 1966 cited in Jensen and Price, 1987),
a case in France (Meyer et al, 1953 cited in Jensen and Price, 1987) and a case in
the US (Prevot et al, 1955, cited in Jensen and Price, 1987). However, these cases
were not well substantiated (Holdemann, 1970). It is not known why type C rarely
causes botulism in humans. BoNT/C can cleave recombinant human syntaxin and
block neurotransmitter release from isolated human neuromuscular junctions
(Coffield et al, 1997). It has been proposed that the human Gl tract does not have
receptors for BoNT/C thereby preventing translocation into the circulation
(Maksymowych and Simpson, 1998). However, a lack of exposure to this toxin by
humans may also account for the absence of disease caused by this toxin type.
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Botulism has been documented in most domestic animals and avian species;
Outbreaks of botulism most frequently affect birds (Lamanna, 1987), and C.
botulinum type C is responsible for the majority of cases of botulism in birds both in
the wild and in commercial flocks, despite birds being susceptible to all types of
botulinum toxins. Outbreaks of type C botulism have also been reported in mink,
ferrets, pigs, cattle, dogs and horses (Mitchell and Rosendal, 1987). There is
variability between species in susceptibility to the botulinum toxins; horses are more
susceptible to botulism than other species, such as cattle, dogs or humans (Lewis
and Metzger, 1980, cited in Whitlock and Buckley, 1997).
Foodborne botulism - Ingestion of preformed toxin
Foodborne botulism is the classical form of the disease and is caused by the
ingestion of pre-formed toxin that has been produced in food. The aetiology of
botulism was identified in 1895 by van Ermengem after the investigation of an
outbreak in Belgium caused by salt-cured uncooked ham (van Ermengem, 1897
cited in Hatheway, 1989). Botulism in humans is relatively rare and has traditionally
been associated with the consumption of home-canned/processed low acid
vegetables (MacDonald et al, 1986). There were 124 reported outbreaks between
1976-1984 in the US with a mean number of 2.7 cases per outbreak (MacDonald et
al, 1986). The disease is more common in animals and this is probably due to an
increased consumption of spoiled foodstuffs that would not be consumed by
humans.
Rotting carcasses, vertebrate and invertebrate, are one of the most common
sources of botulinum toxin for animals and birds. Sarcophagous maggots from
these carcasses, containing pre-formed toxin, can be a significant source of toxin for
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birds (Mitchell and Rosendal, 1987). Maggots from putrefying carrion have been
shown to contain high concentrations of BoNT/C (Haagsma, 1973 cited in Haagsma,
1987). High levels of BoNT/C have been shown to persist over the winter in
sarcophagous larvae and pupae of blow flies collected from carrion, providing a
source of toxin for a potential outbreak of avian botulism in the spring (Hubalek and
Halouzka, 1991).
Death of an animal from botulism without removal of the carcass provides a further
source of contamination; C. botulinum is thought to invade the tissues from the gut,
post-mortem. High levels of BoNT/C were detected for at least 28 days in
carcasses of mice incubated at 23°C (Smith and Turner, 1987); the mice had been
inoculated with type C spores just before death. Higher levels of BoNT/C and
BoNT/D have been experimentally induced in mouse carcasses compared to
BoNT/A, BoNT/B and BoNT/E (Ortiz and Smith, 1994a; Smith and Turner, 1987;
Smith and Turner, 1988). This may account for the observation that botulism in
animals is usually caused by C. botulinum types C and D.
Landfill sites have been shown to be a potential source of botulism for gulls that are
notorious for their scavenging feeding habits (Ortiz and Smith, 1994b). Spores of C.
botulinum types B, C and D were each found in 63% of landfill sites examined (Ortiz
and Smith, 1994b). It is thought that the gulls themselves are probably responsible
for contamination of the landfill sites through the carriage of spores in their
alimentary tracts (Ortiz and Smith, 1994b).
In domestic animals, botulism caused by the ingestion of preformed toxin is often
called 'forage poisoning' as it is associated with the consumption of contaminated
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feed. The source of contamination is often carrion. Forage poisoning in horses is
usually due to type C in Northern Europe, whilst in North America it is usually
caused by type B. There are subtle differences in the clinical signs of botulism




Toxicoinfectious botulism is caused by intestinal colonisation with C. botulinum with
production of toxin in the Gl tract. Infant botulism was first recognised in 1976
(Midura and Arnon, 1976) and is now the most common form of botulism in the US
(Hatheway, 1990). Toxin-producing C. botulinum colonises the Gl tract of infants
less than one year and absorption of the toxin results in flaccid paralysis. It is
thought that the lack of an established normal gut flora permits germination of
spores and growth of C. botulinum in the Gl tract. Honey contaminated with spores
of C. botulinum type B has often been implicated in many cases of infant botulism
caused by type B (Arnon et al, 1979).
Intestinal colonisation with C. botulinum in adults does occur but is extremely rare
and always associated with an altered Gl environment, for example after surgery or
antibiotic usage (Chia et al, 1986). The presence of C. botulinum in the healthy Gl
tract is transient and C. botulinum is not considered to be part of the normal human
flora (Dezfulian, 1989). Both in infant botulism and in adult intestinal colonisation
the organism and toxin have been demonstrated in the faeces long after the patient
has recovered and symptoms gone (Hatheway, 1979; McCroskey and Hatheway,
1988).
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'Shaker foal syndrome' is a toxicoinfectious form of botulism that occurs in foals
between two weeks and eight months of age, and is usually due to type B. It is
thought that spores are ingested from the soil and are able to germinate and
colonise the foal's Gl tract due to the presence of an immature flora. The toxin is
produced in necrotic lesions in the Gl tract; high levels of corticosteroids in the
mare's milk may play a role in the pathogenesis of this disease (Swerczek, 1980a;
Swerczek, 1980b). Unlike in infant botulism, the toxin is only detected in the foal's
faeces during the acute clinical phase of the disease. Cases of adult
toxicoinfectious botulism in the horse have not been documented (Whitlock and
Buckley, 1997).
Toxico-infection with C. botulinum type C can occur in outbreaks of botulism in
broiler chickens (Eklund et al, 1987). The high-energy diet of these broiler chickens
is thought to enhance both the rate and amount of toxin produced in the Gl tract
(Eklund et al, 1987). Toxigenic and non-toxigenic C. botulinum type C strains have
been isolated from the poultry litter; this litter is thought to be a source of intestinal
infection for the chickens (Eklund et al, 1987). Poultry litter, either fed to cattle or
used for the fertilisation of fields, has been the source of outbreaks of type C
botulism in cattle (Ortolani et al, 1997; McLoughlin et al, 1988); carcasses and
spores present in the litter are the sources of contamination.
Wound botulism
Wound botulism was first identified in 1943 when C. botulinum type A was
recovered from an infected wound from a patient who had died of flaccid paralysis
(Davis et al 1951, cited in Hatheway, 1990). Wound botulism is the least common
form of botulism. Only 16 cases were reported between 1976 and 1984 in the US. It
occurs when a wound becomes infected with C. botulinum, and the neurotoxin that
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is subsequently produced enters the circulation causing botulism. The clinical
symptoms of the disease are the same as those caused by ingestion of preformed
toxin. Recently wound botulism has been associated with IV drug abuse
(Macdonald et al, 1985).
1.3.1. Toxins that affect the cytoskeleton
The C2 toxin, C3 exoenzyme and the C. novyi alpha toxin all affect the actin
cytoskeleton, causing a characteristic "rounding-up" of cells in vitro. Whilst this
cytopathic effect is essentially indistinguishable, these toxins are structurally
unrelated and functionally have very different mechanisms of action (Figs. 1.4 and
1.5).
C2 toxin
C2 toxin ADP-ribosylates the G-actin form of p/y cytoplasmic and y smooth muscle
actin (Mauss et al 1990), resulting in the depolymerisation of the actin microfilament
network. C2 is a binary toxin composed of two separate components C2I and C2II
(Aktories et al, 1992a). However, the functional interaction of these components is
required for toxicity. C2I (50kDa) contains the ADP-ribosyltransferase activity; C2II
(100kDa) is responsible for binding to the host cell (Ohishi and Miyake, 1985, cited
in Aktories and Wegner, 1989).
The C2 toxin belongs to a class of actin-specific mono-ADP-ribosyltransferases that
includes the Clostridium perfringens iota toxin, Clostridium spiriforme toxin and
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Figure 1.4: Toxins that act on the cytoskeleton. Structural and functional domains
of (a) C2 toxin, (b) C3 exoenzyme and (c) C. novyi alpha toxin (adapted from Busch












Figure 1.5: Modification of Rho by (a) C3 exoenzyme and (b) C. novyi alpha toxin





C3 exoenzyme is encoded on the same bacteriophages as BoNT/C and BoNT/D
(Popoff et al, 1990). The exoenzyme is a separate protein of 25kDa produced
together with the neurotoxin (Aktories and Hall, 1989).
The C3 exoenzyme belongs to a group of toxins classified as the C3 exoenzyme
family that includes toxins of Clostridium limosum and Bacillus cereus (Aktories et
al, 1992b) and the epidermal differentiation inhibitor (EDIN) produced by
Staphylococcus aureus (Sugai et al, 1990). The C3 exoenzyme family are all
approximately 25kDa in size, with 30-70% amino acid sequence identity and ADP-
ribosylate the small molecular mass Rho GTPases (Aktories, 1997).
C3 exoenzyme does not appear to have domains for binding or membrane
translocation; purified C3 is not able to enter most intact cells (Aktories and Hall,
1989). Therefore, despite the potent catalytic activity observed in vitro when
introduced artificially into a cell, it is debatable whether the enzyme has toxic effects
in vivo.
C. novyi alpha toxin
The C. novyi alpha toxin has been classified as a large clostridial cytotoxin (LCT);
this group also includes Clostridium difficile toxins A and B, and the haemorrhagic
and lethal toxins of Clostridium sordellii (Bette et al, 1991). These toxins are high
molecular weight single-chain molecules (250-300kDa) that glycosylate the low
molecular weight GTP binding proteins of the Rho subfamily. There is 32-76%
amino acid sequence homology between the LCTs (Busch and Aktories, 2000).
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The novyi alpha toxin is a 250,166 Da protein (Hofmann et al, 1995) with 48% amino
acid sequence homology with the C. difficile toxins A and B. A wide range of
mammalian cells have been shown to be susceptible to these toxins in vitro. The
toxin is thought to be composed of three functional domains: the N-terminal domain
involved in catalytic activity, a central hydrophobic domain involved in membrane
translocation and a C-terminal domain involved in cell binding (Von Eichel-Streiber
et al, 1996).
Cell binding
Binding of C2 toxin
Proteolytic activation of the C2II domain is essential for C2 binding and uptake by
cells. Trypsin cleaves a 20kDa peptide from the N-terminus of C2II resulting in an
active form that oligomerises, forming predominantly heptamers (Barth et al, 2000).
Whole C2II (i.e. not trypsinised) does not from oligomers. The C-terminus (amino
acid residues 592 to 721) of the C2II domain is involved in binding to the cell surface
(Blocker et al, 2000); binding of C2II was blocked both by an antibody against the C-
terminus and truncation of this region. The site for receptor binding that is formed
after oligomerisation of C2II may be stabilised by the seven C-terminal amino acids,
as deletion of these residues also blocks binding (Blocker et al, 2000).
Activated (trypsinised) C2II binds to asparagine-linked complex carbohydrates as
determined through the investigation of a CHO (Chinese hamster ovary) cell mutant
that was resistant to C2 toxin. The cell line was found to be deficient in N-
acetlyglucosaminyltransferase I (Eckhardt et al, 2000). This defect prevented the
cells from making N-linked complex and hybrid carbohydrates. Restoration of N-
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acetlyglucosaminyltransferase I, through transfection of the gene, made the cells
sensitive to the C2 toxin (Eckhardt et al, 2000). The p-1,2-GlcNAc linked to the a-
1,3-mannose of the asparagine-linked core structure was found to be essential for
the binding of C2II to the CHO cells.
Although there are sequence homologies between the C2 toxin and other ADP-
ribosylating toxins, there are no sequence similarities in the C-terminal domain of
these toxins indicating different receptor binding. It is not known whether a protein
receptor is also required for cell binding. There is evidence for the involvement of a
carbohydrate receptor alone; no naturally C2 toxin-resistant cell line has been found
suggesting that the C2 receptor is ubiquitously expressed (Eckhardt et al, 2000).
The 225-amino acid N-terminal part of C2I is responsible for the contact of C2I with
a docking site on C2II (Barth et al, 1998a). This docking site is formed after binding
of the C2II to the cell surface receptor. Construction of a fusion protein of the N-
terminal 225 amino acid residues of C2I with a C3-like Rho-ADP-ribosylating toxin
from C. limosum enabled both translocation and intracellular cytotoxicity when the
chimeric protein was applied with C2II to cultured cells.
Binding of C. novyi alpha toxin
Clostridial repetitive oligopeptides (CROPs) have been identified in the C-terminal
domain of the large clostridial cytotoxins (Hofmann et al, 1995). CROPs consist of
20-50 amino acids that are repeated 14-30 times and function as ligands, forming
multivalent receptor binding domains and enabling multiple interactions with a
potential receptor (von Eichel-Streiber et al, 1996). Lectin-like binding has been
described for C. difficile toxin A, but nothing is known of the receptors for the other
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LCTs including C. novyi (Busch and Aktories, 2000). However, there is sequence
homology between the CROPs of the LCTs (von Eichel-Streiber et al, 1996). The C.
novyi alpha toxin is thought to act ubiquitously against mammalian cells (Ball et al,
1993) suggesting the presence of a ubiquitous receptor.
Cell entry - Internalisation and membrane translocation
C2 toxin
C2 toxin enters cells by receptor-mediated endocytosis (Simpson, 1989). It is
thought that the C2 toxin enters the cytosol from an acidified endosomal
compartment. Bafilomycin A1, a fungal metabolite that prevents acidification of
endosomal vesicles through the blocking of the vacuolar-type H+-ATPase in the
endosomal membrane, blocked C2 toxicity (Barth et al, 2000). Activated C2II can
form ion-permeable channels in artificial lipid bilayer membranes (Schmid et al,
1994). It is thought that after acidification of the early endosomal compartment,
oligomeric C2II forms a channel in the membrane thereby mediating translocation of
C2I into the cytosol (Barth et al, 2000).
C. novyi alpha toxin
The novyi alpha toxin is also taken up by receptor-mediated endocytosis and is
thought to require endosomal acidification to enter the cytosol (Ball et al 1993).
Acidification is thought to result in a conformational change in the toxin permitting
translocation into the cytosol. The central hydrophobic domain is thought to
facilitate insertion of the toxin into the membrane of the endosome and the
subsequent translocation process (von Eichel-Streiber et al, 1996).
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Intracellular activity
Modification of actin by C2 toxin
C2I is the enzymatic component of the C2 toxin. The C2I component mono-ADP-
ribosylates G-actin at arginine 177 resulting in inhibition of actin polymerisation
(Aktories et al, 1986). Actin is an essential component of the microfilament network
of the cytoskeleton and is also involved in various motile processes such as
migration, phagocytosis, secretion and intracellular transport (Aktories and Wegner,
1992). The physiological functions of actin are highly dependent on its capacity to
polymerise and form microfilaments. Actin exists in equilibrium between the
filamentous form (F-actin) and the monomeric globular form (G-actin) (Aktories and
Wegner, 1992). The ADP-ribosylated G-actin acts as a capping protein binding to
the ends of actin filaments and preventing further polymerisation; depolymerisation
occurs at the opposite end of the "capped" microfilament (Aktories and Wegner,
1989).
Site directed mutagenesis has enabled characterisation of the catalytic site in the C-
terminal domain of C2I. Conserved glutamic acid residues at positions 389 and 387,
together with serine-348 and arginine-299 were found to be essential for ADP-
ribosyltransferase activity (Barth et al, 1998b). A catalytic glutamic acid residue is
highly conserved within other ADP-ribosyltransferases (Barth et al, 1998b). Serine-
348 thought to be involved through either NAD-binding or catalysis; arginine-299 is
also thought to be involved in NAD binding and/or stabilisation of the active site
structure. These residues are also conserved in other arginine-modifying ADP-
ribosyltransferases from both prokaryotes and eukaryotes.
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Modification of Rho proteins by C3 exoenzyme and C. novyi alpha toxin
C3 exoenzyme and C. novyi alpha toxin both modify the same target proteins, Rho
GTPases, but at different sites and in different ways. The Rho protein subfamily
belongs to the Ras superfamily. C3 exoenzyme ADP-ribosylates Rho-A, -B and -C
(Sekine et al, 1989), whereas C. novyi alpha toxin glycosylates Rac and Cdc42, in
addition to Rho (Selzeret al, 1996). Both modifications occur in the effector region
of the proteins.
Rho-GTPases regulate the actin cytoskeleton and are involved in various eukaryotic
signal transduction processes (Hall, 1998; Bishop and Hall, 2000). The Rho
subfamily primarily regulates the organisation of the actin cytoskeleton: Rho is
involved in the formation of stress fibres and associated focal adhesions, Rac is
involved in the formation of membrane ruffles, lamellipodia and focal contacts, and
Cdc42 is involved in the formation of filopodia. Rho proteins also function as
molecular switches in signal transduction cascades, thus controlling many cellular
responses to a variety of extracellular signals. Rho proteins can regulate migration,
adhesion and cell polarity; control transcription, cell cycle progression and
transformation; and play key roles in the regulation of secretion, phagocytosis,
endocytosis, NADPH oxidase and neurotransmission (Aktories et al, 2000;
Dousseau et al, 2000).
The Rho proteins function as molecular switches through nucleotide exchange in the
GTPase cycle (Bishop and Hall, 2000) (Fig. 1.6). This cycle is regulated by at least
three groups of interacting factors. Rho is bound to GDP in its inactive form and is
found mainly in the cytosol. Binding to guanidine nucleotide dissociation inhibitors
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Figure1.6:TheR oGTPasecycl(adaptedfromK ibuchiel,1999).Bluerepresen sinhibitoryfact rsandin ct vformfR o. Redrepresentsactiva ingfactorsandtivformfRho. 1.GTPaseactivatingprotein( AP)increashyd olysiofGTtD ,c nvert ngRhtina tiGDP-boundform. 2.GDPdissociationinhib tor( I)b ndsspe ficallytR oiGDPboundf rm,prev nt ngdiss c atifGDP. 3.GDIdissociationfactor( F)resul sindisso iati nfGDIfromRho,ie ponsetextrac llularsigna . 4.Guanidinenucleotidexchangefactor( EF)facilitat sbindi gofGTPyRho,c nvertihotha tGTPbouform. 5.TheGTP-boundformistargetedhc llmembranewh ritn e actsitispecifictarg ts.
(GDI) maintains Rho in the inactive GDP-bound form. Rho is activated by
GDP/GTP exchange induced by guanidine nucleotide exchange factors (GEFs).
Binding of GTP results in a conformational change in the protein enabling interaction
with and activation of effector molecules. Hydrolysis of GTP to GDP returns the
protein to its inactive form; this hydrolysis is facilitated by GTPase-activating
proteins (GAPs).
The C. novyi alpha toxin modifies Rho at threonine 37, only when Rho is in the
GDP-bound form; threonine 35 is the homologous amino acid that is modified in Rac
and Cdc42 (Selzer et al, 1996). This threonine residue is a conserved amino acid in
the effector region of the Rho proteins. It is involved in nucleotide (GDP/GTP)
binding by the Rho proteins via the coordination of a magnesium ion. This residue
is only accessible to the alpha toxin in the GDP-bound conformation (Aktories,
1997). The alpha toxin catalyses the transfer of N-acetylglucosamine from UDP-N-
acetylglucosamine to Thr 37/35 of the Rho GTP-binding proteins (Selzer et al,
1996). C. novyi alpha toxin is the only LCT to use UDP-N-acetylglucosamine as the
preferred co-substrate; the other LCTs use UDP-glucose (Busch et al, 2000a). In
the absence of a protein substrate, the alpha toxin acts as a glycohydrolase rather
than a glycosyltransferase.
The glycosylation of Rho has multiple consequences: the coupling of Rho proteins
with their effectors is blocked, nucleotide exchange and membrane cycling is
inhibited and both intrinsic and activated GTPase activity is blocked (Sehr et al,
1998; Busch and Aktories, 2000).
C3 exoenzyme blocks the biological activity of Rho GTPase through ADP
ribosylation of Rho at asparagine-41 (Sekine et al, 1989). However, it is not fully
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understood how this modification affects the functioning of the protein. The modified
residue is also in the effector domain of the protein, but ADP-ribosylation, unlike
glycosylation, has only minor effects on the nucleotide binding, effector binding and
GTPase activity of Rho (Sehr et al, 1998). ADP-ribosylated Rho exhibits enhanced
binding to GDI. Release from GDI is required before activation by GEFs and
nucleotide exchange can occur; this may in part explain how ADP-ribosylation
affects Rho GTPase function (Aktories et al, 2000).
The catalytic activity of the alpha toxin is located in the N-terminal domain. The N-
terminal fragment of 551 amino acids was required for full glycosyltransferase
activity (Busch et al, 2000a). Amino acids from 133 to 517 in the alpha toxin are
thought to contain the region determining the nucleotide-sugar specificity of this
toxin, probably through binding of the sugar moiety of the co-substrate (Busch et al,
2000a). Amino acids towards the C-terminal end of this catalytic domain have also
been implicated in binding of the protein substrate (i.e. Rho proteins) (Hofmann et
al, 1998). There is a conserved DXD motif in a region of high homology in the
catalytic domain of the LCTs; this motif is thought to be involved in binding of the
nucleotide sugar via the coordination of a manganese ion (Busch et al, 1998). The
LCTs have a general dependency on manganese ions (Busch et al, 2000a). In
addition, a conserved tryptophan residue at position 102 is thought to interact with
the nucleotide moiety of the co-substrate (Busch et al, 2000b).
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The role of the toxins in pathogenesis of disease
C2 toxin
The pathophysiological role of the C2 toxin in natural infection is not really
understood, despite the ability of the toxin to cause significant morbidity and
mortality in experimental animals.
C2 toxin is a lethal toxin (Ohishi et al, 1980a) that can cause an increase in vascular
permeability (Ohishi etal, 1980b; Ohishi, 1983a), and fluid accumulation in intestinal
loops (Ohishi, 1983b). This enterotoxic activity is accompanied by histological
damage to the epithelial surface of the intestine (Ohishi and Odagiri, 1984). C2 toxin
can cause hypotension, haemorrhaging and collection of fluids in the thoracic cavity
of experimental animals (Simpson, 1982).
Visceral smooth muscle cells are especially rich in y-actin and poor in a-actin
(Mauss et al, 1990), and therefore represent a potential target for the C2 toxin. It
has been demonstrated that C2 toxin inhibits the contraction of longitudinal muscle
plexus myentericus preparation of guinea pig ileum (Mauss et al, 1989). It is
possible that G-actin/F-actin transition is involved in the regulation of smooth muscle
contraction (Aktories et al, 1992a).
C2 toxin may have an effect on cells of the immune system. It has been shown to
inhibit migration of neutrophils (Aktories et al, 1992a) and to enhance the production
of oxygen free radicals and granule protein release in neutrophils (Norgauer et al,
1988). Stimulation of a premature respiratory burst could facilitate evasion of the
immune response. The inhibition of histamine release from mast cells has also
been reported (Bottinger et al, 1987, cited in Aktories and Wegner, 1989).
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There has been very little documented evidence regarding the isolation of this toxin
in animals other than birds (Kinde et al, 1991). C2 toxin has been implicated in
some cases of type C botulism in broiler chickens where diarrhoea and enteritis
have been observed alongside the neuroparalytic signs of botulism (Ohishi and
DasGupta, 1987). C2 toxin was isolated from the intestinal tract of one horse during
an outbreak of C. botulinum type C intoxication associated with the consumption of
processed alfalfa hay cubes in North America (Kinde et al, 1991). Intramuscular
oedema was observed in five other horses and possibly indicated the involvement of
C2 toxin.
C3 exoenzyme
It is debatable whether the C3 exoenzyme has a role in the pathogenesis of disease
as it is not known if the enzyme can enter cells in vivo. However, the C3 toxin has
been demonstrated to have effects in vitro that could be potentially significant in
disease. C3 exoenzyme has been shown to induce depolymerisation of the actin
cytoskeleton in the vicinity of tight junctions, resulting in the redistribution of the
peripheral tight junction protein ZO-1 (Nusrat et al, 1991). The functional
consequence of this is an increased permeability of the epithelium.
C3 has been shown to cause neuronal degeneration in vitro (Williamson and Neale,
1998). However, high concentrations of C3 are required to observe these effects
and the C3 toxic effects are not specific to neurons, as the underlying glial cells are
also affected. Neuronal degeneration caused by the C3 toxin is less severe than
that caused by BoNT/C toxin and more uniform across cell bodies and processes;
BoNT/C toxin causes degeneration that starts at the synaptic terminal (Williamson
and Neale, 1998).
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C. novyi alpha toxin
The novyi alpha toxin has clearly been implicated in the pathogenesis of gas
gangrene, in man and animals. Gas gangrene is an invasive anaerobic infection of
the muscle, characterised by profound toxaemia, extensive local oedema, massive
death of tissue, and a variable degree of gas production (MacLennan, 1962).
Although gas gangrene can be caused by a number of pathogenic Clostridia,
producing different toxins, C. novyi type A has been implicated in approximately
one-third of cases (Smith, 1975a).
Colonisation of a wound with C. novyi type A, with subsequent toxin production can
cause gas gangrene. There is a high mortality associated with wound infections
involving C. novyi, particularly when accompanied with Clostridium sporogenes
(Smith, 1975a). The pathology and mortality is due to the lethal and necrotising
properties of the alpha toxin. The alpha toxin can damage capillary endothelium
causing an increase in capillary permeability (Elder and Miles, 1957) and oedema.
Recently C. novyi has also been associated with deaths in drug injectors
(http://www.iduoutbreak.abelqratis.com, 2000).
The most common disease caused by C. novyi in animals is infectious necrotic
hepatitis. This disease most commonly affects sheep, and is caused by C. novyi
type B. Therefore, the beta toxin as well as the alpha toxin plays a significant role in
the pathogenesis of this disease.
The use of the alpha toxin as a biological tool to study cellular signal transduction
cascades controlled by the Rho GTPases, has implicated the potential of this toxin
to affect multiple host systems. It has long been known that the alpha toxin can
affect epithelial permeability. However, it is now known that this is probably due to
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its effect on tight junctions due to the redistribution of the actin cytoskeleton. The
alpha toxin could have the potential to effect the functioning of the immune system
due to the dependency of immune cells to respond to extracellular signals.
The large clostridial cytotoxins are implicated in different diseases. C. difficile
causes antibiotic associated diarrhoea and pseudomembraneous colitis due to the
effect of toxins A and B on the colonic mucosa. C. sordelli causes wound infections
(gas gangrene) and enterotoxaemia through the production of the lethal toxin and
haemorrhagic toxin. Although these toxins use a different co-substrate from C.
novyi alpha toxin, the modification of the target protein occurs at the same site and
with the same effect. The lethal toxin of C. sordelli differs in that it modifies Rac but
not Rho, and in addition modifies Ras, Ral and Rap (Just, 1996, Popoff et al, 1996);
the cytopathic effect produced by this toxin is distinguishable from that caused by
the others (von Eichel-Streiber et al, 1996).
The differences in disease caused by these toxins may reflect differences in cell
receptor binding between the toxins, or may be due to differences in the ecology of
the organisms producing the toxins. The pathogenesis of clostridial diseases has
traditionally focussed on the involvement of toxins. However, virulence factors of
the organisms themselves may also be significant in defining the disease i.e.
establishing the difference between an organism that produces toxin in the gut and
one that produces toxin in a wound.
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Hypothesis and Aims of Thesis
The aetiology of equine grass sickness is not known. This thesis investigates the
hypothesis that grass sickness is caused by intestinal toxicoinfection with
Clostridium botulinum type C, i.e. colonisation of the small intestine with in vivo
production of toxin(s).
It is hypothesised that C. botulinum type C is either carried in the Gl tract of affected
animals or is acquired by the ingestion of spores. It is thought that an unknown
trigger, perhaps environmental or nutritional, alters the Gl environment to allow
either overgrowth of C. botulinum type C into the small intestine or the germination
of recently acquired spores. The subsequent absorption of C. botulinum type C
toxin(s) is thought to damage the neurons of the enteric and autonomic nervous
systems severely, resulting in the characteristic neuronal lesions that are seen in
this disease. It is proposed that an immune response, both to C. botulinum type C
and the type C toxin(s), could play a role in the prevention of equine grass sickness
and in recovery from this disease.
To investigate this hypothesis, the aims were as follows:
1) To detect the C. botulinum type C neurotoxin (BoNT/C), and BoNT/C-
producing organisms in the Gl tract of horses with and without equine grass
sickness, in order to establish whether toxico-infection with C. botulinum type
C is associated with the disease.
2) To isolate C. botulinum type C from the Gl tract of horses with and without
equine grass sickness, and to compare these isolates by phenotypic and
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genotypic methods to identify strain types specifically related to equine grass
sickness.
To investigate the role of the immune response to BoNT/C and the surface
antigens of Group III Clostridia in horses with and without equine grass
sickness. To compare specific antibody levels to these antigens in equine
sera, intestinal contents, colostrum and milk, in order to identify the extent of
exposure of horses to C. botulinum type C and to identify a role for an





2.1.1 Samples of gastrointestinal (Gl) contents for detection of BoNT/C
Equine specimens
Intestinal contents were collected from the distal ileum at post-mortem and rectal
faecal samples were collected either antemortem or at post-mortem. Ileum
contents were taken from 29 horses with grass sickness (acute, n=12; subacute,
n=7; chronic, n=10) and 28 controls (normal, i.e. apparently healthy horses, n=2; a
horse which had grass sickness in the past but not at the time of sampling, n=1;
clinical non-grass sickness cases with gut dysfunction, colic n=1, and clinical non-
grass sickness cases without gut dysfunction n=15; and with unknown diagnoses,
n=9). Faecal samples were taken from 45 horses with grass sickness (acute, n=13;
subacute, n=6; and chronic, n=26) and 77 controls (normal, i.e. apparently healthy
horses, n=24; horses which had grass sickness in the past but not at the time of
sampling, n=2; healthy horses in contact with clinical grass sickness cases, n=34;
clinical non-grass sickness cases with gut dysfunction, colic n=4, ileus n=1, and
clinical non-grass sickness cases without gut dysfunction, n=11). Horses with grass
sickness were diagnosed and categorised clinically as described previously (Doxey
et al, 1991a; Doxey et al 1992). The disease was subsequently confirmed in acute,
subacute and fatal chronic grass sickness cases by necroscopy, including
histopathological examination of autonomic and intestinal ganglia (Doxey et al,
1992).
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Specimens from other animals
Intestinal contents were also collected from other animals with dysautonomia: 18
cats (16 cats with dysautonomia and two cats with diarrhoea that were in contact
with 13 of the cats with dysautonomia), one hare and two wild rabbits.
2.1.2 Serum samples for the detection of systemic IgG
Blood was collected from 80 horses with grass sickness: 28 with acute grass
sickness (AGS), 21 with subacute grass sickness (SGS) and 31 with chronic grass
sickness (CGS). Fourteen of the horses with CGS were sampled more than once.
Blood was collected from 142 horses that did not have grass sickness. These
horses were sub-divided into three groups: 'contacts' (n=60), 'high-risk' (n=46), and
'controls' (n=36). The 'contact' group were horses that had been directly in contact
with a case of grass sickness i.e. co-grazing at the time of disease onset. The 'high
risk' group were horses grazing pastures considered to be a high risk for grass
sickness i.e. where grass sickness had occurred frequently in the past. The
'controls' were horses with no known contact with grass sickness i.e. grazing
pastures where grass sickness had not been reported. Of the 36 controls, 17 were
healthy animals and 19 were clinical cases, other than EGS (ten were cases
associated with Gl dysfunction and nine horses were non-GI cases). Six of the
healthy controls were sampled at intervals over a 28-week period.
2.1.3 Samples of equine Gl contents for the detection of specific IgA
Samples of ileum contents were collected at post-mortem and faecal samples were
collected either ante-mortem or post-mortem. Faecal samples were collected from
26 horses with grass sickness: 15 horses with CGS, four horses with SGS and
seven horses with AGS. Faecal samples were collected from 48 horses without
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grass sickness. Faecal samples were collected from ten horses with CGS on more
than one occasion - eight horses were sampled twice, one horse was sampled
three times and one horse was sampled six times, over the course of the disease.
Faecal samples were collected from six healthy horses three times over the course
of a 12-week period - at week one, week four and week 12. Ileum contents were
collected from 20 horses with EGS: five horses with CGS, six horses with SGS and
nine horses with AGS. Ileum contents were collected from 12 horses without grass
sickness.
2.1.4 Gut tissue for antibody extraction and lymphocyte isolation
Sections of small intestine were collected at post-mortem for the isolation of
lymphocytes and handled as described in section 2.5. Tissue samples of Peyer's
patches or lamina propria, for extraction of antibodies with saponin, were separated
from the muscle layers, cut into small pieces and aliquotted into eppendorf tubes.
The samples were stored at -70°C until treated with saponin.
2.1.5 Colostrum and milk samples
Colostrum
Colostrum samples were collected up to 12 hours post-parturition from 36 mares, 22
of which had been in contact with grass sickness and 14 of which had not been in
contact with EGS. "In contact" was defined as grazing land where grass sickness
had previously occurred. Of the 22 mares "in contact", six had been co-grazing with
a case of grass sickness i.e. grazing at the time the disease occurred; 14 mares
were grazing fields after grass sickness had occurred on these fields; two mares
had recovered from chronic grass sickness. The mares involved in this study were
of a variety of breeds and were widely distributed throughout Scotland and England.
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Milk
Milk was collected at two and four weeks post-parturition and then at four weekly
intervals, until weaning, from 36 mares. Twenty-three of the mares had been in
contact with EGS and 13 had not. Of the 23 mares "in contact" with EGS, seven
were co-grazing with a case of EGS, 14 were grazing fields after a case of EGS had
occurred on those fields, and two had recovered from CGS.
Colostrum/milk samples (5-10ml) were collected by the owner into sterile plastic
universals and sent by first class post. Both colostrum and milk samples were
received from 35 mares; only colostrum was received from one mare and only milk
from another.
All samples were labelled with the letter M (for milk study) and each mare was
assigned a number. Each sample also received a letter as a suffix, to identify how
many weeks post-parturition the sample had been collected - the letter A
represented a colostrum sample, B milk collected at two weeks, C for milk at four
weeks, D for milk at eight weeks etc. Therefore, M2A represents the colostrum
sample from mare number two, and M16E, represents the milk sample collected at
12 weeks from mare number 16.
2.2 Treatment of samples for toxin detection
2.2.1 Processing of samples for direct detection of BoNT/C
For direct detection of BoNT/C, weighed specimens (1-1 Og) were infused into a
known volume (5 or 10ml, depending on consistency of sample) of phosphate
buffered saline, pH 7.2, with 0.2% gelatin, (PBSG), and held overnight at 4°C. After
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vortexing, the liquid portion was removed and centrifuged at 3,800g for 20 min. The
supernatant was subsequently collected and stored at -20°C.
2.2.2 Processing of samples for detection of BoNT/C after enrichment
For detection of BoNT/C after enrichment approximately 1-3g of specimen was
added to 15ml pre-reduced CMC-1 medium [developed by Centre for Applied
Microbiological Research, (CAMR), Porton Down, Salisbury, Wiltshire, UK] and
incubated anaerobically at 30°C for 5 days. The samples were centrifuged at
3,800g for 20 min and the supernatant was collected and stored at -20°C.
2.3 Treatment of samples for detection of antibodies
2.3.1 Serum samples
Blood samples were collected in sterile vacutainers with no additives. The blood
samples were allowed to clot overnight at 4°C, and the serum collected after
centrifuging at 1000g for 15 min. Serum was stored at -20°C until assayed.
2.3.2 Treatment of Gl contents with protease inhibitors
In order to detect IgA present in ileum contents and faecal samples, the samples
were treated as soon as possible after collection to inhibit intestinal proteases and
preserve the IgA, using a method adapted from Gaspari et al (1988). Samples not
treated within 24 h of collection were excluded from this study. The reagents used in
treating the samples were all stored at -20°C, and kept on ice during the treatment
procedure. Two parts protease inhibitor solution (soybean trypsin inhibitor 1mg/ml
in PBS, and 50mM EDTA containing 0.05% Tween 20) were added to one part of
weighed sample (approximately 5g) (v/w). Phenylmethlysulphonyl fluoride (PMSF;
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Sigma-Aldrich Company Ltd, Poole, Dorset, UK) (0.1M in 100% ethanol) was then
added to a final concentration of 1mM. The mixture was vortex mixed for 30-60 sec
and then centrifuged at 3800g for 10 min. The supernatant was removed, and
PMSF (0.1M in 100% ethanol) was added to the supernatant to a final concentration
of 2mM, followed by sodium azide (20mg/ml) to a final concentration of 1% (v/v).
The supernatant was mixed well and left to stand for 15 min on ice. Heat inactivated
foetal calf serum (FCS) was then added to a final concentration of 4% (v/v). The
sample was transferred to microcentrifuge tubes and centrifuged at 15,700g for 5
min. The supernatant was removed and stored at -70°C.
2.3.3 Treatment of samples with saponin
Samples of Gl tissue were treated with saponin to extract antibodies. Initially,
samples were thawed for different lengths of time at 4°C in PBS containing 2%
saponin (Sigma), soybean protease trypsin inhibitor (1mg/ml; Sigma),
ethylenediamine-tetraacetic acid sodium salt (EDTA; 0.05M), Tween 20 (0.05%),
PMSF (2mM), sodium azide (0.2mg/ml) and 4% FBS; 2ml of solution was added per
gram of tissue. The samples were centrifuged at 15,700g for 5 min and the
supernatants collected and stored at -70°C until analysed.
2.3.4 Treatment of colostrum and milk samples
Samples were centrifuged at 3,800g for 20 min and the supernatant transferred to
microcentrifuge tubes. The samples were then centrifuged at 15700g for 5 min in a
microcentrifuge. The supernatant was removed and stored at -70°C until assayed.
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2.4 ELISAs
2.4.1 Coating of ELISA plates
ELISA to detect BoNT/C
A sandwich ELISA for the detection of BoNT/C had been developed by CAMR,
Porton Down. A polyvalent guinea pig antiserum (supplied by CAMR) raised against
the purified neurotoxin was used as a capture. Nunc Immuno™ Polysorp™ ELISA
strips (Fisher Scientific UK, Loughborough, Leicestershire, UK) were coated
(100pl/well) overnight at 4°C with 5-10pg/ml of the antiserum diluted in PBS pH 7.4.
Plates were washed three times with PBS containing 0.1% Tween 20 (PBS-T).
ELISA to detect antibodies to EDTA-extracted surface antigens of C. novyi
type A and C. botulinum type C
The surface antigens of C. novyi type A and C. botulinum type C were extracted as
described in Chapter 2.8.4-2.8.5, except that a bulk culture of 1 litre was used for
the extraction. The protein concentration was determined using the Folin protein
assay (Lowry et al, 1951).
Nunc Immuno™ Polysorp™ plates were coated with EDTA-extracted surface
antigens of C. novyi type A (MPRL 2530) or C. botulinum type C (MPRL 4240) at
30|ag/ml in coating diluent (0.05M sodium bicarbonate buffer, pH9.6 containing
0.02% sodium azide), as described by Poxton (1984); 100pl was added to each
well. Plates were incubated overnight at room temperature. After overnight
incubation, plates were washed four times with ELISA wash buffer (PBS containing
0.05% Tween 20 and 0.05% sodium azide, pH7.2).
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ELISA to detect antibodies to BoNT/C
Nunc Immuno™ Polysorp™ plates were coated with purified BoNT/C (CAMR) at
5pg/ml in PBS overnight at 4°C; 10Opil was added to each well. The coating
concentration was determined by CAMR, Porton Down. Plates were washed three
times with PBS-T.
ELISA for total IgG
Preliminary assays were carried out to establish the optimal dilution for the capture
antibody. Two different rabbit anti-equine IgG (H+L) antisera (Nordic Immunology,
Tilburg, Netherlands, UK and ICN Pharmaceuticals, Ltd, Basingstoke, Hampshire,
UK) were compared. Nunc Immuno™ Polysorp™ plates were coated with anti-
equine IgG antisera diluted in ELISA coating diluent (1 OOjul/well). Plates were
incubated overnight at 4°C and then washed four times with ELISA wash buffer.
On the basis of the results of these preliminary assays, (Chapter 7.1.1) plates for
further assays were coated with rabbit anti-equine IgG (H+L) antiserum (ICN) diluted
1 in 2500.
ELISA for total IgA
Preliminary assays were carried out to establish the optimal coating dilution of anti-
equine IgA antibody. Two different antibodies were compared: anti-equine IgA (Fc)
rabbit antiserum (Nordic Immunology) and anti-equine IgA mouse monoclonal
[Bristol Veterinary School (BVS), Bristol University, UK], Nunc Immuno™ Polysorp™
plates were coated with anti-equine IgA antibody diluted in coating diluent
(1 OOpil/well). Plates were incubated overnight at 4°C and then washed four times
with ELISA wash buffer.
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On the basis of these preliminary assays (Chapter 7.1.2) plates were coated with
anti-equine IgA mouse monclonal (BVS) diluted 1 in 1000
2.4.2 Blocking of ELISA plates
ELISA to detect BoNT/C
Plates were blocked with PBS-T containing 5% foetal bovine serum (PBS-TF;
200fa.l/well). Plates were incubated, with shaking, for a minimum of 1 h at 37°C and
then washed three times in PBS-T. Plates were stored at -20° until use.
ELISAs to detect total IgG, total IgA, and specific antibodies
Plates were blocked with PBS containing 3% teleostean gelatin (Sigma) and 0.02%
sodium azide (200p.l/well). Plates were incubated, with shaking, for four hours at
37°C and then washed four times with ELISA wash buffer and stored at -20°C until
use.
However, the blocking conditions differed for the ELISAs to detect antibodies in
serum, both to BoNT/C and C. novyi type A surface antigens: plates coated with
BoNT/C were blocked with PBS-TF (200|il/well) and incubated for 1 h, with shaking,
at 37°C; plates coated with C. novyi type A surface antigens were not blocked.
2.4.3 Addition of samples
ELISA to detect BoNT/C
Sample supernatants were assayed in duplicate at three dilutions (undiluted, 1 in 2,
and 1 in 4 for direct toxin detection; 1 in 5, 1 in 25 and 1 in 125 for enriched
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samples). Samples were diluted in PBS-TF and 100pl added to each well. The
plates were incubated at 37°C, with shaking, for 90 min and then washed three
times with PBS-T.
ELISA for antibodies to surface antigens and to BoNT/C
Serum samples
Previous work had determined the optimum dilution as 1 in 50 for the screening of
serum samples for IgG both to C. novyi type A surface antigens and to BoNT/C (R.
Brown and H.G. Lough, personal communication). Samples were diluted in
antiserum/conjugate diluent (0.05M phosphate buffer, pH7.4, 0.85% sodium
chloride, 0.05% Tween 20 and 0.02% sodium azide), and 10Opil was added to each
well. Plates were incubated for 90 min at 37°C and then washed four times with
ELISA wash buffer.
Other samples
Preliminary assays were carried out to establish the optimum dilution for screening
Gl contents, colostrum and milk samples for specific IgA both to C. novyi type A
surface antigens and to BoNT/C. All samples were diluted in antiserum/conjugate
diluent, and 10Opil added to each well. Plates were incubated overnight at room
temperature and then washed four times with ELISA wash buffer.
ELISA for total IgG
Preliminary assays were carried out to establish the optimal dilution for screening
samples (colostrum, milk and saponin-treated tissue-extracts) to determine total IgG
content. All samples were diluted in antiserum/conjugate diluent and 100^1 added to
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each well. Plates were incubated overnight at room temperature and then washed
four times with ELISA wash buffer.
ELISA for total IgA
Preliminary assays were carried out to determine the optimal dilution of samples
(colostrum, milk and saponin-treated tissue-extracts) for the calculation of total IgA.
Samples were diluted in antiserum/conjugate diluent and 10Opil added per well.
Plates were incubated overnight at room temperature, and washed four times.
2.4.4 Primary detecting antibody
ELISA for IgA to surface antigens and BoNT/C
Anti-equine IgA mouse monoclonal [Immune Systems Ltd. (ISL), Paignton, UK] was
used as the primary detecting antibody in the ELISAs for detecting specific IgA.
Preliminary assays were carried out to determine the appropriate dilution of this
antibody. The antibody was diluted in antiserum/conjugate diluent and 100pl added
to each well. Plates were incubated, with shaking, for 5 hours at 37°C and then
washed four times with ELISA wash buffer.
On the basis of the results of these preliminary assays (Chapter 6.1.1), the anti-
equine IgA mouse monoclonal was used at a dilution of 1 in 200.
ELISA for total IgA
Preliminary assays were carried out to compare different anti-equine IgA antibodies
for use as a primary detecting antibody in an ELISA to detect total IgA and to
establish the most appropriate dilution for use. Rabbit anti-equine IgA (Fc)
antiserum (Nordic Immunology), anti-equine IgA mouse monoclonal (Bristol
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antiserum (Nordic Immunology), anti-equine IgA mouse monoclonal (Bristol
Veterinary School), and anti-equine IgA mouse monoclonal (ISL) were used as
primary detecting antibodies in combination with different capture antibodies. The
primary detecting antibody was diluted in antiserum/conjugate diluent and 10Opil
added to each well. Plates were incubated, with shaking, for 3 h at 37°C and then
washed four times with ELISA wash buffer.
On the basis of the results of these preliminary assays (Chapter 7.1.2), the rabbit
anti-equine IgA (Fc) antiserum (Nordic) was used as a primary detecting antibody at
a dilution of 1 in 400.
2.4.5 Conjugate
ELISA to detect BoNT/C
The anti-BoNT/C guinea pig IgG (supplied by CAMR), conjugated to horseradish
peroxidase (HRP) was used at a dilution of 1 in 300 in PBS-TF (100pl/well). Plates
were incubated for 90 min at 37°C and then washed three times in PBS-T.
ELISA for total and specific IgG
Rabbit anti-horse IgG (whole molecule) alkaline phosphatase conjugate (Sigma)
was diluted 1 in 10000 in antiserum/conjugate diluent and 100^1 added to each well.
The plates were incubated, with shaking, for 90min at 37°C and then washed four
times with ELISA wash buffer.
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ELISA for specific IgA
Goat anti-mouse IgG (whole molecule) alkaline phosphatase conjugate (Sigma) was
diluted 1 in 5000 in antiserum/conjugate diluent and 10Opil added to each well.
Plates were incubated overnight at room temperature and then washed four times
with ELISA wash buffer.
ELISA for total IgA
Goat anti-rabbit IgG (whole molecule) alkaline phosphatase conjugate (Sigma) or
goat anti-mouse IgG (whole molecule) alkaline phosphatase conjugate (Sigma),
depending on the host species of the first antibody, was used. The conjugate was
diluted 1 in 5000 in antiserum/conjugate diluent, 100pl/well added and incubated,
with shaking, for 90 min at 37°C. Plates were washed four times with ELISA wash
buffer. On the basis of preliminary assays, it was decided to use the rabbit anti-
equine IgA (Fc) antiserum (Nordic) and therefore, the goat anti-rabbit IgG (whole
molecule) alkaline phosphatase conjugate (Sigma) was used in further assays for
total IgA.
2.4.6 Substrate
ELISA to detect BoNT/C
The substrate (3, 3', 5, 5'-tetramethyl-benzidine dihydrochloride tablets, Sigma)
dissolved in phosphate-citrate buffer pH5.0 with 2pl 30% H202 per 10ml, was added
to the plate (100pl/well). The reaction was allowed to develop at room temperature
for 30 min or until the background became detectable. The reaction was stopped by
the addition of 50pl/well 2M H2S04 The absorbance was measured at 450nm,
reference at 620nm, in an Anthos plate reader.
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ELISA for total and specific IgG and igA
Alkaline phosphatase substrate tablets, p-nitrophenyl phosphate (Sigma 104), were
dissolved in substrate solvent (0.05M sodium carbonate solution, pH 9.8, with 1mM
magnesium chloride) to give a concentration of 1 mg/ml. The substrate solution was
added to each well (100ju.l/well) and incubated at room temperature. The incubation
times varied between the assays: 30 min for total IgG, total IgA, and specific IgG in
colostrum and milk samples; 1 h for specific IgG in serum samples, specific IgA in
Gl contents, colostrum and milk samples. The absorbance was measured at
405nm, reference 620nm, in an Anthos 2001 plate reader.
2.4.7 Controls
ELISA to detect BoNT/C
Purified BoNT/C, diluted in PBS-TF to 100ng/ml, 20ng/ml, 4ng/ml and 0.8ng/ml was
included as a standard to enable comparison between plates and quantification of
results.
Every third column was left uncoated and received only PBS (1 OOjal/well) during the
coating stage (all wells were blocked). Each sample was therefore added to two
coated wells and one uncoated well. The uncoated well was used to control for non¬
specific binding of the sample to the plate. One row of wells received no samples,
only PBS-TF (1 OOpil/well), as a negative control.
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ELISA to detect specific IgG to surface antigens and BoNT/C
Serum samples
A serum sample had been previously identified that gave an optical density (OD)
reading, after dilution, of approximately 1.0 in the assay to detect IgG to C. novyi
type surface antigens. This serum sample was used as the positive control for both
the ELISA to detect IgG to C. novyi type A surface antigens and to BoNT/C. The
positive control was used to standardise OD readings between plates.
Every third column, in each plate, was left uncoated and received only PBS
(100pl/well; BoNT/C coated plates) or coating diluent (100pl/well; C. novyi type A
coated plates) during the coating stage. Therefore, each serum sample was added
to two coated wells and one uncoated well. It was thought that the uncoated well
would control for non-specific binding of the serum samples to the plates. One row
of wells received no serum samples, only antiserum/conjugate diluent (1 OOpil/well),
as a negative control.
Colostrum and milk samples
A positive control was identified by preliminary assays and this was included on
each plate to allow standardisation of OD readings between plates. Four or more
wells received no samples, only antiserum/conjugate diluent (1 OOjul/well), as the
negative control.
ELISA to detect specific IgA
Gl contents
A positive control was identified by preliminary assays and this was included on
each plate to allow standardisation of OD readings between plates.
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In preliminary assays, every third column was left uncoated and received only
coating diluent (1 OOjul/well) during the coating stage. Each sample was added to
four coated wells and two uncoated wells. The uncoated wells were to control for
non-specific binding of the samples to the plate. Two of the coated wells and one of
the uncoated wells in the next stage, received no primary detecting antibody, only
antiserum/conjugate diluent (100^1/well). This was to control for non-specific
binding of the conjugate to the samples. As there was no significant non-specific
binding of either the samples to the plate or conjugate to the samples, these controls
were not included in further assays. One row of wells received no samples, only
antiserum/conjugate diluent (1 OOptl/ well), as the negative control.
Colostrum and milk samples
A positive control was identified by preliminary assays and this was included on
each plate to allow standardisation of OD readings between plates.
Initially, some samples were added to four wells; two of these wells did not receive
primary detecting antibody, only antiserum/conjugate diluent (1 OOptl/well), in order to
control for non-specific binding of the conjugate to the samples. However, as there
was no significant non-specific binding of the conjugate to the samples this control
was not included in further assays. Four or more wells, received no samples, only
antiserum/conjugate diluent (100^1/well), as a negative control.
ELISA to detect total IgG
Dilutions of equine IgG, of known concentration, were added in duplicate
(1 OOpil/well) to each plate in order to obtain an equine IgG standard curve. This
standard curve was then used to calculate the concentration of IgG in colostrum and
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milk samples and saponin-treated tissue extracts. The equine IgG standard was
prepared from an equine serum sample (LH 346C). This serum sample was put
through a protein G column (Mab Trap Gil kit; Amersham Pharmacia Biotech UK
Ltd, Little Chalfont, Buckinghamshire, UK) and the IgG fraction was eluted and
collected. The protein concentration of this IgG fraction was determined using the
Folin protein assay, and this was taken to represent the IgG concentration in the
standard. Preliminary assays were carried out using known concentrations of this
equine IgG standard to establish the optimal dilutions to obtain an IgG standard
curve. Incubation times and conditions were as described for the samples in this
assay (Chapter 2.4.3). Based on the results of these preliminary assays (Chapter
7.1.1), the IgG standard was diluted twofold between 0.1pg/ml and 0.003pg/ml.
Four or more wells on each plate received no samples, only antiserum/conjugate
diluent (100pl/well), as the negative control.
ELISA to detect total IgA
Dilutions of a colostrum sample, of known IgA concentration, were added in
duplicate (1 OOjul/well) to each plate in order to obtain an equine IgA standard curve.
This standard curve was then used to calculate the concentration of IgA in
colostrum, milk samples and saponin treated tissue extracts. The IgA concentration
of the colostrum sample was calculated using a commercially available radial
immunodiffusion kit (LLA; VMRD Inc., Pullman, WA 99163, USA). Preliminary
assays were carried out using known concentrations of this colostrum sample to
establish the appropriate dilutions to obtain an IgA standard curve. The incubation
times and conditions were as described for the samples (Chapter 2.4.3). Based on
the results of these preliminary assays (Chapter 7.1.2), the IgA standard was diluted
two-fold between 10 jug/ml to 0.31 pg/ml in antiserum/conjugate diluent.
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Initially, some samples (colostrum, milk and saponin-treated Gl extracts) were
added to four coated wells; two of these wells did not receive the primary detecting
antibody, only antiserum/conjugate diluent (100pl/well), to control for non-specific
binding of the conjugate to the sample. However, as there was no significant non¬
specific binding of the conjugate to the samples, this control was not included in
further assays. Four or more wells received no samples, only antiserum/conjugate
diluent (100pl/well), as the negative control.
2.4.8 Calculation of ELISA results
BoNT/C levels in Gl samples
The mean OD for the negative control was subtracted from the mean OD for each
sample (in coated wells). The mean OD for the negative control was also
subtracted from the OD for the sample in the uncoated well. The OD for the
uncoated well (minus the negative control) was then subtracted from the mean
sample OD. This final OD value was used to calculate the amount of BoNT/C
directly present in samples, using the standard BoNT/C curve and correcting for the
original dilution factors. The amount of BoNT/C in samples, which had been
enriched in CMC-1, was not quantified in this way due to amplification of toxin by the
enrichment process. Samples were considered positive if the final OD value was
equal to or greater than that for the 0.8ng/ml BoNT/C standard.
Specific antibody levels
IgG in serum
The negative control was automatically subtracted by the plate-reader software from
both the OD readings for the coated and uncoated wells. The OD for the uncoated
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well for each sample was then subtracted from the mean OD for that sample, in the
coated well, to give the final OD value. The OD readings between plates were
standardised by correcting the OD by reference to the positive control.
Serum was collected on more than one occasion from fourteen of the horses with
CGS and six of the healthy controls. When more than one serum sample had been
collected from a particular horse, the OD readings for the samples from each horse
were averaged, to enable comparison of serum IgG levels between horses.
IgA in Gl contents
Samples were determined as having detectable IgA to a particular antigen if the
mean OD value obtained was greater than the mean + 3 x standard deviation (S.D.)
of the negative control. This gives a probability of p<0.0013 for a negative sample
falling outside this limit. The OD readings between plates were standardised by
correcting the OD by reference to the positive control. When more than one faecal
sample was obtained from an individual horse, the mean OD for the samples was
calculated and used for the comparison of faecal IgA levels between horses.
IgG and IgA in colostrum and milk samples
Samples were determined as having detectable IgG or IgA to a particular antigen if
the OD value obtained from the screening assays was greater than the mean of the
negative control + 3 x S.D. of this control. The OD readings between plates were
standardised by correcting the OD by reference to the positive control. Results for
specific antibody levels were expressed both as corrected OD readings, and as OD
readings per pg total IgA or per mg of total IgG.
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Total antibody levels
The mean OD for the negative control was calculated and subtracted from the mean
OD values for the standards and samples. The standard curve was then used to
calculate the concentration of IgG or IgA in the samples, with correction of the
results for the original dilution factors.
2.4.9 Statistical analysis
BoNT/C in Gl samples
The levels of BoNT/C detected directly in the
compared statistically between the categories of
using the Mann-Whitney U test.
Specific antibody levels
OD values for IgG in serum, colostrum and milk samples and OD values for IgA in
Gl contents, colostrum and milk, were statistically compared between groups of
horses by the Mann Whitney U test, using the SPSS package. An unpaired
Students t-test (Sigmaplot) was also used to statistically compare the levels of IgG
and IgA in colostrum and milk between different groups of horses. Linear regression
analysis was carried out using Sigmaplot.
ileum and faecal samples were
EGS disease and the controls by
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2.5 Isolation of lymphocytes from the lamina propria and
Peyer's patches of equine gut associated lymphoid
tissue (GALT).
2.5.1 Preparation of gut
A length of jejunum, proximal to the ileum, was collected at post-mortem. One end
was tied off as tightly as possible, using nylon braided thread knotted three times
with a surgical knot for the first knot. A section of gut approximately 20 cm in length
was cut out (to include the knotted end). The serosal surface was washed with
Hank's balanced salt solution without calcium and magnesium (GibcoBRL, Life
Technologies Limited, Paisley, UK) containing 5mM HEPES (GibcoBRL) and 0.4g/l
sodium bicarbonate (HBSS), pre-warmed to 37°C. The section of intestine was
inverted by pushing the knotted end through with a glass rod. The section of
intestine was then inflated by pouring HBSS (pre-warmed to 37°C) into it through a
funnel. The HBSS was milked down by hand until all the folds of the mucosa were
stretched out. The upper end of the sausage was clamped with bowel clamps and
then tied off under pressure, to give a length of approximately 10cm of gut. The gut
was examined for the presence of Peyer's patches. If no Peyer's patches were
present, cells were isolated from the lamina propria; if Peyer's patches were present
then cells from the Peyer's patches were isolated.
2.5.2 Removal of epithelium
The intestine was transferred to a wide necked autoclavable container with a lid that
could be tightly sealed. Approximately 250ml of HBSS containing 1mM EDTA (pre-
warmed to 37°C) was added, ensuring that there was enough solution to cover the
gut, and shaken vigorously at 37°C for 20 min in an orbital incubator. The HBSS
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was decanted and discarded, then another 250ml of HBSS containing 1mM EDTA
(pre-warmed to 37°C) was added, and incubated for another 20 min at 37°C with
vigorous shaking. This was repeated for at least six washes, or until the wash
medium was clear i.e. all the epithelium was removed. For initial assays wash
medium was retained from the final EDTA-wash and one of the earlier EDTA-
washes for analysis of the cell content.
2.5.3 Isolation of cells from the lamina propria
The intestine was washed briefly with RPMI 1640 (Dutch modification; Gibco BRL)
to remove as much wash HBSS/EDTA as possible. Approximately 250ml of RPMI
1640 containing 100units/ml collagenase (Sigma) was added and the intestine was
incubated for 45 min at 37°C with vigorous shaking in the orbital incubator. The
incubation medium was decanted and retained. A further 250ml of RPMI 1640
containing 100units/ml collagenase was added and incubated for 45 min at 37°C
with vigorous shaking. The incubation medium from the first wash was centrifuged
for 15 min at 300g, resuspended in HBSS without EDTA and centrifuged again for
15 min at 300g. The cells were resuspended in HBSS. This was repeated with the
medium from the second digestion, and the cells from the first and second wash
were combined. Cells were washed through a cell strainer (Falcon, Fred Baker
Scientific, Runcorn, Cheshire, UK) to ensure there was a single cell suspension.
Cells were resuspended in RPMI 1640 containing 10% FBS, streptomycin (100
fig/ml), and penicillin (100 units/ml) (10% complete RPMI).
2.5.4 Isolation of cells from Peyer's patches
The epithelium was removed from the gut as described above (Chapter 2.5.2). The
Peyer's patches were then dissected out from the section of gut and peeled off from
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the serosa. The Peyer's patch was then cut up into very small pieces and
transferred to a conical flask. RPM11640 (50ml) containing 100units/ml collagenase
was added and incubated for 45 min at 37°C on a magnetic stirrer. The incubation
medium was decanted and retained, and a further 50ml RPMI 1640 containing 100
units/ml collagenase was added and incubated for another 45 min at 37°C with
stirring. The incubation medium was decanted and retained; the remaining tissue
from the digested Peyer's patch was put through a fine-meshed metal sieve and
washed through with RPMI 1640 (without collagenase). The cells from each
incubation were washed with HBSS (without EDTA) and pooled. Cells were washed
through a cell strainer (Falcon) to ensure there was a single cell suspension. Cells
were resuspended in 10% complete RPMI 1640.
2.5.5 Isolation of equine peripheral blood mononuclear cells (PBMCs)
Heparinised whole blood was diluted 1 in 4 in sterile PBS. PBMCs were separated
by layering the diluted blood onto Histopaque 1077 (Sigma), and then centrifuging at
460g for 25 min. The interface layer containing the PBMCs was removed and
washed twice in RPMI 1640; cells were centrifuged at 300g for 15 min. Cells were
counted and resuspended in the appropriate final volume for the application.
2.6 Flow cytometry
2.6.1 Numbers of cells
Approximately 5 x 105 cells were added to each tube for flow cytometry. Ice-cold
PBS (2ml) containing 0.01% BSA and 0.1% sodium azide (PBS/BSA/NaN3) was
added to each tube. Cells were centrifuged for 7 min at 300g and the supernatant
was poured off, to remove the RPMI.
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2.6.2 Blocking
Initial experiments were carried out to see whether a blocking step was necessary;
cells were blocked with 0.2ml normal goat serum (NGS; Scottish Antibody
Production Unit, Carluke, Lanarkshire, UK), diluted 1 in 200 in PBS/BSA/NaN3, for
15 min at 4°C. Cells that were not blocked were resuspended in 0.2ml
PBS/BSA/NaN3. Cells then had 0.5ml of PBS/BSA/NaN3 added and were
centrifuged at 300g for 7 min. The supernatant was poured off.
2.6.3 Primary antibody
Three mouse monoclonal antibodies were used as primary antibodies: anti-human
CD-18 (Dako, Glostrup, Denmark), anti-equine CD3 (J.L. Stott and M. Channel
Blanchard, University of California, Davis, USA) and CVS 36 (M.A. Holmes,
University of Cambridge, Cambridge, UK). The anti-equine CD3 monoclonal
antibody recognises the equine equivalent of the CD3 antigen present on all T cells
(Lunn et al, 1998). The CVS 36 monoclonal antibody is specific for all isotypes of
equine immunoglobulin (Lunn et al, 1998), and therefore can bind to B cells through
their expression of surface immunoglobulin (slg). The anti-human CD18 antibody
had been shown to cross-react with equine leucocytes, amongst other animal
species (Jacobsen et al, 1993); CD18 is present on the surface of all leucocytes in
conjunction with CD11. The negative control received no primary antibody, only
PBS/BSA/NaN3. Initial assays were carried out to determine the appropriate dilutions
of anti-equine CD3, and CVS 36; 10ptl of anti-CD18, diluted 1 in 10, was used in all
the assays. Primary antibodies were diluted in PBS/BSA/NaN3 and incubated for 30
min at 4°C. Cells were washed twice with 2 ml of PBS/BSA/NaN3 and centrifuged at
300g for 7 min.
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2.6.4 Conjugate
Anti-mouse IgG whole molecule-FITC conjugate F(ab')2 fragment of sheep antibody
(Sigma) was diluted 1 in 50 in PBS/BSA/NaN3 and incubated at 4°C for 30 min. The
cells were then washed twice with 2ml of PBS/BSA/NaN3, as before. The cells were
fixed by resuspension in 1ml of 0.1% formal saline and stored at 4°C.
2.6.5 Measurement of cells
Fluorescence was measured using a Coulter EPICS flow cytometer. Negative
control gates were set at approximately 1% using the cells that had been incubated
without first antibody.
2.7 ELISPOT assay for antibody secreting B cells
ELISPOT assays were developed to measure the number of total and antigen
specific IgG and IgA secreting B cells in PBMCs and cells from GALT.
2.7.1 Coating and blocking of plates
Initial experiments were carried out to determine the optimum dilution for capture
antibody for the assay to measure IgG-secreting cells. Multiscreen 96 well plates
with individual mixed cellulose ester membranes (Millipore (UK) Ltd, Watford, UK)
were coated with rabbit anti-equine IgG (H+L) antiserum (ICN) diluted in tris-
buffered saline (TBS); 100|ul was added to each well. Plates were incubated
overnight at 4°C. Plates were washed three times with TBS containing 0.1% Tween
20 (TBS-T) (200pl/well); the third wash solution was left to sit in the wells for 5 min.
The plates were then washed three times with TBS (200jul/well), and again the third
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wash was left to sit in the wells for 5 min. Plates were then blocked with 10%
complete RPMI 1640 (Gibco); 200ju.l were added to each well. Plates were
incubated for 1-2 h at 37°C with 5% C02. The blocking solution was then thrown off.
For the ELISPOT to measure total IgA secreting cells, preliminary assays were
carried out to determine the optimum dilution of capture antibody, anti-equine IgA
mouse monclonal (BVS), as described above. For ELISPOT assays to determine
antigen-specific antibody secreting cells, plates were coated with EDTA-extracted
surface antigens of C. novyi type A and C. botulinum type C diluted in TBS at
30|ig/ml, and BoNT/C diluted in TBS at 5jng/ml, as described above.
2.7.2 Addition of cells
Initial experiments were carried out to determine the optimum number of cells
required for this assay. Cells were diluted in 10% complete RPMI 1640 and 100pl
added to each well. Plates were then incubated for 4 h at 37°C with 5% C02.
Plates were washed three times with TBS and then three times with TBS-T, with the
third wash of each left to sit in the wells for 5 min; 200pl of wash buffer was added to
each well.
2.7.3 Controls
Some wells were coated with 100pl BSA (0.4mg/ml) instead of capture antibody, to
control for non-specific binding to the plate. Some wells received no cells, only 10%
complete RPMI, as a negative control.
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2.7.4 Primary detecting antibody
For ELISPOT assays to detect IgA secreting cells, rabbit anti-equine IgA (Fc)
antiserum (Nordic Immunology) was diluted 1 in 400 in TBS-T containing 1% FBS
and 100fj.l added to each well. Plates were incubated overnight at 4°C, and then
washed as previously described.
2.7.5. Conjugate
For ELISPOT assays to detect IgG secreting cells, rabbit anti-horse IgG (whole
molecule) alkaline phosphatase conjugate (Sigma) was diluted 1 in 10,000 in TBS-T
containing 1% FBS, 100pl added to each well and the plates incubated overnight at
4°C. For ELISPOT assays to detect IgA secreting cells, goat anti-rabbit IgG (whole
molecule) alkaline phosphatase conjugate (Sigma) was diluted 1 in 5,000 in TBS-T
containing 1% FBS, 100pl added to each well and plates incubated for 90 min at
37°C. The plates were then washed as described previously with a final extra two
washes with distilled water (200^1/well).
2.7.6 Substrate
BCIP/NBT (5-Bromo-4-chloro-3-9-indolyl phosphate and Nitro Blue Tetrazolium)
liquid substrate solution (1 OOjul; Sigma) was added to each well. The reaction was
allowed to develop for 5 min before washing with distilled water to stop the reaction.
The plate was then allowed to dry before spots were visualised and counted using a
dissecting microscope with a vertical white light source at x15 and x30
magnification. The nitrocellulose discs from the bottom of the wells were later
removed from microtitre plate using plate-sealing tape (Millipore) and spots
visualised using x2.5 and x10 objectives with a light microscope.
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2.8 Isolation and identification of Group III organisms
2.8.1 Isolation of Group III organisms
Ileum contents and faecal samples that had been inoculated into enrichment broth
(CMC-1; Chapter 2.2.2) were plated out after 24 h of anaerobic incubation at 30°C
onto pre-reduced Fastidious Anaerobe Agar (FAA; Oxoid Ltd, Basingstoke,
Hampshire, UK.) containing 5% egg yolk emulsion (Oxoid) and 10^g/ml gentamicin
(EYAg). Plates were incubated anaerobically at 30°C (anaerobic gas jar) or at 37°C
(MK3 work station; Don Whitley Scientific Ltd., Shipley, West Yorkshire, UK) and
checked at 24 h intervals for the presence of lipase and lecithinase positive
colonies. Lipase-positive and lecithinase positive colonies were isolated by sub-
culturing onto fresh EYAg plates, and finally into cooked meat broth to be kept as
stock cultures.
2.8.2 Identification of group III organisms
Group III organisms were identified by their biochemical properties (lecithinase and
lipase production), morphology when examined in wet films by phase contrast
microscopy and Gram stain by light microscopy (Gram positive rods with
subterminal oval spores), and gas liquid chromatography (GLC) profiles (Brown et
al, 1996).
2.8.3 Bacterial strains
Bacterial type strains of Group III botulinum organisms - C. botulinum type C and D,
and C. novyi type A - were obtained from the National Culture of Type Strains
(NCTC; Central Public Health Laboratory, London, UK), Professor S. Nakamura
(Kazazawa University, Japan), G.R. Smith (Institute of Zoology, Zoological Society
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of London, UK), the Glaxo collection and the Microbial Pathogenicity Reasearch
Laboratory (MPRL) collection (MPRL, Edinburgh University, Teviot Place,
Edinburgh, UK) (Table 2.1).
Table 2.1: Group III type strains used
Lab ID Organism Original ID Source
MPRL 3922 C. botulinum type C„ NCTC 8264 NCTC
MPRL 2510 C. botulinum type Cp NCTC 3732 NCTC








MPRL 3923 C. botulinum type D NCTC 8265 NCTC
MPRL 2530 C. novyi type A NCTC 538 NCTC
MPRL 2531 C. novyi type A GR 2A S277/64(B)
Glaxo collection
MPRL 2532 C. novyi type A NCTC 6737 NCTC
MPRL 2533 C. novyi type A NCTC 6735 NCTC
MPRL 2534 C. novyi type A 2798 MPRL
Original source
unknown




2.8.4 Culture of strains for extraction of surface antigens
All media were pre-reduced before use, and incubation was carried out at 37°C in
an anaerobic work-station (MK3, Don Whitley Scientific). Lyophilised cultures of
type strains were inoculated into cooked meat broth and incubated for 24-48h to
prepare stock cultures. Stock cultures of type strains and isolates were subcultured
into 3 ml of protease peptone yeast extract broth containing 0.5% glucose (PPY-G;
Brown et al, 1996), and after overnight incubation these starter cultures were used
to inoculate 20 ml of the same medium. The 20 ml cultures were incubated
overnight; the cells were then harvested.
2.8.5 EDTA extraction of surface antigens
Bacterial cells were harvested by centrifugation at 3,800g for 20 min. The pellet was
resuspended in 10 ml of PBS pH7.3 (PBS tablets; Oxoid) and washed twice by
centrifugation at 3,800g for 20 min. The bacterial cells were resuspended in 1ml
PBS containing 10mM EDTA, incubated for 90 min at 45°C and then treated for 60
sec in an ultrasonic bath. The treated cells were transferred to microcentrifuge
tubes and the cells removed by centrifugation at 12,700g for 2 min. The
supernatants containing the surface extracted antigens were collected and
centrifuged again at 12,700g for 2 min. The supernatants were collected and stored
at -20°C before use.
2.8.6 Guanidine hydrochloride extraction of surface antigens
Bacteria were cultured, harvested and washed as for EDTA extraction. The pellets
were then resuspended in 1.5 ml PBS containing 5M guanidine hydrochloride
(GHCI), transferred to microcentrifuge tubes and incubated at room temperature for
2 h with shaking. Cells were then removed by centrifugation at 12,700g for 2 min;
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the supernatants were collected and centrifuged again for 12,700g. The
supernatants containing the extracted antigens were collected and the GHCI
removed by overnight dialysis at 4°C against 6.25 mM Tris HCI, pH6.8 using a
SpectralPor®Microdialyser (Orme Scientific Ltd., Middleton, Manchester, UK) with a
membrane of 10,000 MW cut-off. The dialysed extracted antigens were stored at -
20°C until required.
2.8.7 SDS-Polyacrylamide gel electrophoresis (PAGE)
SDS-PAGE was done on 10% slab gels with the buffer system of Laemmli (1970) as
described by Hancock and Poxton (1988). Samples (25-70pl) of EDTA and GHCI-
extracted antigens from type strains and isolates were run so that there was
approximately 50pg protein per track. Gels were stained with Coomassie blue as
described by Hancock and Poxton (1988), or transferred to nitrocellulose for
immunoblotting.
2.8.8 Immunoblotting with rabbit anti-C. novyi type A antiserum
The procedure is based on the method of Towbin et al (1979) as described by
Hancock and Poxton (1988). After separation by SDS-PAGE, the surface antigens
were transferred from the gel onto nitrocellulose paper (0.2pm pore size) overnight
at 12V in electroblot buffer containing 0.025M Tris, 0.192M glycine and 20% (v/v)
methanol at pH 8.3. The gel was then discarded and the nitrocellulose was washed
in Tris buffered saline (TBS:0.02M Tris, 0.5M sodium chloride, pH7.5) for 10 min on
shaker. All the following steps were carried out at room temperature with shaking.
The nitrocelluose was blocked for 45 min with TBS containing 3% (w/v) gelatin, and
then incubated for 3 h with C. novyi type A antiserum (raised against C. novyi type A
MPRL 2530) diluted 1 in 200 in TBS containing 1% gelatin. The nitrocellulose was
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then washed twice in TBS containing 0.025% Tween 20 (TTBS) for 10 min, and then
incubated for 1 h with anti-rabbit IgG-horse radish peroxidase (HRP) conjugate
(Sigma) diluted 1 in 1000 in TBS containing 1% gelatin. The nitrocellulose was then
washed twice in TTBS for 10 min, followed by three changes of tap water to remove
all the Tween. HRP-colour development solution consisted of 60 mg 4-chloro-1-
naphthol (BioRad Laboratories, CA 94547,USA) dissolved in 20ml of methanol,
added, just before use, to 100ml TBS containing 60ptl of a 30% solution of hydrogen
peroxide. The HRP-colour development solution was added to the nitrocellulose
and allowed to develop for 5-25 min. The reaction was stopped by rinsing several
times with tap water and a final rinse with distilled water.
2.8.9 Immunoblotting with equine serum
The EDTA-extracted surface antigens of Group III type strains and isolates,
separated by SDS-PAGE, were immunoblotted with equine serum as described
above, except that equine serum was used at a dilution of 1 in 50. The conjugate,
rabbit anti-horse IgG-HRP (Sigma), was used at a dilution of 1 in 1000.
2.8.10 Analysis of gels
The molecular weights of the bands were calculated using Phoretix 1-D gel analysis
software (Phoretix International, Newcastle upon Tyne, UK) with Novex Mark12™
molecular weight standards (Novex™, San Diego, CA 92121, USA) for calibration of
protein bands on Coomassie stained gels, and Novex See Blue™ pre-stained
molecular weight standards for calibration of bands on immunoblots.
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2.9 Polymerase chain reaction (PCR)
2.9.1 Extraction of DNA for PCR
Bacteria were cultured as described for extraction of surface antigens (Chapter
2.8.4). Bacteria were harvested by centrifugation at 11700g for 10 min at 4°C. The
pellet was washed with 10 ml of 0.15M NaCI and 15mM sodium citrate pH7.0 (SSC)
and centrifuged at 11700g for 10 min at 4°C. The pellet was resuspended in 1 ml of
0.01 M sodium phosphate buffer in 20% sucrose pH7.0 containing 2.5 mg/ml
lysozyme (Sigma) and incubated at 37°C for 45 min. Tris-EDTA buffer pH7.4 (TE
buffer; 10mM Tris and 1mM EDTA) containing 1% SDS was added (9 ml) with
1 mg/ml proteinase K (Sigma) and incubated overnight at 37°C. An equal volume of
phenol:chloroform mixture (10ml; Sigma) was added and shaken to form an
emulsion before centrifugation at 4000g for 15 min at 4°C. The clear fraction at the
top was removed using a glass pipette and transferred to a thick walled glass
universal bottle; the phenol:chloroform separation was repeated until there was no
white precipitate at the interface. The DNA was precipitated by the addition of 2.5
volumes of ice-cold ethanol and 0.1 volume of sodium acetate (3M). Nucleic acids
were collected by centrifugation at 35000g for 30 min at 4°C; the supernatant was
removed and the pellet allowed to dry before resuspension in 500pl TE buffer and
storage at -20°C. DNA was visualised by separation on a 0.7% agarose gel and
staining with ethidium bromide. The absorbance at A280/A260 was measured to
quantify the amount of DNA present.
Initially, DNA was extracted from type strains as described above. However, for
DNA extraction from isolates the process was scaled down, starting with a 1 ml
volume of culture. A step to remove RNA was included, with incubation with 2pl
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RNase (1 Ojag/ml; Sigma) for 1 h at room temperature, after overnight incubation with
proteinase K.
2.9.2 PCR reaction conditions
All PCR reactions were carried out in 10Opil reaction buffer (GibcoBRL) containing
1.5mM MgCI2, 100nM of each primer, 200pM of each dNTP, 5pl of DNA (extracted
as described above) and 2.5 units Taq polymerase (GibcoBRL). The primers used
were chosen from published sequences; the PCR cycling conditions for each primer
set were as published for use with those primers. The primer sequences are given
in Table 2.2, and cycling conditions in Table 2.3; BAC-1/BAC-2 primers were used
at the same reaction conditions as the NOVA primers. The primers were used to
amplify toxin genes from the DNA of type strains and isolates; DNA of type strains
that were known to contain a particular gene were used as positive controls. A
negative control, containing no template DNA, was also included in each PCR
reaction.
2.9.3 Visualisation of PCR products
PCR products (10pl) were added to gel loading solution (2pl; Sigma) and run on 1%
agarose gels in TAE buffer (40mM Tris and 2mM disodium EDTA, pH8.0) containing
ethidium bromide (0.1mg/ml). Products were visualised under ultraviolet light.
Initially, a 4>X174 Hae III digest (Sigma) was used as a molecular weight marker to
size products; the digest had fragment sizes between 1,353 and 72 base pairs.
Later the Readyload™ 100bp ladder (GibcoBRL) was used to size products; this
DNA ladder gives bands between 100bp and 2000bp.
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Detection of BoNT/C in the Gl tract
3.1 Results
3.1.1 Direct Detection of BoNT/C in Gl contents
The presence of BoNT/C, in the ileum contents and faeces of horses with and
without grass sickness, was investigated using a sandwich ELISA specific for
BoNT/C. Overall, BoNT/C was detected directly in 45% (13/29 horses) of samples
of ileum contents from horses with grass sickness compared with only 4% (1/28
horses) of controls. BoNT/C was directly detected in 44% (20/45 horses) of faecal
samples from horses with grass sickness compared with only 4% (3/77 horses) of
controls.
BoNT/C was directly detected in the ileum contents of a greater proportion of
chronic (50%) and acute cases (50%) than subacute cases (29%) (Fig. 3.1). The
toxin was also detected in the faeces of a greater proportion of chronic (50%) and
acute cases (46%) than subacute cases (17%) (Fig. 3.1).
The one control case with detectable toxin in the ileum had been initially clinically
diagnosed as having acute grass sickness. However, histopathology at post¬
mortem failed to show the characteristic lesions, and the final diagnosis was
uncertain. The three control horses that had detectable toxin in their faecal
samples, included two orthopaedic cases (one of which had had chronic grass








Figure 3.1: Percentage of horses with directly detectable BoNT/C in the ileum
and faeces, i.e. before enrichment. The number on top of each bar represents
the number of horses in each category.
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3.1.2 Quantitation of BoNT/C in Gl contents
The amount of BoNT/C detected in the ileum and faeces was quantified as ng of
BoNT/C per gram of wet weight sample, using a standard curve (Fig. 3.2).
Comparisons between samples should be made with caution as the concentration of
toxin is calculated using the wet weight of the sample, and there will be some
variation in consistency between samples. The volume of gut contents can vary
significantly between horses, which may also affect toxin detectability.
There is a statistically significant difference in the levels of toxin detected in the
ileum, between the CGS group and controls (p=0.001), between the SGS group and
controls (p<0.05) and between the AGS group and controls (p<0.001) (Fig. 3.3a).
For the faecal samples, there is a statistically significant difference in the levels of
toxin directly detected between the CGS group and controls (p<0.001), and between
the AGS group and controls (p<0.001) (Fig. 3.3b).
The highest level of BoNT/C (10430ng/g) was detected in the faeces of a horse with
chronic grass sickness of 15 days duration that was sampled at post-mortem. The
ileum of this horse also contained detectable toxin (79.2ng/g). The one control
horse in which BoNT/C was detected in the ileum had a low level of toxin (10ng/g
wet weight sample), but note that this horse had symptoms typical of grass
sickness.
3.1.3 Detection of BoNT/C in Gl contents after enrichment
In order to demonstrate the presence of a BoNT/C-producing organism in the Gl
tract, samples of Gl contents were enriched in culture medium and the culture






Figure 3.2: Example of BoNT/C standard curve with BoNT/C diluted fivefold
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Figure 3.3: Scatterplot showing the range of BoNT/C concentrations directly
detected in (a) ileum samples and (b) faecal samples. The number of samples in
each category which did not have detectable toxin are represented as a proportion of
total sample number in each group, by the numbers below the reference line of the
BoNT/C standard of 0.8ng/ml, on the graph. The detectable limit of the assay is
considered to be equivalent to 0.8ng/ml of the BoNT/C on the standard curve from.
the ELISA. Statistical differences between groups are shown. The mean amount or
BoNT/C in the ileum was 42.9ng/g wet weight sample for horses with CGS; 1.8ng/g
for SGS; 110.5ng/g for AGS and 0.4ng/g for controls. The mean amount of BoNT/C
in the faeces was 230.5ng/g wet weight sample for horses with CGS; 3.8ng/g for
SGS; 504.9ng/g for AGS and 0.3ng/g for controls.
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CMC-1 medium, BoNT/C was detected in 48% (14/29) of ileum samples and 44%
(20/45) of faecal samples from horses with grass sickness, compared to only 7%
(2/27) of ileum samples and 8% (6/72) of faecal samples from controls. Not all
samples that had detectable levels of toxin directly were positive for BoNT/C after
enrichment, and vice versa.
The two control horses, out of 27, with detectable BoNT/C in the ileum after
enrichment were the horse clinically diagnosed as AGS but not histopathologically
confirmed, and a horse with a hepatic disorder. The six horses, of 72 controls, with
detectable BoNT/C in the faeces after enrichment were two orthopaedic cases (one
of which had had grass sickness 16 months previously), two healthy horses, a horse
in-contact with a case of grass sickness, and a horse with ileus.
Ileum samples from horses with acute grass sickness had a higher proportion of
samples positive for BoNT/C (75%), after enrichment, than SGS (43%) and CGS
(20%) (Fig. 3.4). Faecal samples from horses with AGS also had a higher
proportion of samples positive for BoNT/C (54%), after enrichment, than CGS (42%)
and SGS (33%) (Fig. 3.4).
3.1.4 Longitudinal study of horses with CGS
Twelve chronic cases had more than one faecal sample collected, over the course
of the disease. Eleven of these 12 horses were negative for BoNT/C when initially
sampled; five of these 11 had directly detectable levels of BoNT/C in later faecal
samples (whilst the other six remained negative). One horse had
detectable BoNT/C in both faecal samples that were collected. Table 3.1 shows how
the levels of detectable toxin in the faeces of the six horses varied over the course
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Figure 3.4: Percentage of horses with detectable BoNT/C in the ileum and
faeces after enrichment. The number on top of each bar represents the number
of horses in each category.
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of the disease. Five of the six horses recovered; the sixth was euthanased, and a
level of 335ng/g BoNT/C was detected in the ileum at post-mortem. Of the six
horses that had no detectable toxin, three recovered and three were euthanased
(one of these had toxin detectable after enrichment).
Table 3.1: Detection and quantitation of BoNT/C, before and after enrichment, in



















97/150 75 5 No No Euthanasia
75 7.2 Yes
98/540 47 38 No No Recovered
47 42 Yes
97/545 40 6 No Yes Recovered
39 1.36 No
97/623 67 23 147.5 No Recovered
66 43 Yes











3.1.5 Detection of BoNT/C in Gl contents by direct detection and/or
enrichment.
BoNT/C was detected, both before and after enrichment, in the faeces of 27% of
horses with CGS, 17% of horses with SGS and 46% of horses with AGS, compared
to 3% of controls. BoNT/C was detected, both before and after enrichment in the
ileum contents of 20% of horses with CGS, 14% of horses with SGS and 42% of
horses with AGS, compared to 4% of controls.
When the detection methods are combined for individual horses i.e. when toxin can
be detected in the ileum and/or faeces by direct detection and/or enrichment, then
74% of acute cases, 67% of subacute cases and 67% of chronic cases have
detectable toxin compared to 10% of controls.
3.1.6 Detection of BoNT/C in other animals with dysautonomia
The intestinal contents of cats, rabbits and a hare, all with histologically confirmed
dysautonomia, were investigated for the presence of BoNT/C and BoNT/C-
producing organisms. BoNT/C was directly detected in the intestinal contents of
69% (11/16) of cats with dysautonomia but not in the Gl contents of the two cats that
but did not have dysautonomia (these two cats had diarrhoea and were part of the
same breeding colony as 13 of the cats with dysautonomia). The levels of BoNT/C
present in the intestinal contents ranged from 5.3 to 1198.8ng BoNT/C per g wet
weight sample. After enrichment, BoNT/C was detected in 56% (9/16) of cats with
dysautonomia and in one of the cats with diarrhoea. BoNT/C was detected in the
intestinal contents either directly and/or after enrichment in 81% (13/16) of the cats
with dysautonomia. Intestinal contents from only one hare and two rabbits with
dysautonomia were investigated: BoNT/C was detected directly in the intestinal
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contents of the hare and one of the rabbits. Levels of 74 ng BoNT/C per g of wet
weight sample were detected in the hare and 2375 ng of BoNT/C per g of wet
weight sample in the rabbit. After enrichment, BoNT/C was detected only in the
sample from the rabbit that had also had BoNT/C detectable directly.
3.2 Discussion
3.2.1 Detection of BoNT/C in horses
The detection of BoNT/C, before and after enrichment, in horses with grass sickness
shows that there is a strong association between the presence of BoNT/C and
BoNT/C-producing organisms, in the equine Gl tract, and a clinical diagnosis of
equine grass sickness. Toxin was detected antemortem in faecal samples from
chronic cases and post-mortem in ileum and faecal samples of all categories of
grass sickness. Toxin, however, was not detected in all the samples from grass
sickness cases. This may be a reflection on the sensitivity of the assay; the ELISA
is approximately 100 times less sensitive than the conventional mouse (lethality)
bioassay that can be used for toxin testing. Horses are extremely sensitive to
botulinum toxins, and the level of circulating toxin in horses with classical botulism is
usually below the threshold for detection by the mouse bioassay (Whitlock and
Buckley, 1997). Only a very small amount of toxin may be needed to exert a clinical
effect. The absence of detectable toxin in the ileum and faeces may also be due to
the rapid absorption of BoNT/C from the gut, destruction by proteases or
neutralisation of the toxin by mucosal antibodies. Specific IgA to BoNT/C has been
detected in the ileum contents and faeces of horses with grass sickness (Chapter
6.1.2).
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Another factor that may affect the ability to detect BoNT/C is the point in the disease
at which the sample was taken (as well as the volume of gut contents present at
time of sampling). This is of particular relevance with respect to the chronic cases,
where the disease can last from several weeks to several months. The sampling of
horses with chronic grass sickness over the course of the disease showed that the
toxin could be detected in the faeces of six horses towards the end of the disease,
whereas five of these horses had been negative when tested earlier. Five of these
six horses were considered to have recovered but still had toxin in their faeces close
to or on the date that they were sent back to their owners. The ability to detect toxin
in the faeces of these horses is therefore not necessarily an indicator for a poor
prognosis. Horses may be able to tolerate a sub-clinical level of toxin in the faeces:
toxin produced in the large intestine may be poorly absorbed, or destroyed, in
healthy horses. Colonisation of infant mice with C. botulinum does not cause illness
despite the detection of up to 2000 adult mouse intraperitoneal 50% lethal doses of
toxin in the colon and caecum. This is thought to be due to localisation of the toxin to
the colon where it would be poorly absorbed (Sugiyama, 1980).
The presence of toxin in the ileum is probably a more significant finding with respect
to clinical outcome. BoNT/C was detected, pre-enrichment, in the ileum contents of
only one of 28 controls. As noted previously, this horse had been clinically
diagnosed as an acute grass sickness case, however the diagnosis was not
confirmed histologically at post-mortem. This case highlights the need to investigate
the possible role of C. botulinum type C in cases presenting with clinical symptoms
similar to grass sickness. The ileum sample from this horse, as well as an ileum
sample from a horse with a hepatic disorder, had toxin present after enrichment,
demonstrating the presence of C. botulinum type C in the upper Gl tract of only two
control horses.
122
It is interesting to note that the acute grass sickness cases had a higher mean level
of toxin in the ileum and faeces, than the other categories. It is possible that acute
grass sickness may result from exposure to a large amount of toxin whereas the
chronic form may result from the exposure to smaller amounts of toxin over a longer
period of time (Doxey et al, 1995a). The clinical severity and duration of the disease
correlates to the extent of enteric neuronal damage. Enteric neuropathy is
widespread and more severe in acute cases but in chronic cases the neuronal loss
is less and tends to be localised to the distal small intestine (Scholes et al, 1993a).
A higher percentage of horses with acute grass sickness had detectable BoNT/C-
producing organisms in both the ileum and faeces compared to horses with chronic
or subacute grass sickness; this may be evidence of a wider distribution of C.
botulinum type C in horses with acute grass sickness, which may account for the
more widespread enteric neuronal damage observed in these horses.
The hypothesis that is being investigated is that equine grass sickness is caused by
a toxicoinfection with C. botulinum type C. The diagnosis of a toxicoinfection
requires the demonstration of the presence of both toxin and toxin-producing
organism in the affected animal, as is the case for infant botulism (Hatheway, 1979).
42% of horses with acute grass sickness were found to have both BoNT/C and a
BoNT/C-producing organism in the Gl tract, supporting the hypothesis of a
toxicoinfection. The presence of C. botulinum type C in the samples is
demonstrated by detecting the toxin in enrichment culture supernatants. The
production of this neurotoxin is encoded on a prophage that can be lost or acquired
during growth and sporulation. Therefore the detection of BoNT/C after enrichment
does not necessarily mean that an organism was producing toxin in vivo, and
conversely an organism that was producing toxin in vivo may not be detected in
culture due to loss of the prophage. C. botulinum type C is a particularly fastidious
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organism, and successful culture and isolation can be very difficult. A significant
number of samples do demonstrate the presence of C. botulinum type C, for
example 75% of ileum samples from acute cases. The samples, which do not have
detectable toxin after enrichment, could be due to the absence of organism in the
enriched sample, prophage instability, or inhibition of growth or toxin production by
other organisms present. Bacillus and other clostridial species have been shown to
be inhibitory to the growth of C. botulinum type C (Sandler et al, 1998; Graham
1978). The optimum growth temperature for C. botulinum type C appears to vary for
different strains between 30-42°C, and the amount of toxin produced in the culture
supernatants has been shown to be inversely related to growth (Hyun and
Sakaguchi, 1988). This appears to be due to the intracellular accumulation of toxin.
BoNT/C has been shown to bind to specific polysaccharide moieties of the
peptidoglycan of C. botulinum type C strains. Bacterial cell-bound toxin has
increased oral toxicity compared to free toxin when given to chickens (Hyun and
Sakaguchi, 1989). It has been hypothesised that cell bound toxin may be important
in the pathogenesis of toxicoinfectious botulism in broiler chickens. The toxin is
bound to the cell surface via the non-toxic component with which the toxin is
associated; binding occurs at pH2 (Hyun and Sakaguchi, 1989). The ingestion of C.
botulinum type C with intracellular toxin was also more toxic to chickens than the
cell-free toxic supernatant (Hyun and Sakaguchi, 1989). Intracellular and cell-
associated toxin may play a role in the toxicoinfection in other animals, including
grass sickness.
Only six of 72 control faecal samples contained an organism capable of producing
BoNT/C after enrichment. This may indicate the low carriage of toxigenic organisms
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in the normal equine population, or, it may suggest that there are factors preventing
detection of the organisms. Characterisation of isolates from horses with grass
sickness has shown that they resemble C. novyi type A, rather than C. botulinum
type C (Chapter 4). Whilst this does not preclude their ability to produce BoNT/C if
infected with the appropriate bacteriophage, it is possible that non-toxigenic
organisms are normally carried in the Gl tract. These non-toxigenic organisms
would not be detected by the enrichment method used in this study. A PCR for the
detection of C. botulinum type C and related organisms is currently being developed
to enable the more accurate assessment of the carriage of these organisms in the
equine population.
There are some differences in opinion as to the clinical relevance of Clostridium
botulinum isolated from the Gl tract of animals (Kinde et al, 1991). The organism is
commonly found in soil samples and aquatic sediments (Hatheway, 1990) but its
distribution can vary considerably within the local area (Smith, 1975b). Different
types of C. botulinum are found in different geographical areas; for example C.
botulinum type B is predominant in the soils in the eastern US, and consequently
this serotype is the major cause of adult equine botulism and shaker foal syndrome
in that area. Type C is a cause of equine botulism in Europe, but is less common in
the US despite being the predominant type isolated form soils in Florida (Johnston
and Whitlock, 1987). Types C and D have been described as obligate parasites of
animals and birds, seldom being isolated from the soil unless from an area where
birds or domestic animals congregate (Smith, 1975b). Spores of C. botulinum are
commonly found in the faeces of herbivores without clinical symptoms (Kinde et al,
1991). However, it has been reported that spores are rarely isolated from normal,
healthy horses that are not at risk from botulism and that toxin has not been isolated
from the faeces of an adult animal antemortem (Johnston and Whitlock, 1987).
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The results of this investigation have demonstrated that both the organism and the
toxin can be detected in the faeces of horses antemortem, as well as the ileum of
horses post-mortem; these animals did not present with classical botulism but
equine grass sickness. It is important to address the question why these horses do
not present with classical symptoms of botulism. Equine grass sickness does share
some clinical similarities to botulism, particularly in the acute form (Tocher et al,
1923, Greig, 1928). However, many of the neuromuscular symptoms characteristic
of classical botulism are not observed. The chronic and subacute forms develop a
very tucked up 'greyhound-like' abdomen. This is strikingly similar to the 'wasp-
waist' seen when laboratory mice are inoculated with botulinum toxins (I.R. Poxton,
personal communication).
Equine grass sickness is thought to be associated with intestinal colonisation of C.
botulinum with in-vivo production of toxin(s), rather than ingestion of pre-formed
toxin - which is the cause of classical botulism. Consequently the enteric nervous
system of the horse is exposed to a high dose of locally produced toxin, causing
severe neuronal damage and initiating the Gl dysfunction associated with the
disease. It is proposed that there is a concentration gradient affect away from the
focus of toxin production, perhaps generated by axonal transport, with the more
peripheral ganglia being affected to varying degrees. If this is the case, then it is
possible that insufficient neurotoxin reaches the peripheral cholinergic synapses at
the neuromuscular junction to cause the neuromuscular symptoms observed in
botulism (in classical botulism the pre-formed toxin is ingested and rapidly absorbed,
becoming systemic). Hodson et al (1984b) observed that changes in the coeliaco-
mesenteric ganglion resembled those of classical retrograde degeneration after
axotomy. This supports the hypothesis that the primary lesion is in the Gl tract.
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There are some differences in the clinical presentation of toxicoinfectious botulism in
humans (infant botulism, and the extremely rare adult form) compared to ingestion
of pre-formed toxin, particularly with respect to Gl symptoms. Nausea and vomiting
occur in food-borne botulism but not in infant botulism; constipation is a prominent
feature of infant botulism. Disruption or immaturity of normal flora, disturbance in
gut motility, and compromisation of the gastric acid barrier, can all predispose to
intestinal infection with C. botulinum in humans (Chia et al, 1986). Signs and
symptoms of autonomic dysfunction, both parasympathetic and sympathetic, may
be prominent in human botulism (Tacket and Rogawski, 1989); the disease has also
been observed in humans where there is mainly cholinergic autonomic dysfunction
with no neuromuscular involvement (Jenzer et al, 1975).
The symptoms of equine grass sickness may result from the involvement of the
three toxins produced by C. botulinum type C. All three toxins could in theory cause
the neuronal damage observed in EGS. To date only the presence of the C1 toxin
(BoNT/C) has been investigated; reagents to detect the C2 and C3 toxins were not
obtainable. However, the C2 and C3 toxins, together with the in-vivo growth of the
organism may be responsible for the difference in clinical symptoms between grass
sickness and botulism. C2 toxin has been shown to cause hypotension,
haemorrhage, cytotoxicity and increase in vascular permeability (Aktories et al,
1986). In the intestine it has been shown to cause intestinal secretion, fluid
accumulation, histopathological changes (Ohishi, 1983b; Ohishi and Odagiri, 1984)
and inhibition of contraction of guinea pig ileum myenteric plexus longitudinal
muscle preparation (Mauss et al, 1989). However, the role of the C2 toxin in the
pathogenesis of disease in vivo has yet to be determined.
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Ultrastructural investigation of the neuronal lesions of grass sickness has indicated
marked abnormalities of the neuronal cytoskeletal, cytoplasmic and secretory
proteins with disruption or loss of the Golgi associated membranes (Griffiths et al,
1993). It is possible that the C2 and C3 toxins could cause the ultrastructural
damage observed. Actin-polymerisation has a role in governing secretion from
neural cells and consequently is thought to play some role in neurotransmission
(Viviani et al, 1996). All three of the toxins produced by C. botulinum type C could
therefore affect neurotransmission in some way, either by their effect on the
cytoskeleton or the secretory vesicles of the exocytic pathway. The neurotoxicity of
BoNT/C (Williamson and Neale, 1998) may be able to account for some of the
neuronal degeneration that is observed in grass sickness. The type C neurotoxin is
the only botulinum neurotoxin that has been shown to cause overt neuronal
degeneration in vitro; the other botulinum neurotoxins have only a functional effect.
The enteric cholinergic neurones from the ileum of horses with acute grass sickness
exhibit altered cholinergic mechanisms, with a reduction in the release of
acetylcholine (Murray et al, 1994). Botulinum neurotoxins inhibit the release of
acetylcholine from cholinergic nerves. The prokinetic drug Cisapride, an indirect
cholinergic agent, facilitates the release of acetylcholine from the postganglionic
nerves of the myenteric plexus in the gut. This drug has been shown to be of some
therapeutic benefit in the treatment of selected cases of chronic grass sickness
(Milne et al, 1996). Acetylcholine release is stimulated from the remaining
morphologically normal neurones and increases gut motility.
The hypothesis that grass sickness is caused by toxicoinfection with C. botulinum is,
to some extent, a reinvestigation of the hypothesis originally put forward by Tocher
et al in 1923. Their work was not widely accepted at the time. One of the major
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criticisms made, related to their inability to prove conclusively that the organism they
had isolated from grass sickness horses was Bacillus botulinus - they could only say
that it morphologically and toxigenically resembled this organism. Furthermore
there was a lack of acceptance, by Tocher's contemporaries, of the ability of C.
botulinum to produce toxin within a living animal (Anon, 1927; Greig, 1942).
Serotype C of C. botulinum was only first identified in 1922 (Bengston, 1922;
Seddon, 1922). Therefore, this was almost certainly not the serotype that was
vaccinated against in 1922, particularly as the antitoxin used was of US human
origin. C. botulinum type C had not been identified as a cause of human botulism at
that point, and there have only been five suspected human type C cases since
(Sonnabend et al, 1985). C. botulinum type A and B neurotoxins, responsible for
causing botulism in humans, are not immunologically cross-reactive with BoNT/C.
At this point, it is not possible to say whether C. botulinum type C is the primary
cause of grass sickness, a causal co-factor, or whether the organism grows and
produces its toxins as a secondary event due to reduced gut motility. Investigation
of horses with Gi stasis for reasons other than grass sickness could assist in
determining whether type C toxin is produced as a consequence of this stasis. Only
five faecal samples and two ileum samples from horses with GI dysfunction, but not
grass sickness, have been assayed to date. This has shown the presence of toxin
in one faecal sample from a horse with colic, and in one ileum sample from a horse
that had presented clinically with acute grass sickness, but the diagnosis was
unknown after post-mortem. The number of samples investigated is not sufficient to
determine whether toxin is produced after the onset of GI stasis, independently of
grass sickness.
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3.2.2 Detection of BoNT/C in other species with dysautonomia
The clinical, pathological and epidemiological similarities seen between
dysautonomias in cats, rabbits and hares, and equine grass sickness have led to the
suggestion of a common aetiology (Pollin and Griffiths, 1992). The detection of
BoNT/C, before and after enrichment, in the intestinal contents of a rabbit, hare and
cats with dysautonomia, supports both the theory of a common aetiological agent
and the role of toxicoinfection with C. botulinum type C in the cause of equine grass
sickness.
A high percentage of cats with dysautonomia had BoNT/C present in the intestine
and/or a BoNT/C-producing organism. The demonstration of C. botulinum type C in
cats with dysautonomia is perhaps the most surprising as the diet and intestinal
physiology of cats and horses are quite different; rabbits and hares are herbivores
and exposed to the same grazing environment as horses. It would therefore be
likely that hares and rabbits could also acquire or carry similar enteric organisms as
the horse. The cats in question were part of a closed colony in a laboratory. Either
C. botulinum type C is carried by cats or was introduced by an external source,
possibly in the food.
3.2.3 Summary
In summary, there is evidence to support the hypothesis that equine grass sickness
(and possibly other similar dysautonomias) is a toxicoinfection with C. botulinum
type C, with toxin production and absorption predominantly in the ileum. The
organism is either normally present in the large intestine, and overgrows into the
ileum, or the organism is taken up in spore form and is able to germinate in the
ileum, following a change in the environment of the Gl tract due to an environmental
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trigger. Horses are notoriously sensitive to changes in diet, and grass sickness is
associated with grazing, and a change in pasture. The trigger therefore could be a
nutritional one, affecting the gut flora, and facilitating the colonisation of the intestine
with C. botulinum and its subsequent toxin production. The disease severity is likely
to be influenced by an interaction of factors such as the amount of toxin the horse is
exposed to, the local mucosal and systemic immune response to the toxin, the
immune status at the onset of disease and the inherent susceptibility of the horse.
Whether C. botulinum type C is the cause of grass sickness or whether it is involved
as a secondary event, the detection of high levels of toxin in the ileum at post¬
mortem, and ante-mortem in faeces in horses with equine grass sickness, together
with the known sensitivity of horses to botulinum toxins, supports a significant role
for the involvement of C. botulinum type C in equine grass sickness.
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Chapter Four
Isolation and characterisation of Group III organisms
4.1 Results
4.1.1 Isolation of Group III organisms
Sixteen isolates, identified as Group III organisms, were isolated from enrichment
cultures of Gl contents. Group III organisms include C. botulinum type C and D and
C. novyi type A. Twelve Group III organisms were isolated from the Gl contents of
nine horses; three Group III organisms were isolated from the small intestine of a
hare and one from the small intestine of a cat (Table 4.1). All of these organisms
were isolated from animals that had dysautonomia at the time of sampling, or had
previously had dysautonomia and recovered, or had recently been in contact with a
horse with dysautonomia (Table 4.1). Repeated subculturing onto fresh EYA plates
was required before a pure culture could be obtained of any of these isolates, due to
overgrowth on the plates by other bacteria present in the Gl samples.
The Group III isolates, from these animals, produced both lipase and lecithinase and
were Gram positive (or Gram variable) rods with subterminal spores. The isolates
all produced proprionic and butyric volatile fatty acids (VFA) and varying amounts of
acetic and valeric VFA (Table 4.2). These GLC profiles are characteristic of C.
botulinum type C or D or C. novyi type A.
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Table 4.1: Isolates identified as Group III botulinum organisms: description of the
animal and sample from which they were isolated.












































































Horse GS Ileum NT NT
1S. I = small intestine
2NT= not tested
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Table 4.2: GLC profiles of volatile fatty acids produce by the isolates. P= proprionic
acid, B=butyric acid, A=acetic acid, V=valeric acid, L=lactic acid, S=succinic acid.
Letters in upper case represent levels of fatty acids above 10 pmoles/ml, letters in
lower case represent levels of fatty acids between 1-10 ^moles/ml, and letters in
brackets represent levels between 0.2-1 pmoles/ml.

















4.1.2 Production of BoNT/C by isolates
The isolates were cultured anaerobically for five days at 30°C, and the culture
supernatants were tested for the presence of BoNT/C by ELISA (as in Chapter 3).
There was no detectable BoNT/C produced by any of the sixteen isolates.
However, five of these organisms were isolated from samples in which BoNT/C had
been detected either directly or after enrichment (Table 4.1).
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4.1.3 Investigation of the surface antigens of Group III type strains and
isolates
SDS-PAGE of EDTA-extracted surface antigens of isolates and Group III type
strains
The surface antigens of the isolates were extracted with EDTA, separated by SDS-
PAGE and stained with Coomassie blue to compare the surface protein profiles.
The surface proteins of the isolates produced complex banding patterns on the gels
(Fig. 4.1). However, there were similarities, observable by eye, between the
isolates. The majority of isolates had three major bands - one observable near the
top of the gel, one at 45-48kDa and one at 32-34kDa (indicated by arrows in Fig.
4.1) - and many minor bands. The second band was not as dominant in Ich 8 (lane
12) and the third band not as dominant in Ich 9, Ich 12 and MPRL 3690 (lanes 15-
17) (Fig. 4.1). Isolates Ich 1, 3, 5, and 7 (lanes 2, 4, 6 and 7 respectively) had very
similar banding patterns to each other, as did Ich 2 and 4 (lanes 3 and 5) (Fig. 4.1).
Lch 11,13 and 10 (lanes 8, 9 and 11) were also very similar; these isolates had a
slightly higher molecular weight (MW) band at the top of the gel. Lch 14 and 15
(lanes 13 and 14) were almost identical and Ich 12 and MPRL 3690 (lanes 16 and
17) were very similar (Fig. 4.1). Lch 6 was run on a different gel (Fig. 4.2, lane 16)
and has a different pattern of surface proteins from the other isolates.
The surface antigens of the Group III type strains were also extracted with EDTA
and separated by SDS-PAGE. The Coomassie blue stained surface protein profiles
of the type strains also produced complex banding patterns (Fig. 4.2); some
similarities were observable. There are similarities in the surface protein banding
patterns within C. botulinum type C type strains and C. novyi type A strains. C.
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similar to each other, as are MPRL 3493 and MPRL 4240 (lanes 4 and 5, Fig. 4.2).
With the C. novyi type A type strains, MPRL 2533 and MPRL 2535 (lanes 13 and
14, Fig.4.2) appear identical by surface antigen profile, and MPRL 2531 and MPRL
2532 (lanes 11 and 12) look very similar. However, The C. novyi type A type strain,
MPRL 2534 (lane 6, Fig. 4.3), is not as similar to the other C. novyi type A strains.
There are bands in common to the isolates and type strains, however the surface
protein profiles of the isolates do not closely resemble those of the type strains.
There are bands at 45-47kDa and 33-34kDa in all of the type strains. However,
these do not appear as dominant as the bands in the isolates, particularly the band
at 33-34kDa (Fig. 4.1 and 4.2). The surface protein profiles of the isolates appear to
be more similar to each other than to the type strains.
SDS-PAGE of Group III surface antigens extracted with guanidine
hydrochloride
Guanidine hydrochloride (GHCI) has been used to extract the S-layers of
Clostridium difficile and other bacteria. The GHCI-extracted antigens of the Group
III strains were separated by SDS-PAGE and stained with Coomassie blue. There
were some minor differences in the Group III surface protein profiles when antigens
were extracted with GHCI compared to EDTA (Fig. 4.3).
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Immunoblot of EDTA-extracted surface antigens with rabbit C. novyi
antiserum
Group III type strains
The EDTA-extracted surface antigens of four type strains of C. botulinum type C
(MPRL 2510, MPRL 3922, MPRL 4240, MPRL 3493), one type strain of C.
botulinum type D (MPRL 3923) and five type strains of C. novyi type A (MPRL 2530,
MPRL 2531, MPRL 2532, MPRL 2534, MPRL 2535) were separated by SDS-PAGE,
transferred to nitrocellulose and reacted with antiserum raised against C. novyi type
A (MPRL 2530). A major difference was observed between the C. botulinum type
C/D and C. novyi type A strains. The antiserum recognised a major band at 46kDa
in four of the five C. novyi type A type strains that was absent in the C. botulinum
type C and D strains; a major band, at 43kDa, was recognised in the C. botulinum
type C and D strains that was absent in four of the C. novyi type A strains (Fig. 4.4
and 4.5). One C. novyi type A type strain (MPRL 2534; lane 8, Fig. 4.4) had the
43kDa band and not the 46kDa band (the apparent weak band at 46kDa is due to
spillage from lane 9). Other cross-reactions were observed with the antiserum
binding to other surface antigens present in the Group III strains. However, the
bands at 43kDa and 46kDa were the only consistent differences between the
immunoblots of C. novyi type A and C. botulinum types C/D strains. These bands
also reacted strongly with the antiserum, suggesting they were significant
immunogenic antigens. This band difference was also observed when the surface
antigens were extracted with guanidine hydrochloride (Fig. 4.5).
In the Coomassie stained gels, bands at both 46kDa and 43kDa were visible in
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botulinum type D). Only the 43kDa band is recognised by the antiserum in the blot.
However, MPRL 3493 and MPRL 4240 (C. botulinum type C strains) have a band at
46kDa but do not have a visible band at 43kDa in the Coomassie stained gel.
However, these strains do have a band at 43kDa that is recognised in the
immunoblot. The C. novyi type A strains have bands at 46-47kDa in the Coomassie
stained gels and a number of fainter bands below this band, including bands at 43-
44kDa. These bands are visible in the immunoblot, but the band at 46kDa is the
dominant band recognised by the antiserum in these strains.
A ladder pattern is visible at the bottom of the immunoblot of the EDTA-extracted
surface antigens of C. botulinum type C and D type strains and the C. novyi type A
type strains (Fig. 4.4, lanes 2-9; Fig. 5, lanes 2, 4, 6, 8, 11, 13 and 17). This ladder
pattern was also observable when the surface antigens were extracted with GHCI
(Fig. 4.5, lanes 3, 5, 7, 9, 12 and 14). This ladder pattern is not observable in the
Coomassie stained gels.
Group III animal isolates
The EDTA-extracted antigens of the 16 Group III isolates (from the horses, cat and
hare) were also separated by SDS-PAGE and then transferred to nitrocellulose. The
C. novyi type A antiserum recognised many surface antigens of these isolates and
significantly bound to a major band at 46kDa, but not at 43kDa in all 16 isolates (Fig.
4.6). This suggested that they were more closely related to C. novyi type A strains
than C. botulinum types C/D, based on the results of the immunoblots with the type
strains.
There are major bands present on the Coomassie stained gels at around 46kDa in
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the gel (Fig. 4.1), that is not as immunogenic as the band at 46kDa in the blot (Fig.
4.6). However, some isolates do not have a band at 46kDa - Ich 8, Ich 12 and
MPRL 3690 - in the Coomassie stained gel (Fig. 4.1, lane 12, 16 an 17 respectively)
and yet have a band at 46kDa in the immunoblot.
The ladder pattern observed at the bottom of the immunoblot in the type strains was
also observed in some of the isolates. Lch 11, Ich 13, Ich 10, Ich 15, Ich 14, Ich 9
(Fig. 4.6, lanes 8,9, 11, 13-15) all had ladder patterns that reacted strongly with the
anti-novyi serum; weakly reacting ladder patterns may be present in Ich 8 (lane 12),
Ich 12 (lane 16) and MPRL 3690 (lane 17). However, Ich 1-7 (Fig. 4.6, lanes 2-7
and Fig. 4.4, lane 16) did not have a visible ladder pattern in the immunoblot. The
isolates could therefore be grouped into two groups on the basis of the presence of
this ladder pattern.
Immunoblot of EDTA-extracted surface antigens with equine serum
The EDTA-extracted surface antigens of Group III type strains and isolates were
blotted with several different equine serum samples. The distinctive band difference
between C. botulinum type C/D and C. novyi type A strains that was observed with
the rabbit antiserum raised against C. novyi type A was not apparent when equine
serum was used. When equine serum sample LH341 c (from a horse with AGS) was
used, it bound to bands at approximately 46kDa and 43kDa in both C. botulinum
type C/D type stains and C. novyi type A type stains (Fig. 4.7a and b). However, the
profile of bands reacting with equine serum varied between serum samples. When
serum sample LH 214c (from a horse with AGS) was used, it bound to a 48kDa and
44kDa band present in the C. novyi type A surface antigens (MPRL 2532), but not at
46kDa (Fig. 4.8a); this serum sample recognised both a 46kDa and 43kDa band in a
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collected from the horse with CGS from which isolate Ich 7 had been isolated,
recognised a band at 46kDa in the surface antigens of both the C. novyi type A and
Ich 7, and a band at 48kDa the C. botulinum type C (Fig. 4.8b). In addition this
serum sample bound to surface antigens at 34, 28, and 24kDa in the isolate; these
three bands were at different molecular weights to those recognised in either the C.
botulinum type C or C. novyi type A.
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4.1.2 Investigation of Group III toxin genes by PCR
PCR detection of the novyi alpha toxin gene
Three out of five C. novyi type A type strains carried the alpha toxin gene (Table
4.3), as demonstrated by the production of a 260bp PCR product, using the NOVA
primers (Fig. 4.9). The lack of PCR product in the other two type strains suggested
that the phage carrying the alpha toxin gene had been lost. PCR of DNA from the
animal isolates, with the NOVA primers, produced a 260bp product in three out of
the 16 isolates, Ich 14, Ich 15, and MPRL 3690 (Table 4.4).
PCR detection of the BoNT/C and BoNT/D genes
PCR with the CS primers did not produce a product with any of the type strains or
isolates, including the positive control, a C. botulinum type Ca type strain (MPRL
3922). However, subsequent analysis of the culture supernatants of the type strains
for the presence of BoNT/C by ELISA confirmed that none of the type strains were
producing BoNT/C. The isolates also did not produce BoNT/C when tested by
ELISA. Although the results of the PCR could not be confirmed due to the lack of a
positive control, the ELISA results would suggest that none of the type strains or
isolates were carrying the BoNT/C gene. These results suggest that the C.
botulinum type Ca strain had lost the phage carrying the BoNT/C gene.
PCR with the DS primers produced a 497bp product (Fig. 4.10) from DNA of C.
botulinum type D type strain (NCTC 3923: lane 7) demonstrating the presence of the
BoNT/D gene. None of the other Group III type strains or isolates were carrying the
BoNT/D gene (Tables 4.3 and 4.4).
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Figure 4.9: Detection of a 260bp PCR product demonstrating the presence of the C.
novyi type A alpha toxin gene in MPRL 2530, MPRL 2531 and Ich 14 and 15. Lane 1,
<|)X174 Hae III digest; lane 2, MPRL 2530 (standard); lane 3, MPRL 2530 (miniprep),
lane 4, MPRL 2531; lane 5, MPRL 2533; lane 6, Ich 9; lane 7, Ich 14; lane 8, Ich 15;
lane 9, no template DNA.
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Figure 4.10: Detection of a 497 bp PCR product demonstrating the presence of the C.
botulinum type D neurotoxin gene in MPRL 3923. Lane 1, 100bp DNA ladder; lane 2,
MPRL 3922 with CS11/CS22; lane 3, MPRL 3922 with DS11/DS22; lane 4, no template
DNA and no primer; lane 5, MPRL 2510 with CS 11/CS22; lane 6, MPRL 2510 with
DS11/DS22; lane 7, MPRL 3923 with DS11/DS22; lane 8, no template DNA with
CS11/CS22; lane 9, no template DNA with DS11/DS22, lane 10, MPRL 3922 with no
primers; lane 11, MPRL 2510 with no primers.
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PCR detection of C2 toxin gene
PCR with the C2CI primers amplified a 310bp (Fig. 4.11) product in two of the four
C. botulinum type C type strains (MPRL 3922 and MPRL 2510), in the C. botulinum
type D type strain (MPRL 3923) and in two of the five C. novyi type A type strains
(MPRL 2532 and MPRL 2534) demonstrating the presence of the component I gene
of the C2 toxin in these organisms (Table 4.3). The component I gene of the C2
toxin was also detected in all sixteen of the animal isolates (Table 4.4). Two rounds
of amplification were required to detect the 310bp product in 12 of these isolates
(Table 4.4).
PCR with the C2CII primers produced a 1093bp product (Fig. 4.12) with DNA from
three C. botulinum type C type strains (MPRL 3922, MPRL 2510, and MPRL 4240),
demonstrating the presence of the component II gene of the C2 toxin in these
organisms (Table 4.3). Two of these type strains also carried the component I gene
for the C2 toxin (MPRL 3922 and MPRL 2510). The C. novyi type A strains or the
isolates that had been shown to have the component I gene of the C2 toxin did not
produce a product when amplified with the primers for the component II gene
(Tables 4.3 and 4.4).
PCR for bacterial 16S rRNA
The BAC primers detected universal bacterial DNA by amplifying a 763bp product
from a conserved region of the gene encoding 16s rRNA (Fig. 4.13). MPRL 2533
and MPRL 3493 did not produce PCR products when amplified with any of the
primers for toxin genes, but did produce a 763bp product when amplified with the
BAC primers (Table 4.3). Therefore, the BAC primers were used to confirm that the
negative results obtained for these type strains, with the primers for the toxin genes,
were not due to the presence of inhibitors. In addition, the BAC primers amplified a
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Figure 4.12: Detection of 1093 bp PCR product demonstrating the presence of the
component II gene of the C2 toxin in MPRL 3922, MPRL 2510, and MPRL 4240. Lane
1, 100bp DNA ladder; lane 2, MPRL 3922; lane 3, MPRL 2510; lane 4, MPRL 3493;
lane 5, MPRL 4240.
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Figure 4.13: Detection of a 763 bp PCR product demonstrating the presence of the
gene for bacterial 16sRNA. Lane 1, <|)X174 Hae III digest; lane 2, MPRL 3923; lane 3,
MPRL 4240; lane 4, MPRL 2533; lane 5, Ich 11; lane 6, Ich 2; lane 7, Ich 3; lane 8, Ich
4; lane 9, Ich 5; lane 10, Ich 9; lane 11, Ich 10; lane 12, Ich 12.
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763bp product from type strains MPRL 3922, MPRL 2510, MPRL 4240, MPRL
3923, and MPRL 2530 (Table 4.3) and isolates Ich 1-5, 9-12, 14-15 and MPRL 3690
(Table 4.4).
Negative controls
When no template DNA was added to the reaction mixture, no PCR products were
obtained. The negative controls also remained negative when there was more than
one round of amplification i.e. when products were re-amplified.
4.2 Discussion
Sixteen isolates identified as botulinum Group III organisms were isolated from
equine, leporine and feline gastrointestinal samples after enrichment. The standard
methods used in the identification of anaerobic bacteria such as morphology,
biochemical profiles and GLC cannot distinguish between C. botulinum types C and
D or C. novyi type A (Group III organisms). Identification of these organisms to the
species level requires demonstration of their ability to produce the type specific toxin
- BoNT/C for C. botulinum type C, BoNT/D for C. botulinum type D and the C. novyi
alpha toxin for C. novyi type A - each of which is encoded by a separate
bacteriophage. None of the isolates produced BoNT/C in vitro, despite five of the
organisms being isolated from samples in which BoNT/C had been detected either
directly or after enrichment. The bacteriophages encoding the toxin genes are
pseudolysogenic, consequently they are unstable and are easily lost from the host
bacterial cell. Sporulation, subculturing in the laboratory and growth of bacteria at
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temperatures of 37°C can ail predispose to loss of the phage (Eklund et al, 1987).
Repeated subculturing was required to isolate these organisms from the intestinal
samples. There is no selective media for the Group III organisms and they are very
fastidious, making isolation from Gl samples very difficult, as they are usually
overgrown by other bacteria present in the sample. In this study, many of the
samples after plating out were incubated at 37°C in the anaerobic cabinet due to
difficulties in handling large numbers of plates in gas jars. It is therefore possible
that some of these isolates were producing BoNT/C in vivo but had lost the phage
carrying the BoNT/C gene by the time they were isolated in pure culture.
No PCR products were obtained when DNA from the isolates were amplified with
primers for the BoNT/C and BoNT/D genes, thus demonstrating that the isolates
were not carrying either the bacteriophage encoding the BoNT/C gene or the
BoNT/D gene. However, the positive control did not give a PCR product with
primers for the BoNT/C gene so there is a possibility that this PCR reaction did not
work; it was thought that the C. botulinum type Ca type strain used as the positive
control had lost the bacteriophage. This was subsequently confirmed by a negative
toxin result by ELISA. PCR demonstrated the presence of the C. novyi alpha toxin
gene in three of the isolates (Ich 14, 15 and MPRL 3690). The presence of the gene
for the alpha toxin, in conjunction with the GLC profile, microbiological and
biochemical properties of this organism, enabled the identification of these three
organisms as C. novyi type A. Based on the standard identification methods, the
other 13 isolates are not identifiable any further than Group III organisms as they are
no longer carrying the major species-specific toxin genes.
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Immunoblotting of the surface antigens of Group III organisms, with antiserum
raised against C. novyi type A, presented a novel method for distinguishing between
C. botulinum type C/D and C. novyi type A. The antiserum bound to a major band at
46kDa in C. novyi type A type strains and to a major band at 43kDa in the C.
botulinum type C and D strains; the 46kDa band was not recognised in the C.
botulinum type C/D strains and the major band at 43kDa band was not recognised in
the C. novyi type A strains. Application of this immunoblot method to the surface
antigens of the isolates demonstrated the presence of the 46kDa band in all 16
isolates, suggesting that they were C. novyi type A strains as opposed to C.
botulinum type C or D. This enabled the identification of the remaining 13 isolates
as C. novyi type A; three had already been identified as C. novyi type A through
possession of the alpha toxin gene.
The ladder pattern, observed at the bottom of the immunoblots of the C. botulinum
type C/D and C. novyi type A type strains, is similar in appearance to the ladder
pattern produced by lipopolysaccharide from Gram-negative organisms. The ladder
pattern in these blots, not observable in the Coomassie stained gels, is probably
produced by a lipocarbohydrate from the cytoplasmic membrane (Poxton, 1984);
EDTA treatment has been shown to solubilise the membrane carbohydrates from
Clostridium difficile and Clostridium sordelli (Poxton and Cartmill, 1982). Eight of the
animal isolates did not have a visible ladder pattern in the blot. The membrane-
bound lipocarbohydrate is either absent in these isolates, or more likely it is not
cross-reactive with the anti-novyi serum that was used in this immunoblot,
suggesting at least two "serotypes" of this molecule.
It is difficult to compare directly bands present on the immunoblot with those visible
on the Coomassie stained SDS-PAGE gels, due to the complexity of the surface
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protein profiles and possible differences between the molecular weight standards
used for calibration of the bands in the gel and in the blot. There are many bands
visible on the Coomassie stained gel in the region of interest i.e. approximately
between 41 and 49kDa, and some of these bands differ in size by only 1kDa.
Therefore it is difficult to be certain that the band at 46kDa in the immunoblot is the
same antigen as the band calculated as having a molecular weight of 46kDa in the
gel. Despite these uncertainties, several important observations can be made. C.
botulinum type D and two of the type C strains had bands present at both 46kDa
and 43kDa in the gel but only the band at 43kDa was recognised by the rabbit
antiserum in the blot. These results suggest that the band at 46kDa in the C.
botulinum type C and D type strains is not immunologically cross-reactive with any
antigen present in the C. novyi type A type strain MPRL 2530, that was used to
prepare the antiserum used in this blot. However, the band at 43kDa in the
botulinum strains is immunologically cross-reactive with an antigen present in the C.
novyi type A strain. Conversely the other two C. botulinum type C type strains did
not have a band visible at 43kDa in the gel but did have a band at this molecular
weight in the immunoblot. It is possible that this band was only a minor surface
protein in these strains but strongly cross-reactive; the Coomassie blue may not
have been sufficiently sensitive to stain the band in these strains.
The rabbit antiserum reacted strongly with both the band at 46kDa and the band at
43kDa in the immunoblot, suggesting that these bands were strongly immunogenic.
It could be speculated that the immunogenic bands at 43kDa and 46kDa in the
different species represent a similar antigen but with a slight difference in molecular
weight.
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When equine serum was used in blots against the surface antigens, all three of the
serum samples used bound to surface antigens present in both C. botulinum type C
and C. novyi type A, suggesting natural previous exposure to these organisms.
However, the consistent difference in molecular weight of the major immunogenic
band between C. botulinum type C/D and C. novyi type A was not observed when
equine serum was used. In fact, two of the equine serum samples bound to
antigens at both 43 and 46kDa in C. botulinum type C strain; one of these serum
samples also bound to antigens at both these molecular weights in C. novyi type A.
These results may reflect that the horses have been previously exposed to both C.
botulinum type C and C. novyi type A, thereby making immune responses to
antigens which may not necessarily be cross-reactive between these species. One
of the serum samples did not bind to a band at 46kDa in the C. novyi type A but
bound to bands at 43kDa and 46kDa in the C. botulinum type C: it could be
speculated that this horse may have only been exposed to C. botulinum type C
previously. Another consideration may be that the horses have been previously
exposed to other cross-reactive antigens that have enabled recognition of these
surface antigens; horses may also respond to different antigens than the rabbit that
was used to prepare the antiserum. Clearly there were differences in the particular
surface antigens that were recognised by the antibodies in the different equine
serum samples, indicating differences in exposure to these strains, or crossreactive
antigens and possibly also differences between individual horses to respond to
particular antigens. All three equine serum samples investigated bound to a 46kDa
and/or a 43kDa surface antigen in C. botulinum type C and/or C. novyi type A,
indicating that these antigens may be significant immunogens.
The Group III organisms do not appear to have regular crystalline surface proteins
(S-layers) that have been described in many other bacterial species, including
162
Clostridium difficile (Kawata et al, 1984). S-layers are the outermost component of
the cell envelope and are generally composed of one or two protein or glycoprotein
molecules that can assemble into a 2D lattice structure. High concentrations of
guanidine hydrochloride are used to extract the protomeric subunits of the S-layers
from the cell wall, which should appear as a single band when run on a gel.
However, when the group III strains were extracted with GHCI the surface protein
profiles were both complex and very similar to the protein profiles obtained when
these cells were extracted with EDTA. Periodic structures, thought to be S-layers
have been described in C. botulinum (Takagi et al, 1965, cited in Sleytr and
Messner, 1983) and C. novyi (Schallen and Wacke, 1974, cited in Sleytr and
Messner, 1983) but the lattice has not been further characterised. S-layers on
pathogenic bacteria are of interest as potential virulence factors and have been
implicated in a wide range of functions. S-layers can act as a physical barrier to
invasion; some can protect the cell from muramidases, proteases, the host immune
response or from bacteriophages, conversely, others can act as specific receptors
for bacteriophages; some have been involved in adhesion to epidermal surfaces
(Sleytr and Messner, 1983). Different S-layers have been shown to have different
functions: the S-layers of C. botulinum and C. novyi are thought to prevent the
release of macromolecules from the cells, resulting in intracellular accumulation of
toxins (Sleytr and Messner, 1983). However, these S-layers could not be
characterised by the GHCI extraction method used in this study.
PCR was used to determine how many of the Group III type strains carried the C2
toxin gene and whether it could be found on the C. novyi type A strains. The C2
toxin is produced by the majority of C. botulinum type C strains and some C.
botulinum type D strains (Jansen, 1971), but there are no reports of the C2 toxin
being produced by C. novyi type A. It was thought that the detection of the C2 toxin
163
gene could provide a useful alternative method for differentiating between C.
botulinum type C and C. novyi type A. However, the identification of the Group III
organisms was further complicated by the detection of the C2 toxin component I
gene in a C. novyi type A type strain (MPRL 2532) that also carried the C. novyi
alpha toxin gene and in all 16 of the isolates identified as C. novyi type A by the
immunoblot method. The presence of the C2 gene on C. novyi type A strains may
be evidence of genetic transfer from C. botulinum type C or D strains in vivo; the C2
gene may be on a mobile genetic element. The presence of the C2 gene in a C.
novyi type A type strain that is also carrying the alpha toxin gene further
demonstrates the close relationships between the Group III organisms. However,
the C2 toxin is a binary toxin, requiring both components I and II to function; the
gene for component II was not identified in the C. novyi type strains or in the
isolates. ADP-ribosyltransferase activity is associated with component I, and
binding to the cell surface receptor is associated with component II. It is not known
whether the strains and isolates in which only the component I gene could be
detected, are capable of producing active C2 toxin.
The component I gene was detected in only two of the C. botulinum type C type
strains and in the C. botulinum type D strain. The component II gene was also
detected in these two type C strains and in another type C strain that did not have
the component I gene. These results suggest that only two of the four type C type
strains (MPRL 3922 and MPRL 2510) can produce the C2 toxin. However, the other
two type C type strains (MPRL 3493 and MPRL 4240) had been previously
classified as C2 toxin producers - MPRL 3493 is a NCTC type Cp strain and MPRL
4240 has been used to produce C2 toxin by other workers (Ohishi et al, 1980;
Ohishi, 1983). It is possible that there are variations in the CI and CM gene
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sequences between organisms preventing amplification by the PCR primers.
However, the primers for the component I gene had previously been shown to
amplify a 310bp product from MPRL 4240 (Fujii et al, 1996). Heterogeneity in the
structure of component II has been reported (Ohishi and Okada, 1986; Ohishi and
Hama, 1992), as has genetic heterogeneity in the component II gene (Kimura et al,
1998). Strains have been divided into three groups based on differences in
molecular weight and biological activity of the C2 toxin; these differences are
thought to be due to differences in component II (Ohishi and Okada, 1986).
However, the primer sets chosen to amplify the component II gene in this study had
been shown to amplify DNA from all three of these groups (Kimura et al, 1998).
Another possibility is that the component I and II genes are on mobile elements and
have been lost from these type C strains. It is known that these genes are not on
bacteriophages but it is theoretically possible that they are on a transposable
element that has been inserted into the chromosome. Loss of C2 toxin production
by a strain during laboratory culture led Eklund et al (1987) to hypothesise that the
C2 toxin may be encoded on a plasmid.
The investigation of C2 toxin production, in type strains with either one of the two
component genes or neither of the component genes detected by PCR, is required
to establish whether these genes are no longer present or whether the PCR is not
optimised for the detection of the genes in all the type strains. Ideally, the isolates
also need to be tested for their ability to produce active C2 toxin; the reagents to do
this are not available at present.
One C. novyi type A type strain (MPRL 2534) did not fit with the immunoblot method
of identification: the rabbit antiserum reacted with a band at 43kDa and not 46kDa.
On this basis the organism should be identified as C. botulinum type C/D.
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Furthermore, PCR did not detect the C. novyi alpha toxin gene but did detect the C2
toxin component I gene. It is possible that this isolate was originally incorrectly
identified as a non-toxigenic C. novyi type A, when actually it was a non-
neurotoxigenic C. botulinum type C/D. On the basis of the toxin producing results,
the organism can only be identified as a Group III organism; the immunoblot method
identifies it as C. botulinum type C or D. This organism is not a NCTC strain, but an
isolate from the laboratory culture collection, and its source is unknown (it was
isolated in 1972).
There is some question as to whether the Group III organisms should be classified
as separate species. Previously they have only been differentiated from each other
on the basis of the production of a major toxin that is encoded by a bacteriophage.
Not only are these bacteriophages pseudolysogenic, but they can also potentially
infect all three separate species, causing the organisms to produce different toxins
and effectively changing the identity of that organism. Previously, minor toxins
produced by these organisms could be used as an extra tool to differentiate
between them, such as the gamma toxin produced by C. novyi type A and the C2
toxin produced by the majority of C. botulinum type C and D. However, this study
has demonstrated the presence of the C2 toxin gene in a C. novyi type A type strain
that is also carrying the alpha toxin gene, highlighting even further how closely
related these organisms are. However, this study has also demonstrated that there
are antigenic differences in the surface antigens of C. botulinum type C/D and C.
novyi type A.
Only 16 Group III organisms were isolated from samples of small intestinal contents
from 77 animals (48 with dysautonomia and 29 without) and from the faeces of 117
animals (45 with dysautonomia and 72 without). The identification of all these
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isolates as C. novyi type A does not preclude them from being the organisms that
were producing BoNT/C in vivo. It has been shown that Group III organisms can be
infected simultaneously with the BoNT/C phage and alpha toxin phage resulting in
co-expression of BoNT/C and C. novyi alpha toxins. It is thought that this also
happens in vivo but is not identified due to loss of one of the phages during
laboratory isolation; the carriage of two of these phages is an even more unstable
state. An organism producing BoNT/C was isolated from a broiler chicken with
toxicoinfectious botulism and originally identified as C. botulinum type C;
subsequent detection of small quantities of the C. novyi y toxin suggested that the
organism was actually a C. novyi type A infected with the BoNT/C phage (Eklund et
al, 1987). It was hypothesised that the alpha toxin had also been carried in vivo. It
has been suggested that a common bacterial strain exists in nature, and that its
toxigenicity and hence pathogenicity is governed by the presence of the specific
converting phage (Eklund et al, 1974).
It is possible that the isolation technique did miss C. botulinum type C present in the
samples. However, it is unlikely for several reasons that the organisms isolated in
this study were not involved in the disease. Firstly, the organisms were all isolated
from animals that either had dysautonomia at the time of sampling, or had
previously had dysautonomia and recovered, or had recently been in contact with an
animal with dysautonomia. No Group III organisms were isolated from an animal
that had no history of exposure to dysautonomia. Secondly, the surface protein
profiles of many of the isolates were very similar suggesting that the isolates were
closely related. Several isolates were very similar despite geographical distances
separating host animals from which they had been isolated and even despite
species differences between host animals. Isolates with very similar/identical
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surface protein profiles were isolated from a horse and hare both with
dysautonomia; the hare was found on the same pasture as the horse. The majority
of isolates in this study appear to be more closely related to each other than to the
type strains. Although not all the samples from which these organisms were
isolated were positive for BoNT/C, isolates with similar surface protein profiles were
isolated from both BoNT/C-positive and BoNT/C-negative samples. All the isolates
were also carrying the component I gene of the C2 toxin.
The isolation of these organisms from animals all connected in some way with
dysautonomia, combined with similarities between isolates suggest that these
organisms may play a role in dysautonomia. However, an improved method of
isolation is essential to enable further characterisation of a larger number of these
organisms that may be involved in the cause of equine grass sickness and related
dysautonomias. The isolation rate of Group III organisms in this study has been
very low: 27 out of 77 ileum samples and 26 out of 117 faecal samples had BoNT/C-
producing organisms present as determined by toxin detection after enrichment but
only six organisms were isolated from samples that had been shown to contain a
BoNT/C-producing organism. The difficulties in isolating a toxigenic Group III
organism have been previously discussed. Clearly this raises problems when, as in
this case, trying to isolate and identify the aetiological agent of a disease putatively
caused by a Group III organism.
On the basis of the results obtained from characterisation of the isolates to date, it is
possible to hypothesise that animals at risk from dysautonomia are colonised by a
C. novyi type A-like organism, and that these organisms either carry a
bacteriophage encoding BoNT/C or they become infected with a phage carrying the
BoNT/C gene enabling BoNT/C production. The bacteriophage could be introduced
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into the resident population by another Group III organism; if the C. novyi type A was
resident in the Gl tract they would be less likely to be eliminated by a mucosal
immune response. Further investigation is required to establish the carriage of
Group III organisms in the equine Gl tract and their distribution in the environment.
Only six out of 72 control horses were found to carry toxigenic C. botulinum type C
in their faeces (Chapter 3). However, the enrichment method used would not be
able to detect the presence of non-toxigenic organisms or other Group III organisms.
The use of PCR for the detection of Group Ill-specific 16s rRNA and toxin genes in
Gl samples, will enable the determination of the rate of carriage of both Group III
organisms and specific species in the equine population.
The involvement of other Group III toxins in dysautonomia requires investigation. It
has already been hypothesised that the C2 toxin could potentially cause some of the
ultrastructural changes observed in neurons in equine grass sickness, but the role of
the C. novyi alpha toxin has previously not been considered. The alpha toxin is a
large clostridial cytotoxin (LCT) with lethal and necrotising activity; its role in the
pathogenesis of gas gangrene is well established. However, the effects of the toxin
when produced in the Gl tract are not known. Novyi alpha toxin causes retraction
and rounding in cultured endothelial cells. This characteristic cytopathic effect is
associated with disintegration of microfilaments and redistribution of F-actin and
vinculin (Oksche, Nakov and Habermann, 1992). This is due to modification of the
Rho protein. Rho is involved in regulating the steady state of polymerisation of F
actin (Ridley and Hall, 1992). Therefore, the alpha toxin, like the C2 and C3
botulinum toxins, causes microfilament disruption. In vitro, the morphological
changes induced by the C. novyi alpha toxin on cultured cells are indistinguishable
from the changes induced by the C2 toxin. The alpha toxin also shares the same
intracellular target protein as the C3 toxin. However, the novyi alpha toxin has a
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different mode of action to the C2 and C3 toxins. Three of the 16 isolates were
shown to be carrying the alpha toxin gene, other isolates may have been carrying
the gene in vivo. Further investigation is required to establish whether this toxin
could also have a role in the aetiology of equine grass sickness.
170
Chapter Five
Systemic immune response to C. botulinum typeC
5.1 Results
5.1.1 Detection of IgG in serum to C. novyi type A and BoNT/C
A wide range of IgG levels to C. novyi type A surface antigens and to BoNT/C were
detected in horses that had grass sickness and those that did not have the disease
(Table 5.1). The antibody levels to these antigens were compared between six
categories of horses - horses with CGS, SGS and AGS, contacts, high risk and
controls - as illustrated in Table 5.1. The IgG levels to BoNT/C and the surface
antigens were also compared between different groupings of these horses (Fig. 5.1,
5.2 and 5.3). Horses with grass sickness were found to have a significantly lower
level of serum IgG to C. novyi type A surface antigens (p=0.01) and to BoNT/C
(p<0.001), compared to horses that did not have the disease (Fig. 5.1a and 5.1b).
The horses that did not have grass sickness were divided into three groups -
'controls', 'contacts' and 'high risk'. There was a significantly lower level of IgG to
BoNT/C in the serum of horses with grass sickness, compared to horses that had
been in contact with cases of the disease (p<0.01), and horses grazing high risk
pasture (p<0.001) (Fig. 5.2a). There was also a significantly lower level of IgG to C.
novyi type A surface antigens in the serum of horses with grass sickness (p<0.05),
compared to horses in contact with cases of the disease and those grazing high-risk
pasture (Fig. 5.2b). Horses with grass sickness had a lower mean level of serum
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IgG to BoNT/C and C. novyi type A, compared to the control horses, but these were
not significant differences.
Table 5.1: IgG to C. novyi type A surface antigens and to BoNT/C in equine serum.
Antibody level (OD4osnm)
Specific Statistics CGS SGS AGS Controls Contact High
antibody COIIc (n=21) (n=28) (n=36) (n=60) risk
(n=46)
IgG to Mean 0.75 0.75 0.72 0.80 0.89 0.89
surface
antigens SD 0.31 0.41 0.38 0.36 0.37 0.40
Range 0.36- 0.2- 0.17- 0.16- 0.31- 0.26-
1.44 1.63 1.94 1.82 2.20 2.06
IgG to Mean 0.17 0.22 0.18 0.24 0.30 0.36
BoNT/C
SD 0.19 0.17 0.15 0.19 0.34 0.30
Range 0.04- 0.02- 0.03- 0.01- 0.02- 0.07-









































Figure 5.1: (a) IgG to BoNT/C and (b) IgG to C. novyi type A surface antigens
in the serum of horses with and without equine grass sickness (EGS).
The upper line of the box represents the 75th percentile, the lower line of the
box the 25th percentile, and the middle black line in the box the median value
for the distribution. The upper and lower error bars are the 90th and 10th
percentiles, respectively. Circles represent outlying values. The red line
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Figure 5.2: (a) IgG to BoNT/C and (b) IgG to C. novyi type A surface antigens
in the serum of horses with EGS, horses in contact with EGS, horses grazing
high risk pasture and controls not known to be in contact with EGS. The boxplot
is as described for Figure 5.1.
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The control horses consisted of 17 healthy horses, and 19 clinical cases, 10 of
which had gastrointestinal (Gl) associated disease. There was a higher mean IgG
level to both BoNT/C and C. novyi type A surface antigens in the serum of horses
with Gl associated disease, compared to either the healthy controls or the non-GI
clinical cases (Table 5.2). However there were no significant differences in serum
IgG to either BoNT/C or C. novyi type A between healthy horses, Gl cases and non-
GI cases. There were no significant differences between IgG to BoNT/C or to C.
novyi type A between horses in contact with a case of grass sickness, those grazing
land with a high risk of grass sickness or the control horses.













IgG to C. Mean 0.77 0.84 0.80
novyi type A
SD 0.31 0.36 0.47
Range 0.36-1.55 0.24-1.40 0.16-1.82
IgG to Mean 0.24 0.3 0.19
BoNT/C
SD 0.14 0.26 0.2
Range 0.09-0.57 0.05-0.94 0.01-0.66
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There was a significantly higher level of serum IgG to BoNT/C in the horses without
EGS, compared to horses with chronic grass sickness (p<0.01) and acute grass
sickness (p<0.01). Although there was a higher mean level of IgG to BoNT/C in
horses without EGS compared to those with subacute grass sickness, this was not a
significant difference. If horses with chronic and subacute grass sickness are
grouped together (CGS/SGS) then there is a significantly lower level of IgG to
BoNT/C in these horses compared to horses without EGS (p<0.01) (Fig. 5.3a).
There was a significantly higher level of serum IgG to BoNT/C in horses that were in
contact with grass sickness, compared to those with CGS (p<0.05), CGS/SGS
(p<0.05) and AGS (p<0.01). There was also a higher level of serum IgG to BoNT/C
in horses that were grazing high risk property, compared to horses with CGS
(p=0.001), CGS/SGS (p=0.001) and AGS (p<0.005).
There was a significantly higher level of serum IgG to the surface antigens in horses
without EGS compared to those with CGS/SGS (p<0.05), or AGS (p<0.05) (Fig.
5.3b). There were no significant differences between horses without grass sickness
and those with CGS or SGS, if the two groups were considered separately.
There was a significantly higher level of serum IgG to the surface antigens in the
horses in the contact group compared to horses with CGS/SGS or AGS (p<0.05).
Although the mean level of IgG to the surface antigens was higher in the horses
grazing high-risk pasture and in the controls, than horses with AGS or CGS and
SGS, these were not significant differences.
There were no significant differences in serum IgG levels to BoNT/C or surface
















Figure 5.3: (a) IgG to BoNT/C and (b) IgG to C. novyi type A surface antigens
in the serum of horses with CGS/SGS, AGS and horses without equine grass
sickness (EGS). Boxplot is as described for Fig. 5.1.
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5.1.2 IgG to C. novyi type A and BoNT/C in consecutive serum samples
from horses with CGS
Fourteen horses with chronic grass sickness were sampled more than once during
the course of the disease: seven horses were sampled twice (Table 5.3), and seven
horses were sampled more than twice (Fig. 5.4). Ten of these 14 horses showed an
increase in OD both to C. novyi type A surface antigens and to BoNT/C in at least
one sample over the course of the disease; three horses showed an increase in OD
to the surface antigens only; one horse showed an increase to BoNT/C only (Fig.
4a-g and Table 3). In some cases the increase in OD was very small.
Fluctuations in antibody levels were observed over the course of the disease (Fig.
5.4). These fluctuations were not always the same for both the surface antigens
and BoNT/C. Recovery of a horse from CGS was not always associated with an
increase in specific antibody levels to the surface antigens or the toxin (Fig. 5.4). In
all cases the OD for IgG to BoNT/C was much lower than the OD for IgG to C. novyi
type A. Flowever, this reflects differences in the respective ELISA assays, and not
necessarily differences in levels in vivo.
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Table 5.3: Serum IgG to C. novyi type A and BoNT/C in horses with chronic grass

















LH335 6 0.74 0.05 9 Euthanasia
8 0.80 0.03
LH 338 2 0.90 0.08 8 Euthanasia
3 0.93 0.09
LH174 3 0.39 0.06 35 Euthanasia
9 0.46 0.07
LH178 6 0.43 0.15 21 Euthanasia
14 0.54 0.19
LH236 38 0.56 0.12 47 Recovered
47 0.55 0.16
LH219 26 0.52 0.37 32 Recovered
29 0.56 0.34
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Figure 5.4: (a)-(g) Serum IgG to C. novyi type A surface antigens and BoNT/C in
seven horses with chronic grass sickness sampled over the course of the disease.
The arrows on each graph show the endpoint of disease for each horse, and the
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5.1.3 Comparison of specific IgG between horses with CGS that
recovered and those that were euthanased
The levels of serum IgG to surface antigens and to BoNT/C were compared
between horses that had recovered from chronic grass sickness and those that were
euthanased. When more than one sample had been received from a horse, the OD
values were averaged - Table 5.3 and Fig. 5.4 illustrate the range of antibody levels
detected in these horses. There was a higher mean IgG level both to C. novyi type
A surface antigens and to BoNT/C in the serum of horses that had recovered from
CGS, compared to those that were euthanased (Table 5.4). However, these were
not statistically significant differences.
Specific IgG levels, at both the start and the end of the disease, were compared
between horses that recovered from CGS and those that were euthanased. The
horses that recovered from CGS had a higher mean level of IgG to the surface
antigens, at the start of the disease, compared to the horses that did not recover
(Table 5.5a). However, the horses that did not recover had a higher mean level of
IgG to both surface antigens and BoNT/C, at the end of the disease (prior to
euthanasia), than the horses that recovered (Table 5.5b). These results are not
statistically significant.
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Table 5.4: IgG to C. novyi type A surface antigens and to BoNT/C in the serum of
horses with chronic grass sickness. A comparison between horses that were
euthanased and those that recovered from the disease.
Antibody levels OD4o5nm
Horses Statistics IgG to surface IgG to BoNT/C
antigens
CGS cases that Mean 0.84 0.18
recovered (n= 11) SD 0.35 0.10
Range 0.53-1.44 0.07-0.36
CGS cases that were Mean 0.69 0.14
euthanased(n=18) SD 0.27 0.11
Range 0.36-1.27 0.04-0.45
Table 5.5: Comparison of IgG to surface antigens and to BoNT/C between horses
that recovered from CGS and those that were euthanased, (a) specific IgG at
beginning of the disease and (b) specific IgG levels at end of disease.
(a)
Antibody levels OD^snm
Horses with CGS Mean IgG to surface Mean IgG to BoNT/C at
antigens at start of start of disease
disease




Horses with CGS Mean IgG to surface Mean IgG to BoNT/C at
antigens at end of end of disease
disease
Recovered (n=4) 0.67 0.10
Euthanased (n=4) 0.81 0.14
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5.1.4 Longitudinal study of six healthy controls
Serum samples were collected from six healthy control horses at intervals over a 28-
week period. The horses were stabled when samples were collected at weeks one,
and four. The other samples were collected when the horses were grazing pasture.
Grass sickness was not known to have occurred previously on this pasture. Two of
the horses showed an increase in serum IgG to the surface antigens towards the
end of the collection period: at week 19 for horse B3 (Fig. 5.5c) and at week 28 for
horse B4 (Fig. 5.5d). Horse B4 also showed an increase in serum IgG to BoNT/C
(Fig. 5.5d). The other four horses showed minor fluctuations in specific antibody
levels over the course of the collection period (Fig. 5.5a, b, e and f).
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Figure 5.5: (a)-(f) IgG to C. novyi type A surface antigens and to BoNT/C in
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5.2 Discussion
The surface antigens of C. novyi type A were used as a phenotypic marker for C.
botulinum type C. It has been shown that the surface antigens of these organisms
are serologically cross-reactive (Poxton, 1984). Bulk cultures were required for the
extraction of surface antigens for use in the ELISA, and it was considered safer to
grow up large volumes of C. novyi type A rather than neurotoxigenic C. botulinum
type C, especially as there were unvaccinated personnel in the laboratory. For later
work (Chapter 7), a non-neurotoxigenic C. botulinum type C strain was obtained for
large-scale extraction of surface antigens. The surface antigens of this strain were
also shown to be serologically cross-reactive with the surface antigens of C. novyi
type A (Chapter 4.1.3).
Epidemiological evidence suggests that resistance can occur to grass sickness.
There is a decreased incidence of the disease in older horses, in horses that have
been in prior contact with cases of grass sickness, and horses that have been on a
particular pasture for a longer length of time (Gilmour and Jolly, 1974; Doxey, et al,
1991b; Wood et al, 1998). This resistance may be in the form of an immune
response to the aetiological agent. Some experimental ponies were found to be
resistant to the toxic factor present in plasma from acute grass sickness horses that
had been shown to cause neuronal chromatolysis when injected into other ponies
(Doxey et al, 1997). The intraparotid injection of serum from a horse with chronic
grass sickness resulted in an inflammatory reaction in the cranial cervical ganglion
(Griffiths et al, 1994). It was thought that this may have been part of an immune-
mediated response - antibodies may have developed to the neurotoxin (or
components of the autonomic ganglia) in the chronically affected horse.
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There was a significantly higher level of IgG both to the surface antigens and to
BoNT/C in the serum of horses that had been in contact with grass sickness,
compared to the horses that actually had the disease. This suggests that horses in
contact with grass sickness have been exposed both to the surface antigens of a
Group III organism and to BoNT/C and have made a systemic immune response. A
case-control epidemiological study has shown that prior contact with a case of grass
sickness is associated with a ten-fold decrease in the likelihood of the disease
(Wood et al, 1998). It was hypothesised that this observed resistance occurring in
horses in contact with the disease could be in the form of an immune response to
the aetiological agent. The data from this study of specific systemic antibody levels
would support this hypothesis.
There was also a significantly higher level of IgG both to the surface antigens and to
BoNT/C in the serum of horses grazing land considered to be a high risk for equine
grass sickness (grass sickness had occurred there frequently in the past), compared
to horses with the disease. This data would suggest that these horses have also
been exposed to subclinical levels of both the organism and the toxin, resulting in a
systemic immune response. However, it is not known whether these specific serum
antibody levels are protective in these horses. The control horses were not known to
have been exposed to grass sickness and although they had lower mean specific
IgG levels compared to the horses in contact with grass sickness or grazing pasture
where the disease is endemic, these were not significant differences. Subclinical
cases of grass sickness are thought to occur, but have not been proven (Doxey et
al, 1995a; Milne, 1997).
Detection of lower specific antibody levels to the surface antigens and BoNT/C in
horses with grass sickness could also suggest that these horses may be more
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susceptible to the disease due to an inadequate immune response to C. botulinum
type C. However, although the control horses had a higher mean IgG level to these
antigens, they were not significantly different from the horses with grass sickness.
There were no significant differences in antibody levels between the three
categories of grass sickness. It has been hypothesised that a higher level of
specific IgG can be detected to these antigens in the serum of horses with chronic
grass sickness, compared to horses with the acute form of the disease, due to
seroconversion (J.K. Miller, personal communication). However, the data from this
study does not support this theory. An important consideration may be the time-
point in the course of the disease at which the sample is collected - horses surviving
for longer may have higher antibody levels. Chronic grass sickness can last from
seven days to several weeks and even months. In this study, 14 horses with
chronic grass sickness were sampled more than once. When there was more than
one sample for a horse, the results were averaged for the purpose of comparing the
IgG levels between the different categories of horses.
All 14 of the horses with chronic grass sickness that were sampled more than once,
showed an increase in OD to either the surface antigens, BoNT/C or both at least
once during the course of the disease. However, it is doubtful whether this could be
interpreted as seroconversion as the majority of observed increases were very small
changes in OD and were often transient. Decreases in OD to these antigens were
also observed. The fluctuations in OD levels to these antigens over the course of the
disease could be due to the in vivo neutralisation of the organism and toxin,
resulting in a reduction in the level of IgG available for detection by the ELISA. This
may also explain why horses with grass sickness have a significantly lower level of
IgG to these antigens compared to horses without the disease.
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If seroconversion occurred during chronic grass sickness, it would seem plausible
that horses with a higher serum IgG level to the surface antigens and BoNT/C would
have a better prognosis and be more likely to recover. Horses that recovered from
chronic grass sickness did have higher mean antibody levels to BoNT/C and surface
antigens than the horses with chronic grass sickness that were euthanased.
However, lower IgG levels to both the surface antigens and toxin were detected at
the end of the disease course in horses that recovered, compared to those that were
euthanased. These results are based on only eight horses and are not statistically
significant. If systemic antibodies play a role in the prognosis of disease, it might be
expected that horses with higher specific antibody levels at the start of the disease,
would be more likely to recover. Based on IgG levels from only seven horses,
sampled within three days of onset of clinical symptoms, it was found that horses
that recovered from CGS had higher IgG levels to the surface antigens, but not to
BoNT/C, compared to horses that were eventually euthanased. However, serum
samples collected even on the first day of clinical signs are not 'pre-exposure'
samples, as the horse may have been exposed to the organism and toxin for some
time before the onset of clinical symptoms. Again, these results were not
statistically significant.
Antitoxin immunity is not generally thought to develop in humans with food-borne
botulism; it was considered that the lethal dose of botulinum toxin was less than the
antigenic dose (Griffin et al, 1997). However, endogenous antibody production to
botulinum toxin has been demonstrated in a case of adult intestinal colonisation
botulism (Griffin et al, 1997); it was not known whether this contributed to the
patient's recovery. Cattle (Jean et al, 1995) and horses (Whitlock and Buckley,
1997) recovering from type C botulism have been shown to develop protective
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antibody; antibody to botulinum toxin was also detected in healthy cattle in areas
where botulism was considered endemic (Gregory et al, 1996).
Fluctuation in antibody levels to the surface antigens and BoNT/C were also
observed in six healthy control horses, sampled at intervals over a 28-week period.
All of the six horses showed an increase in OD to either the surface antigens,
BoNT/C or both over the collection period. The six horses all had detectable
antibodies to these specific antigens, and the antibody levels differed between the
six horses, despite grazing the same pasture. An increase in OD may be evidence
of recent exposure to the organism and toxin. The collection period ran from
February to September. There is some evidence of an increase in IgG to the
surface antigens and BoNT/C, in some of the horses, between samples collected in
May and September; this may reflect exposure to C. botulinum type C in the
spring/summer months. However, more samples are required to draw conclusions
with respect to seasonal exposure and fluctuations in immunity. It would be
particularly interesting to study fluctuations in antibody levels in horses grazing
pasture where grass sickness is considered to be endemic.
All horses in this study had detectable IgG to both the surface antigens and BoNT/C,
suggesting that they had all been exposed to C. botulinum type C and the toxin.
The higher mean specific antibody levels detected in horses exposed to grass
sickness, either through co-grazing with a case or grazing pasture where the
disease has frequently occurred, may reflect more recent exposure to C. botulinum
type C. Although the systemic immune response may protect horses in contact with
grass sickness from developing the disease, it does not appear to play a significant
part in natural recovery from the disease. The mucosal immune system may prove
to be more important in both the prevention of, and recovery from, grass sickness.
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Chapter Six
Mucosal immune response to C. botulinum type C in
the equine gastrointestinal tract
6.1 Results
6.1.1 Optimisation of ELISA to detect IgA in Gi contents to BoNT/C and
C. novyi type A surface antigens.
ELISA to detect IgA to C. novyi type A
Preliminary experiments were carried out to establish the appropriate dilution range
for both the samples and primary detecting antibody for an ELISA to detect IgA in
equine GI contents. Initial experiments used plates coated with C. novyi type A, as
this antigen was readily available. A sample of equine ileum contents and a faecal
sample were diluted twofold between 1 in 2 and 1 in 128; the primary detecting
antibody, anti-equine IgA (mouse monoclonal) was used at a dilution of 1 in 100 and
1 in 1000. The results of these initial experiments demonstrated that higher OD
levels were obtained when the primary antibody was used at a dilution of 1 in 100,
for both the ileum contents (Fig. 6.1a) and the faecal sample (Fig. 6.1b). A linear
relationship was observed between the 1 in 2 and 1 in 8 dilutions of ileum contents
(Fig. 6.1a). The 1 in 4 dilution of ileum contents appeared to be a suitable dilution
for assaying further samples. The dilution curve for the faecal sample was less
consistent than that for the ileum contents (Fig. 6.1b). However, the results
suggested that a dilution between 1 in 4 and 1 in 16 would be appropriate.
Further assays were carried out with twofold dilutions of the primary detecting
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Figure 6.1: IgA to C. novyi type A surface antigens in (a) ileum contents and
(b) faeces. Each sample was diluted twofold, from 1 in 2 to 1 in 128, with the
detecting anti-equine IgA monoclonal antibody used at dilutions of 1 in 100 and
1 in 1000. Results are also shown for each sample when no detecting anti-
equine IgA was added. These are representative results from single experiments.
Anti-equine IgA 1 in 100




of the ileum contents between 1 in 2 and 1 in 8. The 1 in 200 dilution of the anti-
equine IgA gave the highest OD readings at both 1 in 2 and 1 in 4 dilutions of the
ileum contents, and the relationship between the three dilution points looked the
most linear compared to the other anti-equine IgA dilutions (Fig. 6.2). The 1 in 1600
dilution of anti-equine IgA in this experiment gave almost identical OD readings at
the 1 in 4 sample dilution as the 1 in 200 dilution of this primary detecting antibody
(Fig. 6.2). However, the OD reading for the 1 in 8 sample dilution was almost the
same as the 1 in 4 dilution, indicating the results for the 1 in 1600 dilution of
detecting antibody did not follow a linear relationship between sample dilutions 1 in
2 and 1 in 8 (Fig. 6.2). Further assays suggested that the high OD readings
observed for the 1 in 1600 dilution in this experiment were anomalous. Assays
using different faecal samples demonstrated that the 1 in 4 dilution of faeces and the
1 in 200 dilution of anti-equine IgA would be a suitable dilution for this ELISA (Fig.
6.3a and 6.3b). The 1 in 100 dilution of anti-equine IgA did give slightly higher OD
readings, but was less economical to use at this dilution.
ELISA to detect IgA to BoNT/C
Sample and anti-equine IgA monoclonal dilutions were also investigated for the
ELISA to detect IgA to BoNT/C. Doubling dilutions of a sample of ileum contents
from 1 in 2 to 1 in 32 were added to BoNT/C coated plates. The primary detecting
antibody, anti-equine IgA monoclonal was used at twofold dilutions between 1 in 100
and 1 in 800. The results (Fig. 6.4) indicated that the 1 in 4 dilution of sample, with
a 1 in 200 dilution of anti-equine IgA monoclonal, were appropriate dilutions for use
in the screening ELISA for IgA to BoNT/C as well as to the surface antigens.
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Figure 6.2: IgA to C. novyi type A surface antigens in ileum contents. Ileum
contents were diluted twofold, from 1 in 2 to 1 in 8, with the detecting
anti-equine IgA monoclonal antibody diluted twofold, from 1 in 100 to 1 in 1600.
These are representative results from a single experiment.
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Figure 6.3(a) and (b): IgA to C. novyi type A surface antigens in two different
faecal samples. Faecal samples were diluted twofold between 1 in 2 and 1 in 32,
with the detecting anti-equine IgA monoclonal antibody diluted twofold between
1 in 100 and 1 in 800.
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Figure 6.4: IgA to BoNT/C in ileum contents. Ileum contents were diluted twofold,
from 1 in 2 to 1 in 32, with twofold dilutions of detecting anti-equine IgA monoclonal
antibody, from 1 in 100 to 1 in 800.
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Controls
Initially, samples were added to uncoated wells to control for non-specific binding to
the plate. In preliminary assays, each sample received no primary detecting
antibody to control for non-specific binding of the conjugate to the sample.
However, as there was no significant binding of samples, or other reagents to
uncoated wells, and no significant binding of conjugate directly to sample, in the
absence of a primary detecting antibody, these controls were not incorporated into
the final screening assay. Inclusion of the control for the non-specific binding of the
conjugate to the sample halved the number of samples that could be assayed on
each plate. Sufficient samples were assayed initially, with this control, to indicate
that there was little variation between samples, and this control could be confidently
left out of future screening assays using these reagents. The controls that were
included for the screening assay were a positive and negative control. The positive
control was a sample that had been identified in initial experiments as having a good
OD reading in the ELISA. This control was then included on each plate to enable
standardisation of OD readings between assays. The negative control received only
antiserum/ conjugate diluent at the sample incubation stage, but received all other
reagents.
6.1.2 Detection of specific IgA to C. novyi type A surface antigens and
BoNT/C in faeces and ileum contents
Horses with SGS had detectable IgA to BoNT/C in the highest percentage of both
ileum and faecal samples compared to the other groups of horses with and without
the disease. Ileum samples had detectable IgA to BoNT/C from 83% (5/6) of horses
with SGS, compared to ileum samples from 66.7% (8/12) of horses without grass
sickness, 60% (3/5) of horses with CGS and 33.3% (3/9) of horses with AGS (Fig.
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6.5a). IgA to BoNT/C was detected in all of the faecal samples tested for horses
with SGS (4/4), compared to faecal samples from 80% (12/15) of horses with CGS,
57.1% (4/7) of horses with AGS and 52.1% (25/48) horses without grass sickness
(Fig. 6.5a).
IgA to C. novyi type A surface antigens was detected in ileum samples from 80%
(4/5) of horses with CGS, compared to ileum samples from 66.7% (4/6) of horses
with SGS, 33.3% (4/12) of horses without grass sickness and 11.1% (1/9) of horses
with AGS (Fig. 6.5b). IgA to the surface antigens was detected in faecal samples
from 75% (3/4) of horses with SGS, compared to faecal samples from 46.7% (7/15)
of horses with CGS, 42.9% (3/7) of horses with AGS and 43.8% (21/48) of horses
without grass sickness (Fig. 6.5b).
A higher percentage of horses with grass sickness had detectable IgA both to
BoNT/C and to the surface antigens in the ileum and/or faeces compared to horses
without grass sickness. 71% (22/31) horses with grass sickness had detectable IgA
to BoNT/C in the ileum and/or the faeces compared to 56.3% (27/48) horses without
the disease. 58.1% (18/31) horses with grass sickness have IgA to C. novyi type A
surface antigens in the ileum and/or the faeces, compared to 43.8% (21/48) horses
without the disease.
Horse with grass sickness had a statistically significant higher level (p<0.02) of IgA
to BoNT/C in their faeces compared to horses without grass sickness (Fig. 6.6).
Horses with SGS had the highest mean level of IgA to BoNT/C in their faeces,
followed by horses with AGS, then horses with CGS; horses without grass sickness
had the lowest mean IgA level to BoNT/C (Table 6.1). The difference in IgA levels to
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Figure 6.5: Percentage of horses with detectable IgA to (a) BoNT/C and (b) to
C. novyi type A surface antigens in the ileum and faeces of horses with CGS,








Figure 6.6: IgA to BoNT/C in the faeces of horses with EGS and horses without
EGS. The upper line of the box represents the 75th percentile, the lower line of
the box the 25th percentile, and the middle black line in the box the median value
for the distribution. The upper and lower error bars are the 90th and 10th percentiles
respectively. Circles represent outlying values. The red line is the mean value for
the distribution.
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was the difference between horses with SGS and horses without grass sickness
(p<0.01).
Horses with SGS also had the highest mean level of IgA to C. novyi type A surface
antigens in their faeces (Table 6.1). The level of IgA to the surface antigens was
significantly higher in horses with SGS compared to horses without grass sickness
(p<0.05); this was the only statistically significant difference between these groups
of horses with respect to IgA to the surface antigens.
Table 6.1: IgA to C. novyi type A and BoNT/C in faeces of horses with CGS, SGS,
AGS and horses without grass sickness (non-EGS).
Antibody levels OD4o5nin
Statistics CGS SGS AGS Non-EGS
(n=15) (n=4) (n=7) (48)
IgA to Mean 0.171 0.882 0.24 0.12
BoNT/C SD 0.11 0.67 0.19 0.06
Range 0.04-0.45 0.15-1.75 0.06-0.58 0.04-0.33
IgA to Mean 0.11 0.433 0.11 0.10
surface SD 0.07 0.32 0.09 0.06
antigens Range 0.04-0.29 0.05-0.84 0.02-0.26 0.02-0.29
1. Statistically significant difference between horses with CGS and SGS (p<0.05)
2. Statistically significant difference between horses with SGS and 'non-EGS'(p<0.01)
3. Statistically significant difference between horses with SGS and 'non-EGS' (p<0.05)
Horses with SGS had the highest mean level of IgA to BoNT/C in their ileum
contents, followed by horses with CGS and then horses with AGS; horses without
grass sickness had the lowest mean IgA level to BoNT/C (Table 6.2). There was a
statistically significant higher level of IgA to BoNT/C in the ileum contents of the
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horses with SGS compared to the horses without grass sickness (p<0.05). When
the results for horses with CGS and SGS were compiled as a group, there was a
significantly higher level of IgA to BoNT/C in the ileum contents of these horses
compared to horses without grass sickness (p<0.05) (Fig. 6.7). When all horses with
grass sickness were considered as a group, although the mean IgA level to BoNT/C
was higher in these horses compared to horses without grass sickness, this
difference was not statistically significant.
Table 6.2: IgA to C. novyi type A surface antigens and BoNT/C in ileum contents of
horses with CGS, SGS, AGS and horses without grass sickness (non-EGS)
Antibody levels OD4osnm
Statistics CGS SGS AGS Non-EGS
(n=5) (n=6) (n=9) (12)
IgA to Mean 0.2 0.251 0.15 0.12
BoNT/C SD 0.14 0.12 0.09 0.05
Range 0.04-0.35 0.05-0.37 0.07-0.31 0.07-0.22
IgA to Mean 0.09 0.13 0.08 0.09
surface SD 0.04 0.07 0.08 0.04
antigens Range 0.04-0.14 0.06-0.24 0.02-0.28 0.05-0.18
'Statistically significant difference between horses with SGS and 'non-EGS' (p<0.05)
Horses with SGS had a higher mean level of IgA to the surface antigens in their
ileum contents compared to horses with CGS, AGS or horses without grass
sickness (Table 6.2). However, there were no statistically significant differences in















Figure 6.7: IgA to BoNT/C in ileum contents of horses with CGS or SGS
and horses without EGS.
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There was a higher mean level of IgA to BoNT/C in the faeces, compared to the
ileum contents in horses with SGS and AGS; horses with CGS had a lower level of
IgA to BoNT/C in the faeces; horses without grass sickness had the same mean
level in the faeces and ileum contents (Tables 6.1 and 6.2). There was a higher
mean level of IgA to C. novyi type A surface antigens in the faeces of all the horses
compared to the ileum contents (Tables 6.1 and 6.2). There was also a higher
mean level of IgA to BoNT/C, compared to the surface antigens, in the faeces and
ileum contents of all the horses (Tables 6.1 and 6.2).
The 48 faecal control samples were collected from 33 healthy controls, seven
horses with Gl-associated disease, and eight horses with non-GI associated
disease. The horses with Gl-associated disease had the highest mean level of IgA
to BoNT/C in the faeces (Table 6.3a). However, there were no statistically
significant differences in IgA levels either to BoNT/C or to the surface antigens in the
faeces between the three groups of control horses. Ileum samples were collected
from two healthy controls, three horses with Gl-associated disease and seven
horses with non-GI associated disease. The healthy controls had the highest mean
IgA level both to BoNT/C and to the surface antigens (Table 6.3b). However, there
were no statistically significant differences in specific IgA to these antigens in the
ileum contents between the three groups of control horses.
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Table 6.3: IgA to BoNT/C and to C. novyi type A surface antigens in (a) faeces, and
(b) ileum contents of control horses.
(a)
Antibody levels OD4o5nm
Healthy controls Gl controls Non-GI controls
Statistics (n=33) (n=7) (n=8)
IgA to Mean 0.11 0.19 0.13
BoNT/C SD 0.04 0.10 0.07
Range 0.04-0.18 0.08-0.33 0.05-0.27
IgA to Mean 0.09 0.11 0.11
surface SD 0.06 0.05 0.08
antigens Range 0.02-0.29 0.04-0.18 0.03-0.27
(b)
Antibody levels OD4osnm
Healthy controls Gl controls Non-GI controls
Statistics (n=2) (n=3) (n=7)
IgA to Mean 0.18 0.11 0.11
BoNT/C SD 0.06 0.06 0.05
Range 0.14-0.22 0.07-0.17 0.07-0.20
IgA to Mean 0.14 0.08 0.09
surface SD 0.06 0.05 0.04
antigens Range 0.09-0.18 0.05-0.14 0.05-0.16
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IgA to C. novyi type A surface antigens and BoNT/C in consecutive faecal
samples from horses with CGS
Faecal samples were collected, on more than one occasion, from ten horses with
CGS during the course of the disease: eight horses were sampled twice, one horse
was sampled six times and one horse three times (Fig. 6.8). Six of the ten horses
showed an increase in OD both to the surface antigens and to BoNT/C between the
first and second faecal sample (Fig. 6.8a, c, d, e, g, and j); two of the ten horses
showed an increase in OD to the surface antigens only (Fig. 6.8b and f). The horse
that was sampled six times during the 93-day duration of disease showed a
fluctuation in specific IgA levels to the antigens. IgA to BoNT/C peaked in the
second sample collected at day 12, then began to decrease at days 33, 54 and 83,
before increasing at day 93 (Fig. 6.8a). IgA to the surface antigens in this horse
followed a similar pattern, but levels peaked at day 93 (Fig. 6.8a); the horse
recovered. Three of the horses that showed an increase in IgA both to the surface
antigens and BoNT/C recovered and three were euthanased. The two horses that
showed an increase in IgA only to the surface antigens recovered. Of the two
horses that showed a decrease in IgA both to surface antigens and to BoNT/C, one
recovered and one was euthanased (Fig. 6.8h and i).
Comparison of specific IgA levels between horses with CGS that recovered
and those that were euthanased.
There was a higher mean level of IgA to the surface antigens in horses that had
recovered from CGS compared to those that were euthanased. However, there was
a lower mean level of IgA to BoNT/C in the horses that recovered from CGS
compared to those that were euthanased (Table 6.4). These differences are not
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Figure 6.8(a)-(j): IgA to C. novyi type A and BoNT/C in the faeces of ten horses





































horse, the mean OD of the samples was calculated. Fig. 6.8 shows the variation in
OD values between these samples.
Table 6.4: IgA to C. novyi type A surface antigens and BoNT/C in the faeces of
horses with CGS that recovered and those that were euthanased.
Horses with CGS Statistics
Antibody levels OD405nm
IgA to surface IgA to BoNT/C
antigens
Recovered (n=7) Mean 0.13 0.15
SD 0.08 0.08
Range 0.05-0.29 0.04-0.3
Euthanased (n=8) Mean 0.10 0.17
SD 0.05 0.12
Range 0.04-0.18 0.04-0.42
The IgA levels to the surface antigens and to BoNT/C in faeces, collected at the
start of the disease and the end of the disease, were compared between horses with
CGS that recovered and those that were euthanased. There was a higher level of
IgA to the surface antigens and to BoNT/C both at the start (Table 6.5a) and end of
the disease (Table 6.5b) in horses that eventually recovered, compared to those that
were euthanased. However, these comparisons are based on a small number of
samples, and the differences are not statistically significant. The horses used to
calculate the levels of IgA at the start of the disease are not the same horses used
for calculation of IgA levels at the end of the disease.
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Table 6.5: IgA to C. novyi type A surface antigens and to BoNT/C in (a) faeces
collected at the start of the disease, and (b) faeces collected at the end of the
disease, from horses that recovered from CGS and those that were euthanased.
(a)
Antibody levels OD405nm
Horses with CGS Statistics IgA to surface IgA to BoNT/C
antigens
Recovered (n=2) Mean 0.15 0.17
SD 0.06 0
Range 0.1-0.19 0.17-0.17





Horses with CGS Statistics IgA to surface IgA to BoNT/C
antigens
Recovered (n=4) Mean 0.23 0.19
SD 0.19 0.16
Range 0.03-0.45 0.04-0.41




IgA to surface antigens and BoNT/C in the faeces of healthy horses sampled
over 12 weeks.
Faecal samples from six healthy control horses were collected three times over a
12-week period, at weeks one, four and 12. Fluctuations were observed in the IgA
levels detected both to BoNT/C and the surface antigens between the three faecal
samples collected from each horse (Fig. 6.9). The pattern of fluctuation of IgA to
BoNT/C did not follow the same pattern for IgA to the surface antigens. The
changes in IgA to BoNT/C were not the same for all six horses. Two of the horses
showed a decrease in IgA to BoNT/C in the second faecal sample, followed by an
increase in the third sample (Fig. 6.9a and b). Two horses showed an increase in
IgA to BoNT/C in both the second and third faecal samples compared to the first
(Fig. 6.9c and d). One horse showed little variation in IgA to BoNT/C between the
first and second samples, but an increase in the third faecal sample (Fig. 6.9e). The
sixth horse showed an increase in IgA to BoNT/C between the first and second
sample, with little change in the third (Fig. 6.9f). All six of the horses showed an
increase in IgA to the surface antigens in the second sample followed by a decrease
in the third faecal sample (Fig. 6.9a-f). However, all these observed changes reflect
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Figure 6.9 (a)-(f): IgA to C. novyi type A surface antigens and BoNT/C in























6.1.3 Flow cytometry results
Flow cytometry results for equine PBMCs
Lymphocyte and monocyte populations for equine PBMCs were identified based on
the bitmap formed by forward and side scatter of light, reflecting the size and
granularity of the cells (Fig. 6.10) (Sharpe, 1988). Initial assays were carried out to
determine the optimum dilution and volume of primary antibodies to use for the
detection of T and B cell populations in equine PBMCs: anti-CD3 for the detection of
equine T cells and CVS 36 for the detection of equine B cells. PBMCs were isolated
from two different horses and labelled with 40pl of anti-equine CD3 and CVS 36; the
primary antibodies were used undiluted and at dilutions of 1 in 10 and 1 in 20
dilutions. PBMCs were also labelled with anti-CD18, an antibody that binds to all
leucocytes.
In experiment one, 21% of the PBMCs from both horses were in the lymphocyte
population and 21-22% were in the monocyte population (Table 6.6). There was little
difference in the percentage of cells in the lymphocyte population positively labelled
with the different dilutions of anti-CD3 (Table 6.7). However, there was a significant
drop in percentage of cells positively labelled when CVS 36 was used at either 1 in
10 or 1 in 20 dilutions, compared to the undiluted antibody (Table 6.7), suggesting
that it should be used undiluted for future assays.
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Figure 6.10: Flow cytometric analysis of PBMCs. Cell populations identified by forward
and side scatter of light. Population A respresents the lymphocyte population and
population B the monocyte population.
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Table 6.6: Flow cytometric analysis of PBMCs from a horse with chronic grass
sickness (horse 1) and a healthy control (horse 2), showing the percentage of
lymphocytes and monocytes in PBMCs.
Cells Percentage of cells
In lymphocyte region In monocyte region
PBMCs of horse 1 21A 227
PBMCs of horse 2 21.6 21.1
Table 6.7: Flow cytometric analysis of PBMCs from a horse with chronic grass
sickness (horse 1) and a healthy control (horse 2), showing the percentage of cells
in the lymphocyte population positively labelled with anti-CD18, and different
dilutions of anti-CD3 and CVS 36 (experiment one).
Primary antibody dilutions Percentage positively labelled
lymphocytes
Horse 1 Horse 2
Anti-CD3 Undiluted 83.8 66.6
(T cells) 1 in 10 73.9 70.8
1 in 20 81.0 69.9
CVS 36 Undiluted 21.4 37.4
(B cells) 1 in 10 5.8 8.6
1 in 20 4.0 8.1
Anti-CD18 1 in 10 76.8 81.6
(all leucocytes)
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When anti-equine CD3 was used undiluted, 84% of cells in the lymphocyte
population of the horse with CGS (horse one) and 67% of cells in the lymphocyte
population of the healthy control (horse two) were positively labelled (Table 6.7).
CVS 36 labelled 22% of cells in the lymphocyte population of horse one compared
to 37% of cells in the lymphocyte population of horse two (Table 6.7). The anti-
CD18 antibody detected 77% of cells in the lymphocyte population of horse one and
82% of cells in the lymphocyte population of horse two (Table 6.7).
The anti-equine CD3 and CVS 36 antibodies also positively labelled a high
percentage of the cells in the monocyte population (Table 6.8). CVS 36 positively
labelled a higher percentage of cells in the monocyte population than in the
lymphocyte population in both horses. The anti-CD18 antibody detected 98-99% of
cells in the monocyte population of the two horses (Table 6.8).
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Table 6.8: Percentage of positively labelled cells with anti-CD18, and different
dilutions of anti-CD3 and CVS 36, in the monocyte population of PBMCs from a
horse with CGS (horse 1) and a healthy control (horse 2) (experiment one).
Primary antibody dilutions % of positively labelled monocytes
Horse 1 Horse 2
Anti-CD3 Undiluted 82.1 61.4
(T cells) 1 in 10 80.0 63.6
1 in 20 89.9 66.8
CVS 36 Undiluted 75.9 79.5
(B cells) 1 in 10 48.0 36.8
1 in 20 26.5 32.3
Anti-CD18 1 in 10 98.7 97.9
(all leucocytes)
The high percentage of positively labelled cells with anti-B and T cell antibodies in
the monocyte populations of both horses in experiment one may be due to non¬
specific binding of primary antibodies by monocytes. A blocking step was included
in experiment two to compare labelling of blocked and unblocked cells with anti-CD3
and CVS 36 in the lymphocyte and monocyte populations.
The horse in experiment two had a higher percentage of lymphocytes and a lower
percentage of monocytes in the PBMCs (Table 6.9) compared to both horses in
experiment one (Table 6.6). Blocking of cells, with normal goat serum for 15 min at
4°C, reduced non-specific binding to some extent. Both anti-CD3 and CVS36
antibodies stained a slightly higher percentage of cells in the lymphocyte gate, and a
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slightly lower percentage of cells in the monocyte gate, when the cells were blocked
(Table 6.10). The blocking step was included in further experiments.
Table 6.9: Flow cytometric analysis of PBMCs from a control horse showing the
percentage of lymphocytes and monocytes in PBMCs when cells were blocked and
not blocked (experiment two).
Cells Percentage of cells
In lymphocyte region In monocyte
region
PBMCs with blocking 61.5 15.9
PBMCs without blocking 68.7 9.9
Table 6.10: Effects of blocking on the percentage of cells in the lymphocyte and
monocyte populations of PBMCs isolated from a control horse positively labelled
with anti-CD3, CVS 36 and anti-CD18 (experiment two).
Percentage of positively labelled cells
Primary antibody Blocked Not blocked
dilutions Lymphocyte Monocyte Lymphocyte Monocyte
population population population population
Anti-CD3 Undiluted 83.4 39.6 81.8 41.8
(10nl)
1 in 10 60.7 9.4 68.7 16.5
dilution
(10pl)
CVS 36 Undiluted 13.8 23.2 12 30
(40p.l)
Undiluted 12 17.8 9.7 23.2
(10hI)
Anti-CD 18 95 90.5 92.6 94.0
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Use of a lower volume of undiluted anti-CD3 (1 Ofal as opposed to 40jnl) did not
reduce the percentage of positively labelled cells detected in the lymphocyte
population (Table 6.7 and 6.10). However, the percentage of positively labelled
cells in the monocyte population was reduced when a lower volume of anti-CD3 was
used (Tables 6.8 and 6.10). The 1 in 10 dilution of anti-CD3 reduced both the
percentage of positively labelled cells in the lymphocyte and monocyte regions,
compared to the undiluted antibody (Table 6.10). On this basis, 10pl of undiluted
anti-CD3 antibody was used in further experiments. Use of a lower volume of CVS
36, 10ja.l as opposed to 40pl, also lowered the percentage of positively labelled cells
in both the lymphocyte and monocyte regions (Table 6.10); 40pil of undiluted CVS
36 antibody was used in further experiments. A higher percentage of cells in the
monocyte population were positively labelled with the CVS 36, compared to cells in
the lymphocyte population, regardless of whether the cells were blocked or not.
When the cells were blocked, 95% of the cells in the lymphocyte population were
positively labelled with anti-CD18, 83% positively labelled with anti-CD3 and 14%
positively labelled with CVS 36 (Fig. 6.11a, c and e). When the cells in the
lymphocyte population were labelled with anti-CD18, two peaks of fluorescence
were observed (Fig. 6.11a), indicating the presence of two populations of cells. One
fluorescence peak was observed with monocytes labelled with anti-CD18; this peak
was shifted to the right in comparison to the labelled lymphocytes, indicating a
greater intensity of fluorescence with CD18+ monocytes (Fig. 6.11b). A diffuse
population of lymphocytes were labelled with CVS 36 as illustrated by the intensity
of fluorescence in these labelled cells (Fig. 6.11c). The CVS 36 monocytes
appeared to have a more defined population of cells positively labelled, but the
actual numbers of positively labelled cells were much lower in this population (Fig.



























Figure 6.11: Flow cytometric analysis of equine PBMCs labelled with anti-CD18,
anti-CD3 and CVS 36. Plots of cell number per channel versus relative fluoresence
intensity of cells labelled with antibodies.
(a) Cells in the lymphocyte population and (b) cells in the monocyte population
positively labelled with anti-CD18. (c) Cells in the lymphocyte population and (d)
cells in the monocyte population positively labelled with CVS 36 (slg+). (e) Cells in
the lymphocyte population and (f) cells in the monocyte population positively
labelled with anti-CD3.
Gates were set to approximately 1% fluoresence with negative controls. The mean
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lymphocyte population (Fig. 6.11 e); the anti-CD3 antibody labelled a population of
monocytes with similar fluorescence intensity but the actual numbers of cells
labelled were much lower than in the lymphocyte population (Fig. 6.11 f).
Flow cytometry results for cells isolated from equine GALT
Lymphocyte and monocyte populations isolated from the lamina propria and Peyer's
patches of the equine gastric associated lymphoid tissue (GALT), were identified
based on the bitmap formed by forward and side scatter of light (Fig. 6.12). Cells
were collected both during and after the removal of the epithelium and after
collagenase digestion of either the lamina propria or Peyer's patches in order to
compare the cell populations recovered at different stages in the isolation
procedure. For these experiments, 10pl of undiluted anti-CD3, 40pl of undiluted
CVS 36 and 10pl of anti-CD18 (diluted 1 in 10) were used as determined by the
experiments with equine PBMCs.
In experiment three, cells were isolated from the lamina propria of a horse with SGS,
and collected after the 6th and 8th (final) EDTA wash to remove the epithelium, and
after collagenase digestion of the lamina propria. The percentage of cells in the
lymphocyte region increased from 15% after the 6th EDTA wash, to 19% after the 8th
(final) EDTA wash, reaching 43% after collagenase digestion (Table 6.11). The
percentage of monocytes decreased from 22% in the final wash with EDTA to 7%
after collagenase digestion (Table 6.11). The percentage of cells in the lymphocyte
population that were positively labelled with anti-equine CD3 increased from 22%
after the 6th EDTA wash, to 49% after the final EDTA wash, and 62% after the
collagenase digestion (Table 6.12). There was little difference in the percentage of
cells positively labelled with CVS 36 between the 6th and 8th EDTA wash; only 3% of
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Figure 6.12: Flow cytometric analysis of cells isolated from the lamina propria. Cell
populations identified by forward and side scatter of light. Population A represents
the lymphocyte population and population B the monocytes.
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cells were positive after the 6th wash and 2% positive after the final EDTA wash
(Table 6.12). The increase in positively labelled cells after collagenase digestion
was very small, with only 5% of cells positive for CVS 36 (Table 6.12). In experiment
three, there was a higher percentage of cells positively labelled with the CVS 36
antibody in the monocyte population compared to cells in the lymphocyte population
(Table 6.12).
Table 6.11: Flow cytometric analysis of cells isolated from the lamina propria of the
GALT from a horse with SGS. Percentage of lymphocytes and monocytes in cells
collected during and after removal of epithelium with EDTA, and after collagenase
digestion of lamina propria (experiment three).
Isolation stage Percentage of cells
In lymphocyte region In monocyte
region
After 6tn EDTA wash 1A9 TlJ
After 8th EDTA wash (final wash) 18.6 22.2
After collagenase digestion 42.7 7 2
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Table 6.12: Flow cytometric analysis of cells isolated from the lamina propria of the
GALT from a horse with SGS. The percentage of cells in the lymphocyte and
monocyte populations that were positively labelled with anti-CD3, CVS 36 and anti-
CD18 antibodies (experiment three).
Isolation stage Primary
antibody
Percentage of positively labelled cells
Lymphocytes Monocytes
EDTA wash 6 Anti-CD3 21.6 4.9
CVS 36 3.4 9.8
EDTA wash 8 Anti-CD3 49.3 3.5
(final EDTA wash) CVS 36 2.3 3.5
After collagenase Anti-CD3 61.8 31.8
digestion CVS 36 4.8 8.7
Anti-CD18 55 28.6
In experiment four, cells were isolated from both the lamina propria and a Peyer's
patch from a horse with glomerulonephritis (two separate sections of gut were
collected). Monocytes were removed from the cells that had been isolated by
collagenase digestion, through the ability of the monocytes to stick to a plastic
surface. The cells were incubated in a plastic petri dish or tissue culture flask
depending on volume, for one hour at 37°C with 5% C02. The cell suspension was
mixed gently by swirling to resuspend any lymphocytes that had settled out and then
the supernatant was poured off, leaving monocytes stuck to the plastic surface.
Monocytes were removed using a cell scraper and resuspended in RPMI 1640, if
required. The cells collected at different stages in the isolation procedure were
again compared, and the effect of monocyte removal on the populations of cells
investigated.
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The cells isolated from the lamina propria after collagenase digestion had a higher
percentage of cells in the lymphocyte population, and a lower percentage of cells in
the monocyte population, compared to the cells recovered in the final wash with
EDTA (Table 6.13). This was also the case for cells isolated after collagenase
digestion of the Peyer's patch (Table 6.13). Removal of monocytes from cells
isolated after collagenase digestion, followed by separation of the remaining cells on
Histopaque, increased the percentage of cells in the lymphocyte population by 17%
for cells from the lamina propria and 12% for cells from the Peyer's patches (Table
6.13). The percentages of cells in the monocyte populations were only decreased
by 2% after monocyte removal and Histopaque separation of cells from both the
lamina propria and Peyer's patch (Table 6.13). There was a higher percentage of
cells in the lymphocyte region in the cells isolated after collagenase digestion of the
Peyer's patch compared to those from the lamina propria: 65% of cells isolated from
the Peyer's patch were lymphocytes, compared to 51% from the lamina propria
(Table 6.13).
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Table 6.13: Flow cytometric analysis of cells isolated from the lamina propria and
Peyer's patch of the GALT of a horse with glomerulonephritis. Percentage of
lymphocytes and monocytes in cells collected during and after removal of epithelium
with EDTA, and after collagenase digestion of lamina propria (experiment four).
GALT Stage of isolation procedure Percentage of cells
In lymphocyte In monocyte
region region
LAMINA 10th EDTA wash 40.7 20.5
PROPRIA 13th EDTA wash (final wash) 38.4 16.5
After collagenase digestion 51.4 8.5
After collagenase digestion, 67.7 6.6
removal of monocytes and
isolation on histopaque
PEYER'S 9th EDTA wash 32 24.4
PATCHES 13th EDTA wash (final wash) 38.2 19.4
After collagenase digestion 65.4 6.9
After collagenase digestion, 76.9 4.5
removal of monocytes and
isolation on histopaque
There was a higher percentage of cells binding to anti-CD3 in the lymphocyte
population of cells isolated after collagenase digestion of the lamina propria and
Peyer's patch, compared to those recovered from the final EDTA wash (Table 6.14).
However, there were also a higher percentage of cells binding to the anti-CD3
antibody in the monocyte population, in the cells isolated from the lamina propria
and Peyer's patch (Table 6.14). CVS 36 antibody bound to a higher percentage of
cells in both the lymphocyte and monocyte populations after collagenase digestion
of the lamina propria compared to the final EDTA wash (Table 6.14). In cells
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isolated from the Peyer's patch, there was a 2% increase in binding of CVS 36 to
ceils in the lymphocyte population, and a 4% decrease in the binding of the antibody
to cells in the monocyte population after collagenase digestion compared to cells
recovered from the final EDTA wash (Table 6.14).
Removal of monocytes and separation by Histopaque of the remaining cells from
the collagenase digestion of the lamina propria resulted in an increase in the
percentage of cells in the lymphocyte population positively labelled with anti-CD3
from 58 to 74% of cells (Table 6.14). There was also a 2% increase in the
percentage of cells in the monocyte population labelled with anti-CD3 from 16 to
18% (Table 6.14). A lower percentage of cells in both the lymphocyte and monocyte
populations were stained positive with CVS 36 after removal of monocytes and
separation on Histopaque of cells (Table 6.14). Similar results were found after the
removal of monocytes and separation on Histopaque of cells from the Peyer's patch:
there was an increase in the percentage of cells staining with anti-CD3 in the
lymphocyte and monocyte populations and a decrease in the percentage of cells
staining with CVS 36 in both populations (Table 6.14).
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Table 6.14: Flow cytometric analysis of cells isolated from the lamina propria and
Peyer's patch of the GALT of a horse with glomerulonephritis. The percentage of
cells in the lymphocyte and monocyte populations positively labelled with anti-CD3
and CVS 36 antibodies (experiment four).
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There were higher percentages of cells positive for anti-CD3 and CVS 36 in the
lymphocyte population of cells isolated from the lamina propria compared to cells
from the Peyer's patch. In the cells isolated by collagenase digestion of the lamina
propria, 58% of cells in the lymphocyte region stained positive with anti-CD3 and
26% of cells stained positive with CVS 36 (Fig. 6.13). The CVS 36 antibody labelled
a discrete population of cells in the lymphocyte population (Fig. 6.13a). A more
diffuse population of cells were labelled with the CVS 36 antibody in the monocyte
population - one population had a similar fluorescence intensity to the CVS36+
lymphocytes, but there were also cells with a greater intensity of fluorescence in the
monocyte population (Fig. 6.13b). Flowever, fewer cells were fluorescent in the
monocyte population. The anti-CD3 antibody labelled a discreet population of cells
in the lymphocyte population (Fig. 6.13c); this antibody labelled a less discreet
population of cells in the monocyte population and fewer cells were fluorescent (Fig.
6.13d). In cells isolated from the Peyer's patch, 52% of cells in the lymphocyte
population were positive for anti-CD3 and 18% were positive with CVS 36. There
were also higher percentages of cells in the monocyte population of cells isolated
from the lamina propria that stained positively with anti-CD3 and CVS 36, compared
to cells from the Peyer's patch (Table 6.14).
In experiment five, cells were isolated from the lamina propria of the GALT from a
horse that had been diagnosed with having equine motor neurone disease (EMND).
The monocytes were again removed after collagenase digestion of the lamina
propria, and the remaining cells were separated on Flistopaque. In this experiment












Figure 6.13: Flow cytometric analysis of cells isolated from the lamina propria
of equine GALT positively labelled with anti-CD3 and CVS 36. Plots of cell
number per channel versus relative fluoresence intensity of cells labelled with
antibodies.
(a) Cells in lymphocyte population and (b) cells in monocyte population
positively labelled with CVS 36 (slg+). (c) Cells in lymphocyte population and
(d) cells in monocyte population positively labelled with anti-CD3.
Gates were set to approximately 1% fluoresence with negative controls. The









Removal of monocytes after collagenase digestion, resulted in 61% of the isolated
cells falling in the lymphocyte region and 13% of cells falling in the monocyte region
(Table 6.15). After separation on Histopaque, the percentage of cells in the
lymphocyte region increased to 75% and the percentage of cells in the monocyte
region decreased to 8% (Table 6.15). However, when the monocytes that had been
removed were examined it was found that 60% of these cells fell into the lymphocyte
region and only 7% in the monocyte region (Table 6.15).
Table 6.15: Flow cytometric analysis of the cells isolated from the lamina propria of
the GALT of a horse with EMND, showing the percentage of cells in lymphocyte and
monocyte regions (experiment five).
Cells Percentage of cells
In lymphocyte In monocyte
region region
Lamina propria cells after removal 61 13
of monocytes
Lamina propria cells after 75 8
separation on Histopaque
Monocytes 60 7
Separation of the cells isolated by collagenase digestion, on Histopaque, increased
the percentage of cells in the lymphocyte region positively labelled with anti-CD3
from 48% (after removal of the monocytes) to 70%; the percentage of cells positively
staining with CVS 36 decreased from 24-14% (Table 6.16). The percentage of cells
in the monocyte region binding either anti-CD3 or CVS 36 decreased after
separation on Histopaque (Table 6.16). There were a similar percentage of cells,
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staining positively with anti-CD3 and CVS 36, in the monocytes that were removed
after collagenase digestion and in the cells from which they had been removed
(Table 6.16).
Table 6.16: Flow cytometric analysis of the cells isolated from the lamina propria of
the GALT of a horse with EMND. The percentage of cells in the lymphocyte and
monocyte populations, positively labelled with anti-CD3 and CVS 36 antibodies,
after the removal of monocytes and separation on Histopaque (experiment five).




Lamina propria cells after Anti-CD3 48 14
removal of monocytes CVS 36 24 68
Lamina propria cells after Anti-CD3 70 10
separation on Histopaque CVS 36 14 63
Monocytes Anti-CD3 41 15
CVS 36 22 62
In all three groups of cells, there were higher percentages of cells in the monocyte
populations positively labelled with CVS 36 compared to the cells in the lymphocyte
populations (Table 6.16). The differences in percentage of cells in the monocyte
populations positively labelled with CVS 36 between the three groups reflected the
differences in percentages of cells in the monocyte region between the three groups
(Tables 6.15 and 6.16). For example, there was a 5% decrease in cells in the
monocyte region after separation on Histopaque, and there was also a 5% decrease
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in percentage of cells staining with CVS 36 in the monocyte region after separation
on Histopaque.
6.1.4 ELISPOT for IgG secreting cells
ELISPOT results for total IgG secreting cells in PBMCs
Preliminary assays were carried out to determine the optimum dilutions of capture
antibody and the optimum number of cells for an ELISPOT assay to detect total IgG-
secreting B cells. Plates were coated with anti-horse IgG (H+L) at dilutions of 1 in
1250 and 1 in 2500 in TBS. Wells were also coated with BSA to control for non¬
specific binding. PBMCs were diluted twofold from 7.8 x 106 cells/ml to 7.7 x 103
cells/ml and 10Opil added to each well. Each dilution of cells was added in duplicate
to the wells coated with anti-equine IgG and to wells coated with BSA.
When high numbers of cells were used there was a high background level of
staining that appeared as lots of small crystal-like blue dots. Whilst the background
staining could be differentiated from true ELISPOTS, it was difficult to determine the
number of real ELISPOTs present in these wells. No ELISPOTs were detected at
the highest number of cells, 7.8 x 105 cells/well (Table 6.17). The background
staining was a problem until the fourth dilution of cells, 9.8 x 104 cells/well, for both
dilutions of capture antibody. There was a prozone effect with the number of
ELISPOTs detected with both dilutions of capture antibody - the greatest number of
ELISPOTs were detected at the fourth dilution of cells (9.8 x 104 cells/well) (Table
6.17). There may have been more ELISPOTs in the wells that had higher numbers
of cells but these were not countable due to the background staining.
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Non-specific binding of IgG-secreting B cells was not a significant problem; for
dilutions of cells from 2x105 to 2.5x104 cells/well, and 6.1 x 103 cells/well, means of
less than one ELISPOT per BSA-coated well were detected (Table 6.17).
Table 6.17: ELISPOT for IgG-secreting B cells. Mean number of ELISPOTS
detected per well when different numbers of cells added per well. Wells coated with
two dilutions of anti-horse IgG and BSA.
Number of cells/well Mean number of ELISPOTs
Anti-horse IgG Anti-horse IgG BSA
(1 in 1250) (1 in 2500) (0.4mg/ml)
7.8x105 0 0 0
3.9x105 5 7 0
2.0x10s 12 7 <1/well
9.8x104 13 18 <1/well
4.9x104 7 9 <1/well
2.5x104 8 6 <1/well
1.2x104 4 2 0
6.1x103 1 <1/well <1/well
3.1x103 0 2 0
1.5x103 0 0 0
7.7x102 0 <1/well 0
No cells <1/well 0 0
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The 1 in 2500 dilution of capture antibody detected the highest number of
ELISPOTs, at the dilution of 9.8 x 104 cells/well. The numbers of IgG secreting
cells/105 PBMCs were more consistent between the dilutions of cells from 9.8 x 104
to 1.2 x 104 cells/well at the 1 in 2500 dilution of capture antibody, than for the same
dilutions of cells at the 1 in 1250 dilution of capture antibody (Table 6.18). There
was a mean number of 17 (range 12-22) IgG secreting cells/105 PBMCs detected at
the 1 in 2,500 dilution of capture antibody, and a mean number of 28 (range 13-56)
IgG secreting cells/105 PBMCs detected at the 1 in 1250 dilution.
Table 6.18: ELISPOT for IgG secreting B cells. Number of IgG-secreting B cells per
105 PBMCs, with different dilutions of capture antibody and different numbers of
cells.
No. of cells/well No. of IgG - secreting B cells/105 PBMCs
Anti-horse IgG Anti-horse IgG





The ELISPOT assay was repeated with further titrations of the capture antibody, to
ensure optimisation. The ELISPOT plates were coated with anti-horse IgG diluted
twofold from 1 in 625 to 1 in 10000. PBMCs isolated from a control horse were used
to compare the results with the previous experiment. The cells were added to wells
coated with the five dilutions of coating antibody and to wells coated with BSA at 105
cells/well and 104 cells/well. Cells (5x104 cells/well) were also added to wells coated
with 1 in 625 to 1 in 2500 dilutions of capture antibody, and those coated with BSA.
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ELISPOTs were detected when wells were coated with anti-horse IgG diluted from 1
in 625 to 1 in 2500; very few ELISPOTs were detected at a dilution of 1 in 5000, and
none at 1 in 10000 dilution of capture antibody (Table 6.19). At each dilution of
capture antibody, the decrease in the number of ELISPOTS detected was not
consistent with a decrease in the number of cells/well. The greatest number of
ELISPOTs were detected with 5x104 cells/well at dilutions of 1 in 625 and 1 in 1250
capture antibody, and with 104 cells/well for the 1 in 2500 dilution. At dilutions of 105
cells/well, and 5x104 cells/well there was a decrease in the number of ELISPOTs
with increasing dilutions of capture antibody. However with 104 cells/well there was
an increase in the number of ELISPOTS detected with decreasing dilutions of
capture antibody. There was no detection of ELISPOTS in wells coated with BSA.
Table 6.19: ELISPOT for IgG-secreting B cells. Mean number of ELISPOTS
detected per well. Wells coated with doubling dilutions of anti-horse IgG capture
antibody between 1 in 625 and 1 in 10,000 and BSA (see experiment two for flow
cytometry results for these PBMCs).
Capture Dilution of Mean number of ELISPOTS/well
antibody capture 105 5x10 10 No cells
/coating antibody cells/well cells/well cells/well
antigen
Anti- 1 in 625 11 16 1 0
horse 1 in 1250 5 6 2 0
IgG 1 in 2500 3 0 4 1
1 in 5000 1 NT1 2 NT
1 in 10000 0 NT 0 NT
BSA 0 0 0 <1
'
NT = not tested at this dilution
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When the results were calculated as number of IgG-secreting cells/105 PBMCs,
there was variation in the numbers obtained, depending on the original numbers of
cells used (Table 6.20). The highest mean number of IgG-secreting cells were
detected at the 1 in 625 dilution of capture antibody as 18 (range 10-32) IgG-
secreting cells/105 PBMCs, followed by the 1 in 2,500 dilution that detected a mean
number of 14 (3-40) IgG-secreting cells/105 PBMCs. The detection of 14 IgG-
secreting cells/105 PBMCs is equivalent to only 2% of all B cells as determined by
the flow cytometry results for this horse (see experiment two).
Table 6.20: ELISPOT for IgG-secreting B cells. Mean number of IgG-secreting B
cells per 105 PBMCs when different numbers of PBMCs added per well. Wells
coated with doubling dilutions of anti-horse IgG capture antibody between 1 in 625
and 1 in 10000 and BSA (see experiment two for flow cytometry results for these
PBMCs).
Dilution of Number of IgG-secreting cells/105 PBMCs
anti-horse IgG 10s cells/well 5 x 104 cells/well 104 cells/well
1 in 625 11 32 10
1 in 1250 5 12 20
1 in 2500 3 ND1 40
1 in 5000 1 NT2 20
'
ND = not determined as no ELISPOTs detected in well
2
NT = not tested at this dilution of cells
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ELISPOT for IgG secreting cells specific for C. novyi type A surface antigens
and BoNT/C in PBMCs
PBMCs from a horse with CGS were added to an ELISPOT plate coated with C.
novyi type A surface antigens. The numbers of cells added to the wells were 2.1 x
104 cells/well, 1.1 x104, 1.1 x 103 cells/well and 1.1 x 102 cells/well. Some wells
received no cells. However, no ELISPOTs were detected.
The experiment was repeated using PBMCs from two other horses with CGS.
Plates were coated with BoNT/C as well as C. novyi type A surface antigens.
PBMCs were added from one horse at 105 cells/well, 5 x 103 cells/well, and 5 x 102
cells/well; the other horse had PBMCs added at 2 x 105 cells/well, 104 cells/well and
103 cells/well. Some wells received no cells. Again, no ELISPOTS were detected in
wells coated with the surface antigens or BoNT/C.
ELISPOT for IgG secreting cells from the lamina propria and Peyer's patches
of the equine GALT
Preliminary assays were carried out to determine the optimum dilution of capture
antibody for an ELISPOT assay to detect IgG secreting B cells isolated from lamina
propria or Peyer's patches. An ELISPOT plate was coated with fivefold dilutions of
anti-horse IgG antiserum from 1 in 100 to 1 in 12500. Cells were isolated from the
lamina propria and Peyer's patches of the GALT of a horse with glomerulonephritis
(see experiment four in flow cytometry results). The cells used in the ELISPOT
assays were those isolated after the digestion of the relevant tissue with
collagenase. Cells isolated from the lamina propria were added to wells at dilutions
of 2 x 105 cells/well and 105 cells/well, and cells isolated from the Peyer's patches
were added to the wells at a dilution of 2 x105 cells/well. Cells were also added to
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wells coated with C. novyi type A surface antigens, C. botulinum type C surface
antigens, BoNT/C and BSA. Cells were added in triplicate.
When wells were coated with anti-equine IgG at dilutions of 1 in 100 to 1 in 2500,
the numbers of ELISPOTS produced were too many to count accurately when either
2 x 105 cells/well or 105 cells/well cells from the lamina propria or Peyer's patches
were used. However, when wells were coated with the 1 in 12500 dilution of anti-
equine IgG ELISPOTS were only detected with cells isolated from the Peyer's patch;
a mean of three ELISPOTS were detected per well (Table 6.21). These results
suggest that the cells need to be titrated out further and added to wells coated with
at least 1 in 2500 dilution of capture antibody.
A mean number of two ELISPOTs per well were counted to C. novyi type A surface
antigens when 2 x 105 cells/well were added from the lamina propria or Peyer's
patch. No ELISPOTs were detected to BSA or BoNT/C. A mean of less than one
ELISPOT per well was detected to the surface antigens of C. botulinum type C.
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Table 6.21: ELISPOT for IgG-secreting B cells, (a) Mean number of ELISPOTS
detected per well when different numbers of lamina propria and Peyer's patches
cells were added per well. Wells were coated with fivefold dilutions of anti-horse
IgG capture antibody between 1 in 100 and 1 in 12500, C. novyi type A surface
antigens, C. botulinum type C surface antigens, BoNT/C and BSA.
Capture antibody/
coating antigen









C. novyi type A
Cells Cells Cells
isolated isolated isolated
from lamina from lamina from Peyer's
propria propria patch

















When results were expressed as mean number of IgG secreting cells/105 cells, only
two IgG-secreting cells per 105 Peyer's patch cells were detected at the 1 in 12500
dilution of capture antibody (Table 6.22). This is equivalent to 0.17% of the B cells
as determined by the flow cytometry results (see experiment four). However, the
capture antibody diluted 1 in 12500 is below the optimum for this assay and
therefore this percentage is probably not a true reflection of the detection abilities of
this assay. The number of IgG secreting cells could not be calculated for the other
dilutions of capture antibody as there were too many ELISPOTs to count. One anti-
novyi IgG secreting cell per 105 Peyer's patch cells and one anti-novyi IgG secreting
cell per 105 lamina propria cells were detected. This is equivalent to 0.08% of the B
cells in the Peyer's patch and 0.07% of B cells in the lamina propria, being specific
for C. novyi type A. When a mean of less than one ELISPOT was detected per well,
the number of IgG secreting cells per 105 cells could not be calculated.
Table 6.22: ELISPOT for IgG-secreting B cells. Mean number of IgG-secreting B
cells per 105 cells isolated from GALT when different numbers of lamina propria and
Peyer's patches cells added per well. Wells were coated with fivefold dilutions of
anti-horse IgG capture antibody between 1 in 100 and 1 in 12500, C. novyi type A
surface antigens, C. botulinum type C surface antigens, BoNT/C and BSA.
Capture antibody/ Number of IgG-secreting cells/105 GALT cells
coating antigen Lamina propria Lamina propria Peyer's patch
(2x10s cells/well) (10s cells/well) (2x10s cells/well)
Anti-equine IgG ND1 ND 2
(1 in 12500)
C. novyi type A 1 ND 1
surface antigens
'ND: not determined as a mean of less than one ELISPOT per well was detected
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The assay was repeated with cells isolated from the lamina propria of the GALT
from a horse initially clinically diagnosed with AGS, but not confirmed by
histopathology at post-mortem. The subsequent diagnosis was thought to be
botulism. The cells used in the assay were the cells released by collagenase
digestion of the lamina propria, the cells at the interface after separation of these
cells on Histopaque, and PBMCs from the same horse. Wells were coated with 1 in
2500 dilution of anti-equine IgG antibody. Cells from the lamina propria were added
to the wells in triplicate at numbers of 106, 105 and 104 cells per well; cells form the
lamina propria separated on Histopaque were added at 5x105, 5x104 and 5x103
cells/well; and PBMCs were added at 104, 5x103 and 103 cells/well. Cells were also
added to wells coated with C. novyi type A surface antigens, BoNT/C and BSA, but
only at 106 lamina propria cells/well, 5x105 lamina propria cells separated on
Histopaque/well and 104 PBMCs/well. Cells were added to wells coated with C.
botulinum type C at 106 and 105 lamina propria cells/well, 5x105, 5x104 lamina
propria cells separated on Histopaque/well, and 104, 5x103 PBMCs/well.
For cells isolated from the lamina propria, including those separated by Histopaque,
when 106 or 5x105 cells/well were used there were too many ELISPOTS for total IgG
secreting cells to count. However 105 cells/well or less produced countable numbers
of ELISPOTs. 104 and 5x103 PBMCs/well produced countable numbers of
ELISPOTs in wells coated with anti-equine IgG antibodies (Table 6.23). There was
a noticeable decrease in background staining with decreasing numbers of cells.
ELISPOTs were detected in wells coated with C. novyi and C. botulinum surface
antigens when cells from the lamina propria were added. However, cells from the
lamina propria also secreted IgG to BSA. The number of ELISPOTs in wells coated
with C. botulinum type C surface antigens was greater than the numbers of
ELISPOTs in wells coated with BSA for all three cell groups.
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Table 6.23: ELISPOT for IgG-secreting B cells. Mean number of ELISPOTS
detected per well when different numbers of lamina propria cells added per well.
Wells were coated with anti-horse IgG capture antibody, C. novyi type A surface
antigens, C. botulinum type C surface antigens, BoNT/C and BSA.
Mean number of ELISPOTS per well

















Lamina 106 >50 11 13 8 11
propria cells 105 24 NT1 3 NT NT
104 5 NT NT NT NT
Lamina 5x105 >50 6 14 5 6
propria cells 5x104 23 NT 1 NT NT
(Histopaque) 5x103 1 NT NT NT NT
PBMCs 104 9 0 <1 0 0
5x103 4 NT 0 NT
103 <1 NT NT NT




When results were expressed as the number of IgG-secreting cells B cells per 105
isolated cells there was some variation in these numbers when calculated for the
different numbers of cells added initially (Table 6.24). A mean of 37 total IgG-
secreting cells/105 lamina propria cells were detected compared to a mean of 33
total IgG-secreting cells when the lamina propria cells were separated on
Histopaque. A mean of 85 total IgG-secreting cells/105 PBMCs were detected, a
greater number than from the lamina propria. A mean of two anti-C. botulinum type
C IgG-secreting cells/105 lamina propria cells were detected, compared to a mean of
three anti-C. botulinum type C IgG-secreting cells when the lamina propria cells
were separated on Histopaque. These results are equivalent to the detection of 5%
of B cells isolated from the lamina propria, and 0.3% of the isolated B cells are
specific for C. botulinum type C (flow cytometry results not shown for this horse).
Another way of expressing these results is that 5% of IgG-secreting B cells in this
assay were specific for C. botulinum type C.
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Table 6.24: ELISPOT for IgG-secreting B cells. Mean number of IgG-secreting B
cells per 105 cells isolated from GALT when different numbers of lamina propria
cells added per well. Wells coated with anti-horse IgG capture antibody, C. novyi
type A surface antigens, C. botulinum type C surface antigens, BoNT/C and BSA.
Number of IgG-secreting B cells per 105 isolated cells
Capture antibody/ coating antigen
Cells No. of Anti- C. novyi C. botulinum BoNT/C BSA
cells/ equine IgG type A type C
Well (1 in 2500) surface surface
antigens antigens
Lamina 10B ND1 1 1 1 1
propria cells 105 24 NT3 3 NT NT
104 50 NT NT NT NT
Lamina 5x105 ND1 1 3 1 1
propria cells 5x104 46 NT 2 NT NT
(Histopaque) 5x103 20 NT NT NT NT
PBMCs 104 90 ND2 ND2 ND2 ND2
5x103 80 NT ND2 NT NT
103 <20 NT NT NT NT
1
ND = not determined as more than 50 ELISPOTS counted in original well
2
ND = not determined as less than one ELISPOT counted per well
3
NT = Not tested
251
ELISPOT for IgA secreting cells from the lamina propria and Peyer's patches
of the equine mucosa
Preliminary assays were carried out to determine the optimum dilution of capture
antibody for an ELISPOT assay to detect IgA-secreting B cells. An ELISPOT plate
was coated with tenfold dilutions of anti-equine IgA mouse monoclonal (BVS) from 1
in 100 to 1 in 100000. Cells were isolated from the lamina propria and Peyer's
patch of the GALT of a horse with glomerulonephritis. Cells were added to the wells
in triplicate to give 2 x 105 cells/well and 105 lamina propria cells/well, and 105
Peyer's patch cells/well. Cells were also added to wells coated with C. novyi type A
surface antigens, C. botulinum type C surface antigens, BoNT/C and BSA.
However, no ELISPOTs were detected.
The ELISPOT was repeated using PBMCs and cells isolated from the lamina propria
from the horse diagnosed as query botulism. Wells were coated with anti-equine
IgA at dilutions of 1 in 1000 and 1 in 10000. Cells were added in triplicate to wells
coated with anti-equine IgA diluted 1 in 1000 to give 106, 105 and 104 lamina propria
cells/well, 5x105, 5x104 and 5x103 lamina propria cells (after separation on
Histopaque)/well; and 104, 5x103 and 103 PBMCs /well. Wells coated with anti-
equine IgA diluted 1 in 10000, C. novyi type A, C. botulinum type C, BoNT/C and
BSA received 106 lamina propria cells/well, 5x105 lamina propria cells (after
separation on Histopaque)/well, and 104 PBMCs/well. However, again there were
no ELISPOTs detected. There was a great deal of background staining, particularly
when cells were coated with anti-equine IgA. This made it very difficult to determine
whether there were true ELISPOTs present.
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6.1.5. Detection of antibodies in saponin-extracted GALT
ELISA for total IgG in GALT extracts
Optimisation of dilutions for assay
Samples of tissue from Peyer's patches or lamina propria were treated overnight
with saponin and the supernatant assayed for antibody content. Preliminary assays
were carried out to identify the appropriate dilution range for the screening of
extracts for calculation of total IgG content in the GALT extracts. Extracts from the
lamina propria and Peyer's patches from two horses were diluted tenfold between 1
in 5 and 1 in 500000. The IgG content in the extracts of lamina propria and Peyer's
patches from each horse were very similar, but there was a difference in IgG content
between horses (Fig. 6.14a).
Faecal and ileum content extracts, treated with protease inhibitors (Chapter 2.3.2),
from three horses were also assayed for total IgG content. Samples were diluted
tenfold between 1 in 5 and 1 in 500000. There was some variation in IgG content
both between horses and between samples. A prozonal effect was observed up to
the 1 in 50 dilution with faecal sample 2 and ileum contents 2 and up to the 1 in 500
dilution with ileum contents 3 (Fig. 6.14b). However, the other samples showed a
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Figure 6.14: ELISA for total IgG in (a) saponin-digested GALT extracts from two
different horses (1 and 2) and (b) protease inhibitor treated faeces and intestinal
contents from three different horses (1, 2 and 3). Samples diluted tenfold from




On the basis of these results, GALT extracts should be titrated tenfold between 1 in
50 and 1 in 50000 for further screening of samples to determine total IgG content;
faecal and ileum contents should be titrated tenfold between 1 in 5 and 1 in 5000.
This should enable calculation of IgG content based on a dilution falling on the linear
part of the dilution curve for individual samples.
Optimisation of length of incubation with saponin
Preliminary assays were carried out to investigate the effect of incubation time with
saponin on antibody recovery in the extract. Tissue samples from the lamina propria
were treated with saponin for different incubation lengths - 2 h, 4 h, 6 h, 8 h and 30
h. The extracts were diluted fivefold between 1 in 1000 to 1 in 125000 and assayed
for total IgG content by ELISA.
It was found that the longer the incubation length with saponin, the greater the level
of IgG antibody in the tissue extract; this was the case for up to 30 h (Fig. 6.15).
There was little difference in the IgG content of the extract between 4 and 8h
incubation. In previous studies, tissue samples had been thawed overnight in the
presence of saponin (Bergquist et al, 2000; Bergquist et al, 1995). All further
samples were incubated overnight with saponin.
Total IgG content in GALT extracts
Saponin extraction of the tissue from the lamina propria and Peyer's patches
resulted in a ten-fold increase in total IgG compared to the protease inhibitor-treated
ileum contents, and a 100-fold increase in IgG compared to the faeces (Table 6.25).









Figure 6.15: Total IgG in lamina propria extracts incubated for 2 h, 4 h, 6 h, 8 h,
and 30 h with saponin. Extracts diluted fivefold between 1 in 1,000 and
1 in 125,000.
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Table 6.25: Total IgG in saponin extracts from the lamina propria and Peyer's
patches, and in protease treated faeces, ileum contents and jejunal contents.
Statistics
Total IgG mg/ml
Lamina Peyer's Ileum Faeces Jejunum
propria patches contents (n=3) contents
(n=2) (n=2) (n=3) (n=1)
Mean 1.07 1.42 0.11 0.014 0.02
SD 1.46 1.95 0.06 0.02 N/A1
Range 0.04-2.1 0.04-2.8 0.04-0.15 0.001-0.04 N/A
1 N/A = not applicable as only one sample in group
ELISA for total IgA in GALT extracts
Optimisation of assay
Preliminary assays were carried out to determine the dilution range suitable for
assaying tissue extracts for total IgA. Saponin extracts, from the lamina propria and
Peyer's patches of two horses, were diluted tenfold between 1 in 5 and 1 in 500000.
However, IgA could only be detected at the lowest dilution (1 in 5) in the extracts
from the lamina propria and Peyer's of horse two (Fig. 6.16a); horse two had a lower
total IgG content in these extracts compared to horse one (Fig. 6.14a). The OD
measurements for IgA in both the lamina propria and Peyer's patches extracts were
below the negative control for horse one, even at the 1 in 5 dilution.
The highest OD reading was obtained for the protease treated faecal sample two
(Fig. 6.16b). Ileum contents two and three, faecal sample three and jejunal
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Figure 6.16: IgA in (a) saponin extracts of lamina propria and Peyer's patches from
two different horses and (b) protease inhibitor treated faeces and ileum contents
from three different horses. Samples were diluted tenfold between 1 in 5 and
1 in 500,000. LP=lamina propria; PP=PeyerJs patches.
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dilution. However, only faecal sample two had an OD level above the negative
control at the 1 in 50 dilution.
Calculation of total IgA
It was not possible to calculate the total IgA content in these samples by ELISA due
to failure of the IgA standard. However, the total IgA content of both extracts from
the lamina propria and Peyer's patches from horse two (LP2 and PP2) were
determined by RID to be 1.5mg/ml.
6.2 Discussion
6.2.1 Optimisation of ELISA to detect IgA to C. novyi type A surface
antigens and BoNT/C in Gl contents
Several problems were encountered in the development of an ELISA to detect
specific IgA in samples from the equine Gl tract. The most significant initial problem
was the lack of a known positive control for either the assay for IgA to the surface
antigens or to BoNT/C. At the time of this study, it was not possible to determine
total IgA content in equine faecal and ileum samples - attempts to develop an
ELISA for total IgA with available reagents had been unsuccessful. Therefore it was
not possible to assess if the treatment of samples, for inhibition of intestinal
proteases, was effective in preserving intestinal IgA.
Initial assays, used C. novyi type A surface antigen coated plates. Previous work
had shown that the majority of horses had high levels of serum IgG to the surface
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antigens (Chapter five). On this basis it was initially thought that the majority of
horses might also have intestinal IgA to the surface antigens. EDTA-extracted
antigens were also readily available, unlike purified BoNT/C, and therefore it was
considered more economical to do the initial assays using the surface antigen
coated plates. Previous work also had shown the presence of C. botulinum type C
in the Gl tract of horses with grass sickness (Chapter three). Therefore initial
assays were done using samples from horses with chronic grass sickness, on the
basis that they were more likely to have been exposed to the organism and to have
made a specific intestinal IgA response to it.
Initial incubation times for the ELISA were lengthy - overnight with sample, five
hours with primary detecting antibody, overnight with conjugate - in order to
increase the chances of detection of specific IgA. Samples were identified that gave
positive OD readings in this ELISA, allowing optimisation of the assay with respect
to dilution of reagents. However, attempts to shorten the incubation times to make
the ELISA more time-effective resulted in a significant decrease in OD
measurements, and initial incubation lengths were kept.
In retrospect, the development of the assay may have been less time consuming if
BoNT/C coated plates had been used, as it was found that higher levels of IgA to
BoNT/C than IgA to the surface antigens were usually detected in faeces and ileum
contents.
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6.2.2 Detection of specific IgA to C. botulinum type C in equine Gl tract
IgA, both to surface antigens and BoNT/C, was detected in the ileum and/or the
faeces of a higher percentage of horses with grass sickness compared to controls.
Horses with grass sickness also had a statistically significant higher level of IgA to
BoNT/C in their faeces compared to controls. These results suggest that horses
with grass sickness had been exposed to BoNT/C in the Gl tract, resulting in the
production of specific IgA to the toxin. As the mucosal immune response is thought
to be relatively short-lived (Pierce and Cray, 1982), detection of IgA to BoNT/C in
the Gl tract also suggests that horses with grass sickness had recently been
exposed to BoNT/C.
When the horses with grass sickness were grouped by disease category, only
horses with the subacute form of the disease had significantly higher levels of IgA to
BoNT/C and to the surface antigens in the faeces, compared to the control horses.
Horses with subacute grass sickness also had significantly higher levels of IgA to
BoNT/C in the ileum contents compared to controls. Horses with subacute grass
sickness had detectable IgA to BoNT/C and surface antigens in the highest
percentage of faecal samples, and IgA to BoNT/C in the highest percentage of ileum
samples, compared to the other groups of horses. Differences in duration of
exposure to toxin and size of toxin dose may explain differences in antibody levels
detected in the different clinical categories of equine grass sickness. Grass
sickness is a spectrum of disease that has been divided up into three categories.
The clinical severity of grass sickness is associated with the extent of neuronal
damage (Scholes et al, 1993a). It has been hypothesised that the extent of
neuronal damage reflects the size of the toxic insult (Doxey et al, 1995a): acute
grass sickness would be associated with a large amount of toxin, and chronic grass
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sickness a much smaller amount of toxin. The duration of the disease is also
governed by the extent of neuronal damage; less neuronal damage results in less
severe disease and longer survival time.
Hypothetically, horses with subacute grass sickness would be exposed to an
intermediate amount of toxin in comparison to horses with acute and chronic grass
sickness. The neuronal damage is less than in acute grass sickness and horses
with the subacute form can survive for up to seven days. The amount of toxin in the
gut may be sufficient to stimulate a mucosal immune response, and the longer
duration is sufficient to detect the production of specific IgA. Although horses with
acute grass sickness are probably exposed to large doses of toxin, they die or are
euthanased within 48 hours of onset of clinical symptoms. The short duration of
disease may account for the lower levels of IgA detected in horses with acute grass
sickness.
However, the detection of IgA in the gut of some of horses with acute grass sickness
is particularly interesting, as it suggests that these horses were exposed to BoNT/C
prior to the onset of clinical symptoms. BoNT/C has been detected in the Gl tract of
horses with grass sickness (Chapter 3), but it has not yet been demonstrated to be
the cause of the disease. Gl stasis is a major clinical finding in equine grass
sickness, and it is possible that overgrowth of C. botulinum type C into the ileum
with subsequent production of BoNT/C occurs as a result of Gl stasis rather than
causing it. However, if BoNT/C was produced after the onset of Gl stasis, it would
be unlikely that specific IgA to BoNT/C could be detected in horses with acute grass
sickness, theoretically within 24-48h of exposure to the toxin. Therefore, detection
of IgA to BoNT/C in the Gl tract of horses with acute grass sickness may be
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evidence in support of the hypothesis that C. botulinum type C is the cause of
equine grass sickness.
The only significant difference between the groups of grass sickness horses, were in
IgA levels to BoNT/C in the faeces of horses with subacute grass sickness and
horses with chronic grass sickness. This may reflect exposure to a smaller dose of
toxin in horses with chronic grass sickness, resulting in production of lower levels of
specific antibodies. However, the differences in antibody levels may also reflect the
point in the disease at which the faecal sample was collected. Fluctuation in IgA
both to surface antigens and to BoNT/C was observed in the faeces of horses with
CGS that were sampled more than once. These fluctuations in specific IgA levels
between faecal samples may be evidence of a mucosal immune response being
made to the antigens, as well as neutralisation of the antigens by antibody.
Decreases in OD may be due to the inability of the ELISA to detect antibody bound
to specific antigen. With the EndoCAb ELISA, an ELISA which measures antibodies
specific for the endotoxin core, decreases in antibody levels to endotoxin are seen in
patients exposed to systemic endotoxin (Barclay, 1995). The observed changes in
IgA levels over the course of grass sickness were relatively small changes in OD
measurements, and therefore it is not known whether they are significant in vivo.
There is insufficient evidence to state whether specific IgA to these antigens are
important in the recovery of horses from chronic grass sickness. In horses that were
sampled more than once, recovery was not always associated with an increase in
faecal IgA to the surface antigens and toxin. Horses that recovered from chronic
grass sickness had a higher mean level of IgA both to the surface antigens and toxin
at the start and end of the disease compared to horses that were euthanased, but
this difference was not statistically significant.
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Theoretically, the presence of IgA to BoNT/C would be considered to be beneficial
to the horse as it would limit exposure to the toxin, preventing or limiting the severity
of the disease. However, the detection of IgA to BoNT/C in this study in horses with
grass sickness that were euthanased, would not appear to support a positive role for
mucosal IgA. It may be that these horses did not have a primed mucosal immune
response to BoNT/C - the IgA detected in this study may be the result of a primary
mucosal immune response, the production of which was too slow to prevent toxin
damage. Horses with grass sickness have been shown to have lower systemic IgG
both to surface antigens and BoNT/C compared to controls (Chapter 5). Whilst the
control horses in this study had lower levels of IgA to BoNT/C in the faeces than
horses with grass sickness, this may be due to the fact that they have not been
recently exposed to the organism. The control horses may have good mucosal
memory responses to BoNT/C. The detection of IgA to BoNT/C in the faeces of
some control horses may reflect subclinical cases of grass sickness. Subclinical
cases of grass sickness are thought to occur, although they have not been proven.
Investigation of faeces from horses co-grazing with cases of grass sickness, for the
presence of IgA to BoNT/C would help to identify a role for mucosal IgA in the
prevention of grass sickness.
Changes in specific IgA both to BoNT/C and surface antigens were observed in the
faeces of six healthy control horses. Whilst these changes may reflect exposure to
the organism and toxin, they are only small differences in OD measurements and
may not be significant in vivo. The differences in OD between faecal samples from
these healthy horses were generally smaller than those changes observed between
consecutive faecal samples from horses with chronic grass sickness.
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Only faecal samples from horses with SGS had significantly higher levels of IgA to
the surface antigens compared to the control horses. The mean IgA levels to the
surface antigens were lower than the mean IgA levels to BoNT/C in both the faeces
and ileum contents of all the groups of horses. This is an interesting contrast to the
results for systemic IgG to these antigens, where higher levels of IgG were detected
to the surface antigens than to BoNT/C (Chapter 5). Although differences in ELISA
results do not necessarily reflect real difference in vivo, the same antigens were
used in both assays for systemic and mucosal responses. C. novyi type A is
ubiquitous in the environment (Smith, 1975a) and may normally be present in the Gl
tract of horses. It is possible that there is a degree of immune tolerance to C. novyi
type A in the Gl tract of the horse due to its common presence; this may account for
the low levels of specific IgA detected to the surface antigens in the Gl tract. C.
novyi type A has been used as a surrogate marker for the surface antigens of C.
botulinum type C in this study. However, results of poor correlation between IgA to
C. novyi type A surface antigens and IgA to C. botulinum type C surface antigens in
milk, suggested that C. novyi type A might not be as suitable a surrogate marker for
the investigation of local immune responses (Chapter 7.1.6). This may be due to
immune tolerance to C. novyi and therefore also immune tolerance to some of the
shared epitopes of C. botulinum type C. The local immune response may be more
organism-specific than the systemic immune response due to mechanisms of
immune tolerance to commensal organisms.
This study has identified higher levels of IgA to BoNT/C in the Gl tract of horses with
grass sickness compared to controls. However, there are several problems
associated with this study. Faecal and ileum samples from different horses may
have different intestinal protease activity. The breakdown of IgA in samples could
not be monitored due to the lack of an assay for total IgA at the time of the study.
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Differences in consistency of samples between horses may also effect results, as
wet weight of sample was used in calculating dilution factors. Horses with acute and
subacute grass sickness often have liquid stomach and ileum contents due to fluid
accumulation. It would probably be expected that this would result in lower OD
measurements for these samples due to increased dilution. Although horses with
subacute grass sickness had significantly higher levels of specific IgA in this study,
the levels produced may indeed have been higher than those detected. Another
consideration might be that there may be movement of fluid, out of the intestinal wall
into the lumen, leaching high levels of mucosal antibodies into the gut. In contrast to
horses with acute or subacute grass sickness, the Gl tract of a horse with the
chronic form, can be empty of contents at post-mortem, and faeces may be
irregularly produced over the course of the disease. An investigation of the mucosal
immune response to the specific antigens at the cellular level would eliminate
problems associated with protease breakdown of IgA and variation in sample
consistency.
6.2.3 Investigation of the Gl mucosal immune response at the cellular
level
To investigate the mucosal immune response to C. botulinum type C at a cellular
level, a method for the isolation of functionally active lymphocytes from the equine
gut associated lymphoid tissue (GALT) had to be developed. A method for the
isolation of lymphocytes from GALT that had been developed and successfully used
in the pig (M. Bailey and K. Haverson, personal communication) was adapted for
use in the horse. There was no available published data for leucocyte populations
in the equine mucosa, and to ensure that lymphocytes could also be isolated from
the horse by this method, cells were analysed by flow cytometry. Prior to analysis
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of the isolated GALT cells, equine PBMCs were analysed by flow cytometry to
identify equine leucocyte populations by bitmap, check specificity of primary
antibodies (specific for CD3, surface immunoglobulin and CD18), and optimise
conditions for labelling the cells.
Flow cytometric analysis of equine PBMCs
There are few commercially available anti-equine antibodies for use in flow
cytometry. However, there have been three international equine leucocyte antigen
workshops to date (ELAW I, II and III), and the results of ELAW I and II have been
published (Kydd et al, 1991; Lunn et al, 1998). These workshops have identified
and evaluated antibodies recognising equine leucocyte antigens, and many of these
are available on request from the respective researchers.
The anti-equine CD3 monoclonal antibody used in these experiments recognises
the equine equivalent of the CD3 antigen present on all T cells (Lunn et al, 1998). In
experiments one and two, the anti-CD3 antibody positively labelled 67-84% of cells
in the lymphocyte population. These results are comparable with the results from
ELAW II when this antibody was shown to label positively a mean of 75% (range 54-
92%) of peripheral blood leucocytes (Lunn et al, 1998). The CVS 36 monoclonal
antibody is specific for all isotypes of equine immunoglobulin (Lunn et al, 1998), and
therefore can bind to B cells through their expression of surface immunoglobulin
(slg). CVS 36 positively labelled between 12 and 37.4% of cells in the lymphocyte
populations in experiments one and two. These results are also comparable with
the results from ELAW II, where CVS 36 was shown to label 12% of lymphocytes
and 100% of B lymphocytes (defined as CD5-ve lymphocytes) (Lunn et al, 1998).
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The anti-CD18 antibody positively labelled 77-95% of cells in the lymphocyte
population and 91-99% of cells in the monocyte population of the PBMCs analysed
in experiments one and two. The anti-CD18 monoclonal antibody used in this study
was an anti-human CD18. CD18 is present on the surface of all leucocytes in
conjunction with CD11. The anti-CD18 antibody was not included in the ELAW
workshops but had been shown to cross-react with equine leucocytes, amongst
other animal species; the antibody had been shown to bind to 100% of equine
lymphocytes, monocytes and granulocytes (Jacobsen et al, 1993).
A high percentage of cells in the monocyte population (as determined by the bitmap)
in experiment one, were also positively labelled with anti-CD3 and CVS 36. This
indicated either inappropriate gating of leucocyte populations by bitmap, or non¬
specific binding of reagents. The inclusion of a blocking step was successful in
reducing the percentage of positively labelled cells in the monocyte population and
increasing the percentage of positively labelled cells in the lymphocyte population,
but only by a few percent. Even after blocking, CVS 36 still positively labelled a
higher percentage of cells in the monocyte population than the lymphocyte
population. However, in terms of numbers, there were a greater number of cells in
the lymphocyte population positively labelled with CVS 36 than in the monocyte
population.
Binding of CVS 36 to cells in the monocyte population may be due to Fc receptor
(FcR) binding of equine immunoglobulin by monocytes, with FcR-bound
immunoglobulin being detected by the CVS 36 (anti-immunoglobulin) antibody. At
ELAW II, monocytes were removed from peripheral blood leucocytes before FACS
analysis with anti-immunoglobulin reagents. B cells were pre-incubated in an
equine serum-free medium for at least eight hours prior to FACS analysis to ensure
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turnover of Fc receptors and removal of any equine immunoglobulin bound to the Fc
receptors (Lunn et al, 1998). It was found that if B cells were not pre-incubated or
were incubated for less than eight hours, the presence of immunoglobulins bound to
Fc receptors resulted in the detection of a variety of different isotype-producing B
cells by antibodies specific for only one isotype: the antibodies were binding FcR
bound immunoglobulins as well as the slg. As CVS 36 can detect all
immunoglobulin isotypes anyway, pre-incubation to ensure B cell Fc receptor
turnover was not really necessary in this study. However, the monocytes had not
been removed from the PBMCs and therefore the Fc receptor binding of equine
immunoglobulin by monoctyes may be responsible for some binding of CVS 36 to
these cells. The monocytes may also be non-specifically binding the anti-CD3
antibody through their Fc receptors, accounting for the CD3 positively labelled cells
in the monocyte population. The conjugate is the F(ab')2 fragment of antibody to
prevent non-specific binding of the conjugate via Fc receptors; the negative controls
demonstrated that there was no binding of the conjugate to cells in the absence of
primary antibody.
Isolation of lymphocytes from equine GALT
Initially it was decided to isolate cells from the Peyer's patches as this is where the
effector and memory responses are generated in the GALT. GALT can be divided
into organised (O-MALT) and diffuse mucosal-associated lymphoid tissue (D-
MALT). The O-MALT consists of single lymphoid follicles distributed along the
length of the Gl tract, Peyer's patches in the small intestine (aggregates of lymphoid
follicles) and the mesenteric lymph nodes that drain the mucous membranes. The
D-MALT consists of lymphocytes, plasma cells and antigen presenting cells (APC)
in the lamina propria, interstitial tissue of the mucosa and glands, and epithelia.
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Cells activated in the O-MALT recirculate to the D-MALT where they carry out their
effector functions.
Lymphoid follicles and Peyer's patches in the O-MALT are covered by follicle
associated epithelium, composed of the normal columnar enterocytes and
specialised membranous epithelial cells (M cells) which are adapted for antigen
sampling of the luminal contents. Luminal-derived antigens are presented by
antigen presenting cells (APC) in the O-MALT and activated lymphocytes
preferentially recirculate to the lamina propria of the D-MALT. This recirculation is
possibly due, in part, to the up-regulation in surface expression of a4p7 that binds to
the mucosal addressin cell adhesion molecule (MAdCAM-1) expressed by blood
vessels in the mucosa (Mowatt and Viney, 1997).
In the ileum of young horses, aggregates of lymphoid tissue have been shown to
consist of three different morphological forms of follicle - follicle/dome structures,
proprial follicles and lymphoglandular complexes (Lowden and Heath, 1995). The
follicle/dome structure is the only follicle form described in the Peyer's patches in the
small intestine of other animals; the lymphoglandular complexes have been
described in the large intestine but not the small intestine in many other species
(Lowden and Heath, 1995). However, the study was a structural not functional one
and therefore it is not known what the impact (if any) is of the presence of these
different follicle structures in the equine ileal lymphoid tissue on the equine mucosal
immune response.
The method of lymphocyte isolation involved the inversion of a section of gut,
followed by digestion from the mucosal surface inwards with EDTA to remove the
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epithelium, and then collagenase to release lamina propria lymphocytes. To isolate
cells from a Peyer's patch, the patch was dissected out of the gut section after
removal of the epithelium, and then digested with collagenase. To compare cells
isolated from Peyer's patches between horses, the chosen section of gut had to
contain at least one Peyer's patch. However, unlike in the pig, equine Peyer's
patches are not macroscopically visible from the serosal surface due to the
muscular thickness of the equine small intestine. The presence of a Peyer's patch in
the selected section of gut could only be confirmed when the gut had been inverted
and filled with buffer. The procedure to this point was relatively time consuming -
the muscular thickness of the gut caused problems both in tying knots that did not
leak and in the actual inversion of the gut section, making repeated attempts at
obtaining an appropriate section of gut impractical. To compare cells isolated from
the lamina propria between horses, the chosen section of gut should not contain any
Peyer's patches. The lamina propria contains a large number of B cells that are
mainly terminally differentiated plasma cells. These cells would also be useful for
investigating specific mucosal antibody responses. Lymphocytes were therefore
isolated from either the Peyer's patches or lamina propria, depending on the
presence or absence of Peyer's patches in the section of gut collected at the time.
This would also enable comparison of the lymphocytes isolated from the two sites
for their use in the ELISPOT assay.
The existence of a common mucosal immune system has been well documented
(McDermott and Bienenstock, 1979; Weisz-Carrington et al, 1979; Czerkinsky et al,
1987; Forrest, 1992), with lymphocytes activated in the O-MALT also recirculating to
distant mucosal tissues. However, it has also been observed that local exposure to
an antigen can result in higher levels of specific IgA at the site of antigen-stimulation
compared to more distant sites; higher levels of specific IgA within the intestine were
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observed in the segment of intestine exposed to cholera toxin (Pierce and Cray,
1982) or poliovirus (Ogra and Karzon, 1969). BoNT/C and IgA specific for BoNT/C
had been detected in the ileum of horses with grass sickness, (Chapters 3 and 6.1).
However, it was not possible to use ileum sections for the isolation of lymphocytes
as the muscle layers were too thick to allow inversion of the gut; jejunum, proximal
to the ileum, was used instead. The ileum in the horse is relatively very short
(approximately 1 metre in length) therefore it was thought that there would be little
difference in the specificities of the cells isolated from the jejunum compared to
those in the ileum.
Flow cytometric analysis of cells isolated from the equine GALT
Cells, collected at different stages in the lymphocyte isolation procedure, were
analysed by flow cytometry to determine the percentage of lymphocytes isolated at
the different stages and to determine the percentage of T and B cells within these
populations. The ultimate aim of the isolation procedure was to isolate B cells that
could be used in an ELISPOT assay. Therefore, it was essential to ensure that the
procedure used was indeed isolating B lymphocytes.
Although the results obtained in this study were from individual experiments each
using cells from a different horse, there were some common findings. Lymphocytes
were detected in the EDTA wash medium, and these were presumably the
intraepithelial lymphocytes (lELs). There was a higher percentage of T cells
compared to B cells released at this stage. lELs are usually found between the
enterocytes, separated from the gut lumen and lamina propria by the epithelial cell
tight junctions and the basement membrane respectively. During the isolation
procedure the EDTA causes the breakdown of the tight junctions between the
epithelial cells. The last EDTA-wash medium contained between 19 and 38%
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lymphocytes, with approximately 50% of the lymphocytes CD3+ and between 2 and
20% slg+. However, this may reflect the distribution of cells closest to the basement
membrane as it was the final wash; the cells were not pooled from all the EDTA-
washes. In the pig, 27% of epithelial cells are CD2+ (Zhang, 1992, cited in Stokes
et al, 1994); over 90% of the lELs express CD2 and of these 77% are CD8+ and 5%
are CD4+ (Zhang, 1992, cited in Stokes et al, 1994). In humans and rodents, the
majority of lELs are also T cells, with approximately 85% CD8+ (Kraehenbuhl and
Neutra, 1992). The lELs in the human are relatively enriched for the y8 T cell
receptor (Mowatt and Viney, 1997), but this is not the case in the pig (Stokes et al,
1994). The equine lELs were not characterised beyond CD3+ and slg+ cells.
Collagenase breaks down the basement membrane thus releasing cells from the
lamina propria or Peyer's patch. A greater percentage of lymphocytes were
released by digestion of the lamina propria with collagenase, than by removal of the
epithelium. The percentage of positively labelled T and B cells in the lymphocyte
population also increased after collagenase digestion. The percentage of cells in
the monocyte population was lower after collagenase digestion compared to cells
released during removal of the epithelium. Collagenase digestion of the lamina
propria released between 43-51% lymphocytes and 7-9% monocytes. Collagenase
digestion of the Peyer's patch released 65% lymphocytes and 7% monocytes. 58-
62% of the lamina propria lymphocytes were CD3+ T cells compared to 5-26% slg+
B cells. Similar proportions of T and B cells were found in the Peyer's patch with
52% CD3+ and 18% slg+. In mice, 40% of lamina propria lymphocytes were found
to be slgA+, and 25% were positive for T cell markers (Kraehenbuhl and Neutra,
1992).
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As with the PBMCs, the CVS 36 antibody bound to a higher percentage of cells in
the monocyte population than in the lymphocyte population. However, in terms of
numbers, the antibody bound to a greater number of ceils in the lymphocyte
population. To ascertain whether the positively labelled cells in the monocyte
population were due to non-specific binding or incorrect gating of the lymphocyte
population on the bitmap, the monocytes were removed by adherence to plastic. In
experiment four, removal of the monocytes left 5-6% of the remaining cells in the
monocyte bitmap, therefore monocyte removal reduced the percentage of cells in
this population by only a couple of percent. A decrease in the percentage of cells
positively labelled with CVS 36 was also seen in the monocyte population, however
the same decrease was observed in positively labelled cells in the lymphocyte
population. The cells had been separated on Histopaque after removal of the
monocyte and prior to flow cytometric analysis, therefore the differences in cell
populations may be due to cells lost in the separation rather than due to removal of
the monocytes. Removal of monocytes and separation on Histopaque increased
the percentage of cells in the lymphocyte population by 12-26% percent for cells
isolated from the Peyer's patch and lamina propria. The percentage of positively
labelled T cells in the lymphocyte population also increased, but the percentage of B
cells decreased. Even after removal of the monocytes in experiment four there were
still more cells positively labelled with CVS 36 in the monocyte population than in the
lymphocyte population. This suggests that either monocyte removal was not
effective and this was non-specific binding or that indeed the lymphocyte population
gate was incorrectly set. It may be that granular plasma cells were outside the gate
that had been set for the lymphocytes. Whilst theoretically plasma cells do not
express slg, during differentiation it is likely that there is still some surface
expression that could be bound by the CVS 36 antibody.
274
The cells were analysed after monocyte removal and prior to separation on
Histopaque in experiment five. Unfortunately, it was not possible to compare cells
before monocyte removal due to contamination of these cells. There were still 13%
of cells in the monocyte region after monocyte removal, 68% of which were labelled
with CVS 36 and 14% were labelled with anti-CD3. This would suggest that the
lymphocyte gate was incorrect. However, analysis of the cells removed as
'monocytes' by adherence to plastic, demonstrated that only 7% of these cells were
in the monocyte population as defined by the bitmap and 60% of the cells were in
the lymphocyte population. This would suggest that the monocyte and lymphocyte
populations are overlapping in the bitmap. However, the cells also showed very
similar positive labelling with CVS 36 and anti-CD3 as the cells from which they had
been removed, suggesting that monocyte removal had not been effective or that
lymphocytes had also been removed. Subsequent to this experiment it was
discovered that equine B cells can be separated from T cells by the preferential
adherence of equine B cells to plastic (Crepaldi et al, 1986). This may account for B
cells being present in the population of cells removed as 'monocyte', but it does not
account for the high percentage of T cells in this group. It is possible that mixed cell
aggregates may have formed.
It is unlikely that the lymphocyte population included non-lymphocytes as when anti-
CD18 was used alongside the T and B cell markers, the percentage of positively
labelled T and B cells was approximately equal to or greater than the number of
leucocytes labelled with anti-CD18. If some lymphocytes were excluded from the
lymphocyte population in the analysis then it is likely that the actual numbers of
excluded cells were low as the percentage of cells in the monocyte region was not
greater than 15% in any of the experiments. Therefore whilst there was a high
percentage of cells binding CVS 36 and CD3 in the monocyte population, the actual
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numbers of cells binding these antibodies in the monocyte population were very low;
extension of the lymphocyte gate to include these cells did not significantly alter the
percentage of positively labelled cells.
In order to determine whether there was non-specific binding by the monocytes, it
would have been necessary to obtain a monocyte marker and look for double
labelling of monocytes with CVS 36 and anti-CD3. However, there were no directly
conjugated monocyte markers available, therefore preventing dual labelling
analysis.
Although the primary aim of the flow cytometric analysis was to determine whether
lymphocytes could be successfully isolated from equine GALT, some differences
between horses were noted. In experiment one, the horse with CGS had a higher
percentage of positively labelled T cells and lower percentage of B cells in the
lymphocyte population than the healthy control. However, this is probably a
reflection on variation in lymphocyte populations between horses, rather than a
feature of equine grass sickness. There was no difference in the percentage of
lymphocytes and monocytes in the PBMCs collected from these two horses. The
horse in experiment two did not have grass sickness and had an equivalent
percentage of T cells but lower B cells in the lymphocyte population compared to the
horse with chronic grass sickness in experiment one. The horse with subacute
grass sickness in experiment three, had a lower percentage of B cells in the lamina
propria than the other horses investigated. More horses would have to be
compared to determine whether there are changes in the T and B cell populations at
either the systemic or mucosal level in horses with grass sickness.
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Detection of immunoglobulin secreting equine B cells by ELISPOT
The ELISPOT assay, first described by Czerkinsky et al (1983) and Sedgwick and
Holt (1983), is a modified ELISA that can detect antibody secreting cells in vitro;
antigen-specific and total antibody secreting cells of a particular isotype can be
determined by this assay. Initial ELISPOT assays were carried out using equine
PBMCs as these were readily obtainable but the ultimate aim was to compare the
specific- antibody secreting cells to C. botulinum type C and BoNT/C in the lamina
propria or Peyer's patches of horses with and without grass sickness.
Total IgG-secreting cells (SC) were detected with PBMCs and cells isolated from the
lamina propria and Peyer's patches. An ELISA had been developed for total IgG
(Chapter 7.1.1) and the same reagents were used in the ELISPOT. However the
capture antibody, anti-equine IgG, was titrated again to optimise the coating
concentration; this might have differed between the two assays due to the different
binding abilities of the cellulose wells in the ELISPOT plates, and plastic wells in the
ELISA microtitre plates. Variable results were achieved with the different dilutions of
capture antibody. Few ELISPOTs were detected when plates were coated with
dilutions of capture antibody at 1 in 5,000 or higher; the 1 in 2,500 dilution appeared
to be the highest dilution that gave detectable ELISPOTs.
The number of cells added to the wells appeared to be a crucial factor in influencing
the amount of background staining. Initial assays with PBMCs, demonstrated that
IgG secreting cells could be most accurately counted between 105 cells/well and 104
cells/well. Above 105 cells/well there was a lot of background, making the
identification of true ELISPOTs difficult, and below 104 cells/well very few ELISPOTs
were detected. This was also evident in the initial ELISPOT assay using cells
isolated from the lamina propria and Peyer's patch, with too many spots to count
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when 2x105 cells/well or 105 cells/well added to wells coated with anti-horse IgG at
dilutions of 1 in 2,500 or higher. For cells isolated from the lamina propria of another
horse, total IgG secreting cells could be counted between 105 and 104 cells/well.
The PBMCs from this horse had countable total IgG-secreting cells between 104 and
5x103 cells/well. The variations in numbers of cells/well giving optimum numbers of
ELISPOTs that are countable between horses, highlights the need to assay cells at
two or three different dilutions.
Similar numbers of IgG-SC were detected in PBMCs and cells isolated from GALT.
A mean of 39 (range 14-85) total lgG-SC/105 PBMCs could be detected by
ELISPOT (capture antibody dilution 1 in 2,500; results from three horses). With
cells isolated from GALT, the ELISPOT assay detected 37 total lgG-SC/105 lamina
propria cells, reduced to 33 total lgG-SC/105 lamina propria cells if the cells were
separated on Histopaque. In this horse, 5% of B cells isolated from the lamina
propria (as determined by flow cytometric analysis) were detected as IgG-SC in the
ELISPOT assay. Flow cytometric results were available for one of the assays using
PBMCs: 2% of the total B cells secreted IgG in the ELISPOT assay. The detection
of a lower percentage of IgG-SC in the circulating B cells compared to cells from the
lamina propria, may reflect the large numbers of terminally differentiated plasma
cells in the lamina propria.
The proportions of the different isotype-producing B cells in the equine lamina
propria has not been published therefore it is not known whether the detection of 5%
of lamina propria B cells as IgG secreting is an accurate reflection of the
percentages of these cells. Certainly the ELISPOT assay will not detect all IgG-SC
as not all will secrete IgG during the 4 h incubation period. In humans, IgA is the
predominant immunoglobulin isotype in the mucosal immune system. Flowever, the
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studies on the immunoglobulin content of equine intestinal secretions showed that
there was almost as much IgG present as IgA (Widders et al, 1984). If these
immunoglobulin levels are reflected by the same proportions of antibody secreting
cells in the lamina propria then this would suggest that the ELISPOT assay is
detecting a low percentage of the IgG-secreting cells that are actually present.
Other studies, using ELISPOT assays, express results as antibody secreting cells
/number of cells added and do not compare them to real percentages of cells
present, so it is difficult to compare the sensitivity of this assay with other published
results. The ELISPOT assay to detect IgA secreting cells was not successful. High
backgrounds were a problem making it impossible to detect the presence of true
ELISPOTs.
Antigen-specific antibody secreting cells were detected, but in low numbers. One
anti-novyi lgG-SC/105 Peyer's patches cells (0.08% of all B cells) and one anti-novyi
lgG-SC/105 lamina propria cells (0.07% of all B cells) were detected in a horse with
glomerulonephritis. Two anti-C. botulinum type C lgG-SC/105 lamina propria cells
(0.03% of all B cells or 5% of total IgG-SC as detected by ELISPOT) were detected
in a horse with suspected botulism. This horse had one anti-novyi lgG-SC/105
lamina propria cells, and one anti-BoNT/C/105 lamina propria cells. However, one
anti-BSA lgG-SC/105 lamina propria cells was also detected in this horse. This may
be evidence of non-specific binding to the nitrocellulose wells, or this horse may
have had cross-reactive antibodies to BSA. Antibodies to BSA had not been
detected in previous assays. The low numbers of specific ELISPOTs detected,
demonstrates the need to add high numbers of cells to the wells when looking for
specific antibody secreting cells. The numbers of cells that need to be added to
detect a specific B cell are much greater than the numbers required for determining
total numbers of IgG secreting cells. No specific antibody secreting cells were
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detected in the PBMCs, reflecting low levels/no circulating B cells specific to these
antigens.
In the one horse that had cells isolated from both the lamina propria and a Peyer's
patch, there was little difference in total IgG-SC and specific IgG-SC between the
cells from the two lymphoid sites. Separation of the GALT cells on Histopaque had
little effect on the ELISPOT results. However, separation did result in a 2.5-5-fold
decrease in total cell numbers. Flow cytometry demonstrated an increase in the
lymphocyte population and decrease in the monocyte population after separation on
Histopaque but there was also a decrease in the percentage of slg+ cells. These
results suggest that it is probably better not to separate the GALT cells on
Histopaque prior to an ELISPOT assay.
Isolation of lymphocytes from the lamina propria and Peyer's patches followed by
analysis of the antibody secreting cells by ELISPOT enabled demonstration of the
presence of IgG-SC, as well as anti-C. novyi and anti-C. botulinum IgG-SC.
However, on several occasions the ELISPOT assay was not possible due to
contamination of cells during the isolation procedure. The horses used are not
experimental animals but real clinical cases, often suffering from a Gl-related
disease. The conditions of the guts were therefore not always healthy, increasing
the chances of microbial contamination of the cells. The isolation procedure is
lengthy taking approximately 10 hours. The first incubation in the ELISPOT assay is
for 4 h and often the isolated cells had to be kept in tissue culture flasks for 6-8h at
37°C in 5% C02, prior to starting the ELISPOT assay. This prolonged incubation
also increased the chances of contamination. As stated previously the horses were
not experimental animals and therefore their euthanasia could not be planned for.
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To isolate the lymphocytes and carry out the ELISPOT in a reasonable time frame,
the horse would have to be euthanased first thing in the morning, but this was
usually not the case.
The ELISPOT has advantages over the ELISA, for example results are not affected
by the absorption or elimination of antibody, or dilution factors of intestinal contents.
However, the length of time required to isolate the cells from equine GALT followed
by the ELISPOT assay, combined with the frequent contamination of cells, does not
merit its use for the large scale investigation of mucosal immunity in equine clinical
cases. It would however, be a useful technique for the future investigation of the
mucosal immune responses, if experimental animals could be used. The
appearance of antigen-specific IgA-SC in the peripheral blood, has been used by
some investigators, as an indirect measure of the intestinal immune response to oral
vaccination (Czerkinsky et al, 1987; Czerkinsky et al, 1991; Forrest, 1992). The
appearance of these specific antibody secreting cells in the blood is transient and
therefore this would not be a suitable method to use at this stage for the
investigation of mucosal immunity to C. botulinum in equine grass sickness, as the
time of exposure is not yet known.
6.2.4 Detection of antibodies in saponin extracted GALT
An alternative approach to investigating mucosal antibodies is the use of the
detergent saponin to extract antibodies from mucosal GALT. Extraction of equine
GALT tissue with saponin in the presence of protease inhibitors was effective at
releasing antibodies detectable by both ELISA and RID. Saponin releases antibody
from cells by solubilising the cell membranes. The IgG and IgA content of lamina
propria tissue and Peyer's patch tissue from the same horse were very similar. This
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correlates with the numbers of total IgG-SC isolated from the lamina propria and
Peyer's patches as these were also very similar. However, there was a 50-fold
difference in IgG levels between the two horses, which meant that samples should
be assayed at more than one dilution for the calculation for total IgG to account for
variation.
Extraction of GALT tissue with saponin resulted in a higher detectable level of IgG,
compared to protease treated ileum contents and faeces. However this was not the
case with the detection of total IgA as one horse had no detectable IgA in the GALT
extracts. IgA in GALT extracts, from the second horse investigated, could be
quantified by RID, whereas the IgA in a sample of ileum contents was below the
threshold concentration for detection by RID.
The extraction method was less time consuming than the ELISPOT assay, and the
ELISA results were easier to interpret compared to the enumeration of ELISPOTs.
The extraction method also has an advantage over the detection of IgA in ileum
contents and faeces as the results should not be affected by antibody fluctuations
due to absorption and elimination of antibody. Degradation of extracted antibody by
proteases should be less compared to protease degradation of antibody in intestinal
contents or faeces, as the extracted antibody will not have been in contact with the
gut contents.
A possible criticism of this method of investigation of the mucosal immune response
is the potential contamination of extracted antibody with systemic antibody derived
from blood in the tissues. Although this factor was not investigated here, previous
studies by other investigators have shown this to be negligible. In humans, IgA
levels in extracted biopsies correlated with IgA-SC from mucosal biopsies but not
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with IgA levels in plasma (Bergquist et al, 2000). Studies in mice showed that there
was less than 2% systemic antibodies in mucosal extracts (Bergquist et al, 1995;
Johansson et al, 1998).
Although the levels of IgA could not be calculated by ELISA, the value obtained by
RID was almost the same as the IgG levels. A previous study had shown that there
was slightly higher IgA in intestinal contents (0.08mg/ml) compared to IgG
(0.07mg/ml) determined by RID (Widders et al, 1984). In this study, in horse two,
the IgG level was 2.1mg/ml in the extract from the lamina propria and 2.8mg/ml in
the extract from the Peyer's patches, compared to an IgA level of 1.5mg/ml both in
extracts from the lamina propria and Peyer's patches. These differences may be a
reflection of differences in the two techniques used. The anti-equine IgG used in the
ELISA for total IgG was raised against the light chain as well as the heavy chain of
IgG and therefore may detect other equine isotypes (as discussed in Chapter 7).
Solubilisation of GALT with saponin and subsequent analysis of released antibodies
by ELISA may prove to be a more efficient method for the investigation of specific
mucosal antibody responses in clinical cases of grass sickness. However, the
detection of IgA in the faeces of horses has a major advantage over both the
ELISPOT and saponin extraction techniques, in that it can compare antibody levels




Detection of IgG and IgA in colostrum and milk to C.
botulinum type C surface antigens and BoNT/C
7.1 Results
7.1.1 Optimisation of assay for total IgG ELISA
Capture antibody
Two rabbit anti-equine IgG (H+L) antisera (Nordic and ICN) were compared for use
as a capture antibody for an ELISA to detect total equine IgG. ELISA plates were
coated with each antisera diluted fivefold from 1 in 20 to 1 in 12500. An equine
serum sample was used to compare which capture antibody gave optimal binding.
The serum sample was serially diluted fivefold, between 1 in 4 and 1 in 500, and
titrated against the capture antibody. Approximately three-fold higher OD values
were observed when the ICN affinity-purified rabbit anti-equine IgG (H+L) antiserum
was used as the capture antibody, compared to the Nordic antiserum (Fig. 7.1).
Therefore, it was decided to use the ICN antiserum as the capture antibody and
experiments were carried out to optimise this assay. Equine IgG was titrated
against a twofold dilution series of the ICN anti-equine IgG (H+L), from 1 in 2500 to
1 in 200000. The 1 in 2500 dilution of capture antibody gave the highest OD
readings at 0.1 and 0.05 pg/ml IgG (Fig. 7.2). It was decided to use the ICN anti-
equine IgG antiserum at a dilution of 1 in 2500 (protein concentration of 0.8|ug/ml)
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Figure 7.1: Comparison of two different anti-equine IgG antibodies for coating ELISA
plates for the detection of total IgG in a serum sample.
(a) Plates were coated with five dilutions of anti-equine IgG (H+L) antiserum (ICN)
and (b) anti-equine IgG (H+L) antiserum (Nordic). Serum sample was diluted
fivefold between 1 in 4 and 1 in 500.
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Figure 7.2: Equine IgG titrated against different coating dilutions of anti-equine IgG




In order to calculate the concentration of IgG in each sample, it was necessary to
have a positive control of a known IgG concentration. Equine IgG was obtained
from an equine serum sample using a protein G column (MAb Trap Gil kit,
Pharmacia Biotech). The eluted IgG fraction had a protein concentration of
2.94mg/ml and this was taken to represent the IgG concentration. In order to
determine the dilution range that would give a linear relationship, the equine IgG
standard was initially diluted tenfold from 1000pg/ml to 0.001 jag/ml, then fivefold
from 1pg/ml to 0.00032pg/ml, and finally twofold from 0.2pg/ml to 0.0008^g/ml. It
was established that dilution of the equine IgG sample twofold from 0.1pg/ml to
0.003|ag/ml produced a standard curve with a linear relationship (Fig. 7.3). The
equation of the line could then be used to calculate the IgG concentration of the
samples assayed on the ELISA plate.
Dilution of colostrum and milk samples
Preliminary assays were carried out to determine the optimum dilutions for assaying
colostrum and milk samples for total IgG. The OD values for these samples had to
fall within the linear part of a titration curve, be above the background level of the
ELISA (i.e. greater than the mean of the blank control + 3 x S.D.) and within the
range of the standard curve for total IgG.
Initial fivefold dilutions of two colostrum samples, between 1 in 100 and 1 in 312500,
demonstrated that they would have to be titrated further. The same was observed
when three colostrum samples were diluted twofold from 1 in 5x104 to 1 in 1.6x10®.
Finally, a decrease in OD was observed when three colostrum samples were diluted
fivefold from 1 in 1x10® to 1 in 3.125x109 (Fig. 7.4). Twelve colostrum samples were
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Figure 7.4: Total IgG in three colostrum samples diluted from 1 in 1,000,000
to 1 in 3,125,000,000
diluted tenfold from 1 in 100 to 1 in 107 to determine the optimum dilution for
screening all the colostrum samples for total IgG (Fig. 7.5a and b). However, due to
the variability observed in the IgG content of these samples it was decided that it
would be more accurate to assay each sample at four dilutions. Colostrum samples
were therefore diluted fivefold between 1 in 105 to 1 in 1.25x107, a dilution curve
plotted, and the most appropriate dilution for each sample chosen to calculate the
total amount of IgG in each sample (Fig. 7.6).
Three milk samples collected at two weeks, four weeks and eight weeks post-
parturition were assayed at fivefold dilutions from 1 in 20 to 1 in 6.25x104. A
prozone effect was observed up to the 1 in 500 dilution, but there was little variation
in the IgG content between two and eight weeks (Fig. 7.7a). Subsequently three
milk samples collected at two weeks post-parturition were diluted fivefold from 1 in
400 to 1 in 1250000 (Fig. 7.7b).
Due to the variation observed in IgG levels in colostrum and milk samples between
mares (Fig. 7.5 and 7.7b), it was decided to screen all milk samples at four dilutions.
Milk samples were therefore diluted fivefold between 1 in 1000 and 1 in 125,000 and
a dilution curve was plotted for each sample (Fig. 7.8). From this dilution curve, the

























Figure 7.5(a) and (b) - Total IgG in twelve colostrum samples diluted tenfold from

















Figure 7.6: Total IgG in seven colostrum samples. Fivefold dilutions of colostrum




















Figure 7.7: Total IgG in (a) three milk samples collected at 2, 4 and 8 weeks
post-parturition, diluted fivefold from 1 in 20 to 1 in 62,500 and in (b) three milk
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Figure 7.8: Total IgG in eight milk samples collected at 2 weeks, diluted fivefold
from 1 in 1,000 to 1 in 125,000
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7.1.2 Optimisation of ELISA for total IgA in colostrum and milk
samples
Capture antibody and primary detecting antibody
Various combinations of anti-equine IgA antibodies were investigated for use as the
capture (coating) antibody and the primary detecting antibody for an ELISA to
determine total IgA (there was no directly conjugated anti-equine IgA antibody
available). These antibodies were titrated to establish the optimum dilutions for the
ELISA. A colostrum sample was used as the positive control to optimise the assay.
Table 7.1 illustrates the various combinations of reagents and dilutions used.
Initially, plates were coated with anti-horse IgA (Fc) rabbit antiserum (Nordic) or anti-
horse IgA mouse monoclonal (BVS), with the ISL mouse monoclonal as the primary
detecting antibody (combinations 1 and 2 in Table 7.1). High backgrounds were
observed when the BVS monoclonal was the capture antibody, with the sample OD
values only slightly higher than background. This was probably due to the anti-
mouse conjugate binding to the mouse monoclonal capture antibody: using a
capture antibody and primary detecting antibody of the same host species is not a
suitable combination for the ELISA. When the rabbit antiserum was used as the
capture antibody (combination 2) the backgrounds were lower, but the sample OD
values were also very low.
Different combinations of capture antibody and primary detecting antibody were
therefore investigated. Plates were coated with the anti-horse IgA (Fc) rabbit
antiserum (Nordic), with the BVS mouse monoclonal as the primary detecting
antibody (combination 3). However, this combination still gave very low OD levels.
When these antibodies were reversed, with the BVS monoclonal used as the
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capture antibody and the Nordic rabbit antiserum used as the primary detecting
antibody (combination 4), the OD readings for IgA in the colostrum sample were
significantly higher. Therefore, further work concentrated on optimising the ELISA
using the anti-horse IgA mouse monoclonal (BVS) as the capture antibody and the
anti-horse IgA (Fc) rabbit antiserum (Nordic) as the primary detecting antibody
(combinations 5 and 6). From these experiments, it was established that the
capture antibody should be used at a dilution of 1 in 1000 (Fig. 7.9a), the primary
detecting antibody at 1 in 400 (Fig. 7.9c) and the conjugate at 1 in 5000 (Fig. 7.9a &
b). Using the capture antibody at a dilution of 1 in 1000 gave high OD levels and
was reasonably economical. When the conjugate was used at 1 in 5000 a threefold
higher OD was obtained for the sample than when the conjugate was used at 1 in
10000. The primary detecting antibody dilution of 1 in 400 was chosen because this
dilution gave the highest OD without high background OD reading.
IgA standard
In order to calculate the amount of total IgA in each sample, a positive control of
known IgA concentration was required. The amount of IgA in a selected colostrum
sample (M16A) was found to be 6mg/ml using a RID kit (LLA RID kit, VMRD, Inc.).
This colostrum sample was used as a positive control and titrated in the ELISA for
total IgA. The sample was diluted tenfold between 100pg/ml and 0.001 pg/ml and
twofold between lOpg/ml to 0.3125pg/ml, in order to establish the appropriate
dilution range to achieve a standard curve. A logarithmic relationship (log2) was
observed between 10p.g/ml and 0.15|ug/ml IgA. It was therefore decided to dilute
the colostrum sample twofold, between 10pg/ml and 0.15pg/ml IgA to produce a
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Dilution of colostrum sample Capture antibody dilutions
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Figure 7.9: ELISA for total IgA. Fivefold dilutions of capture antibody, monoclonal
anti-equine IgA (BVS) from 1 in 200 to 1 in 15,625,000 with (a) the conjugate
diluted 1 in 5,000 and (b) 1 in 10,000. The colostrum sample was used at dilutions
of 1 in 100 and 1 in 1000. The graphs also show the OD when no colostrum sample
was added.
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Figure 7.9(c): ELISA for total IgA. Twofold dilutions of rabbit anti-equine IgA
antiserum as primary detecting antibody, from 1 in 100 to 1 in 6,400 with BVS
capture antibody at 1 in 1,000 and conjugate diluted 1 in 5,000. The colostrum






Figure 7.10: Total IgA in colostrum standard. Colostrum standard diluted twofold
between 10 and 0.3125 ng/ml.
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Dilution of colostrum and milk samples for determination of total IgA
Twelve colostrum samples were diluted between 1 in 500 and 1 in 16000 to
establish a suitable dilution for screening samples (Fig. 7.11a). However, only two
colostrum samples were significantly above background in this dilution range and
these were further titrated out fivefold from 1 in 500 to 1 in 1562500 (Fig. 7.11b).
Eight other colostrum samples were diluted fivefold from 1 in 10 to 1 in 1250 (Fig.
7.11c). All samples had positive OD values at 1 in 10 dilution. These results
showed that there was considerable variation in IgA levels between the colostrum
samples. Therefore, all the colostrum samples were diluted tenfold and assayed at
4 dilutions between 1 in 10 and 1 in 10000 (Fig. 7.11 d). A dilution curve was plotted
and the most appropriate dilution was chosen for the calculation of total IgA in each
sample.
All milk samples were diluted fivefold and assayed at four dilutions from 1 in 5 to 1 in
625. A dilution curve for each sample was plotted and the most appropriate dilution
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Figure 7.11: Total IgA in colostrum samples (a) colostrum samples diluted twofold
between 1 in 500 and 1 in 16,000, (b) colostrum samples diluted fivefold between
1 in 500 and 1 in 1,562,500, (c) colostrum samples diluted fivefold between 1 in 10

















































Figure 7.12: Total IgA in nine milk samples. Fivefold dilutions of milk samples
from 1 in 25 to 1 in 625.
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7.1.3 Optimisation of ELISAs for detection of IgG and IgA surface
antigens and BoNT/C
Dilution of colostrum and milk samples for IgG screening assays
Preliminary assays were carried out to establish the optimal dilutions of colostrum
and milk samples for a screening assay to detect IgG to surface antigens and
BoNT/C. Initially, eight colostrum samples and 14 milk samples (collected at
intervals over the suckling period) were diluted fivefold between 1 in 4 to 1 in 100,
for both the ELISA for IgG to surface antigens (Fig. 7.13) and to BoNT/C (Fig. 7.14).
From this, it was determined that the colostrum samples would have to be titrated
out further to establish the optimum dilution, whereas the milk samples had a much
lower level of detectable specific IgG. Six colostrum samples were titrated further,
by fivefold dilution between 1 in 5 to 1 in 6,250, for the ELISA for IgG to the surface
antigens, and twofold dilution between 1 in 5 and 1 in 160 for the ELISA for IgG to
BoNT/C (Fig. 7.15).
On the basis of these preliminary experiments, all colostrum samples were diluted 1
in 100 for the screening ELISAs for C. novyi and C. botulinum type C surface
antigens, and 1 in 20 for the screening ELISA for BoNT/C. Milk samples were
diluted 1 in 10 for both ELISA assays. At these dilutions, the majority of sample had
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Figure 7.13: IgG in colostrum and milk samples to C. novyi type A surface
antigens (a) colostrum samples and (b), (c) and (d) colostrum and milk
samples diluted fivefold from 1 in 4 to 1 in 100. Samples with the suffix A
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Figure 7.14: IgG in colostrum and milk to BoNT/C (a) fivefold dilutions of colostrum
from 1 in 4 to 1 in 100 and (b), (c), and (d), fivefold dilutions of colostrum and milk




































—□- ■ Mean +3SD


















































Figure 7.15: (a) IgG to C. novyi type A surface antigens in colostrum, samples
diluted fivefold from 1 in 5 to 1 in 6,250. (b) IgG to BoNT/C in colostrum, samples
diluted twofold from 1 in 5 to 1 in 160.
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Dilution of colostrum and milk samples for IgA screening assay
Preliminary assays were carried out to establish the optimal dilutions of colostrum
and milk samples, for a screening assay to detect IgA to surface antigens and
BoNT/C. Initially, three colostrum and 13 milk samples (collected at intervals over
the suckling period) were diluted twofold between 1 in 2 and 1 in 64 (Fig. 7.16 and
7.17). Eight colostrum samples were titrated out further, with twofold dilutions from
1 in 5 to 1 in 160 (Fig. 7.18).
On the basis of these preliminary assays, it was decided to screen all colostrum
samples at a 1 in 10 dilution for the ELISA for IgA to surface antigens and 1 in 5
dilution for the ELISA for IgA to BoNT/C. Milk samples were screened at a 1 in 4
dilution for the ELISAs for detecting IgA to both surface antigens and BoNT/C. At
these dilutions, the majority of samples had positive OD values that also fell on the
linear part of the dilution curve.
7.1.4 Calculation of total antibody levels in colostrum and milk by
ELISA
Fivefold dilution of the colostrum samples between 1 in 100000 and 1 in 12500000
(Fig. 7.6), and milk samples between 1 in 1000 and 1 in 125000 (Fig. 7.8), produced
a standard dilution curve for each sample. The OD of the dilution falling on the
linear part of the dilution curve was chosen for calculation of total IgG in each
sample. The equation of the line for the equine IgG standard was used to calculate
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Figure 7.16: IgA to C. novyi type A surface antigens.
(a), (b), and (c) colostrum and milk samples diluted twofold from 1 in 2 to 1 in 64
The suffix of A denotes a colostrum sample e.g. M16A, and the suffix of B, C, D, E,


























2 3 4 5 6
Dilution factor (log2)












Figure 7.17: IgA to BoNT/C. (a), (b), and (c) colostrum and milk samples diluted
twofold from 1 in 2 to 1 in 64.
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Figure 7.18: (a) IgA to C. novyi type A and (b) IgA to BoNT/C in colostrum
Samples diluted twofold from 1 in 5 to 1 in 160
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The mean value for total IgG in the 36 colostrum samples was found to be
116.2mg/ml, compared to a mean value of 2mg/ml in the milk samples (Table 7.2).
Wide ranges of IgG levels were obtained. There was no significant difference in the
levels of IgG in the colostrum or milk between grass sickness contact and non-
contact groups.
For total IgA measurement, colostrum samples were diluted tenfold from 1 in 10 to 1
in 10,000 (Fig. 7.11 d), and milk samples fivefold from 1 in 5 to 1 in 625 (Fig. 7.12).
The OD of the dilution falling on the linear part of the dilution curve was chosen to
calculate the total IgA present in each sample. The equation of the line of the IgA
standard was used to calculate the amount of IgA in each sample, taking into
account the initial dilution factor, and the log2 scale of the IgA standard.
The mean value for total IgA was 140 |ng/ml for the colostrum samples and 20)^g/ml
for the milk samples (Table 7.2). There was no significant difference in total IgA
content of the colostrum or milk, between the grass sickness contact and non-
contact groups.
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Table 7.2: The total IgG and IgA concentrations determined by ELISA in colostrum
and milk samples
Statistics Colostrum Milk
Total IgG Total IgA Total IgG Total IgA
(mg/ml) (mg/ml) (mg/ml) (mg/ml)
Mean 116.2 T4 ZO 002
Range 1.5-1110.9 0.002-33.4 0.6-4.3 0.002-0.2
S.D. 194 57 0.8 0.4
7.1.5 Detection of IgG and IgA, in colostrum and milk, to surface
antigens and BoNT/C
All 36 colostrum samples had positive OD values for IgG to the surface antigens of
C. novyiiype A and C. botulinum type C and to BoNT/C, irrespective of whether the
mare had been in contact with grass sickness previously or not (Fig. 7.19).
There was no significant difference between the levels of IgG to the surface
antigens or to BoNT/C, detected in the colostrum of mares that had previously been
in contact with grass sickness, compared to those that had not. This was the case
irrespective of whether the results were expressed as corrected OD values or as OD
values per mg of total IgG. Wide ranges of antibody levels were detected in the
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Figure 7.19: Percentage of mares with detectable IgG and IgA to C. botulinum
type C surface antigens, C. novyi type A surface antigens and BoNT/C in
colostrum and milk, (a) all mares, (b) mares in contact with grass sickness and
(c) mares not in contact with grass sickness.
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Colostrum Milk
■1 IgG to C. botulinum type C surface antigens
SSH IgG to C. novyi type A
■H IgG to BoNT/C
r i IgA to C. botulinum type C surface antigens
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320
Table 7.3: IgG and IgA levels to C. botulinum type C and C. novyi type A surface


















IgG to Mean 0.57 0.66 0.14 0.16
BoNT/C Range 0.12-1.34 0.12-2.0 0.08-0.31 0.09-0.53
S.D. 0.43 0.54 0.06 0.12
IgG to C. Mean 0.95 1.03 0.33 0.38
bot. type C Range 0.19-1.68 0.38-1.82 0.14-0.58 0.22-0.62
surface S.D. 0.53 0.48 0.13 0.12
antigens
IgG to C. Mean 0.4 0.41 0.24 0.26
novyi type A Range 0.09-0.97 0.08-0.95 0.12-0.43 0.18-0.35
surface S.D. 0.28 0.25 0.11 0.06
antigens
IgA to Mean 0.09 0.14 0.11 0.14
BoNT/C Range 0.04-0.24 0.04-0.38 0.04-0.37 0.04-0.36
S.D. 0.06 0.11 0.08 0.11
IgA to C. Mean 0.3 0.47 0.26 0.33
bot. type C Range 0.03-1.25 0.03-1.2 0.03-0.78 0.03-1.4
surface S.D. 0.32 0.45 0.24 0.42
antigens
IgA to C. Mean 0.27 0.39 0.19 0.23
novyi type A Range 0.03-1.47 0.03-1.44 0.03-0.53 0.03-1.1
surface S.D. 0.35 0.42 0.17 0.32
antigens
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Specific IgA was detected, by ELISA, in 58% (21/36) of colostrum samples both to
the surface antigens of C. botulinum type C and to BoNT/C (Fig. 7.19a). 59%
(13/22) of mares that had been in contact with grass sickness had detectable IgA in
the colostrum to these specific antigens (Fig. 7.19b), compared with the colostrum of
57% (8/14) of mares that had not been in contact with grass sickness (Fig. 7.19c).
IgA was detected to the surface antigens of C. novyi type A in 53% (19/36) of
colostrum samples. 50% (11/22) of mares in contact with grass sickness, and 57%
(8/14) of mares not in contact, had detectable IgA to C. novyi in the colostrum.
There was no significant difference between the levels of IgA detected to either the
surface antigens or to BoNT/C, between the mares that had been in contact with
grass sickness and those that had not (Table 7.3). A wide range of antibody levels
was detected in the colostrum of mares in both these groups (Table 7.3).
All the colostrum samples that were negative for IgA to BoNT/C were also negative
for IgA to C. botulinum type C surface antigens and C. novyi type A surface
antigens, with two exceptions from the "contact" group. M18A had detectable IgA to
BoNT/C but not to the surface antigens, and M25A had detectable IgA to the surface
antigens but not to BoNT/C. Another colostrum sample from the "contact" group,
M35A, did not have detectable IgA to C. novyi type A surface antigens but did have
detectable antibodies to the surface antigens of C. botulinum type C and BoNT/C.
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A positive correlation was seen in the colostrum between the levels of IgG to
BoNT/C and the levels of IgG to C. botulinum type C surface antigens (R=0.75) (Fig.
7.20a). A positive correlation was also seen between the levels of IgA in colostrum
to BoNT/C and to C. botulinum type C surface antigens (R=0.83) (Fig. 7.21a). A
greater level of correlation was observed between the IgG and IgA responses to
these antigens when the OD values were expressed as OD/mg total IgG (R=0.93) or
as OD/fig total IgA (R=0.84) (Fig. 7.20b and 7.21b).
A greater correlation between the IgG response to BoNT/C and surface antigens
was seen in the colostrum of mares in contact with grass sickness (R=0.87), than
those not in contact with grass sickness (R=0.6) (or R=0.97 and R=0.81 respectively
when expressed as OD/mg total IgG) (Fig. 7.20c-f and Table 7.4).
A greater level of correlation was also observed between the IgA response to
BoNT/C and surface antigens in the colostrum of mares in contact with grass
sickness (R=0.94), than those not in contact (R=0.77) (or R=0.91 and R= 0.78
respectively when expressed as OD/pg total IgA) (Fig. 7.21 c-f and Table 7.4).
IgG to C. botulinum type C surface antigens was detected in all 36 milk samples
(Fig. 7.19a). IgG to BoNT/C was detected in 92% (33/36) of the milk samples (Fig.
7.19a). The three milk samples that did not have detectable IgG to BoNT/C were
from mares that had been in contact with grass sickness, and two out of the three
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Figure 7.20: IgG to BoNT/C against IgG to C. botulinum type C surface antigens in
colostrum (a), (c) and (e) levels of IgG expressed as OD readings and (b), (d) and
(f) levels of specific IgG expressed as OD/mg total IgG. (a) and (b) all mares, (c ) and
(d) mares in contact with grass sickness, and (e) and (f) mares not in contact with
grass sickness.
Correlation is significant at the 0.01 level.
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Figure 7.21: IgA to BoNT/C against IgA to C. botulinum type C surface antigens in
colostrum (a), (c) and (e) IgA expressed as OD readings, and (b), (d), and (f),
specific IgA expressed as OD/pg total IgA. (a) and (b) all mares, (c) and (d) mares
in contact with grass sickness, and (e) and (f), mares not in contact with grass




























































There were no significant differences between IgG levels in milk to BoNT/C or to
surface antigens between mares that had been in contact with grass sickness and
those that had not. Wide ranges in levels of antibodies were seen in both groups
(Table 7.3).
IgA was detected to C. botulinum type C surface antigens in 53% (19/36) of milk
samples and to BoNT/C in 39% (14/36) of milk samples (Fig. 7.19a). IgA was
detected to surface antigens in 57% of the milk samples from mares that had been
in contact with grass sickness and to BoNT/C in 35% of these milk samples (Fig.
7.19b). 46% of milk samples from mares not in contact with grass sickness had
detectable IgA to both the surface antigens and BoNT/C (Fig. 7.19c).
All of the 17 samples, which did not have detectable IgA to surface antigens in milk
also did not have detectable IgA to BoNT/C in the milk. 15 of these samples were
from mares that also did not have detectable IgA in the colostrum to surface
antigens or BoNT/C.
The correlation between IgG to BoNT/C and IgG to surface antigens observed in
milk samples (R=0.47) was not as great as that observed in colostrum (R=0.93).
Expression of results as specific IgG/mg total IgG, increased the level of correlation
from R=0.11 to R=0.5 (Fig. 7.22a and 7.22b). Greater correlation between IgG to
BoNT/C and surface antigens was observed in milk from mares which had been in
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Figure 7.22: IgG to C. botulinum type C against IgG to BoNT/C in milk of 36 mares,
(a) IgG expressed as OD readings, and (b) expressed as OD/mg total IgG.
Correlation is significant at the 0.01 level.
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Greater correlation was observed between IgA to BoNT/C and surface antigens in
milk (R=0.84) (Fig. 7.23) compared to the IgG response (R=0.5) (Fig. 7.22). The
correlation was comparable to that observed for the IgA response to BoNT/C and
surface antigens observed in the colostrum samples (R=0.84) (Fig. 7.21). There
was a higher level of correlation between the IgA response to BoNT/C and surface
antigens in the milk of mares in contact with EGS (R=0.89), compared to those that
had not been in contact (R=0.73) (Table 7.4).
7.1.6 Correlation between surface antigens of C. botulinum type C and
C. novyi type A
There was a correlation between IgG to the surface antigens of C. botulinum type C
and IgG to the surface antigens of C. novyi type A in the colostrum (R=0.84) (Fig.
7.24). There was also a correlation between the levels of IgA, in colostrum, to
surface antigens of C. botulinum type C and IgA to surface antigens of C. novyi type
A (R= 0.78) (Fig. 7.24). However, there was little or no correlation observed
between either the IgG or IgA response to the surface antigens in the milk (results
not shown).
A higher mean OD, in colostrum and milk samples, was seen to the surface
antigens of C. botulinum type C, compared to the surface antigens of C. novyi type
A, in both the ELISAs to detect IgG and IgA to these antigens (Table 7.3).
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Figure 7.23: IgA to C. botulinum type C surface antigens against IgA to BoNT/C
in milk of 36 mares, (a) IgA expressed as OD readings, and (b) IgA expressed as






















OD405 to C. botulinum type C
Figure 7.24: (a) IgA to C. botulinum type C against IgA to C. novyi type A in
colostrum, and (b) IgG to C. botulinum type C against IgG to C. novyi type A in
colostrum. Correlation is significant at the 0.01 level.
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7.1.7 Longitudinal study of the levels of specific and total antibodies
over the course of the suckling period.
Six mares were chosen to investigate the levels of specific IgG and IgA to C.
botulinum type C surface antigens and BoNT/C, and total IgG and IgA, over the
course of the suckling period. Three of the mares had been "in contact" with grass
sickness and three had no known previous exposure to cases of grass sickness.
There was a drop in total IgG (Fig. 7.25a) and total IgA concentration (Fig. 7.25b)
from the colostrum sample to the first milk sample collected at two weeks post-
parturition, in each of the six mares. Milk samples were collected at four weeks and
then at four weekly intervals until weaning. There was little variation in total IgG and
IgA levels in the milk from two weeks until weaning (Fig. 7.25).
A similar pattern was also seen in the levels of specific antibodies. There was a
drop in specific antibody levels between the colostrum sample and the first milk
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Figure 7.25: (a) Total IgG and (b) total IgA in the colostrum and milk of six mares
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Figure 7.26: (a) IgG to C. botulinum type C surface antigens, (b) IgG to BoNT/C,
(c) IgA to the surface antigens and (d) IgA to BoNT/C in the colostrum and milk
of mares over the course of the suckling period.
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7.2.1 Development and optimisation of assays
Many problems were encountered in both the development and optimisation of the
assays to detect total and specific IgG and IgA in equine colostrum and milk. Limited
availability of anti-equine immunoglobulin reagents was a significant problem. The
lack of commercially available directly conjugated anti-equine IgA, meant the use of
a primary detecting antibody in the ELISA for total IgA. Although an "extra layer"
can improve the sensitivity of an ELISA, in this ELISA it raised problems of cross-
reactivity and non-specific binding between the reagents, and further limited the
choice of suitable reagents. For example, use of a capture antibody and primary
detecting antibody of the same host species was not possible due to the conjugate
being able to bind to the capture antibody. Using a mouse monoclonal anti-equine
IgA antibody as the capture antibody, with a polyclonal rabbit antiserum as the
primary detecting antibody, and an anti-rabbit conjugate gave the best results with
little or no non-specific binding, either between conjugate and capture antibody or
conjugate and sample.
A commercial RID kit was available for determining total IgA. However, due to the
expense of the kit it was uneconomical to assay all the samples using the kit, and so
this was used to quantify one colostrum sample as a standard.
Fewer problems were encountered with the ELISA for total IgG as there was a
directly conjugated anti-equine IgG antiserum available. However, one
disadvantage of this ELISA is that it may also detect other isotypes of
immunoglobulin, as both the capture antibody and conjugate are raised against the
light chain as well as the heavy chain of IgG.
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Another problem was the lack of commercially available equine IgG or IgA for use
as a positive control in the ELISAs. Therefore these had to be developed from
equine serum and colostrum, and quantified before use.
Optimising the ELISAs for specific IgG and IgA to the surface antigens and to
BoNT/C was difficult due to the lack of a known positive and negative control. A
variety of samples had to be assayed in order to establish the optimum dilution for
an assay for screening all samples. In addition, there was a limited availability of
BoNT/C coated plates, which restricted the number of samples that could be initially
titrated.
7.2.2 Specific antibodies and total immunoglobulins in colostrum and
milk
IgG to both C. botulinum type C surface antigens and BoNT/C was detected in the
colostrum of all 36 mares involved in this study, irrespective of whether the mares
had previously been in contact with grass sickness. The presence of these specific
antibodies in the colostrum, suggests that maternal antibodies may play a role in the
protection of foals from the proposed aetiological agent of grass sickness.
There is no significant transplacental transfer of immunoglobulins in the horse due to
the diffuse epitheliochorial nature of the placenta. Passive protection for the foal is
therefore all colostrum derived. Colostrum is formed by the selective concentration
of serum immunoglobulins in the mammary gland, just prior to parturition (Jeffcott,
1974a). IgG is the major immunoglobulin component in equine colostrum, and is all
serum derived. IgA is a minor component of colostrum and is part serum derived
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and part locally synthesised in the mammary gland. 58% of mares in this study had
IgA to the surface antigens and BoNT/C in their colostrum.
Colostrum is absorbed by the foal, in the first 24 hours after birth, through
specialised intestinal epithelial cells. The colostral immunoglobulins enter the
circulation and provide systemic passive protection. After birth, there is a rapid
turnover of the foal's epithelial cells and by 24-36 hours post-birth the intestinal
epithelium is replaced by mature cells, a process named "closure" (Jeffcott, 1975).
The foal can no longer absorb macromolecules from the gut, directly into the
circulation.
Colostrum derived antibodies, absorbed through the intestinal tract, enter the foal's
circulation reaching a peak at about 18 hours (Jeffcott, 1974b). Circulating
colostrum-derived antibody then declines, reaching a very low level at about one to
two months after birth (McGuire and Crawford, 1973) and becoming undetectable by
five months (Jeffcott, 1974b). Levels of colostral derived IgA and IgM decline at a
quicker rate reaching very low levels at 16-24 and 6-16 days post-birth respectively
(McGuire and Crawford, 1973).
The foal can begin its own immunoglobulin synthesis after about two weeks
(Jeffcott, 1974b), reaching protective levels after about a month, coinciding with the
decline in colostrum-derived IgG. Genetic immunodeficiencies usually become
apparent at around one-two months. Production of IgG by the foal does not
approach adult levels until about four months (Jeffcott, 1974b). During this time, the
foal receives milk from the mare, which offers additional passive immunological
protection from environmental microorganisms, particularly enteric pathogens.
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IgA to C. botulinum type C surface antigens was detected in the milk of 53% of the
mares and 39% of the mares had IgA to BoNT/C in their milk. Seventeen mares
had no detectable IgA in the milk to either surface antigens or BoNT/C, and 15 of
these did not have detectable IgA in the colostrum to these antigens. IgA is the
major immunoglobulin component in milk and is locally produced in the mammary
gland (Jeffcott, 1975). Although the immunoglobulins in milk cannot be absorbed
into the circulation, they do provide the foal with local passive protection in the Gl
tract. Therefore, some but not all foals in this study, also received local passive
protection as well as systemic protection against C. botulinum type C. The
longitudinal study suggested that when specific antibodies were detected in the milk,
the levels remained more or less constant throughout the suckling period. The foals
therefore would continue to receive local passive protection up to weaning.
The presence of locally produced IgA in the milk to C. botulinum type C and BoNT/C
may be evidence of recent exposure of these mares to the organism and its toxin.
There is thought to be a "gut - mammary gland link" with exposure to a micro¬
organism in the gut resulting in a local immune response in the mammary gland,
thus protecting the foal from a specific enteric pathogen (Newby et al, 1982). Whilst
the local IgA response in the gut is thought to be relatively short-lived, the specific
antibodies produced in the mammary gland persist for longer (Evans et al, 1980).
Local passive protection against C. botulinum type C in the Gl tract may prevent
intestinal colonisation with this organism, whilst enabling the foal to establish its own
local immune response against the organism. Foals that do not receive local
passive protection against C. botulinum type C may be more susceptible to
colonisation by this organism. Conversely, they may not be exposed to this
organism during the suckling period, and therefore may be more susceptible to
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colonisation by this organism and effects of the toxin later in life, due to the absence
of an already primed local immune response. It is unlikely that the presence of local
passive protection prevents the exposure and development of an active local
immune response by the foal. It has been shown that breast-feeding does not
inhibit the response to the oral poliovirus vaccine (Deforest et al, 1973 cited in
Newby et al, 1982). Finally, there is the possibility that some horses are unable to
make a local IgA response to the organism and toxin, making them more
susceptible to this disease. Certainly there appears to be a genetic based
susceptibility to grass sickness, however the demonstration of IgA to BoNT/C in the
gut of some horses with grass sickness (Chapter 6), suggests that the inability to
mount a local immune response cannot account for all of this recognised
susceptibility.
There were no significant differences in levels of specific IgG or IgA to BoNT/C and
C. botulinum type C surface antigens in either colostrum or milk between mares that
had or had not been in contact with grass sickness. This is in agreement with the
serological study of the presence of specific IgG in serum to these antigens
(Chapter 5). This investigation showed that although there were statistically
significantly higher levels of specific antibodies in horses that were in contact with
grass sickness compared to those with the disease, there were no significant
differences between horses not known to be in contact with grass sickness and
those that had been in contact with the disease. However, the classification of
mares in the milk study into two groups should be considered. "In contact", in the
milk study was defined as co-grazing land at the time a case of grass sickness
occurred, or subsequently grazing the land after a case had occurred. Only seven
mares had actually been co-grazing with a case of grass sickness. The majority of
"in contact" mares were grazing land where grass sickness had not occurred for
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many years. The mares defined as "not in contact" were not known to have grazed
land where grass sickness had occurred. As we do not know whether there is a
difference in distribution of C. botulinum type C between fields where grass sickness
has occurred and those where it has not, it may be that the majority of horses are
exposed to this organism.
Results for specific antibody levels were expressed as OD levels and also as OD
per mg of IgG or pg of IgA in the sample, to take into account variation in amount of
immunoglobulin present. Some immunoglobulin might have been lost during transit
of samples to the laboratory, thus decreasing the amount of specific antibody
available for detection by ELISA; expression of specific antibody as a proportion of
total would therefore take this into account. However, variation in total
immunoglobulin content will naturally occur between horses, and as the amount of
specific antibody present is the important factor when considering protection against
a specific pathogen, irrespective of the total immunoglobulin levels present, the
results were also expressed as OD readings.
A high level of correlation both between IgG to BoNT/C and IgG to surface antigens
and between IgA to BoNT/C and IgA to surface antigens in colostrum demonstrates
exposure of the mares to both the organism, reflected by the response to surface
antigens, and to the BoNT/C. A high level of correlation between the IgA responses
to these antigens was also seen in milk. There was a higher level of correlation
between the immune response to these antigens in mares that had been in contact
with grass sickness compared with those that had no known contact with the
disease. This may indicate a higher frequency of exposure to toxin-producing
organisms in the mares that had been exposed to grass sickness. Expression of the
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results as a proportion of total IgG or IgA increased the level of correlation, as this
corrected for extremes in the distribution points.
Correlation of IgG and IgA levels in the colostrum between the surface antigens of
C. botulinum type C and C. novyi type A validates the use of the surface antigens of
the latter organism as a surrogate marker for the former organism, in previous
serological assays (Chapter 5). However, little correlation was seen with IgG and
IgA in the milk between the surface antigens, and therefore perhaps C. novyi type A
is a less useful surrogate marker for investigating local immunity to C. botulinum
type C. Local immunity may be directed at organism-specific antigenic epitopes and
not cross-reactive epitopes.
The level of IgG and IgA, in the colostrum and milk, was higher to the surface
antigens of C. botulinum type C, compared to C. novyi type A. The surface antigens
of these organisms were extracted by the same method and the ELISA plates were
coated with the same concentration, therefore the results should be comparable.
The higher antibody levels to C. botulinum type C may reflect increased exposure of
the mares in the study to this organism.
IgG is the major immunoglobulin component of equine colostrum, quantified as
between 9 to 80mg/ml, depending on the investigator (McGuire and Crawford, 1973;
Rouse and Ingram, 1970; and Pahud and Mach, 1972). The mean value
determined in this study for total IgG content of colostrum was 116.2mg/ml, which is
slightly higher than previously determined values. In this study, an ELISA was used
to determine the concentration of IgG in colostrum, whereas previous studies used
single radial immunodiffusion assays. The use of different techniques may account
for the differences in antibody levels between the studies.
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IgA is a relatively minor component of colostrum making up only 10% of the total
immunoglobulin content (Pahud and Mach, 1972). The level of IgA in colostrum is
reported to be between 1.5mg/ml and 9mg/ml depending on the investigator
(McGuire and Crawford, 1973 and Pahud and Mach, 1972), again detected by
single radial immunodiffusion assay. The ELISA detected a mean concentration of
1.40mg/ml for total IgA in colostrum in our study, comparable with previously
reported findings.
The immunoglobulin content of colostrum falls dramatically in the first 12 hours post-
parturition, particularly after suckling by the foal. Rouse and Ingram (1970) reported
a drop in total IgG from 45mg/ml measured at 0-3 hours post-parturition to
7.26mg/ml at four to eight hours post-parturition. Similarly McGuire and Crawford
(1973) showed a decrease in colostral IgG from 19.2mg/ml to 2.7mg/ml, one day
after birth. These findings not only demonstrate the importance of early suckling by
the foal (usually two to three hours after birth) to ensure adequate passive
protection, but also may account for the differences for immunoglobulin content
reported in the literature. As colostrum is secreted only once, the immunoglobulin
content of colostrum may also be decreased by premature lactation prior to birth
(Jeffcott, 1974b).
IgA is the major immunoglobulin component of milk, making up 67% of the total
immunoglobulin, compared to 10% of the total immunoglobulin in colostrum (Pahud
and Mach, 1972). Again, there is variation in the reported concentrations of IgA and
IgG in milk. The concentration of IgA in milk is reported in the literature as 0.8mg/ml
or 0.85mg/ml and that of IgG as 0.35mg/ml or 0.64mg/ml (Pahud and Mach, 1972
and McGuire and Crawford, 1973). Our study found a mean concentration of
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0.02mg/ml total IgA, and 1.95mg/ml total IgG in the 36 milk samples. The IgA
concentration was lower than previously reported findings, whereas the IgG
concentration was higher. This may reflect the differences in techniques for
determining the concentration values. The levels of IgG detected by the ELISA may
be higher than the actual amount of IgG present, as both the coating antibody and
the conjugate were polyclonal anti-equine IgG (H+L). The fact that these antisera
could also bind to equine light chains may result in cross-reaction with other
immunoglobulin isotypes.
In summary the differences in IgG and IgA concentrations found in colostrum and
milk compared to published findings may be due to the difference in technique
(ELISA compared to RID), different times of sampling colostrum (up to 12 hours post
birth) and also the many different breeds of horse used. It has been reported that
different breeds produce different concentrations of immunoglobulins in the
colostrum and serum (Rouse and Ingram, 1970). In this study, milk was collected
from a wide variety of breeds of horses and no attempt was made to separate the
mares on the basis of breed.
There is little published information on specific antibody titres after the colostral
period. Browning et al (1991), investigated antibody to rotavirus in the serum and
milk of normal, infected and vaccinated horses. They found that the specific
antibody levels in the milk did not differ significantly over the period of seven to 70
days postpartum and inferred that a rise during this period would indicate a
response to an infection or vaccination. Findings in our study also showed little
change in the specific antibody levels to the surface antigens or the toxin in the milk
of the six mares investigated. This may be evidence of non-infection over the
suckling period. However, the specific antibody levels did not drop significantly in
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these samples and so alternatively this may indicate constant or repeated exposure
to these specific antigens in order to maintain a specific immune response.
Antibody levels in milk persist for longer than the equivalent immune response in the
gut. Where small variation was observed in specific antibody levels it was not
possible to conclude whether it was a significant increase, i.e. resulting from
exposure.
In summary, the demonstration of specific IgG to surface antigens and to BoNT/C in
the colostrum of all the mares investigated is evidence that foals may be protected
systemically from the proposed aetiological agent of equine grass sickness.
Demonstration of IgA to these antigens, in the milk of some of the mares, is
evidence that some foals also receive local passive protection against the organism
and the toxin. However, in the absence of challenge experiments, it is not known
whether the levels of specific maternal antibodies detected in the colostrum and milk




This thesis has investigated the hypothesis that equine grass sickness is caused by
toxicoinfection with C. botulinum type C. As an initial investigation, this study has
taken a broad approach in order to obtain evidence for the involvement of C.
botulinum type C in equine grass sickness. Thus, detection of BoNT/C, isolation
and characterisation of BoNT/C-producing organisms from the Gl tract and detection
of systemic and mucosal antibodies, in horses with and without grass sickness,
have been studied.
In the absence of a known aetiological agent, epidemiological studies suggested
that grass sickness might have an infectious aetiology, albeit an unconventional
one, whilst the pathology and experimental findings suggested a toxic aetiology.
Toxicoinfection with C. botulinum type C could potentially fulfil the criteria of both an
infectious and toxic aetiology.
Detection of BoNT/C and BoNT/C-producing organisms in the Gl tract of horses with
grass sickness, has demonstrated a strong association between C. botulinum type
C and the disease. While these results support the involvement of a toxicoinfection
with C. botulinum type C with the disease, they cannot demonstrate that this is the
cause of grass sickness. However, the detection of IgA to BoNT/C in the Gl tract of
horses with grass sickness, not only confirms recent exposure to the toxin, but also
suggests exposure to the toxin, at least in horses with acute grass sickness, prior to
the onset of Gl stasis.
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The clinical, pathological and epidemiological similarities between grass sickness
and dysautonomias, more recently recognised in other animals, such as cats, hares
and rabbits, suggested a common aetiological agent. During the course of this
thesis, BoNT/C and BoNT/C-producing organisms have also been detected in the Gl
tract of cats, hares and a rabbit, all with dysautonomia. This provides evidence of
common exposure to C. botulinum type C and BoNT/C in animals with
dysautonomia, thus both supporting a role for a common aetiological agent in these
diseases and supporting the hypothesis that the common aetiology in these
dysautonomias is toxicoinfection with C. botulinum type C. However, it should be
emphasised that the investigation of animals, other than horses, with dysautonomia,
was a very minor part of this thesis. Therefore the role of C. botulinum type C in
these dysautonomias requires further investigation, with more control animals, to
confirm these initial findings.
Epidemiological evidence suggests that an immune response to the aetiological
agent occurs in grass sickness. Investigation of the immune response of horses to
C. botulinum type C and BoNT/C demonstrated that horses that had been in contact
with grass sickness had higher serum IgG levels to BoNT/C and surface antigens,
than horses that had the disease. This suggests that horses in contact with grass
sickness have been subclinical^ exposed to C. botulinum type C and BoNT/C and
have made a systemic immune response. Epidemiological findings have
demonstrated that prior contact with a case of grass sickness is associated with a
ten-fold decrease in likelihood of the disease (Wood et al, 1998). The results of the
investigation of systemic antibody levels, suggest that this decrease in likelihood of
disease might be due to the presence of protective systemic antibodies. In addition,
grass sickness is rarely seen in foals prior to weaning. The presence of antibodies
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to C. botulinum type C and BoNT/C in all colostrum samples investigated, suggests
that foals are passively protected from C. botulinum type C and BoNT/C.
In theory, if grass sickness is caused by toxicoinfection with C. botulinum type C,
then it should be preventable by vaccination against both the organism and its
toxins. However, whilst the detection of serum and colostrum antibodies to C.
botulinum type C and BoNT/C, suggest their role in preventing the disease in horses
that have been in contact with grass sickness and suckling foals, respectively, there
is no evidence that the levels of antibodies detected in these studies are protective.
Challenge experiments would be necessary to establish this. The demonstration of
a significantly higher level of mucosal IgA to BoNT/C in the Gl contents of horses
with grass sickness, compared to controls, raises the issue of whether a specific
mucosal immune response to this toxin can be effective in the prevention of and
recovery from the disease. As the enteric nervous system is severely damaged in
grass sickness, it would appear preferable to have a primed mucosal immune
response to limit the exposure of enteric neurons to the toxin. Further investigation
of the mucosal immune response is therefore required to establish whether a
potential vaccine should also stimulate mucosal immunity.
Further work is required to ascertain the involvement of other toxins potentially
produced by C. botulinum type C, such as C2, C3 and the C. novyi alpha toxin, in
this disease. In addition, the source of infection with C. botulinum type C should be
established. At present, the prevalence of Group III organisms in the Gl tract of the
equine population is not known. Systemic antibody levels in horses to the surface
antigens of Group III organisms suggest common exposure. However, Group III
organisms, all identified as C. novyi type A, were only isolated from animals that had
been exposed in some way to dysautonomia. The future use of PCR might prove to
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be a more sensitive technique for determining the carriage of Group III organisms in
the equine Gl tract. Investigation of pasture for the presence of Group III organisms
and the relevant phages, should demonstrate whether there is an environmental
reservoir. Identification of the presence of toxin genes in organisms in the Gl tract
and in the environment should provide evidence of whether toxigenic or non-
toxigenic organisms are carried. Equine grass sickness may result only when a
phage, carrying a toxin gene, is introduced into a microorganism that is normally
non-toxigenic.
The alteration of the Gl environment, by an unknown factor, is considered important
for the establishment of toxicoinfection with C. botulinum type C, and hence the
onset of disease. However, investigation of this trigger factor was beyond the remit
of this thesis. Without determining this predisposing factor, there may be difficulties
in reproduction of the disease experimentally, and hence difficulties in establishing
toxicoinfection with C. botulinum type C as the cause of the equine grass sickness.
Research is currently being carried out in areas which may lead to the identification
of a trigger factor, for example, antioxidant levels in herbage (McGorum et al, 2000),
and cyanide levels in clover on pastures (B. McGorum, personal communication).
The study of other animals with dysautonomias likely to be caused by the same
aetiological agent as grass sickness should enable the establishment of an
experimental model for the disease, in which to investigate the hypothesis.
However, differences in trigger factors between the dysautonomias in other animals
might well occur. Establishment of in vitro cultures of equine enteric neurons should
enable the investigation of the toxic effects of the implicated toxins - BoNT/C, C2 or
C. novyi alpha toxin -on these neurons.
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In conclusion, the findings of these initial investigations support the hypothesis that
toxicoinfection with a Group III botulinum organism, producing BoNT/C, is involved
in the aetiology of equine grass sickness. Additionally, a basis has been established
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Summary
The cause of grass sickness, an equine dysautonomia, is
unknown. The disease usually results in death.
Gastrointestinal (GI) dysfunction is a common clinical
manifestation in all forms of the disease. It is generally
thought that equine grass sickness (EGS) is caused by an
t ingested or enterically produced neurotoxin which is
absorbed through the GI tract. Clostridium botulinum was
first implicated as a causative agent when it was isolated from
the GI tract of a horse with EGS in 1919. The aim of the
present study was to investigate the hypothesis that EGS
results from toxicoinfection with C. botulinum type C: growth
of the bacterium in the GI tract with production of toxin
(BoNT/C). Ileum contents and faeces from horses with EGS
were investigated for BoNT/C, and indirectly for the presence
of C. botulinum type C, and compared with control samples
from horses without EGS. BoNT/C was detected directly by
ELISA in the ileum of 45% (13/29) of horses with EGS
compared to 4% (1/28) of controls, and in the faeces of 44%
(20/45) of horses with EGS compared to 4% (3/77) of controls.
Levels of up to 10 pg toxin/g wet weight of gut contents were
observed. The one control horse with detectable toxin in the
ileum had been clinically diagnosed as having acute EGS, but
this was not confirmed by histopathology. The organism was
detected indirectly by assaying for BoNT/C by ELISA after
enrichment in culture medium. C. botulinum type C was
shown to be present in 48% (14/29) of ileum samples and 44%
(20/45) of faecal samples from horses with EGS, compared
with 7% (2/27) of ileum samples and 8% (6/72) of faecal
samples from controls. These results support the hypothesis
that EGS results from a C. botulinum type C toxicoinfection.
Introduction
Equine grass sickness (EGS) is a frequently fatal dysautonomia
of unknown aetiology. The disease is most commonly reported in
Great Britain, particularly Scotland, but EGS also occurs in other
parts of Northern Europe, Australia and the Falkland Islands
(Cottrell et cd. 1999). Mai seco, an equine dysautonomia, which
is probably identical to EGS, is seen in Argentina and Chile
(Uzal and Robles 1993).
Author to whom correspondence should be addressed.
The clinical, pathological and epidemiological features of the
disease are well documented (Gilmour 1987; Edwards 1987;
Doxey et al. 1991a,b; Wood et al. 1998). There is severe neuronal
degeneration and widespread neuronal loss in both the enteric and
autonomic nervous systems. EGS can present in 3 forms
classified on the basis of duration and severity of clinical signs.
The acute and subacute form invariably result in death or
euthanasia; some selected chronic cases have recovered with
appropriate treatment, the mainstay of which is thorough nursing
care (Doxey et al. 1998). The most common clinical signs are
dysphagia and gastrointestinal stasis/dysfunction. Horses with the
subacute and chronic forms rapidly lose weight and condition.
The cause of grass sickness is still unknown. Many putative
causative agents have been considered since the disease was first
recognised early this century, including fungal, plant and
chemical toxins (Greig 1942; Doxey et al. 1990). Tocher et al.
(1923) presented the first evidence to support a hypothesis that
Clostridium botulinum was the cause of grass sickness. A
bacterium morphologically and toxigenically resembling Bacillus
botulinus (now Clostridium botulinum) was first isolated from the
gastrointestinal (GI) tract of a case of EGS in 1919 and,
subsequently, from the spleens of a number of horses with grass
sickness (Tocher et al. 1923). However, further investigation and
a subsequent vaccine trial failed to convince Tocher's
contemporaries that this was the causative agent, despite some
reduction in the incidence of the disease in vaccinated animals.
Horses were vaccinated with a combination of toxin and antitoxin
(Tocher et al. 1923), which had been prepared from known
strains, and not from the organisms isolated from the EGS cases.
The antitoxin was in fact from a US human source.
It is proposed that the disease is caused by an ingested or
enterically produced neurotoxin that is absorbed through the GI
tract, severely damaging the enteric nerves. There is a correlation
between the clinical severity and the extent and distribution of
enteric neuronal damage (Doxey et al. 1992; Pogson et al. 1992;
Scholes et al. 1993) with the greatest neuronal loss usually
observed in the ileum. It is thought that the neurotoxin reaches
the peripheral autonomic ganglia via the circulation and/or by
retrograde axonal transport (Griffiths et al. 1994).
There are several factors that point to the disease being of an
infectious aetiology, with the development of an immune
response to the causative organism. EGS is seasonal with cases
predominantly seen between April and July and as the name
suggests it is associated with grazing. Older horses and those that
have spent longer on a particular pasture have a decreased
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CGS = chronic grass sickness; SGS = subacute grass sickness; AGS = acute grass sickness
Fig 1: Percentage ofhorses with detectable BoNT/C in the ileum andfaeces (a) directly, i.e. before enrichment, and (b) after enrichment. The number
on top ofeach bar represents the number of horses in each category on which calculation of the percentages has been based.
incidence of grass sickness. Prior contact with a case of EGS is
associated with a 10-fold reduction in the likelihood of the
disease (Wood et al. 1998).
In 1994, J. K. Miller (personal communication) hypothesised
that the aetiopathogenesis of EGS results from a toxicoinfection
by an organism of the Clostridium botulinum group III phenotype
(serotype C or D). The organism grows in the GI tract with
elaboration of toxin in vivo, a situation similar to human infant
botulism. C. botulinum type C predominantly affects animals and
can produce 3 toxins; CI, (BoNT/C), C2 and C3.
BoNT/C is a botulinum neurotoxin that inhibits the release of
acetylcholine at cholinergic nerve terminals. It prevents
neurotransmitter release by specific proteolysis of syntaxin
(Schiavo etal. 1995) and SNAP-25 (Foran etal. 1996; Osen-Sand
et al. 1996; Williamson et al. 1996). Syntaxin and SNAP-25 are
both synaptosomal proteins that are involved in synaptic vesicle
exocytosis. These proteins are conserved within neuronal
synapses, and, therefore as would be expected, botulinum
neurotoxins can inhibit other neurotransmitters besides
acetylcholine in vitro (Bigalike and Habermann 1981; Mackenzie
et al. 1982; Foran et al. 1996; Williamson and Neale 1998).
BoNT/C is severely neurotoxic to mouse spinal cord neurones
(Williamson and Neale 1998) and rat hippocampal and cortical
neurones (Osen-Sand et al. 1996) in culture. This neurotoxicity is
unique to BoNT/C; the other clostridial neurotoxins block
neurotransmission, but only BoNT/C can cause overt neuronal
degeneration (Williamson et al. 1995). It is therefore possible that
BoNT/C can cause damage to a wide range of neurones in vivo.
C. botulinum type C differs from the other botulinum
serotypes in that it can produce a further 2 toxins, both of which
have ADP-ribosylating activity. C2 is a binary toxin which ADP-
ribosylates the G-actin form of (3/y cytoplasmic and y smooth
muscle actin (Mauss et al. 1990), resulting in the
depolymerisation of the actin microfilament network. C3 is an
exoenzyme which ADP-ribosylates the Rho-family of low
molecular weight GTP binding proteins required for the
organisation of the microfilament network (Hara-Yokoyama et
al. 1994). C2 and C3, by their effect on the cytoskeleton of the
cell, can bring about ultrastructural disarray. C3 can cause
neuronal degeneration in vitro (Williamson and Neale 1998).
A pilot serological study (J.K. Miller etal. unpublished data)
suggested that a serum IgG response was made to surface
antigens of C. novyi type A (used as a surrogate marker, as it is
phenotypically identical to C. botulinum type C/D [Poxton
1984]) and to BoNT/C during chronic grass sickness.
The aim of the present study was to investigate intestinal
contents and faeces from horses with EGS for the presence of
BoNT/C. These were compared with control samples from
horses without EGS, to determine whether there is evidence for
a role for C. botulinum type C in the aetiology of this disease.
Preliminary findings of this study were presented at the 10th
Biennial Symposium of the Society for Anaerobic Microbiology
in Cambridge in July 1997, and results published in the
Proceedings (Poxton et al. 1997).
Materials and methods
Clinical ileal and faecal samples
Intestinal contents were taken from the distal ileum at
postmortem and rectal faecal samples were taken antemortem.
Ileal samples were taken from 30 horses with EGS (acute,
n = 12; subacute, n = 8; chronic, n = 10) and 28 controls (normal,
i.e. apparently healthy horses, n = 2; a horse which had EGS in
the past but not at the time of sampling, n = 1; clinical nonEGS
cases with gut dysfunction, colic, n = 1; and without gut
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CGS = chronic grass sickness; SGS = subacute grass sickness; AGS = acute grass sickness
SGS AGS CONTROLS
Category of disease
Fig 2: Scatterplot showing the range ofBoNT/C concentrations directly detected in (a) ileum samples and (b) faecal samples. There is a statistically
significant difference in the levels of toxin detected in the ileum of the CGS group and controls (P = 0.001), between the SGS group and controls
(P<0.05) and between the AGS group and controls (P<0.001). There is a statistically significant difference in the levels of toxin directly detected in
the faeces between the CGS group and controls (P<0.001), and between the AGS group and controls (P<0.001). The number of samples in each
category which did not have detectable toxin are represented as a proportion oftotal sample number in each group, by the numbers below the reference
line of the BoNT/C standard of 0.8 ng/ml, on the graph. The detectable limit of the assay is considered to be equivalent to 0.8 ng/ml of the BoNT/C
on the standard curve from the ELISA.
dysfunction, n = 15; and with unknown diagnoses, n = 9).
Faecal samples were taken from 45 horses with EGS (acute,
n = 13; subacute, n = 6; and chronic, n = 26) and 77 controls
(normal, i.e. apparently healthy horses, n = 24; horses which had
EGS in the past but not at the time of sampling, n = 3; healthy
horses in contact with clinical EGS cases, n = 34; clinical
nonEGS cases with gut dysfunction, colic, n = 4, ileus, n = 1,
and without gut dysfunction, n = 11).
Processing ofsamples for toxin detection
1) Direct detection: weighed specimens (1-10 g) were infused
into a known volume (5 or 10 ml, depending on consistency of
sample) of phosphate-buffered saline, pH 7.2, with 0.2% gelatin
(PBSG), and held overnight at 4°C. After vortexing, the liquid
portion was removed and centrifuged at 3,800 g for 20 min. The
supernate was subsequently collected and stored at -20°C.
2) Enrichment: approximately 1-3 g of specimen was added to
15 ml prereduced CMC-1 medium (developed by Centre for
Applied Microbiology Research (CAMR)1 and incubated at
30°C for 5 days. The samples were centrifuged at 3,800 g for 20
min and the supernatant was collected and stored at -20°C.
Enzyme-linked immunosorbent assay (ELISA): a sandwich
ELISA for the detection of C. botulinum type CI (BoNT/C) had
been developed by CAMR1. A polyvalent guinea pig antiserum
raised (supplied by CAMR) against the purified neurotoxin was
used as a capture. The micro plates (Nunc F8 Polysorp)2 were
coated (100 pl/well) overnight at 4°C with 5-10 pg/ml of the
antiserum diluted in phosphate buffered saline, pH 7.4 (PBS).
Plates were washed 3 times with PBS containing 0.1% Tween 20
(PBS-T). Plates were postcoated with PBS-T containing 5%
foetal bovine serum (PBS-TF) for a minimum of 1 h at 37°C and
then washed 3 times in PBS-T. Sample supernates were assayed
in duplicate at 3 dilutions (undilute, 1 in 2, and 1 in 4 for direct
toxin detection; 1 in 5, 1 in 25 and 1 in 125 for enriched samples)
in PBS-TF (100 pl/well). Purified BoNT/C diluted in PBS-TF to
100 ng/ml, 20 ng/ml, 4 ng/ml and 0.8 ng/ml was included as a
standard to enable comparison between plates and quantification
of results. The plates were incubated at 37°C for 90 min and then
washed 3 times with PBS-T. The anti-BoNT/C guinea pig IgG
(supplied by CAMR)1, conjugated to HRP, was used at a dilution
of 1 in 300 in PBS-TF (100 pl/well). Plates were incubated for
90 min at 37°C. After washing 3 times in PBS-T, the substrate
(3, 3', 5, 5'-tetramethyl-benzidine dihydrochloride tablets3
dissolved in phosphate-citrate buffer pH 5.0 with 2 pi 30%
H2O2/IO ml was added (100 pl/well). The reaction was allowed
to develop at room temperature for 30 min or until the
background became detectable. The reaction was stopped by the
addition of 50 pl/well 2 mol/1 H2S04. Plates were read in an
Anthos plate reader at 450 nm, with a reference at 620 nm.
Samples were considered positive if the mean optical
density was equal to or greater than that for the 0.8 ng/ml
BoNT/C standard. A standard curve was used to quantify the
toxin concentrations in samples that had been infused in PBSG,
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TABLE 1: Detection and quantitation of BoNT/C, before and after enrichment, in multiple faecal samples taken from horses with
CGS
BoNT/C detected
Horse reference Duration of before (ng/g wet BoNT/C after
number disease (days) Day sampled weight sample) enrichment Outcome
97/150 75 5 No No Euthanasia
75 7.2 Yes
98/540 47 38 No No Recovered
47 42 Yes
97/545 40 6 No Yes Recovered
39 1.36 No
97/623 67 23 147.5 No Recovered
66 43 Yes










correcting for the original dilution factors. The amounts of
BoNT/C in samples, which had been enriched in CMC-1, were
not quantified in this way due to amplification of toxin in the
enrichment process.
Statistical analysis
The levels of BoNT/C detected directly in the ileal and faecal
samples were compared statistically between the categories of
EGS disease and the controls by the Mann-Whitney U test.
Results
Direct detection ofBoNT/C in the ileum andfaeces
Overall BoNT/C was directly detected in 45% (13/29 horses) of
ileum contents from EGS cases compared with 4% (1/28 horses)
of controls and in 44% (20/45 horses) of EGS faecal samples
compared with 4% (3/77 horses) of controls.
BoNT/C was detected in the ileum contents of a greater
proportion of chronic (50%) and acute cases (50%) than
subacute cases (29%). It was detected in the faeces of a greater
proportion of chronic (50%) and acute cases (46%) than
subacute cases (17%). This is summarised in Figure la.
The one control case with detectable toxin in the ileum had
been initially diagnosed clinically as acute EGS. However,
histopathology at postmortem failed to show the characteristic
lesions, and the final diagnosis was uncertain. The 3 control
horses, which had detectable toxin in their faecal samples,
included 2 orthopaedic cases, one of which had had chronic
EGS 16 months previously, and a horse with surgical colic.
Quantitation ofBoNT/C in the ileum and faeces
The amount of BoNT/C detected in the ileum and faeces was
quantified as ng of BoNT/C/g wet weight sample. Comparisons
between samples should be made with caution as the
concentration of toxin is calculated using the wet weight of the
sample and there will be some variation in consistency between
samples. The volume of gut contents can vary significantly
between horses, which may also affect toxin detectability.
There was a statistically significant difference in the levels of
toxin detected in the ileum, between the CGS group and controls
(P = 0.001), between the SGS group and controls (P<0.05) and
between the AGS group and controls (P<0.001). There was a
statistically significant difference in the levels of toxin directly
detected in the faeces between the CGS group and controls (P =
0.001) and between the AGS group and controls (P<0.001).
The highest level of BoNT/C (10430 ng/g) was detected in
the faeces of a horse with chronic grass sickness of 15 days
duration, which was sampled at postmortem. The ileum of this
horse also contained detectable toxin (79.2 ng/g). The one
control horse in which BoNT/C was detected in the ileum had a
low level of toxin (10 ng/g wet weight sample), but note that this
horse had clinical signs typical of EGS.
Longitudinal study of horses with CGS
Twelve chronic cases had more than one faecal sample collected.
Eleven of these horses were initially negative for BoNT/C and 5
of these had detectable levels in later faecal samples (the others
remained negative). The twelfth horse had detectable BoNT/C in
both faecal samples. Table 1 shows how the levels of detectable
toxin in the faeces of the 6 horses varied over the course of the
disease. Five of the 6 horses recovered; the sixth was subjected
to euthanasia, and a level of 335 ng/g BoNT/C was detected in
the ileum at postmortem. Of the 6 horses that had no detectable
toxin, 3 recovered and 3 were subjected to euthanasia (one of
these had toxin detectable after enrichment).
Detection of BoNT/C after enrichment of samples in culture
medium
Detection of BoNT/C after enrichment of samples in culture
medium indicates that C. botulinum type C was present in a
sample. After enrichment in CMC-1 medium, BoNT/C was
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detected in 48% (14/29) of ileum samples and 44% (20/45) of
faecal samples of EGS cases, and 7% (2/27) of ileum samples
and 8% (6/72) of faecal samples from controls (Fig 1).
The 2 control horses, out of 27, with detectable BoNT/C in
the ileum after enrichment were the horses clinically diagnosed
as AGS but not histopathologically confirmed, and the other a
horse with a hepatic disorder. The 6 horses, of 72 controls, with
detectable BoNT/C in the faeces after enrichment were 2
orthopaedic cases (one of which had had grass sickness 16
months previously), 2 healthy horses, a horse in contact with an
EGS case, and a horse with ileus.
Ileal samples from AGS cases had a higher proportion of
positive samples after enrichment (75%) than SGS (43%) and
CGS (20%). Faecal samples from AGS cases also had a higher
proportion of positive samples after enrichment (54%) than CGS
(42%) and SGS (33%). The relationships between detectable
BoNT/C in the ileum and faeces both before and after enrichment
between the different groups of horses are illustrated in Figure 1 b.
Not all samples that had detectable levels of toxin directly
were positive for BoNT/C after enrichment, and vice versa.
Table 1 shows which of the consecutive faecal samples from the
chronic EGS cases were positive after enrichment.
Detection of BoNT/C in ileum and/or faeces by direct detection
and/or enrichment.
When the detection methods are combined for individual horses
i.e. when toxin can be detected in the ileum and/or faeces by
direct detection and/or enrichment, then 74% of acute cases,
67% of subacute cases and 67% of chronic cases have detectable
toxin compared to 10% of controls.
Discussion
The results show that there is a strong association between
BoNT/C toxin in the equine gastrointestinal tract and a clinical
diagnosis of EGS. Toxin was detected antemortem in faecal
samples from chronic cases and postmortem in ileum and faecal
samples of all categories of EGS. Toxin was not detected in all
the samples from EGS cases. However, this may be a reflection
on the sensitivity of the assay; the ELISA is approximately 100
times less sensitive than the conventional mouse (lethality)
bioassay that can be used for toxin testing. Horses are extremely
sensitive to botulinum toxins, and even the mouse bioassay
cannot detect toxin in the serum of horses with classical botulism
(Johnston and Whitlock 1987). Only a very small amount of
toxin may be needed to exert a clinical effect. The absence of
detectable toxin in the ileum and faeces may also be due to the
rapid absorption of BoNT/C from the gut, destruction by
proteases or neutralisation of the toxin by mucosal antibodies.
Another factor that may affect the ability to detect BoNT/C
is the point in the disease at which the sample was taken (as well
as the volume of gut contents present at time of sampling). This
is of particular relevance with respect to the chronic cases, where
the disease can last from several weeks to several months. The
sampling of chronic horses over the course of the disease
showed that the toxin could be detected in the faeces of 6 horses
towards the end of the disease, whereas 5 of these horses had
been initially negative when tested earlier. Five of these 6 horses
were considered to have recovered but still had toxin in their
faeces close to or on the date that they were sent back to their
owners. The ability to detect toxin in the faeces of these horses
is therefore not necessarily an indication for a poor prognosis.
Horses may be able to tolerate a subclinical level of toxin in the
faeces: toxin produced in the large intestine may be poorly
absorbed, or destroyed, in healthy horses. Colonisation of infant
mice with C. botulinum does not cause illness despite the
detection of up to 2000 mature mouse intraperitoneal 50% lethal
doses of toxin in the colon and caecum. This is thought to be due
to localisation of the toxin to the colon where it would be poorly
absorbed (Sugiyama 1980).
The presence of toxin in the ileal is probably a more
significant finding with respect to clinical outcome. BoNT/C was
detected, pre-enrichment, in the ileal contents of only one of 28
controls. As noted previously, this horse had been clinically
diagnosed as an acute EGS case; however, the characteristic
neuronal lesions of EGS were not found on histopathological
investigation at postmortem. This case highlights the need to
investigate the possible role of C. botulinum type C in cases
presenting with clinical signs similar to EGS. This sample, as
well as an ileal sample from a horse with a hepatic disorder, had
toxin present after enrichment, demonstrating the presence of C.
botulinum type C in the upper GI tract.
It is interesting to note that the acute EGS cases had a higher
mean level of toxin in the ileum and faeces, than the other
categories. It is possible that acute EGS may result from
exposure to a large amount of toxin, whereas the chronic form
may result from the exposure to smaller amounts of toxin over a
longer period of time (Doxey et al. 1995). The clinical severity
and duration of the disease correlates to the extent of enteric
neuronal damage. Enteric neuropathy is widespread and more
severe in acute cases but in chronic cases the neuronal loss is
less and tends to be localised to the distal small intestine
(Scholes et al. 1993). BoNT/C was detected in both the ileum
and faeces of approximately 50% of acute EGS horses. This
suggests that either there are toxin-producing organisms along
the length of the gut, or toxin has been produced in the ileum and
has passed along the length of the gut prior to the formation of
the impactions that often occur.
We are investigating the hypothesis that EGS is a
toxicoinfection with C. botulinum type C. The diagnosis of a
toxicoinfection requires the demonstration of the presence of
both toxin and toxin-producing organism in the affected animal,
as is the case for infant botulism (Hatheway 1979). The presence
of C. botulinum type C in the samples is demonstrated by
detecting the toxin in enrichment culture supernates. The
production of this neurotoxin is encoded on a prophage that can
be lost or acquired during growth and sporulation. Therefore the
detection of BoNT/C after enrichment does not necessarily mean
that an organism was producing toxin in vivo, and conversely an
organism that was producing toxin in vivo may not be detected
in culture due to loss of the prophage. C. botulinum type C is a
particularly fastidious organism, and successful culture and
isolation can be very difficult. A significant number of samples
do demonstrate the presence C. botulinum type C, for example,
75% of ileal samples from acute cases, which would support the
hypothesis of a toxicoinfection. The samples, which do not have
detectable toxin after enrichment, could be due to the absence
of organism in the enriched sample, prophage instability,
or inhibition of growth or toxin production by other
organisms present.
Only 4% of 72 control faecal samples contained an organism
capable of producing BoNT/C after enrichment. This may
indicate the low carriage of toxigenic organisms in the normal
equine population, or it may suggest that there are factors
preventing detection of the organisms. We are developing a
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PCR technique for the more accurate assessment of the carriage
of this organism in the equine population.
There are some differences in opinion as to the clinical
relevance of Clostridium botulinum isolated from the GI tract of
animals (Kinde et al. 1991). The organism is found commonly
in soil samples and aquatic sediments (Hatheway 1990) but its
distribution can vary considerably even locally (Smith 1975).
Different types of C. botulinum are found in different
geographical areas; for example, C. botulinum type B is
predominant in the soils in the eastern US, and consequently this
serotype is the major cause of adult equine botulism and shaker
foal syndrome in that area (Johnson and Whitlock 1987). Type C
is a cause of equine botulism in Europe, but is less common in
the US despite being the predominant type isolated from soils in
Florida (Johnston and Whitlock 1987). Types C and D have been
described as obligate parasites of animals and birds, seldom
being isolated from the soil unless from an area where birds or
domestic animals congregate (Smith 1975). Spores of C.
botulinum are commonly found in the faeces of herbivores
without clinical signs (Kinde et al. 1991). However, it has been
reported that spores are rarely isolated from normal, healthy
horses that are not at risk from botulism, and that toxin has not
been isolated from the faeces of a mature animal antemortem
(Johnston and Whitlock 1987). Here, we have demonstrated that
both the organism and the toxin can be detected in the faeces of
horses antemortem, as well as the ileum of horses postmortem;
these animals did not present with classic botulism, but equine
grass sickness.
It is important to address the question why these horses do
not present with classic signs of botulism. EGS does share some
clinical similarities to botulism, particularly in the acute form
(Tocher et al. 1923; Greig 1928). However, many of the
neuromuscular signs characteristic of classical botulism are not
observed. The chronic and subacute forms develop a very tucked
up 'greyhound-like' abdomen (Gilmour 1988). This is strikingly
similar to the 'wasp-waist' seen when laboratory mice are
inoculated with botulinum toxins.
Equine Grass Sickness is thought to be associated with
intestinal colonisation of C. botulinum with in vivo production of
toxin(s), rather than ingestion of preformed toxin, which is the
cause of classic botulism. Consequently the enteric nervous
system of the horse is exposed to a high dose of locally produced
toxin, causing severe neuronal damage and initiating the GI
dysfunction associated with the disease. We propose that there is
a concentration gradient effect away from the focus of toxin
production, perhaps generated by axonal transport, with the more
peripheral ganglia being affected to varying degrees. If this is the
case, then it is possible that insufficient neurotoxin reaches the
peripheral cholinergic synapses at the neuromuscular junction to
cause the neuromuscular signs observed in botulism (in classic
botulism the preformed toxin fs ingested and absorbed rapidly,
becoming systemic). Hodson et al. (1984) observed that changes
in the coeliacomesenteric ganglion resemble those of classic
retrograde degeneration after axotomy. This supports the
hypothesis that the primary lesion is in the GI tract. The
analogous toxicoinfectious botulism in humans (infant botulism,
and the extremely rare adult form) has a different clinical
presentation from that caused by ingestion of preformed toxin.
Disruption or immaturity of normal flora, disturbance in gut
motility, and compromisation of the gastric acid barrier, can all
predispose to intestinal infection with C. botulinum in man (Chia
et al. 1986). Botulism has also been observed in man where there
is mainly cholinergic autonomic dysfunction with no
neuromuscular involvement (Jenzer et al. 1975).
The clinical signs of EGS may result from the involvement
of the 3 toxins produced by C. botulinum type C. To date we
have only assayed for CI (BoNT/C); we do not have assays for
the C2 and C3 toxins at present. However, the C2 and C3
toxins, together with the in vivo growth of the organism, may be
responsible for the difference in clinical symptoms between
EGS and botulism. C2 toxin has been shown to cause
hypotension, haemorrhage, cytotoxicity and increase in
vascular permeability (Aktories et al 1986). In the intestine it
has been shown to cause intestinal secretion, fluid
accumulation, histopathological changes (Ohishi and Odagiri
1984) and inhibition of contraction of guinea pig ileum
myenteric plexus longitudinal muscle preparation (Mauss et al.
1989). However, its role in the pathogenesis of disease in vivo
has yet to be determined.
Ultrastructural investigation of the neuronal lesions of EGS
has indicated marked abnormalities of the neuronal
cytoskeletal, cytoplasmic and secretory proteins with disruption
or loss of the Golgi-associated membranes (Griffiths et al.
1993). It is possible that the C2 and C3 toxins could cause the
ultrastructural damage observed. Actin-polymerisation has a
role in governing secretion from neural cells and consequently
is thought to play some role in neurotransmission (Viviani et al.
1996). All 3 of the toxins produced by C. botulinum type C
could therefore affect neurotransmission in some way, either by
their effect on the cytoskeleton or the secretory vesicles of the
exocytic pathway. The neurotoxicity of BoNT/C (Williamson
and Neale 1998) may account for some of the neuronal
degeneration that is observed in EGS.
The enteric cholinergic neurones from the ileum of horses
with acute EGS exhibit altered cholinergic mechanisms, with a
reduction in the release of acetylcholine (Murray et al. 1994).
Botulinum neurotoxins inhibit the release of acetylcholine
from cholinergic nerves. The prokinetic drug Cisapride, an
indirect cholinergic agent, facilitates the release of
acetylcholine from the postganglionic nerves of the myenteric
plexus in the gut. It has been shown to be of some therapeutic
benefit in the treatment of selected cases of chronic EGS
(Milne et al. 1996). Acetylcholine release is stimulated from
the remaining morphologically normal neurones and increases
gut motility.
This is, to some extent, a reinvestigation of the hypothesis
originally put forward by Tocher et al. in 1923. Their work was
not widely accepted at the time. One of the major criticisms was
their inability to prove conclusively that the organism they had
isolated from grass sickness horses was Bacillus botulinus; they
could only say that it morphologically and toxigenically
resembled this organism. However, serotype C of C. botulinum
was first identified.only in 1922 (Bengston 1922; Seddon 1922).
This was almost certainly not the serotype which was vaccinated
against in 1922, particularly as the antitoxin used was of US
human origin. C. botulinum type C had not been identified as a
cause of human botulism at that point, and there have only been
5 suspected human type C cases since (Sonnabend et al. 1985).
The neurotoxins of different types of C. botulinum are not
immunologically cross-reactive.
At this point, it is not possible to say whether C. botulinum
type C is the primary cause of EGS, a causal cofactor, or whether
the organism grows and produces its toxins as a secondary event
due to reduced gut motility. Five faecal samples (one horse with
ileus and 4 with colic) and 2 ileal samples (one horse with colic
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and one with an unknown diagnosis) from horses with GI
dysfunction, but not grass sickness, have been assayed to date.
This has shown the presence of toxin in one faecal sample from
a horse with colic and, in one ileal sample, from a horse which
had presented clinically with AGS, but the diagnosis was
unknown after postmortem.
In summary, we propose that EGS is a toxicoinfection by C.
botulinum type C with toxin production and absorption
predominantly in the ileum. The organism is either normally
present in the large intestine, and overgrows into the ileum, or
the organism is taken up in spore form and is able to germinate
in the ileum, following a change in the environment of the GI
tract due to an environmental trigger. Horses are notoriously
sensitive to changes in diet, and grass sickness is associated with
grazing and a change in pasture. The trigger therefore could be a
nutritional one, affecting the gut flora, and facilitating the
colonisation of the intestine with C. botulinum and its
subsequent toxin production.
The disease severity is likely to be influenced by an
interaction of factors such as the amount of toxin the horse is
exposed to, the local mucosal and systemic immune response to
the toxin, the immune status at the onset of disease and the
inherent susceptibility of the horse. Whether C. botulinum type
C is the cause of grass sickness or whether it is involved as a
secondary event, the detection of high levels of toxin in the
ileum at postmortem, and antemortem in faeces in horses with
EGS, together with the known sensitivity of horses to botulinum
toxins, supports a significant role for the involvement of C.
botulinum type C in equine grass sickness.
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Introduction
Equine grass sickness (EGS) is an often fatal dysau¬
tonomia of unknown aetiology. It is found in North¬
ern Europe, especially in the eastern half of the United
Kingdom. It is characterized by gastrointestinal
dysfunction due to degeneration of the enteric
autonomic nerves, particularly in the ileum. EGS
presents in acute, subacute and chronic forms [1]. The
disease mal seco, reported in horses from the
Patagonia region of Argentina and Chile, appears
clinically and pathologically equivalent to EGS [2],
EGS was first recognized in Scotland in 1907,
but despite a great deal of research the aetiology of
the disease remains a mystery. The epidemiology
'Corresponding author. Tel.: +44 131 650 3128; Fax: +44 131 650
3128 or 6531; E-mail: ip".poxton@ed.ac.uk
suggests that EGS may be caused by a toxin, probably
of microbial origin, which is either ingested or
produced in the intestine following a nutritional
trigger. Clustering of cases occurs and the disease is
seasonal. The disease generally occurs in younger
animals, and animals imported from a non-endemic
area to an endemic area appear more susceptible to
EGS — both of which suggest the development of
immunity. The disease is restricted to certain geogra¬
phical areas, even down to certain pastures on the
same property.
The link between botulism and EGS was made as
early as the 1920s when Tocher et al. [3] claimed that
EGS was caused by Clostridium botulinum (possibly
type A). This claim was discounted when vaccine
field trials, with vaccine imported from the U.S.A.,
failed to show complete protection. However, vacci-
nees had partial protection [4]. In the 1970s unpub¬
lished anecdotal evidence was suppressed that
suggested that C. botulinum type C was involved. In
1075-9964/99/030291 + 03 $30.00/0 © 1999 Academic Press
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the early 1990s, Jean Robb, after researching the old
literature, suggested to us that a reappraisal of the role
of C. botulinum should be made. Later, J.K. Miller
formulated a hypothesis (unpublished) that EGS is a
toxico-infection — based on the likely consequences
of the action of toxin(s) of C/D C. botulinum on the
enteric autonomic nervous system. There were several
parallels to infant botulism in humans (e.g. dyspha¬
gia, constipation, diminished appetite, spectrum of
severity).
Clostridium botulinum type C produces three exo¬
toxins: (1) CI toxin (BoNT/C, the classical neurotoxin)
is a protease that cleaves syntaxin when inserted into
the lipid bilayer of a presynaptic membrane, inhibit¬
ing release of neurotransmitters. Its action in classical
botulism is flaccid paralysis. However, its likely action
when produced locally, and possibly slowly, in the GI
tract is unknown. (2) The C2 toxin, a binary toxin,
ADP-ribosylates the G-actin of beta /gamma cytoplas¬
mic and gamma smooth muscle actin, resulting in
depolymerization of actin microfilament network. (3)
The C3 toxin ADP-ribosylates the rho family of low
molecular weight GTP-binding proteins which are
required for the organization of the microfilament
network. All three toxins could affect neurotransmis¬
sion by their effects on the cytoskeleton or the
secretory vesicles of the exocytic pathway, but could
these toxins cause the clinical and pathological
changes of EGS?
The aim of the current study was to investigate
whether BoNT/C could be detected in clinical cases of
EGS and compare this with control animals to see if
there was any correlation between presence of toxin
and symptoms of EGS. In a parallel serological study,
antibodies were assayed to BoNT/C, and to cell
surface antigens of Clostridium novyi, a non-botuli-
num-toxin-producing species identical in cell surface
composition to group III C. botulinum [5]. The results
of the serological study are being published elsewhere
[6] and preliminary results for both toxin and serology
have been published recently [7],
Materials and Methods
Horses investigated
To date 36 cases of clinically confirmed EGS and 45
controls (including contacts) with and without in¬
testinal symptoms have been investigated. If animals
have gone to post mortem, the contents of the distal
ileum and rectum have been collected. Those chronic
cases that have survived, as well as many of the
controls, have only had faecal samples taken (per
rectum).
Immunoassay for BoNT/C
Weighed specimens (l-10g) were infused into a
known volume (5 or 10 mL depending on consis¬
tency) of PBS pH 7.2 containing 0.2% gelatin, and held
overnight at 4°C. After thorough mixing, the heavy
debris was allowed to settle, and the liquid phase
clarified by centrifugation (4000 xg, 20 min). The
supernate was stored briefly at — 20°C. A sandwich
ELISA developed at CAMR, Porton Down, U.K., and
used under licence, was used to measure BoNT/C.
Briefly, microwell plates coated with polyclonal
guinea pig anti-serum raised against purified
BoNT/C were used to detect toxin in the supernates.
A standard curve was included on each plate using
purified BoNT/C. Captured toxin was detected with
guinea pig IgG conjugated to horseradish peroxidase
and HRP substrate (3,3',5,5', -tetramethyl-benzidine
dihydrochloride and hydrogen peroxide). Results
were expressed as ng of toxin per g wet weight of
sample.
Antibodies to BoNT/C (antitoxin) were assayed in
a similar manner, with plates coated at CAMR with
purified BoNT/C. The antitoxin in horse serum was
detected with anti-equine alkaline phosphatase con¬
jugate.
Results
Detection of CI toxin (BoNT/C)
Clinical cases and controls have been investigated for
the presence of C. botulinum type CI neurotoxin
(BoNT/C) in post-mortem specimens of contents of
distal ileum, and in rectal samples of living horses
(Figure 1).
CI toxin has been detected in the ileum contents of
43% chronic (three of seven), 83% acute (five of six),
50% subacute (two of four) and 7% controls (one of
14), and in the faeces in 65% chronic (11 of 17), 20%
acute (two of seven), 20% subacute (one of five) and 3%




Figure 1. Percentage of horses with detectable BoNT/C in (□)
ileum and faecal (□) samples.
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Days of illness
Figure 2. BoNT/C in faeces (□) and serum IgG (-
samples from a case of chronic EGS.
consecutive
in Figure 1. CI toxin was detected more often in the
ileum contents of more animals with acute or
subacute disease than with chronic cases, and,
conversely, in the faeces of more of the chronic cases.
The single horse where toxin was detected in the
ileum contents was admitted with a provisional
clinical diagnosis of acute grass sickness. However,
the characteristic pathology of EGS could not be
observed on necropsy. The single control animal in
which toxin was detected in faeces was diagnosed as
having colic, and the toxin levels were low.
In parallel serological studies, we have seen rising
titres of specific anti-BoNT/C IgG during the course
of the illness in chronic cases (an example is shown in
Figure 2), but overall, serological data have proved
difficult to interpret when single samples have been
investigated [5]. The results shown in Figure 2 show
the appearance of toxin in faeces followed by
apparent seroconversion.
Discussion
We have demonstrated an association between clinical
symptoms of grass sickness and BoNT/C in the
ileum, but we are aware that we have not yet proved
that there is a causal relationship. Although the
association is not absolute, the ELISA system that
we are employing is not as sensitive as the biological
action of botulinum toxin; several samples may have
had levels of CI toxin below the detectable limits.
Currently we are examining the hypothesis that the
development of grass sickness involves a nutritional
trigger and susceptibility to disease may be deter¬
mined by the natural defences of the horse, such as
the ileal mucosal immunity. It is possible that most if
not all horses are exposed to C. botulinum type C, but
that any toxin produced in the intestine is usually
neutralized by mucosal antibodies or destroyed by
natural proteases. Grass sickness may develop after
intestinal bacteria produce amounts of toxin that
cannot be controlled by the normal defences, perhaps
subsequent to increased bacterial multiplication. The
nutritional trigger is unknown but presumably
involves the biochemical status of the grass. Similarly
the mechanisms of enteric nerve regeneration remain
unclear. In summary, we have assembled both
toxicological and serological correlations with EGS
that suggest several new avenues worth pursuing.
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